US20230146195A1 - Bcma binding molecules and methods of use thereof - Google Patents
Bcma binding molecules and methods of use thereof Download PDFInfo
- Publication number
- US20230146195A1 US20230146195A1 US18/055,188 US202218055188A US2023146195A1 US 20230146195 A1 US20230146195 A1 US 20230146195A1 US 202218055188 A US202218055188 A US 202218055188A US 2023146195 A1 US2023146195 A1 US 2023146195A1
- Authority
- US
- United States
- Prior art keywords
- seq
- amino acid
- acid sequence
- cell
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 title claims abstract description 309
- 238000000034 method Methods 0.000 title claims description 82
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract description 323
- 102000036639 antigens Human genes 0.000 claims abstract description 323
- 108091007433 antigens Proteins 0.000 claims abstract description 323
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 249
- 210000004027 cell Anatomy 0.000 claims abstract description 224
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 116
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 116
- 239000002157 polynucleotide Substances 0.000 claims abstract description 116
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 93
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 92
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 92
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 57
- 201000011510 cancer Diseases 0.000 claims abstract description 51
- 229920001184 polypeptide Polymers 0.000 claims abstract description 51
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 17
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 347
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 139
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 139
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 110
- -1 CD86 Proteins 0.000 claims description 49
- 230000000139 costimulatory effect Effects 0.000 claims description 43
- 239000003446 ligand Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 24
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 24
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 24
- 230000003213 activating effect Effects 0.000 claims description 23
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 20
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 20
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102100038078 CD276 antigen Human genes 0.000 claims description 19
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 18
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 17
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 17
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 17
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 17
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 16
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 16
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 14
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 14
- 101710185679 CD276 antigen Proteins 0.000 claims description 13
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 13
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 13
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims description 12
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 12
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 12
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 12
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 12
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 12
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 11
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 11
- 102100024263 CD160 antigen Human genes 0.000 claims description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 11
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 11
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims description 11
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 11
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 11
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 11
- 102100039904 Integrin alpha-D Human genes 0.000 claims description 11
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 11
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 11
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 11
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 11
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 11
- 102000014128 RANK Ligand Human genes 0.000 claims description 11
- 108010025832 RANK Ligand Proteins 0.000 claims description 11
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 11
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 10
- 201000003444 follicular lymphoma Diseases 0.000 claims description 10
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100035793 CD83 antigen Human genes 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 8
- 208000007452 Plasmacytoma Diseases 0.000 claims description 8
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 7
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 7
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 7
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 7
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 7
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 7
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 7
- 102000006495 integrins Human genes 0.000 claims description 7
- 108010044426 integrins Proteins 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 6
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 108010017009 CD11b Antigen Proteins 0.000 claims description 6
- 102100038077 CD226 antigen Human genes 0.000 claims description 6
- 108010062802 CD66 antigens Proteins 0.000 claims description 6
- 102100027217 CD82 antigen Human genes 0.000 claims description 6
- 101710139831 CD82 antigen Proteins 0.000 claims description 6
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 6
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims description 6
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims description 6
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 6
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 6
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims description 6
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims description 6
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 6
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims description 6
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 6
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 6
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 6
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims description 6
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims description 6
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 6
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 6
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 6
- 101000633782 Homo sapiens SLAM family member 8 Proteins 0.000 claims description 6
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 claims description 6
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 6
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 6
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 6
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 6
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims description 6
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 6
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 6
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 6
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 6
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 6
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 6
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 6
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 6
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims description 6
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims description 6
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 6
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 6
- 102100029214 SLAM family member 8 Human genes 0.000 claims description 6
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 6
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 6
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 6
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 6
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 5
- 102100037904 CD9 antigen Human genes 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 5
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 5
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 5
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 5
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 5
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 5
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 claims description 4
- 206010053869 POEMS syndrome Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 210000004180 plasmocyte Anatomy 0.000 claims description 4
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 102000027581 NK cell receptors Human genes 0.000 claims description 3
- 108091008877 NK cell receptors Proteins 0.000 claims description 3
- 102100023884 Probable ribonuclease ZC3H12D Human genes 0.000 claims description 3
- 108010062314 Signaling Lymphocytic Activation Molecule Family Proteins 0.000 claims description 3
- 102000010841 Signaling Lymphocytic Activation Molecule Family Human genes 0.000 claims description 3
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 3
- 208000023761 AL amyloidosis Diseases 0.000 claims description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims description 2
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 201000003791 MALT lymphoma Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 208000002774 Paraproteinemias Diseases 0.000 claims description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims description 2
- 230000001589 lymphoproliferative effect Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 claims description 2
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- ZUXNHFFVQWADJL-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methoxyethyl)-n-(4-phenyl-1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C=2C=CC=CC=2)=CSC=1N(CCOC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZUXNHFFVQWADJL-UHFFFAOYSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 48
- 238000000338 in vitro Methods 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 9
- 238000011357 CAR T-cell therapy Methods 0.000 abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 description 128
- 108020004414 DNA Proteins 0.000 description 104
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 104
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 90
- 229910052757 nitrogen Inorganic materials 0.000 description 67
- 229910052698 phosphorus Inorganic materials 0.000 description 63
- 229910052721 tungsten Inorganic materials 0.000 description 54
- 239000013598 vector Substances 0.000 description 52
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 46
- 229910052739 hydrogen Inorganic materials 0.000 description 45
- 102000046935 human TNFRSF17 Human genes 0.000 description 43
- 239000002773 nucleotide Substances 0.000 description 39
- 125000003729 nucleotide group Chemical group 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 32
- 229910052720 vanadium Inorganic materials 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 26
- 108090000695 Cytokines Proteins 0.000 description 26
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 25
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 25
- 241000282414 Homo sapiens Species 0.000 description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 24
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 23
- 210000002865 immune cell Anatomy 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 20
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 19
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 239000012636 effector Substances 0.000 description 15
- 238000002659 cell therapy Methods 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 11
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 11
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 10
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000011534 wash buffer Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
- 239000013603 viral vector Substances 0.000 description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 8
- 101710205775 Inducible T-cell costimulator Proteins 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 230000004068 intracellular signaling Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241000713666 Lentivirus Species 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 238000011130 autologous cell therapy Methods 0.000 description 6
- 230000001461 cytolytic effect Effects 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000006471 dimerization reaction Methods 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002463 transducing effect Effects 0.000 description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 108010056102 CD100 antigen Proteins 0.000 description 5
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 description 5
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000012004 kinetic exclusion assay Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 101710178046 Chorismate synthase 1 Proteins 0.000 description 4
- 101710152695 Cysteine synthase 1 Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 102000001398 Granzyme Human genes 0.000 description 4
- 108060005986 Granzyme Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 102100032831 Protein ITPRID2 Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- 102000000013 Chemokine CCL3 Human genes 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 108010092694 L-Selectin Proteins 0.000 description 3
- 102000016551 L-selectin Human genes 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241001225883 Prosopis kuntzei Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101710163413 Signaling lymphocytic activation molecule Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000003284 homeostatic effect Effects 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 229960002450 ofatumumab Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 239000003819 Toceranib Substances 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102400000084 Tumor necrosis factor ligand superfamily member 6, soluble form Human genes 0.000 description 2
- 101800000859 Tumor necrosis factor ligand superfamily member 6, soluble form Proteins 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960002923 denileukin diftitox Drugs 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 229950001845 lestaurtinib Drugs 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000002483 superagonistic effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229960005048 toceranib Drugs 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- HEQRYQONNHFDHG-TZSSRYMLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 HEQRYQONNHFDHG-TZSSRYMLSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102000004634 CD30 Ligand Human genes 0.000 description 1
- 108010017987 CD30 Ligand Proteins 0.000 description 1
- 210000004773 CD4-positive, alpha-beta T lymphocyte Anatomy 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108010007056 CKGGRAKDC-GG-D(KLAKLAK)2 Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 108010082169 Chemokine CCL17 Proteins 0.000 description 1
- 108010083701 Chemokine CCL22 Proteins 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 108010086911 MICB antigen Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000005464 Radotinib Substances 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000002825 class switched memory b cell Anatomy 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940127276 delta-like ligand 3 Drugs 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000026058 directional locomotion Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003258 hemophagocytic effect Effects 0.000 description 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 229960004655 masitinib Drugs 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229950004043 radotinib Drugs 0.000 description 1
- DUPWHXBITIZIKZ-UHFFFAOYSA-N radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical class C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005325 sonidegib Drugs 0.000 description 1
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000940 tivozanib Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- This invention relates to chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule which binds to B-cell maturation antigen (BCMA), polynucleotides encoding the same, and methods of treating a cancer or other disease or disorder in a patient using the same.
- CARs chimeric antigen receptors
- TCRs engineered T cell receptors
- BCMA B-cell maturation antigen
- cancers are by their nature comprised of normal cells that have undergone a genetic or epigenetic conversion to become abnormal cancer cells. In doing so, cancer cells begin to express proteins and other antigens that are distinct from those expressed by normal cells. These aberrant tumor antigens can be used by the body's innate immune system to specifically target and kill cancer cells. However, cancer cells employ various mechanisms to prevent immune cells, such as T and B lymphocytes, from successfully targeting cancer cells.
- Human T cell therapies rely on enriched or modified human T cells to target and kill cancer cells in a patient.
- methods have been developed to engineer T cells to express constructs which direct T cells to a particular target cancer cell.
- CARs Chimeric antigen receptors
- TCRs engineered T cell receptors
- the present invention is directed to an isolated polynucleotide encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) comprising a binding molecule that specifically binds to B-cell maturation antigen (BCMA), wherein the binding molecule comprises: (a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145) wherein: X 2 is not present or G; X 3 is not present or S; X 4 is F, G, I, or Y; X 5 is S or T; X 6 is F or S; and X 7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 11 X 3 X 4 X 5 X 6 X 7 X 8 X 9
- the invention is directed to an isolated polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, wherein the antibody or the antigen binding molecule thereof comprises: (a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2 is not present or G; X 3 is not present or S; X 4 is F, G, I, or Y; X 5 is S or T; X 6 is F or S; and X 7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15
- the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9-16.
- the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25-32.
- the VL CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 81-88.
- the VL CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 97-104.
- the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 113-120.
- the binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 9; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 25; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 41; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113; (b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 10; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 42; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; a VL CDR2 region comprising the amino acid
- the binding molecule is single chained. In some embodiments, the binding molecule comprises an scFv.
- the CAR comprises a transmembrane domain.
- the transmembrane domain is a transmembrane domain of CD28, 4-1BB/CD137, CD8 (e.g., CD8 alpha, CD4, CD19, CD3 epsilon, CD45, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, a zeta chain of a T cell receptor, or any combination thereof.
- the CAR comprises a hinge region between the transmembrane domain and the binding molecule.
- the hinge region is of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, CD28, or CD8 alpha.
- the CAR or TCR comprises a costimulatory region.
- the costimulatory region is a signaling region of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR
- the invention is directed to a vector comprising the polynucleotide or a polypeptide encoded by the polynucleotide.
- the invention is directed to a cell comprising the polynucleotide, the vector, the polypeptide, or any combination thereof.
- the invention is directed to a cell, e.g., an immune cell, e.g., a tumor-infiltrating lymphocyte (TIL), autologous T cell, engineered autologous T cell (eACT), an allogeneic T cell, or any combination thereof.
- TIL tumor-infiltrating lymphocyte
- eACT engineered autologous T cell
- an allogeneic T cell or any combination thereof.
- the invention is directed to a method of inducing an immunity against a tumor comprising administering to a subject an effective amount of a cell comprising the polynucleotide, the vector, the polypeptide, or any combination thereof.
- Other aspects of the invention include a method of treating a cancer in a subject in need thereof comprising administering to the subject the polynucleotide, the vector, the polypeptide, the cell, or the composition.
- the cancer treatable by the method can be a hematologic cancer.
- FIG. 1 A- 1 F show CLUTSTAL W (1.83) multiple sequence alignments of eight example anti-BCMA binding molecules disclosed herein.
- FIG. 1 A shows a sequence alignment of example anti-BCMA binding molecules comprising a VH domain. Complementarity determining regions (CDRs) and framework regions (FRs) are shown, as determined by Chothia.
- FIG. 1 B is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated in FIG. 1 A .
- FIG. 1 C shows a sequence alignment of example anti-BCMA binding molecules comprising a VH domain, with alternate CDRs and FRs shown.
- FIG. 1 D is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated in FIG. 1 C .
- FIG. 1 E shows a sequence alignment of example anti-BCMA binding molecules comprising a VL domain. CDRs and FRs are shown, as determined by Chothia.
- FIG. 1 F is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated in FIG. 1 E .
- FIGS. 2 A- 2 F show BCMA expression in various cells.
- FIG. 2 A shows multiple myeloma cell expression of BCMA, CD138, CS-1, CD38, and CD19. Box-plot analysis shows the distribution of gene expression levels in the various multiple myeloma cell lines tested ( FIG. 2 A ).
- FIGS. 2 B- 2 D show BCMA expression in EoL1 ( FIG. 2 B ), MM1S ( FIG. 2 C ), and NCI-H929 ( FIG. 2 D ) cancer cell lines as measured by flow cytometric analysis of BCMA cell surface expression on the respective cell lines.
- FIG. 2 A shows multiple myeloma cell expression of BCMA, CD138, CS-1, CD38, and CD19. Box-plot analysis shows the distribution of gene expression levels in the various multiple myeloma cell lines tested ( FIG. 2 A ).
- FIGS. 2 B- 2 D show BCMA expression in EoL1 ( FIG. 2 B ), MM1S ( FIG
- FIG. 2 E shows the expression of BCMA, CS-1, CLL-1, DLL3, CD70, and FLT3 in alternatively activated macrophages; CD14-positive, CD16-negative cells; CD38-negative na ⁇ ve B cells; CD4-positive, alpha-beta T cells; central memory CD4-positive cells; central memory CD8-positive cells; class switched memory B cells; cytotoxic CD56-dim natural killer cell; effector memory CD4-positive cells; effector memory CD8-positive cells; inflammatory macrophages; macrophages; mature neutrophils; memory B cells; monocytes; myeloid cells; and regulatory T cells.
- FIG. 3 A and FIG. 3 B show CAR expression in lentivirus transduced primary human T cells from a first healthy donor ( FIG. 3 A ) and a second healthy donor ( FIG. 3 B ).
- FIGS. 4 A- 4 F shows IFN ⁇ , TNF ⁇ , and IL-2 production by lentivirus transduced CAR T cells from two healthy donors following 16 hours of co-cultured with EoL-1 (Black), NCI-H929 (light grey), or MM1S (grey) target cell lines.
- FIGS. 4 A and 4 B show the IFN ⁇ (pg/ml; y-axis) production in lentivirus transduced CAR T cells from a first donor ( FIG. 4 A ) and a second donor ( FIG. 4 B ).
- FIGS. 4 C and 4 D show the TNF ⁇ (pg/ml; y-axis) production in lentivirus transduced CAR T cells from a first donor ( FIG.
- FIGS. 4 E and 4 F show the IL-2 production (pg/ml; y-axis) in lentivirus transduced CAR T cells from a first donor ( FIG. 4 E ) and a second donor ( FIG. 4 F ).
- FIGS. 5 A- 5 F show the average cytolytic activity (as a percentage of viable target cells remaining; y-axis) over time from two healthy donors expressing the indicated CARs co-cultured with EoL1 ( FIGS. 5 A and 5 B ), NCI-H929 ( FIGS. 5 C and 5 D ), or MM1S ( FIGS. 5 E and 5 F ) target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.
- FIGS. 5 A and 5 B show the average cytolytic activity of transduced CART cells from a first donor ( FIG. 5 A ) and a second donor ( FIG.
- FIGS. 5 B and 5 B show the average cytolytic activity of transduced CAR T cells from a first donor ( FIG. 5 C ) and a second donor ( FIG. 5 D ) co-cultured with NCI-H929 target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.
- FIGS. 5 E and 5 F show the average cytolytic activity of transduced CART cells from a first donor ( FIG. 5 E ) and a second donor ( FIG. 5 F ) co-cultured with MM1S target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.
- FIGS. 6 A and 6 B show proliferation of CFSE-labeled lentivirus transduced CART cells from a first healthy donor ( FIG. 6 A ) and a second healthy donor ( FIG. 6 B ) following 5 days of co-culture with CD3-CD28 beads (top row), EoL-1 (second row), NCI-H929 (third row), or MM1S (bottom row) target cell lines.
- FIG. 7 A shows Clone FS-26528 HC DNA sequence (SEQ ID NO: 271)
- FIG. 7 B shows Clone FS-26528 HC AA sequence (SEQ ID NO: 272)
- FIG. 7 C shows HC CDR sequences for clone FS-26528.
- FIG. 7 D shows Clone FS-26528 LC DNA sequence (SEQ ID NO: 276).
- FIG. 7 E shows Clone FS-26528 LC AA sequence (SEQ ID NO: 277).
- FIG. 7 F shows LC CDR sequences for clone FS-26528.
- FIG. 7 G shows Clone FS-26528 CAR DNA H ⁇ L sequences (SEQ ID NO: 281)
- FIG. 7 H shows Clone FS-26528 CAR H ⁇ L AA sequences (SEQ ID NO: 282)
- FIG. 7 I shows Clone FS-26528 CAR DNA L ⁇ H sequences (SEQ ID NO: 283).
- FIG. 7 J shows Clone FS-26528 CAR L ⁇ H sequences (SEQ ID NO: 284).
- FIG. 8 A shows Clone PC-26534 HC DNA sequence (SEQ ID NO: 285).
- FIG. 8 B shows Clone PC-26534 HC sequence (SEQ ID NO: 286).
- FIG. 8 C shows HC CDR sequences for clone FS-26528.
- FIG. 8 D shows Clone PC-26534 LC DNA sequences (SEQ ID NO: 290).
- FIG. 8 E shows the Clone PC-26534 LC sequence (SEQ ID NO: 291).
- FIG. 8 F shows LC CDR sequences for Clone PC-26534.
- FIG. 8 G shows the Clone PC-26534 CAR DNA H ⁇ L sequence (SEQ ID NO: 295).
- FIG. 8 H shows the Clone PC-26534 CAR H ⁇ L AA sequence (SEQ ID NO: 296)
- FIG. 8 I shows the Clone PC-26534 CAR DNA L ⁇ H sequence (SEQ ID NO: 297).
- FIG. 8 J shows Clone PC-26534 CAR L ⁇ H sequence (SEQ ID NO: 298).
- FIG. 9 A shows Clone AJ-26545 HC DNA sequence (SEQ ID NO: 299).
- FIG. 9 B shows Clone AJ-26545 variable HC sequence (SEQ ID NO: 300).
- FIG. 9 C shows HC CDR sequences for Clone AJ-26545.
- FIG. 9 D shows Clone AJ-26545 variable LC DNA sequence (SEQ ID NO: 304).
- FIG. 9 E shows Clone AJ-26545 variable LC AA sequence (SEQ ID NO: 305)
- FIG. 9 F shows Clone AJ-26545 LC CDR sequences.
- FIG. 9 G shows Clone AJ-26545 CAR DNA H ⁇ L sequence (SEQ ID NO: 309).
- FIG. 9 H shows Clone AJ-26545 CAR H ⁇ L AA sequence (SEQ ID NO: 310)
- FIG. 9 I shows Clone AJ-26545 CAR DNA L ⁇ H sequence (SEQ ID NO: 311)
- FIG. 9 J shows Clone AJ-26545 CAR L ⁇ H sequence (SEQ ID NO: 312).
- FIG. 10 A shows Clone AJ-26554 HC DNA sequence (SEQ ID NO: 313)
- FIG. 10 B shows Clone AJ-26554 HC AA sequence (SEQ ID NO: 314).
- FIG. 10 C shows Clone AJ-26554 HC CDR sequences
- FIG. 10 D shows Clone AJ-26554 LC DNA sequence (SEQ ID NO: 318).
- FIG. 10 E shows Clone AJ-26554 LC AA sequence (SEQ ID NO: 319).
- FIG. 10 F shows Clone AJ-26554 LC CDR sequences.
- FIG. 10 G shows Clone AJ-26554 CAR DNA H ⁇ L chain sequences (SEQ ID NO: 323).
- FIG. 10 H shows Clone AJ-26554 CAR H ⁇ L chain AA sequences (SEQ ID NO: 324).
- FIG. 10 I shows Clone AJ-26554 CAR DNA L ⁇ H chain sequences (SEQ ID NO: 325).
- FIG. 10 J shows Clone AJ-26554 CAR L ⁇ H AA sequences (SEQ ID NO: 326).
- FIG. 11 A shows Clone NM-26562 HC DNA sequence (SEQ ID NO: 327).
- FIG. 11 B shows Clone NM-26562 HC AA sequence (SEQ ID NO: 328).
- FIG. 11 C shows Clone NM-26562 HC CDR sequences.
- FIG. 11 D shows Clone NM-26562 LC DNA sequence (SEQ ID NO: 332).
- FIG. 11 E shows Clone NM-26562 LC AA sequence (SEQ ID NO: 333).
- FIG. 11 F shows the Clone NM-26562 LC CDR sequences.
- FIG. 11 G shows the Clone NM-26562 CAR DNA H ⁇ L sequences (SEQ ID NO: 337)
- FIG. 11 H shows Clone NM-26562 CAR H ⁇ L AA sequences (SEQ ID NO: 338).
- FIG. 11 I shows Clone NM-26562 CAR DNA L ⁇ H sequences (SEQ ID NO: 339).
- FIG. 11 J shows Clone NM-26562 CAR L ⁇ H AA sequences (SEQ ID NO: 340).
- FIG. 12 A shows Clone TS-26564 HC DNA sequence (SEQ ID NO: 341).
- FIG. 12 B shows Clone TS-26564 HC AA sequence (SEQ ID NO: 342).
- FIG. 12 C shows the Clone TS-26564 HC CDR sequences.
- FIG. 12 D shows the Clone TS-26564 LC DNA sequence (SEQ ID NO: 346).
- FIG. 12 E shows the Clone TS-26564 LC AA sequence (SEQ ID NO: 347).
- FIG. 12 F shows the Clone TS-26564 LC CDR sequences.
- FIG. 12 G shows the Clone TS-26564 CAR DNA H ⁇ L sequences (SEQ ID NO: 351).
- FIG. 12 H shows the Clone TS-26564 CAR H ⁇ L chain AA sequences (SEQ ID NO: 352).
- FIG. 12 I shows the Clone TS-26564 CAR DNA L ⁇ H sequences (SEQ ID NO: 353)
- FIG. 12 J shows the Clone TS-26564 CAR L ⁇ H AA sequences (SEQ ID NO: 354)
- FIG. 13 A shows the Clone RY-26568 HC DNA sequence (SEQ ID NO: 355)
- FIG. 13 B shows the Clone RY-26568 HC AA sequence (SEQ ID NO: 356).
- FIG. 13 C shows the Clone RY-26568 HC CDR sequences.
- FIG. 13 D shows the Clone RY-26568 LC DNA sequence (SEQ ID NO: 360).
- FIG. 13 E shows the Clone RY-26568 LC AA sequence (SEQ ID NO: 361).
- FIG. 13 F shows the Clone RY-26568 LC CDR AA sequences.
- FIG. 13 G shows the Clone RY-26568 CAR DNA H ⁇ L sequences (SEQ ID NO: 365)
- FIG. 13 H shows the Clone RY-26568 CAR H ⁇ L AA sequences (SEQ ID NO: 366).
- FIG. 13 I shows the Clone RY-26568 CAR DNA L ⁇ H sequences (SEQ ID NO: 367).
- FIG. 13 J shows the Clone RY-26568 CAR L ⁇ H AA sequences (SEQ ID NO: 368).
- FIG. 14 A shows the Clone PP-26575 HC DNA sequence (SEQ ID NO: 369).
- FIG. 14 B shows the Clone PP-26575 HC AA sequence (SEQ ID NO: 370).
- FIG. 14 C shows the Clone PP-26575 HC CDR AA sequences.
- FIG. 14 D shows the Clone PP-26575 LC DNA sequence (SEQ ID NO: 374).
- FIG. 14 E shows the Clone PP-26575 LC AA sequence (SEQ ID NO: 375).
- FIG. 14 F shows the Clone PP-26575 LC CDR AA sequences.
- FIG. 14 G shows the Clone PP-26575 CAR DNA H ⁇ L sequences (SEQ ID NO: 379).
- FIG. 14 H shows Clone PP-26575 CAR H ⁇ L AA sequences (SEQ ID NO: 380).
- FIG. 14 I shows Clone PP-26575 CAR DNA L ⁇ H sequence (SEQ ID NO: 381).
- FIG. 14 J shows the Clone PP-26575 CAR L ⁇ H AA sequence (SEQ ID NO: 382).
- FIG. 15 A shows the Clone RD-26576 HC DNA sequence (SEQ ID NO: 383)
- FIG. 15 B shows Clone RD-26576 HC AA sequence (SEQ ID NO: 384).
- FIG. 15 C shows the Clone RD-26576 HC CDR sequences.
- FIG. 15 D shows the Clone RD-26576 LC DNA sequence (SEQ ID NO: 388)
- FIG. 15 E shows the Clone RD-26576 LC AA sequence (SEQ ID NO: 389).
- FIG. 15 F shows the Clone RD-26576 LC CDR sequences.
- FIG. 15 G shoes the Clone RD-26576 CAR DNA H ⁇ L sequences (SEQ ID NO: 393).
- FIG. 15 H shows the Clone RD-26576 CAR H ⁇ L chain AA sequences (SEQ ID NO: 394).
- FIG. 15 I shows the Clone RD-26576 CAR DNA L ⁇ H sequences (SEQ ID NO: 395).
- FIG. 15 J shows the Clone RD-26576 CAR L ⁇ H AA sequences (SEQ ID NO: 396).
- FIG. 16 A shows the Clone RD-26578 HC DNA sequences (SEQ ID NO: 397).
- FIG. 16 B shows the Clone RD-26578 HC AA sequence (SEQ ID NO: 398).
- FIG. 16 C shows the Clone RD-26578 HC CDR AA sequences.
- FIG. 16 D shows the Clone RD-26578 LC DNA sequence (SEQ ID NO: 402).
- FIG. 16 E shows the Clone RD-26578 LC AA sequence (SEQ ID NO: 403)
- FIG. 16 F shows the Clone RD-26578 LC CDR sequences.
- FIG. 16 G shows the Clone RD-26578 CAR DNA H ⁇ L chain sequence (SEQ ID NO: 407).
- FIG. 16 H shows the Clone RD-26578 CAR H ⁇ L AA sequence (SEQ ID NO: 408).
- FIG. 16 I shows the Clone RD-26578 CAR DNA L ⁇ H sequences (SEQ ID NO: 409).
- FIG. 16 J shows the Clone RD-26578 CAR L ⁇ H AA sequence (SEQ ID NO: 410).
- FIG. 17 shows the outcome of an in vivo study examining the efficacy of clone RD-21530 in a subcutaneous RPMI-8226 mouse model. Cohorts of 10 mice each were tested for the CAR (dashed lines) and mock transduced (bolded lines) T cells.
- FIG. 18 A and FIG. 18 B show the outcome of an in vitro cytotoxicity assay using the optimized BCMA scFv variants cocultured with NCI-H929 and MM.1S cells, respectively.
- CAR T cells using these optimized scFvs were incubated overnight with luciferase labeled target cells in 3:1 and 1:1 effector to target cell ratios.
- FIG. 19 shows the pGAR vector map.
- the present invention relates to antibodies, antigen binding molecules thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, which bind BCMA, polynucleotides encoding the same, and in vitro cells comprising the same.
- CARs chimeric antigen receptors
- engineered T cell receptors which bind BCMA
- polynucleotides encoding the same, and in vitro cells comprising the same.
- the polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy, e.g., an autologous cell therapy (eACTTM), for the treatment of a patient suffering from a cancer.
- eACTTM autologous cell therapy
- the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
- administering refers to the physical introduction of an agent to a subject, using any of the various methods and delivery systems known to those skilled in the art.
- exemplary routes of administration for the formulations disclosed herein include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion.
- parenteral administration means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation.
- the formulation is administered via a non-parenteral route, e.g., orally.
- non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically.
- Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
- antibody includes, without limitation, a glycoprotein immunoglobulin which binds specifically to an antigen.
- antibody can comprise at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen binding molecule thereof.
- Each H chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
- the heavy chain constant region comprises three constant domains, CH1, CH2 and CH3.
- Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region.
- the light chain constant region is comprises one constant domain, CL.
- VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
- CDRs complementarity determining regions
- FR framework regions
- Each VH and VL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
- the constant regions of the Abs may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
- Antibodies can include, for example, monoclonal antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain-antibody heavy chain pair, intrabodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), heteroconjugate antibodies, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain Fvs (scFv), camelized antibodies, affybodies, Fab fragments, F(ab′) 2 fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (including, e.g., anti-anti-Id antibodies), minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as
- An immunoglobulin may derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM.
- IgG subclasses are also well known to those in the art and include but are not limited to human IgG1, IgG2, IgG3 and IgG4.
- “Isotype” refers to the Ab class or subclass (e.g., IgM or IgG1) that is encoded by the heavy chain constant region genes.
- antibody includes, by way of example, both naturally occurring and non-naturally occurring Abs; monoclonal and polyclonal Abs; chimeric and humanized Abs; human or nonhuman Abs; wholly synthetic Abs; and single chain Abs.
- a nonhuman Ab may be humanized by recombinant methods to reduce its immunogenicity in man.
- the term “antibody” also includes an antigen-binding fragment or an antigen binding molecule of any of the aforementioned immunoglobulins, and includes a monovalent and a divalent fragment or portion, and a single chain Ab.
- an “antigen binding molecule,” “antigen binding portion,” or “antibody fragment” refers to any molecule that comprises the antigen binding parts (e.g., CDRs) of the antibody from which the molecule is derived.
- An antigen binding molecule can include the antigenic complementarity determining regions (CDRs).
- Examples of antibody fragments include, but are not limited to, Fab, Fab′, F(ab′)2, and Fv fragments, dAb, linear antibodies, scFv antibodies, and multispecific antibodies formed from antigen binding molecules.
- Peptibodies i.e., Fc fusion molecules comprising peptide binding domains are another example of suitable antigen binding molecules.
- the antigen binding molecule binds to an antigen on a tumor cell. In some embodiments, the antigen binding molecule binds to an antigen on a cell involved in a hyperproliferative disease or to a viral or bacterial antigen. In certain embodiments, the antigen binding molecule binds to BCMA. In further embodiments, the antigen binding molecule is an antibody of fragment thereof, including one or more of the complementarity determining regions (CDRs) thereof. In further embodiments, the antigen binding molecule is a single chain variable fragment (scFv). In some embodiments, the antigen binding molecule comprises or consists of avimers.
- variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-terminal 110 to 120 amino acids in the mature heavy chain and about 90 to 115 amino acids in the mature light chain, which differ extensively in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen.
- CDRs complementarity determining regions
- FR framework regions
- variable region is a human variable region.
- variable region comprises rodent or murine CDRs and human framework regions (FRs).
- FRs human framework regions
- the variable region is a primate (e.g., non-human primate) variable region.
- the variable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FRs).
- VL and “VL domain” are used interchangeably to refer to the light chain variable region of an antibody or an antigen-binding fragment thereof.
- VH and “VH domain” are used interchangeably to refer to the heavy chain variable region of an antibody or an antigen-binding fragment thereof.
- a number of definitions of the CDRs are commonly in use: Kabat numbering, Chothia numbering, AbM numbering, or contact numbering.
- the AbM definition is a compromise between the two used by Oxford Molecular's AbM antibody modelling software.
- the contact definition is based on an analysis of the available complex crystal structures.
- Kabat numbering and like terms are recognized in the art and refer to a system of numbering amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding molecule thereof.
- the CDRs of an antibody can be determined according to the Kabat numbering system (see, e.g., Kabat EA & Wu TT (1971) Ann NY Acad Sci 190: 382-391 and Kabat E A et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242).
- CDRs within an antibody heavy chain molecule are typically present at amino acid positions 31 to 35, which optionally can include one or two additional amino acids, following 35 (referred to in the Kabat numbering scheme as 35A and 35B) (CDR1), amino acid positions 50 to 65 (CDR2), and amino acid positions 95 to 102 (CDR3).
- CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3).
- the CDRs of the antibodies described herein have been determined according to the Kabat numbering scheme.
- the CDRs of an antibody can be determined according to the Chothia numbering scheme, which refers to the location of immunoglobulin structural loops (see, e.g., Chothia C & Lesk AM, (1987), J Mol Biol 196: 901-917; Al-Lazikani B et al., (1997) J Mol Biol 273: 927-948; Chothia C et al., (1992) J Mol Biol 227: 799-817; Tramontano A et al., (1990) J Mol Biol 215(1): 175-82; and U.S. Pat. No. 7,709,226).
- Chothia numbering scheme refers to the location of immunoglobulin structural loops
- the Chothia CDR-H1 loop is present at heavy chain amino acids 26 to 32, 33, or 34
- the Chothia CDR-H2 loop is present at heavy chain amino acids 52 to 56
- the Chothia CDR-H3 loop is present at heavy chain amino acids 95 to 102
- the Chothia CDR-L1 loop is present at light chain amino acids 24 to 34
- the Chothia CDR-L2 loop is present at light chain amino acids 50 to 56
- the Chothia CDR-L3 loop is present at light chain amino acids 89 to 97.
- the end of the Chothia CDR-HI loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34).
- the CDRs of the antibodies described herein have been determined according to the Chothia numbering scheme.
- constant region and “constant domain” are interchangeable and have a meaning common in the art.
- the constant region is an antibody portion, e.g., a carboxyl terminal portion of a light and/or heavy chain which is not directly involved in binding of an antibody to antigen but which can exhibit various effector functions, such as interaction with the Fc receptor.
- the constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence relative to an immunoglobulin variable domain.
- the term “heavy chain” when used in reference to an antibody can refer to any distinct type, e.g., alpha ( ⁇ ), delta ( ⁇ ), epsilon ( ⁇ ), gamma ( ⁇ ) and mu ( ⁇ ), based on the amino acid sequence of the constant domain, which give rise to IgA, IgD, IgE, IgG and IgM classes of antibodies, respectively, including subclasses of IgG, e.g., IgG 1 , IgG 2 , IgG 3 and IgG 4 .
- the term “light chain” when used in reference to an antibody can refer to any distinct type, e.g., kappa ( ⁇ ) or lambda ( ⁇ ) based on the amino acid sequence of the constant domains. Light chain amino acid sequences are well known in the art. In specific embodiments, the light chain is a human light chain.
- Binding affinity generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
- the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K D ). Affinity can be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (K D ), and equilibrium association constant (K A ).
- K D is calculated from the quotient of k off /k on
- K A is calculated from the quotient of k on /k off
- k on refers to the association rate constant of, e.g., an antibody to an antigen
- k off refers to the dissociation of, e.g., an antibody to an antigen.
- the k on and k off can be determined by techniques known to one of ordinary skill in the art, such as BIAcore® or KinExA.
- a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
- Families of amino acid residues having side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
- an “epitope” is a term in the art and refers to a localized region of an antigen to which an antibody can specifically bind.
- An epitope can be, for example, contiguous amino acids of a polypeptide (linear or contiguous epitope) or an epitope can, for example, come together from two or more non-contiguous regions of a polypeptide or polypeptides (conformational, non-linear, discontinuous, or non-contiguous epitope).
- the epitope to which an antibody binds can be determined by, e.g., NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g., site-directed mutagenesis mapping).
- NMR spectroscopy e.g., NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g., site-directed mutagenesis mapping).
- crystallization may be accomplished using any of the known methods in the art (e.g., Giegé R et al., (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189: 1-23; Chayen N E (1997) Structure 5: 1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303).
- Antibody:antigen crystals may be studied using well known X-ray diffraction techniques and may be refined using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see e.g.
- an antigen binding molecule, an antibody, or an antigen binding molecule thereof “cross competes” with a reference antibody or an antigen binding molecule thereof if the interaction between an antigen and the first binding molecule, an antibody, or an antigen binding molecule thereof blocks, limits, inhibits, or otherwise reduces the ability of the reference binding molecule, reference antibody, or an antigen binding molecule thereof to interact with the antigen.
- Cross competition can be complete, e.g., binding of the binding molecule to the antigen completely blocks the ability of the reference binding molecule to bind the antigen, or it can be partial, e.g., binding of the binding molecule to the antigen reduces the ability of the reference binding molecule to bind the antigen.
- an antigen binding molecule that cross competes with a reference antigen binding molecule binds the same or an overlapping epitope as the reference antigen binding molecule. In other embodiments, the antigen binding molecule that cross competes with a reference antigen binding molecule binds a different epitope as the reference antigen binding molecule.
- RIA solid phase direct or indirect radioimmunoassay
- EIA solid phase direct or indirect enzyme immunoassay
- sandwich competition assay Stahli et al., 1983, Methods in Enzymology 9:242-253
- solid phase direct biotin-avidin EIA Karlin et al., 1986, J. Immunol.
- solid phase direct labeled assay solid phase direct labeled sandwich assay (Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using 1-125 label (Morel et al., 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (Cheung, et al., 1990, Virology 176:546-552); and direct labeled RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82).
- the terms “immunospecifically binds,” “immunospecifically recognizes,” “specifically binds,” and “specifically recognizes” are analogous terms in the context of antibodies and refer to molecules that bind to an antigen (e.g., epitope or immune complex) as such binding is understood by one skilled in the art.
- a molecule that specifically binds to an antigen may bind to other peptides or polypeptides, generally with lower affinity as determined by, e.g., immunoassays, BIAcore®, KinExA 3000 instrument (Sapidyne Instruments, Boise, Id.), or other assays known in the art.
- molecules that specifically bind to an antigen bind to the antigen with a K A that is at least 2 logs, 2.5 logs, 3 logs, 4 logs or greater than the K A when the molecules bind to another antigen.
- molecules that specifically bind to an antigen bind with a dissociation constant (K d ) of about 1 ⁇ 10 ⁇ 7 M.
- K d dissociation constant
- the antigen binding molecule specifically binds an antigen with “high affinity” when the K d is about 1 ⁇ 10 ⁇ 9 M to about 5 ⁇ 10 ⁇ 9 M.
- the antigen binding molecule specifically binds an antigen with “very high affinity” when the K d is 1 ⁇ 10 ⁇ 10 M to about 5 ⁇ 10 ⁇ 10 M.
- the antigen binding molecule has a K d of 10 ⁇ 9 M.
- the off-rate is less than about 1 ⁇ 10 ⁇ 5 .
- the antigen binding molecule binds human BCMA with a K d of between about 1 ⁇ 10 ⁇ 7 M and about 1 ⁇ 10 ⁇ 13 M. In yet another embodiment, the antigen binding molecule binds human BCMA with a K d of about 1 ⁇ 10 ⁇ 10 M to about 5 ⁇ 10 ⁇ 10 M.
- molecules that specifically bind to an antigen do not cross react with other proteins under similar binding conditions. In another specific embodiment, molecules that specifically bind to an antigen do not cross react with other non-BCMA proteins. In a specific embodiment, provided herein is an antibody or fragment thereof that binds to BCMA with higher affinity than to another unrelated antigen.
- an antibody or fragment thereof that binds to BCMA (e.g., human BCMA) with a 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher affinity than to another, unrelated antigen as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay.
- BCMA e.g., human BCMA
- a radioimmunoassay e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay.
- the extent of binding of an anti-BCMA antibody or antigen-binding fragment thereof described herein to an unrelated, non-BCMA protein is less than 10%, 15%, or 20% of the binding of the antibody to BCMA protein as measured by, e.g., a radioimmunoassay.
- provided herein is an antibody or fragment thereof that binds to human BCMA with higher affinity than to another species of BCMA.
- an antibody or fragment thereof described herein, which binds to human BCMA will bind to another species of BCMA protein with less than 10%, 15%, or 20% of the binding of the antibody or fragment thereof to the human BCMA protein as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay.
- an “antigen” refers to any molecule that provokes an immune response or is capable of being bound by an antibody or an antigen binding molecule.
- the immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both.
- An antigen can be endogenously expressed, i.e. expressed by genomic DNA, or can be recombinantly expressed.
- An antigen can be specific to a certain tissue, such as a cancer cell, or it can be broadly expressed.
- fragments of larger molecules can act as antigens.
- antigens are tumor antigens.
- the antigen is BCMA.
- neutralizing refers to an antigen binding molecule, scFv, antibody, or a fragment thereof that binds to a ligand and prevents or reduces the biological effect of that ligand.
- the antigen binding molecule, scFv, antibody, or a fragment thereof directly blocking a binding site on the ligand or otherwise alters the ligand's ability to bind through indirect means (such as structural or energetic alterations in the ligand).
- the antigen binding molecule, scFv, antibody, or a fragment thereof prevents the protein to which it is bound from performing a biological function.
- BCMA refers to B cell maturation antigen, which can include, but is not limited to, native BCMA, an isoform of BCMA, or an interspecies BCMA homolog of BCMA.
- BCMA also known as TNFRSF17, CD269, and TNFRSF13A
- TNF tumor necrosis factor
- BCMA is expressed on the surface of multiple myeloma cells, while highly restricted to plasma cells and a subset of mature B cells in healthy tissue ( FIG. 2 A and FIG. 2 C ).
- the amino acid sequence of human BCMA (hBCMA) is provided in NCBI Accession Q02223.2 (GI:313104029) (SEQ ID NO: 163).
- BCMA includes human BCMA and non-human BCMA homologs, as well as variants, fragments, or post-transnationally modified forms thereof, including, but not limited to, N- and O-linked glycosylated forms of BCMA.
- BCMA proteins may further include fragments comprising all or a portion of the extracellular domain of BCMA (e.g., all or a portion of amino acids 1-54 of hBCMA).
- autologous refers to any material derived from the same individual to which it is later to be re-introduced.
- eACTTM engineered autologous cell therapy
- allogeneic refers to any material derived from one individual which is then introduced to another individual of the same species, e.g., allogeneic T cell transplantation.
- the vector is a retroviral vector, a DNA vector, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector, a lentiviral vector, or any combination thereof.
- a “cancer” refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and may also metastasize to distant parts of the body through the lymphatic system or bloodstream.
- a “cancer” or “cancer tissue” can include a tumor. Examples of cancers that can be treated by the methods of the present invention include, but are not limited to, cancers of the immune system including lymphoma, leukemia, myeloma, and other leukocyte malignancies.
- the methods of the present invention can be used to reduce the tumor size of a tumor derived from, for example, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, multiple myeloma, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine
- NHL non
- the cancer is multiple myeloma.
- the particular cancer can be responsive to chemo- or radiation therapy or the cancer can be refractory.
- a refractor cancer refers to a cancer that is not amendable to surgical intervention and the cancer is either initially unresponsive to chemo- or radiation therapy or the cancer becomes unresponsive over time.
- an “anti-tumor effect” as used herein refers to a biological effect that can present as a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in tumor cell proliferation, a decrease in the number of metastases, an increase in overall or progression-free survival, an increase in life expectancy, or amelioration of various physiological symptoms associated with the tumor.
- An anti-tumor effect can also refer to the prevention of the occurrence of a tumor, e.g., a vaccine.
- a “cytokine,” as used herein, refers to a non-antibody protein that is released by one cell in response to contact with a specific antigen, wherein the cytokine interacts with a second cell to mediate a response in the second cell.
- a cytokine can be endogenously expressed by a cell or administered to a subject. Cytokines may be released by immune cells, including macrophages, B cells, T cells, and mast cells to propagate an immune response. Cytokines can induce various responses in the recipient cell. Cytokines can include homeostatic cytokines, chemokines, pro-inflammatory cytokines, effectors, and acute-phase proteins.
- homeostatic cytokines including interleukin (IL) 7 and IL-15, promote immune cell survival and proliferation, and pro-inflammatory cytokines can promote an inflammatory response.
- homeostatic cytokines include, but are not limited to, IL-2, IL-4, IL-5, IL-7, IL-10, IL-12p40, IL-12p70, IL-15, and interferon (IFN) gamma.
- IFN interferon
- pro-inflammatory cytokines include, but are not limited to, IL-1a, IL-1b, IL-6, IL-13, IL-17a, tumor necrosis factor (TNF)-alpha, TNF-beta, fibroblast growth factor (FGF) 2, granulocyte macrophage colony-stimulating factor (GM-CSF), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular adhesion molecule 1 (sVCAM-1), vascular endothelial growth factor (VEGF), VEGF-C, VEGF-D, and placental growth factor (PLGF).
- TNF tumor necrosis factor
- FGF fibroblast growth factor
- GM-CSF granulocyte macrophage colony-stimulating factor
- sICAM-1 soluble intercellular adhesion molecule 1
- sVCAM-1 soluble vascular adhesion molecule 1
- VEGF vascular endothelial growth factor
- VEGF-C vascular endot
- effectors include, but are not limited to, granzyme A, granzyme B, soluble Fas ligand (sFasL), and perforin.
- acute phase-proteins include, but are not limited to, C-reactive protein (CRP) and serum amyloid A (SAA).
- “Chemokines” are a type of cytokine that mediates cell chemotaxis, or directional movement. Examples of chemokines include, but are not limited to, IL-8, IL-16, eotaxin, eotaxin-3, macrophage-derived chemokine (MDC or CCL22), monocyte chemotactic protein 1 (MCP-1 or CCL2), MCP-4, macrophage inflammatory protein 1 ⁇ (MIP-1 ⁇ , MIP-1 ⁇ ), MIP-1 ⁇ (MIP-1b), gamma-induced protein 10 (IP-10), and thymus and activation regulated chemokine (TARC or CCL17).
- a “therapeutically effective amount,” “effective dose,” “effective amount,” or “therapeutically effective dosage” of a therapeutic agent, e.g., engineered CAR T cells, is any amount that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction.
- the ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
- lymphocyte as used herein includes natural killer (NK) cells, T cells, or B cells.
- NK cells are a type of cytotoxic (cell toxic) lymphocyte that represent a major component of the inherent immune system. NK cells reject tumors and cells infected by viruses. It works through the process of apoptosis or programmed cell death. They were termed “natural killers” because they do not require activation in order to kill cells.
- T-cells play a major role in cell-mediated-immunity (no antibody involvement). Its T-cell receptors (TCR) differentiate themselves from other lymphocyte types. The thymus, a specialized organ of the immune system, is primarily responsible for the T cell's maturation.
- T-cells There are six types of T-cells, namely: Helper T-cells (e.g., CD4+ cells), Cytotoxic T-cells (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CD8+ T-cells or killer T cell), Memory T-cells ((i) stem memory T SCM cells, like naive cells, are CD45RO ⁇ , CCR7+, CD45RA+, CD62L+(L-selectin), CD27+, CD28+ and IL-7R ⁇ +, but they also express large amounts of CD95, IL-2R ⁇ , CXCR3, and LFA-1, and show numerous functional attributes distinctive of memory cells); (ii) central memory T CM cells express L-selectin and the CCR7, they secrete IL-2, but not IFN ⁇ or IL-4, and (iii) effector memory TEM cells, however, do not express L-selectin or CCR7 but produce effect
- B-cells play a principal role in humoral immunity (with antibody involvement). It makes antibodies and antigens and performs the role of antigen-presenting cells (APCs) and turns into memory B-cells after activation by antigen interaction. In mammals, immature B-cells are formed in the bone marrow, where its name is derived from.
- the term “genetically engineered” or “engineered” refers to a method of modifying the genome of a cell, including, but not limited to, deleting a coding or non-coding region or a portion thereof or inserting a coding region or a portion thereof.
- the cell that is modified is a lymphocyte, e.g., a T cell, which can either be obtained from a patient or a donor.
- the cell can be modified to express an exogenous construct, such as, e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR), which is incorporated into the cell's genome.
- CAR chimeric antigen receptor
- TCR T cell receptor
- an “immune response” refers to the action of a cell of the immune system (for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils) and soluble macromolecules produced by any of these cells or the liver (including Abs, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and/or elimination from a vertebrate's body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues.
- a cell of the immune system for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils
- soluble macromolecules produced by any of these cells or the liver including Abs, cytokines, and complement
- immunotherapy refers to the treatment of a subject afflicted with, or at risk of contracting or suffering a recurrence of, a disease by a method comprising inducing, enhancing, suppressing or otherwise modifying an immune response.
- immunotherapy include, but are not limited to, T cell therapies.
- T cell therapy can include adoptive T cell therapy, tumor-infiltrating lymphocyte (TIL) immunotherapy, autologous cell therapy, engineered autologous cell therapy (eACT), and allogeneic T cell transplantation.
- TIL tumor-infiltrating lymphocyte
- eACT engineered autologous cell therapy
- T cell therapies are described in U.S. Patent Publication Nos. 2014/0154228 and 2002/0006409, U.S. Pat. No. 5,728,388, and International Publication No. WO 2008/081035.
- T cells of the immunotherapy can come from any source known in the art.
- T cells can be differentiated in vitro from a hematopoietic stem cell population, or T cells can be obtained from a subject.
- T cells can be obtained from, e.g., peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors.
- PBMCs peripheral blood mononuclear cells
- the T cells can be derived from one or more T cell lines available in the art.
- T cells can also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLLTM separation and/or apheresis. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety.
- T cells can be engineered to express, for example, chimeric antigen receptors (CAR) or T cell receptor (TCR).
- CAR positive (+) T cells are engineered to express an extracellular single chain variable fragment (scFv) with specificity for a particular tumor antigen linked to an intracellular signaling part comprising at least one costimulatory domain and at least one activating domain.
- the costimulatory domain can be derived from, e.g., CD28, and the activating domain can be derived from, e.g., CD3-zeta.
- the CAR is designed to have two, three, four, or more costimulatory domains.
- the CAR scFv can be designed to target, for example, CD19, which is a transmembrane protein expressed by cells in the B cell lineage, including all normal B cells and B cell malignances, including but not limited to NHL, CLL, and non-T cell ALL.
- the CAR is engineered such that the costimulatory domain is expressed as a separate polypeptide chain.
- Example CAR T cell therapies and constructs are described in U.S. Patent Publication Nos. 2013/0287748, 2014/0227237, 2014/0099309, and 2014/0050708, and these references are incorporated by reference in their entirety.
- a “patient” as used herein includes any human who is afflicted with a cancer (e.g., a lymphoma or a leukemia).
- a cancer e.g., a lymphoma or a leukemia.
- subject and patient are used interchangeably herein.
- an in vitro cell refers to any cell which is cultured ex vivo.
- an in vitro cell can include a T cell.
- peptide refers to a compound comprised of amino acid residues covalently linked by peptide bonds.
- a protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence.
- Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds.
- the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types.
- Polypeptides include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others.
- the polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
- polypeptides and/or proteins have deletions from, additions to, and/or substitutions of one or more amino acid of antigen-binding protein, and in some embodiments preferably no more than 8 amino acid substitutions therein.
- Useful polypeptide fragments may include immunologically functional fragments of antigen binding molecules, including not limited to one or more CDR regions, variable domains of a heavy and/or light chain, a portion of other portions of an antibody chain, and the like. Additionally, polypeptide fragments of activating and/or costimulatory molecules and the like are within the scope of the invention.
- activation refers to a primary response induced by binding of an activating molecule with its cognate ligand, wherein the binding mediates a signal transduction event.
- An “activating molecule” or “stimulating molecule” refers to a molecule on a T cell, e.g., the TCR/CD3 complex that specifically binds with a cognate stimulatory ligand present on an antigen present cell. Suitable activating molecules are described herein.
- a “stimulatory ligand” is a ligand that when present on an antigen presenting cell (e.g., an aAPC, a dendritic cell, a B-cell, and the like) can specifically bind with a stimulatory molecule on a T cell, thereby mediating a primary response by the T cell, including, but not limited to, activation, initiation of an immune response, proliferation, and the like.
- Stimulatory ligands include, but are not limited to, an MHC Class I molecule loaded with a peptide, an anti-CD3 antibody, a superagonist anti-CD28 antibody, and a superagonist anti-CD2 antibody.
- costimulatory signal refers to a signal, which in combination with a primary signal, such as TCR/CD3 ligation, leads to a T cell response, such as, but not limited to, proliferation and/or upregulation or down regulation of key molecules.
- a “costimulatory ligand” as used herein includes a molecule on an antigen presenting cell that specifically binds a cognate co-stimulatory molecule on a T cell. Binding of the costimulatory ligand provides a signal that mediates a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. A costimulatory ligand induces a signal that is in addition to the primary signal provided by a stimulatory molecule, for instance, by binding of a T cell receptor (TCR)/CD3 complex with a major histocompatibility complex (MHC) molecule loaded with peptide.
- TCR T cell receptor
- MHC major histocompatibility complex
- a co-stimulatory ligand can include, but is not limited to, CD7, B7-1 (CD80), B7-2 (CD86), programmed death (PD) L1, PD-L2, 4-1BB ligand, OX40 ligand, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30 ligand, CD40, CD70, CD83, human leukocyte antigen G (HLA-G), MHC class I chain-related protein A (MICA), MHC class I chain-related protein B (MICB), herpes virus entry mediator (HVEM), lymphotoxin beta receptor, 3/TR6, immunoglobulin-like transcript (ILT) 3, ILT4, an agonist or antibody that binds Toll ligand receptor and a ligand that specifically binds with B7-H3.
- a co-stimulatory ligand includes, without limitation, an antibody that specifically binds with a co-stimulatory molecule present on a T cell, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, tumor necrosis factor superfamily member 14 (TNFSF14 or LIGHT), natural killer cell receptor C (NKG2C), B7-H3, and a ligand that specifically binds with CD83.
- an antibody that specifically binds with a co-stimulatory molecule present on a T cell such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, tumor necrosis factor superfamily member 14 (TNFSF14 or LIGHT), natural killer cell receptor C (NKG2C), B7-H3,
- a “costimulatory molecule” is a cognate binding partner on a T cell that specifically binds with a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation.
- Costimulatory molecules include, but are not limited to, CD28, CD28T, OX40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), D
- reducing and “decreasing” are used interchangeably herein and indicate any change that is less than the original. “Reducing” and “decreasing” are relative terms, requiring a comparison between pre- and post-measurements. “Reducing” and “decreasing” include complete depletions.
- Treatment or “treating” of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease.
- treatment or “treating” includes a partial remission. In another embodiment, “treatment” or “treating” includes a complete remission.
- the sequences being compared are typically aligned in a way that gives the largest match between the sequences.
- One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.).
- GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined.
- the sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm).
- a standard comparison matrix (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.
- the terms “about” or “comprising essentially of” refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system.
- “about” or “comprising essentially of” can mean within 1 or more than 1 standard deviation per the practice in the art.
- “about” or “comprising essentially of” can mean a range of up to 10% (i.e., ⁇ 10%).
- about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%).
- the terms can mean up to an order of magnitude or up to 5-fold of a value.
- the meaning of “about” or “comprising essentially of” should be assumed to be within an acceptable error range for that particular value or composition.
- any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
- the present invention is directed to a polynucleotide encoding an anti-BCMA antibody or antigen binding molecule thereof which cross competes with one or more antibodies described herein (i.e., one or more described in FIG. 1 ) or an antibody or antigen binding molecule thereof encoded by the polynucleotide.
- the invention is directed to a polynucleotide encoding an anti-BCMA antibody or antigen binding molecule thereof which binds to the same epitope as one or more antibodies described in FIG. 1 or an antibody or antigen binding molecule thereof encoded by the polynucleotide.
- the polynucleotide encodes an antibody or antigen binding molecule thereof that specifically binds to BCMA, wherein the antibody or binding molecule comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2 is not present or G; X 3 is not present or S; X 4 is F, G, I, or Y; X 5 is S or T; X 6 is F or S; and X 7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17 (SEQ ID NO: 146), wherein:
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11 (SEQ ID NO: 263), wherein: X 1 is not present or G; X 2 is not present or S X 3 is F, G, I, or Y; X 4 is S or T; X 5 is F or S; X 6 is S or T; X 9 is A, G, S, or Y; X 10 is I, M, or W; and X 11 is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17 (SEQ ID NO: 148), wherein X 1 is K or R; X 2 is A or S; X 5 is G or S; X 6 is I, L, or V; X 7 is L or S; X 8 is not present or H or Y; X 9 is not present or S; X 10 is not present or N or S; X 11 is not present or G or N; X 12 is not present or N; X 13 is not present or K or Y; X 14 is N, R, or S; X 15 is N, W
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2 is not present or G; X 3 is not present or S; X 4 is F, G, I, or Y; X 5 is S or T; X 6 is F or S; and X 7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17 (SEQ ID NO: 146), wherein:
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11 (SEQ ID NO: 263), wherein: X 1 is not present or G; X 2 is not present or S X 3 is F, G, I, or Y; X 4 is S or T; X 5 is F or S; X 6 is S or T; X 9 is A, G, S, or Y; X 10 is I, M, or W; and X 11 is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH and a VL, wherein: (i) the VH comprises: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2 is not present or G; X 3 is not present or S; X 4 is F, G, I, or Y; X 5 is S or T; X 6 is F or S; and X 7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH and a VL, wherein: (i) the VH comprises: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11 (SEQ ID NO: 263), wherein: X 1 is not present or G; X 2 is not present or S X 3 is F, G, I, or Y; X 4 is S or T; X 5 is F or S; X 6 is S or T; X 9 is A, G, S, or Y; X 10 is I, M, or W; and X 11 is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2 is not present or G; X 3 is not present or S; X 4 is F, G, I, or Y; X 5 is S or T; X 6 is F or S; and X 7 is S or T.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 TFSSY (SEQ ID NO: 151), wherein: X 2 is F or G.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 SSY (SEQ ID NO: 152), wherein: X 2 is not present or G; X 3 is not present or S; X 4 is F, G, or I; X 5 is S or T; and X 6 is F or S.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11 (SEQ ID NO: 263), wherein: X 1 is not present or G; X 2 is not present or S X 3 is F, G, I, or Y; X 4 is S or T; X 5 is F or S; X 6 is S or T; X 9 is A, G, S, or Y; X 10 is I, M, or W; and X 11 is G, H, N, or S.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 TFX 4 SYX 7 X 8 X 9 (SEQ ID NO: 265), wherein: X 1 is F, G, or Y; X 4 is S or T; X 7 is A, G, S, or Y; X 8 is I or M; and X 9 is H, N, or S.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence FTFSSYX 7 MX 9 (SEQ ID NO: 266), wherein: X 7 is A, G, or S; and X 9 is H, N, or S.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17 (SEQ ID NO: 146), wherein: X 1 is A, G, I, S, T, or V; X 3 is I, N, or S; X 4 is G, P, S, or Y; X 5 is D, G, I, or S; X 6 is F, G, or S; X 7 is G or S; X 8 is not present or N, S, or T; X 9 is A, I, K, or T; X 10 is N, S, or Y; X 12 is A or N; X 13 is D, P, or Q; X 14 is K or S;
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YAX 13 X 14 X 15 X 16 G (SEQ ID NO: 153), wherein: X 1 is A, G, I, T, or V; X 3 is I, N, or S; X 4 is G, P, S, or Y; X 5 is D, G, I, or S; X 6 is F, G, or S; X 7 is G or S; X 8 is N, S, or T; X 9 is A, I, K, or T; X 10 is N, S, or Y; X 13 is D or Q; X 14 is K or S; X 15 is F or V; and X 16 is K or Q.
- X 1 is A,
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 ISX 4 X 5 X 6 X 7 X 8 X 9 YYADSVKG (SEQ ID NO: 154), wherein: X 1 is A, T, or V; X 4 is G, S, or Y; X 5 is D or S; X 6 is G or S; X 7 is G or S; X 8 is N, S, or T; and X 9 is I, K, or T.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 PX 5 X 6 GX 8 X 9 X 10 YAQKFQG (SEQ ID NO: 155), wherein: X 1 is G or I; X 3 is I or N; X 5 is G or I; X 6 is F or G; X 8 is S or T; X 9 is A or T; and X 10 is N or S.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19 (SEQ ID NO: 147) and wherein: X 1 is A or V; X 2 is K or R; X 3 is not present or D, G, or T; X 4 is not present or A, D, G, P, R, or S; X 5 is not present or E, F, G, L, Q, or T; X 6 is not present or E, M, Q, W, or Y; X 7 is not present or A, E, L, or S; X 8 is not present or G, P, S
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence ARX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19 (SEQ ID NO: 156) and wherein: X 3 is not present or D, G, or T; X 4 is not present or A, D, G, P, R, or S; X 5 is not present or E, F, G, Q, or T; X 6 is not present or E, M, W, or Y; X 7 is not present or A, L, or S; X 8 is not present or G, S, or T; X 9 is not present or G or S; X 10 is not present or I, L, or P;
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 DX 21 (SEQ ID NO: 264) and wherein: X 1 is A or V; X 2 is K or R; X 3 is not present or D, G, or T; X 4 is not present or D, G, or P; X 5 is not present or F, L, or T; X 6 is not present or P, Q, R, W, or Y; X 7 is not present or E, G, L, or S; X 8 is not present or A, G, P, S, or Y
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence ARX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 DX 21 (SEQ ID NO: 267), wherein: X 3 is not present or D or T; X 4 is not present or D or G; X 5 is not present or F or T; X 6 is not present or P, R, W, or Y; X 7 is not present or E, G, L, or S; X 8 is not present or A, G, S, or Y; X 9 is A, E, G, Q, or S; X 10 is E, L, M, P, S, or T; X
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises one, two, or all three of any of the VH CDRs listed above or described in FIG. 1 A or FIG. 1 B .
- the antibody or antigen binding molecule comprises the VH framework regions (FRs) described herein.
- the antibody or antigen binding molecule comprises the VH FRs of an antibody set forth in FIG. 1 A or FIG. 1 B (e.g., one, two, three, or four of the FRs in one sequence of FIG. 1 A ).
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17 (SEQ ID NO: 148), wherein: X 1 is K or R; X 2 is A or S; X 5 is G or S; X 6 is I, L, or V; X 7 is L or S; X 8 is not present or H or Y; X 9 is not present or S; X 10 is not present or N or S; X 11 is not present or G or N; X 12 is not present or N; X 13 is not present or K or Y; X 14 is N, R, or S; X 15 is N, W, or Y; and X 17 is A or D.
- X 1 is K or
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence RASQX 5 X 6 SX 8 X 9 LA (SEQ ID NO: 157), wherein: X 5 is G or S; X 6 is I or V; X 8 is R or S; and X 9 is N, W, or Y.
- BCMA e.g., hBCMA
- VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence RASQX 5 X 6 SX 8 X 9 LA (SEQ ID NO: 157), wherein: X 5 is G or S; X 6 is I or V; X 8 is R or S; and X 9 is N, W, or Y.
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 SSQSX 6 LX 8 SX 10 X 11 X 12 X 13 NYLX 17 (SEQ ID NO: 158), wherein: X 1 is K or R; X 6 is L or V; X 8 is H or Y; X 10 is N or S; X 11 is G or N; X 12 is not present or N; X 13 is K or Y; and X 17 is A or D.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7 (SEQ ID NO: 149), wherein: X 1 is D, G, L, S, or W; X 2 is A or G; X 4 is N, S, or T; X 5 is L or R; X 6 is A, E, or Q; and X 7 is S or T.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 ASX 4 RAT (SEQ ID NO: 159), wherein: X 1 is D, G, or S; and X 4 is N or T.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 ASX 4 X 5 X 6 X 7 (SEQ ID NO: 160), wherein: X 1 is D, G, or S; X 4 is N, S, or T; X 5 is L or R; X 6 is A or Q; and X 7 is S or T.
- VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 ASX 4 X 5 X 6 X 7 (SEQ ID NO: 160), wherein: X 1 is D, G, or S; X 4 is N, S, or T; X 5 is L or R; X 6 is A or Q; and X 7 is S or T.
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 RX 6 S (SEQ ID NO: 161), wherein X 1 is L or W; X 2 is A or G; X 4 is N or T; and X 6 is A or E.
- BCMA e.g., hBCMA
- VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 RX 6 S (SEQ ID NO: 161), wherein X 1 is L or W; X 2 is A or G; X 4 is N or T; and X 6 is A or E.
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein: X 1 is M or Q; X 3 is F, G, H, I, R, or Y; X 4 is A, F, H, I, L, or Y; X 5 is A, G, H, S, T, V, or Y; X 6 is F, L, T, W, or Y; and X 8 is not present or F, L, P, or W.
- BCMA e.g., hBCMA
- the antibody or antigen binding molecule which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QQX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 162), wherein: X 3 is H, I, R, or Y; X 4 is A, F, H, I, or Y; X 5 is A, S, T, V, or Y; X 6 is F, W, or Y; and X 8 is not present or F, L, P, or W.
- BCMA e.g., hBCMA
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises one, two, or all three of any of the VL CDRs listed above or described in FIG. 2 .
- the antibody or antigen binding molecule comprises the VL framework regions (FRs) described herein.
- the antibody or antigen binding molecule comprises the VL FRs of an antibody set forth in FIG. 4 (e.g., one, two, three, or four of the FRs in one row of FIG. 4 ).
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH CDR1, wherein the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9-16.
- the antibody or antigen binding molecule comprises a VH CDR1, wherein the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 215-222.
- the antibody or antigen binding molecule comprises a VH CDR2, wherein the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25-32.
- the antibody or antigen binding molecule comprises a VH CDR2, wherein the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 231-238. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR3, wherein the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 41-48. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR3, wherein the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 247-254.
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH CDR1, a VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprise the amino acid sequence of the VH CDR1, VH CDR2, and VH CDR3 of an antibody in FIG. 1 A or FIG. 1 B , respectively.
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL CDR1, wherein the VL CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 81-88.
- the antibody or antigen binding molecule comprises a VL CDR2, wherein the VL CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 97-104.
- the antibody or antigen binding molecule comprises a VL CDR3, wherein the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 113-120.
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL CDR1, a VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprise the amino acid sequence of the VL CDR1, VL CDR2, and VL CDR3 of an antibody in FIG. 1 C , respectively.
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH framework region 1 (FR1), wherein the VH FR1 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 1-8 and 207-214.
- FR1 VH framework region 1
- the antibody or antigen binding molecule comprises a VH FR2, wherein the VH FR2 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 17-24 and 223-23.
- the antibody or antigen binding molecule comprises a VH FR3, wherein the VH FR3 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 33-40 and 239-246.
- the antibody or antigen binding molecule comprises a VH FR4, wherein the VH FR4 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 49-56 and 255-262.
- the antibody or antigen binding molecule or a fragment thereof comprises a VL FR1, wherein the VL FR1 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 73-80.
- the antibody or antigen binding molecule or a fragment thereof comprises a VL FR2, wherein the VL FR2 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 89-96.
- the antibody or antigen binding molecule or a fragment thereof comprises a VL FR3, wherein the VL FR3 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 105-112.
- the antibody or antigen binding molecule or a fragment thereof comprises a VL FR4, wherein the VL FR4 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 121-128.
- the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises any one, two, and/or three VH CDR sequences disclosed herein.
- the antibody or antigen binding molecule comprises a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of any VH CDR1, VH CDR2, and VH CDR3 disclosed herein, respectively.
- the antibody or antigen binding molecule comprises any one, two, and/or three VL CDR sequences disclosed herein.
- the antibody or antigen binding molecule comprises a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of any VL CDR1, VL CDR2, and VL CDR3 disclosed herein, respectively.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 9; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 25; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 41; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 10; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 42; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 43; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 28; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 44; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 13; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 45; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 14; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 46; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 47; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 16; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 32; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 48; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 215; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 231; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 247; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 216; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 232; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 248; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 217; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 233; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 249; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:218; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 234; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 250; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 219; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 235; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 251; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 220; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 236; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 252; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 221; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 237; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 253; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119.
- the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 222; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 238; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 254; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120.
- the antibody or antigen binding molecule comprises a heavy chain variable region sequence comprising an amino acid sequence of FIG. 1 A or FIG. 1 B . In some embodiments, the antibody or antigen binding molecule comprises a heavy chain variable region sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72. In some embodiments, the antibody or antigen binding molecule comprises a light chain variable region sequence comprising an amino acid sequence selected from FIG. 1 C . In some embodiments, the antibody or antigen binding molecule comprises a light chain variable region sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-144.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 65; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO 137.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 66; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 138.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 67; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 139.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 68; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 140.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 69; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 141.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 70; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 142.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 71; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 143.
- the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 72; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 144.
- the polynucleotide of the present invention comprises a nucleotide sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a nucleotide sequence selected form the group consisting of SEQ ID NOs: 57-64.
- the polynucleotide of the present invention comprises a nucleotide sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a nucleotide sequence selected form the group consisting of SEQ ID NOs: 129-136.
- the antibody or antigen binding molecule encoded by the polypeptide of the present invention can be single chained or double chained.
- the antibody or antigen binding molecule comprises is single chained.
- the antigen binding molecule is selected from the group consisting of an scFv, an Fab, an Fab′, an Fv, an F(ab′)2, a dAb, and any combination thereof.
- the antibody or antigen binding molecule comprises an scFv.
- the antibody or antigen binding molecule comprises a single chain, wherein the heavy chain variable region and the light chain variable region are connected by a linker.
- the VH is located at the N terminus of the linker and the VL is located at the C terminus of the linker. In other embodiments, the VL is located at the N terminus of the linker and the VH is located at the C terminus of the linker.
- the linker comprises at least about 5, at least about 8, at least about 10, at least about 13, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 amino acids. In some embodiments, the linker comprises at least about 18 amino acids.
- the linker comprises an amino acid sequence that is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence GSTSGSGKPGSGEGSTKG (SEQ ID NO: 174) or a poly-Gly linker such as the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO: 268). Or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 411).
- the linker is a Whitlow linker.
- the antibody or antigen binding molecule comprises a single chain, wherein the heavy chain variable region and the light chain variable region are connected by a linker, wherein the linker comprises the amino acid sequence of SEQ ID NO: 174.
- the antibody or antigen binding molecules of the present invention specifically bind BCMA (e.g., hBCMA).
- BCMA e.g., hBCMA
- an anti-BCMA antibody or antigen binding molecule of the present invention binds human BCMA with a K D of less than 1 ⁇ 10 ⁇ 6 M, less than 1 ⁇ 10 ⁇ 7 M, less than 1 ⁇ 10 ⁇ 8 M, or less than 1 ⁇ 10 ⁇ 9 M.
- the anti-BCMA antibody or antigen binding molecules binds human BCMA with a K D of less than 1 ⁇ 10 ⁇ 7 M.
- the anti-BCMA antibody or antigen binding molecules binds human BCMA with a K D of less than 1 ⁇ 10 ⁇ 8 M.
- the anti-BCMA antibody or antigen binding molecules binds human BCMA with a K D of about 1 ⁇ 10 ⁇ 7 M, about 2 ⁇ 10 ⁇ 7 M, about 3 ⁇ 10 ⁇ 7 M, about 4 ⁇ 10 ⁇ 7 M, about 5 ⁇ 10 ⁇ 7 M, about 6 ⁇ 10 ⁇ 7 M, about 7 ⁇ 10 ⁇ 7 M, about 8 ⁇ 10 ⁇ 7 M, about 9 ⁇ 10 ⁇ 7 M, about 1 ⁇ 10 ⁇ 8 M, about 2 ⁇ 10 ⁇ 8 M, about 3 ⁇ 10 ⁇ 8 M, about 4 ⁇ 10 ⁇ 8 M, about 5 ⁇ 10 ⁇ 8 M, about 6 ⁇ 10 ⁇ 8 M, about 7 ⁇ 10 ⁇ 8 M, about 8 ⁇ 10 ⁇ 8 M, about 9 ⁇ 10 ⁇ 8 M, about 1 ⁇ 10 ⁇ 9 M, about 2 ⁇ 10 ⁇ 9 M, about 3 ⁇ 10 ⁇ 9 M, about 4 ⁇ 10 ⁇ 9 M, about 5 ⁇ 10 ⁇ 9 M, about 6 ⁇ 10 ⁇ 9 M, about 7 ⁇ 10 ⁇ 9 M, about 8 ⁇ 10 ⁇
- the K D is calculated as the quotient of k off /k on , and the k on and k off are determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology.
- the K D is calculated as the quotient of k off /k on , and the k on and k off are determined using a bivalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology.
- the anti-BCMA antibody or antigen binding molecule binds human BCMA-Fc with a K D of less than 1 ⁇ 10 ⁇ 9 M, less than 3 ⁇ 10 ⁇ 9 M, less than 5 ⁇ 10 ⁇ 9 M, less than 1 ⁇ 10 ⁇ 10 M, less than 3 ⁇ 10 ⁇ 10 M, or less than 5 ⁇ 10 ⁇ 10 M.
- the anti-BCMA antibody or antigen binding molecules binds cyno BCMA-Fc with a K D of less than 1 ⁇ 10 ⁇ 5 M, less than 1 ⁇ 10 ⁇ 6 M, less than 1 ⁇ 10 ⁇ 7 M, less than 1 ⁇ 10 ⁇ 8 M, less than 1 ⁇ 10 ⁇ 9 M, or less than 1 ⁇ 10 ⁇ 10 M.
- the anti-BCMA antibody or antigen binding molecule binds human BCMA with an association rate (k on ) of less than 1 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 3 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 4 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 5 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 6 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 7 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 8 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 9 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 1 ⁇ 10 ⁇ 5 M ⁇ 1 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 5 M ⁇ 1 s ⁇ 1 , less than 3 ⁇ 10 ⁇ 5 M ⁇ 1 ⁇ 1 ⁇
- the k on is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology.
- the k on is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
- the anti-BCMA antibody or antigen binding molecule binds human BCMA with an dissociation rate (k off ) of less than 1 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 3 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 4 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 5 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 6 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 7 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 8 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 9 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 1 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 3 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 4 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 5 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 6 ⁇ 10 ⁇ 3 s
- the k off is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology.
- a monovalent antibody such as a Fab fragment
- the k off is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
- the polynucleotide of the present invention encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule cross competes with a reference antibody disclosed herein.
- the antibody or antigen binding molecule cross competes with a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-56, 65-128, and 137-144.
- the antibody or antigen binding molecule cross competes with a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72 and 137-144.
- the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-16. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 25-32. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-48.
- the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 89-96. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-112. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 121-128.
- the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72. In another embodiment, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-144.
- the polynucleotide of the present invention encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody disclosed herein (e.g., FIG. 1 ).
- the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-56, 65-128, and 137-144.
- the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72 and 137-144.
- the present invention is also directed to polynucleotides encoding chimeric antigen receptors (CARs) or T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to BCMA described in Section II, and engineered T cells comprising an antigen binding molecule that specifically binds to BCMA described in Section II.
- an anti-BCMA CAR or TCR encoded by the polynucleotide of the present invention comprises an antigen binding molecule that specifically binds to BCMA.
- the anti-BCMA CAR or TCR encoded by the polynucleotide further comprises a costimulatory domain.
- the costimulatory domain in the anti-BCMA CAR or TCR encoded by the polynucleotide comprises an extracellular domain (i.e., a hinge region), a transmembrane domain, and/or an intracellular (signaling) domain.
- the anti-BCMA CAR or TCR encoded by the polynucleotide further comprises a CD3 zeta activating domain.
- the anti-BCMA CAR or TCR encoded by the polynucleotide comprises an antigen binding molecule that specifically binds BCMA (e.g., hBCMA), a costimulatory domain comprising an extracellular domain, a transmembrane domain, and an intracellular domain, and a CD3 zeta activating domain.
- BCMA e.g., hBCMA
- costimulatory domain comprising an extracellular domain, a transmembrane domain, and an intracellular domain
- CD3 zeta activating domain e.g., CD3 zeta activating domain
- the polynucleotide of the present invention encodes a TCR, wherein the TCR comprises an antigen binding molecule that specifically binds to BCMA, and wherein the TCR further comprises a fourth complementarity determining region (CDR4).
- the polynucleotide encodes a TCR, wherein the TCR comprises an antigen binding molecule that specifically binds to BCMA, and a constant region.
- the constant region is selected from a constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM.
- the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an antigen binding molecule that specifically binds to BCMA (one or more antigen binding molecules in Section II), and wherein the CAR further comprises a costimulatory domain.
- the costimulatory domain is positioned between the antigen binding molecule and an activating domain.
- the costimulatory domain can comprise an extracellular domain, a transmembrane domain, and an intracellular signaling domain.
- the extracellular domain comprises a hinge region (e.g., a spacer region).
- the extracellular domain is from or derived from (e.g., comprises) CD28, CD28T, OX40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), ICOS, April, BAFF, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule
- the extracellular domain in the costimulatory domain is positioned between the antigen binding molecule and the transmembrane domain.
- the extracellular domain in the costimulatory domain is from or derived from an immunoglobulin.
- the extracellular domain in the costimulatory domain is selected from the hinge regions of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM, or a fragment thereof.
- the extracellular domain in the costimulatory domain is from or derived from the hinge region of CD8 alpha. In one particular embodiment, the extracellular domain in the costimulatory domain is from or derived from the hinge region of CD28.
- the extracellular domain in the costimulatory domain comprises a fragment of the hinge region of CD8 alpha or a fragment of the hinge region of CD28, wherein the fragment is anything less than the whole hinge region.
- the fragment of the CD8 alpha hinge region or the fragment of the CD28 hinge region comprises an amino acid sequence that excludes at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 amino acids at the N-terminus or C-Terminus, or both, of the CD8 alpha hinge region of the CD28 hinge region.
- the extracellular domain in the costimulatory domain comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence LDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 167) or a fragment thereof.
- the extracellular domain in the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 167 or a fragment thereof.
- the extracellular domain in the costimulatory domain is encoded by a nucleotide sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the nucleotide sequence CTTGATAATGAAAAGTCAAACGGAACAATCATT CACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCA (SEQ ID NO: 166) or a fragment thereof.
- the extracellular domain in the costimulatory domain is encoded by a nucleotide sequence that comprises the nucleotide sequence of SEQ ID NO: 166 or a fragment thereof.
- the CD28T domain is derived from a human CD28 hinge region. In other embodiments, the CD28T domain is derived from a rodent, murine, or primate (e.g., non-human primate) CD28 hinge region. In some embodiments, the CD28T domain is derived from a chimeric CD28 hinge region.
- the extracellular domain comprises some or all of a member of the immunoglobulin family such as IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, or fragment thereof.
- the costimulatory domain for the CAR or TCR of the invention can further comprise a transmembrane domain.
- the transmembrane domain can be designed to be fused to the extracellular domain in the costimulatory domain. It can similarly be fused to the intracellular domain in the costimulatory domain.
- the transmembrane domain that naturally is associated with one of the domains in a CAR is used.
- the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.
- the transmembrane domain may be derived either from a natural or from a synthetic source.
- the domain can be derived from any membrane-bound or transmembrane protein.
- the transmembrane domain is derived from CD28, OX-40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, zeta), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD3 gamma, CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF ⁇ , integrin, signaling lymphocytic activ
- a short oligo or polypeptide linker preferably between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic signaling domain of the CAR.
- a glycine-serine doublet provides a particularly suitable linker.
- the transmembrane domain in the CAR of the invention comprises the CD8 transmembrane domain.
- the CD8 transmembrane domain comprises the transmembrane portion of the nucleic acid sequence of GCTGCAGCATTGAGCAACTCAATAATGTATTTTAGTCACTTTGTACCAGTGTTCTTGCCGGC TAAGCCTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGC CTCTGTCCCTGCGCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGA CTGGATTTCGCCTGCGATATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCT GCTGTCCCTGGTCATCACGCTCTATTGTAATCACAGGAAC (SEQ ID NO: 269).
- the CD8 transmembrane domain comprises the nucleic acid sequence that encodes the transmembrane amino acid sequence contained within
- the transmembrane domain in the costimulating domain is a CD28 transmembrane domain.
- the transmembrane domain comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 169).
- the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 169.
- the transmembrane domain is encoded by a nucleotide sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the nucleotide sequence TTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGC TTTTATAATCTTCTGGGTT (SEQ ID NO: 168).
- the transmembrane domain is encoded by a nucleotide sequence that comprises the nucleotide sequence of SEQ ID NO: 168.
- Intracellular (signaling) Domain The intracellular (signaling) domain of the engineered T cells of the invention can provide signaling to an activating domain, which then activates at least one of the normal effector functions of the immune cell. Effector function of a T cell, for example, can be cytolytic activity or helper activity including the secretion of cytokines.
- suitable intracellular signaling domain include (i.e., comprise), but are not limited to CD28, CD28T, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1,
- nucleotide sequence encoding the intracellular signaling domain is set forth in SEQ ID NO. 170:
- the polynucleotide encoding an intracellular signaling domain within a costimulatory domain comprises a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the nucleotide sequence of SEQ ID NO: 170.
- An example of an intracellular signaling domain is set forth in SEQ ID NO. 171:
- the intracellular signaling domain within a costimulatory domain comprises an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of SEQ ID NO: 171.
- the intracellular signaling sequences within the CAR of the invention can be linked to each other or to an activating domain in a random or specified order.
- a short oligo- or polypeptide linker preferably between 2 and 10 amino acids in length may form the linkage.
- a glycine-serine doublet provides a particularly suitable linker.
- costimulatory regions described herein can be expressed in a separate chain from the antigen binding molecule (e.g., scFv) and activating domains, in so-called “trans” configuration.
- intracellular domains for use in the engineered T cell of the invention include cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen/receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability.
- CD3 is an element of the T cell receptor on native T cells, and has been shown to be an important intracellular activating element in CARs.
- the activating domain is CD3, e.g., CD3 zeta, the nucleotide sequence of which is set forth in SEQ ID NO. 172:
- AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCC AGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGA CGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCA AGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATA AGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAG GGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAG GATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG.
- the polynucleotide encoding an activating domain comprises a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the nucleotide sequence of SEQ ID NO: 172.
- the activating domain comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of SEQ ID NO: 173.
- the activating domain comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of a CD3 zeta variant as set forth in SEQ ID NO: 412:
- the polynucleotide of the present invention encodes a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, and wherein the CAR or the TCR further comprises a leader peptide (also referred to herein as a “signal peptide”).
- the leader peptide comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 165).
- the signal peptide comprises the amino acid sequence of SEQ ID NO: 165.
- the leader peptide is encoded by a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 164.
- the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises a leader peptide (P), an antigen binding molecule (B), a hinge domain (H), a transmembrane domain (T), a costimulatory region (C), and an activation domain (A), wherein the CAR is configured according to the following: P-B-H-T-C-A.
- the antigen binding molecule comprises a VH and a VL, wherein the CAR is configured according to the following: P-VH-VL-H-T-C-A or P-VL-VH-H-T-C-A.
- the VH and the VL are connected by a linker (L), wherein the anti-BCMA CAR is configured according to the following, from N-terminus to C-terminus: P-VH-L-VL-H-T-C-A or P-VH-L-VL-H-T-C-A.
- L linker
- the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from Table 2.
- the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence selected from Table 2.
- the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206.
- the CAR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206.
- the CAR comprises the amino acid sequence of SEQ ID NO: 176.
- the CAR comprises the amino acid sequence of SEQ ID NO: 178.
- the CAR comprises the amino acid sequence of SEQ ID NO: 180.
- the CAR comprises the amino acid sequence of SEQ ID NO: 182.
- the CAR comprises the amino acid sequence of SEQ ID NO: 184.
- the CAR comprises the amino acid sequence of SEQ ID NO: 186. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 188. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 190. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 192. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 194. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 196. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 198. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 200. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 202. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 204. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 206.
- the polynucleotide of the present invention comprises an nucleotide sequence at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, and 205.
- the polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, and 205.
- the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 175.
- the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 177.
- the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 179.
- the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 181. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 183. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 185. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 187. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 189. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 191.
- the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 193. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 195. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 197. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 199. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 201. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 203. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 205.
- the invention relates to Clone FS-26528 HC DNA (SEQ ID NO: 271) as follows:
- the invention relates to the Clone FS-26528 HC amino acid sequence (SEQ ID NO: 272):
- the invention relates to HC CDR1 thereof: SCAASGFTFDDYAMA (SEQ ID NO: 273).
- the invention relates to HC CDR2 thereof: AISDAGDRTYYADSVRG (SEQ ID NO: 274).
- the invention relates to HC CDR3 thereof: ARAEMGAVFDI (SEQ ID NO: 275) [HC CDR3]
- the invention relates to Clone FS-26528 LC DNA (SEQ ID NO: 276):
- the invention relates to Clone FS-26528 LC AA sequence (SEQ ID NO: 277):
- the invention relates to LC CDR1 thereof: RASQSVSRYLA (SEQ ID NO: 278). In further embodiments, the invention relates to LC CDR2 thereof: DASNRAT (SEQ ID NO: 279). In further embodiments, the invention relates to the LC CDR3 thereof: QQRISWPFT (SEQ ID NO: 280).
- the invention relates to Clone FS-26528 CAR DNA H ⁇ L (SEQ ID NO: 281):
- the invention relates to Clone FS-26528 CAR H ⁇ L AA sequence (SEQ ID NO: 282):
- the invention relates to Clone FS-26528 CAR DNA L ⁇ H (SEQ ID NO: 283):
- the invention relates to the Clone FS-26528 CAR L ⁇ H AA sequence (SEQ ID NO: 284):
- the invention relates to Clone PC-26534 HC DNA (SEQ ID NO: 285) as follows:
- the invention relates to Clone PC-26534 HC (SEQ ID NO: 286):
- the invention relates to HC CDR1 thereof: FTFSEHGMH (SEQ ID NO: 287). In further embodiments, the invention relates to HC CDR2 thereof: AISYDGRNKHYADSVKG (SEQ ID NO: 288). In further embodiments, the invention relates to HC CDR3 thereof: ARDGTYLGGLWYFDL (SEQ ID NO: 289).
- the invention relates to Clone PC-26534 LC DNA (SEQ ID NO: 290) as follows:
- the invention relates to Clone PC-26534 LC AA sequence (SEQ ID NO: 291):
- the invention relates to LC CDR1 AA sequence thereof: RSSQSLLHSNGYNYLD (SEQ ID NO: 292). In further embodiments, the invention relates to LC CDR2 thereof: LGSNRAS (SEQ ID NO: 293). In further embodiments, the invention relates to LC CDR3 thereof: MQGLGLPLT (SEQ ID NO: 294).
- the invention relates to Clone PC-26534 CAR DNA H ⁇ L (SEQ ID NO: 295) as follows:
- the invention relates to Clone PC-26534 CAR H ⁇ L AA sequence (SEQ ID NO: 296):
- the invention relates to Clone PC-26534 CAR DNA L ⁇ H (SEQ ID NO: 297):
- the invention relates to Clone PC-26534 CAR L ⁇ H chain sequences (SEQ ID NO: 298):
- the invention relates to Clone AJ-26545 HC DNA (SEQ ID NO: 299):
- the invention relates to Clone AJ-26545 HC AA sequence (SEQ ID NO: 300):
- the invention relates to HC CDR1 thereof: YTFMEHYMH (SEQ ID NO: 301). In further embodiments, the invention relates to HC CDR2 thereof: VIGPSGGKTSYAQKFQG (SEQ ID NO: 302). In further embodiments, the invention relates to HC CDR3 thereof: ARESWPMDV (SEQ ID NO: 303).
- the invention relates to Clone AJ-26545 LC DNA (SEQ ID NO: 304):
- the invention relates to Clone AJ-26545 LC AA sequence (SEQ ID NO: 305):
- the invention relates to LC CDR1 thereof: RASQSVSSNLA (SEQ ID NO: 306). In further embodiments, the invention relates to LC CDR2 thereof: GASTRAT (SEQ ID NO: 307). In further embodiments, the invention relates to the LC CDR3 thereof: QQYAAYPT (SEQ ID NO: 308).
- the invention relates to Clone AJ-26545 CAR DNA H ⁇ L (SEQ ID NO: 309):
- the invention relates to Clone AJ-26545 CAR H ⁇ L AA sequence (SEQ ID NO: 310):
- the invention relates to Clone AJ-26545 CAR DNA L ⁇ H (SEQ ID NO: 311):
- the invention relates to Clone AJ-26545 CAR L ⁇ H AA sequence (SEQ ID NO: 312):
- the invention relates to Clone AJ-26554 HC DNA (SEQ ID NO: 313):
- the invention relates to Clone AJ-26554 HC (SEQ ID NO: 314):
- the invention relates to HC CDR1 thereof: YTFTEHYMH (SEQ ID NO: 315). In further embodiments, the invention relates to HC CDR2 thereof: VIGPSGGKTSYAQKFQG (SEQ ID NO: 316). In further embodiments, the invention relates to HC CDR3 thereof: ARESWPMDV (SEQ ID NO: 317).
- the invention relates to Clone AJ-26554 LC DNA (SEQ ID NO: 318):
- the invention relates to Clone AJ-26554 LC AA sequence (SEQ ID NO: 319):
- the invention relates to the LC CDR1 thereof: RASQSVSSNLA (SEQ ID NO: 320). In further embodiments, the invention relates to the LC CDR2 thereof: GASTRAT (SEQ ID NO: 321). In further embodiments, the invention relates to LC CDR3 thereof: QQYAAYPT (SEQ ID NO: 322).
- the invention relates to Clone AJ-26554 CAR DNA H ⁇ L (SEQ ID NO: 323):
- the invention relates to Clone AJ-26554 CAR H ⁇ L AA sequence (SEQ ID NO: 324):
- the invention relates to Clone AJ-26554 CAR DNA L ⁇ H (SEQ ID NO: 325):
- the invention relates to Clone AJ-26554 CAR L ⁇ H AA sequence (SEQ ID NO: 326):
- the invention relates to Clone NM-26562 HC DNA (SEQ ID NO: 327):
- the invention relates to Clone NM-26562 HC AA sequence (SEQ ID NO: 328):
- the invention relates to HC CDR1 thereof: GSIGSGGSYWS (SEQ ID NO: 329). In further embodiments, the invention relates to HC CDR2 thereof: LIYYDGSTYYNPSLKS (SEQ ID NO: 330). In further embodiments, the invention relates to HC CDR3 thereof: ARGRGYETSLAFDI (SEQ ID NO: 331).
- the invention relates to Clone NM-26562 LC DNA (SEQ ID NO: 332):
- the invention relates to Clone NM-26562 LC AA sequence (SEQ ID NO: 333):
- the invention relates to LC CDR1 AA sequence thereof: RASQSVSSYLA (SEQ ID NO: 334) In further embodiments, the invention relates to LC CDR2 AA sequence thereof: DASNRAT (SEQ ID NO: 335). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQRHVWPPT (SEQ ID NO: 336) (LC CDR3).
- the invention relates to Clone NM-26562 CAR DNA H ⁇ L (SEQ ID NO: 337):
- the invention relates to Clone NM-26562 CAR H ⁇ L (SEQ ID NO: 338):
- the invention relates to Clone NM-26562 CAR DNA L ⁇ H (SEQ ID NO: 339):
- the invention relates to Clone NM-26562 CAR L ⁇ H (SEQ ID NO: 340):
- the invention relates to Clone TS-26564 HC DNA sequence (SEQ ID NO: 341):
- the invention relates to Clone TS-26564 HC AA sequence (SEQ ID NO: 342):
- the invention relates to HC CDR1 AA sequence thereof: FTFSSYSMN (SEQ ID NO: 343).
- the invention relates to HC CDR2 AA sequence thereof: TISSSSSIIYYADSVKG (SEQ ID NO: 344).
- the invention relates to HC CDR3 AA sequence thereof: ARGSQEHLIFDY (SEQ ID NO: 345).
- the invention relates to Clone TS-26564 LC DNA (SEQ ID NO: 346):
- the invention relates to Clone TS-26564 LC AA sequence (SEQ ID NO: 347):
- the invention relates to LC CDR1 AA sequence thereof: RASQSVSRYLA (SEQ ID NO: 348). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: DASNRAT (SEQ ID NO: 349). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQRFYYPWT (SEQ ID NO: 350).
- the invention relates to Clone TS-26564 CAR DNA H ⁇ L (SEQ ID NO: 351):
- the invention relates to Clone TS-26564 CAR H ⁇ L AA sequence (SEQ ID NO: 352):
- the invention relates to Clone TS-26564 CAR DNA L ⁇ H (SEQ ID NO: 353):
- the invention relates to Clone TS-26564 CAR L ⁇ H AA sequence (SEQ ID NO: 354):
- the invention relates to Clone RY-26568 HC DNA (SEQ ID NO: 355):
- the invention relates to Clone RY-26568 HC AA sequence (SEQ ID NO: 356):
- the invention relates to HC CDR1 thereof: FTFGSYGMH (SEQ ID NO: 357).
- the invention relates to HC CDR2 thereof: VIHYDGSVEYYADSVKG (SEQ ID NO: 358).
- the invention relates to HC CDR3 thereof: ARTDFWSGSPPSLDY (SEQ ID NO: 359).
- the invention relates to Clone RY-26568 LC DNA (SEQ ID NO: 360):
- the invention relates to Clone RY-26568 LC AA sequence (SEQ ID NO: 361):
- the invention relates to LC CDR1 AA sequence thereof: RASRGISSWLA (SEQ ID NO: 362). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: GASSLQS (SEQ ID NO: 363). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQIYTFPFT (SEQ ID NO: 364) (LC CDR3).
- the invention relates to Clone RY-26568 CAR DNA H ⁇ L (SEQ ID NO: 365):
- the invention relates to Clone RY-26568 CAR H ⁇ L AA sequence (SEQ ID NO: 366):
- the invention relates to Clone RY-26568 CAR DNA L ⁇ H (SEQ ID NO: 367):
- the invention relates to Clone RY-26568 CAR L ⁇ H AA sequence (SEQ ID NO: 368):
- the invention relates to Clone PP-26575 HC DNA (SEQ ID NO: 369):
- the invention relates to Clone PP-26575 HC AA sequence (SEQ ID NO: 370):
- the invention relates to HC CDR1 AA sequence thereof: GILSSLAIS (SEQ ID NO: 371). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: GVIPILGRANYAQKFQG (SEQ ID NO: 372). In further embodiments, the invention relates to HC CDR3 thereof: ARTPEYSSSIWHYYYGMDV (SEQ ID NO: 373).
- the invention relates to Clone PP-26575 LC DNA (SEQ ID NO: 374):
- the invention relates to Clone PP-26575 LC AA sequence (SEQ ID NO: 375):
- DIVMTQSPDS LAVSLGERAT INC KSSQSVL YSSNNKNYLA WYQQKPGQPP KLLIY WASTR ES GVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQ QFAHT PFT FGGGTKV EIKR.
- the invention relates to LC CDR 1 AA sequence thereof: KSSQSVLYSSNNKNYLA (SEQ ID NO: 376). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: WASTRES (SEQ ID NO: 377). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQFAHTPFT (SEQ ID NO: 378).
- the invention relates to Clone PP-26575 CAR DNA H ⁇ L (SEQ ID NO: 379):
- the invention relates to Clone PP-26575 CAR H ⁇ L AA sequence (SEO TD NO: 3801:
- the invention relates to Clone PP-26575 CAR DNA L ⁇ H (SEQ ID NO: 381):
- the invention relates to Clone PP-26575 CAR L ⁇ H AA sequence (SEQ ID NO: 382):
- the invention relates to Clone RD-26576 HC DNA (SEQ ID NO: 383):
- the invention relates to Clone RD-26576 HC AA sequence (SEQ ID NO: 384):
- the invention relates to HC CDR1 AA sequence thereof: FTFSSYGIH (SEQ ID NO: 385). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: VIGYDGQEKYYADSVKG (SEQ ID NO: 386). In further embodiments, the invention relates to the HC CDR3 AA sequence thereof: VKGPLQEPPYAFGMDV (SEQ ID NO: 387).
- the invention relates to Clone RD-26576 LC DNA (SEQ ID NO: 388):
- the invention relates to Clone RD-26576 LC AA sequence (SEQ ID NO: 389):
- the invention relates to LC CDR1 AA sequence thereof: RASQSVSSNLA (SEQ ID NO: 390). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: SASTRAT (SEQ ID NO: 391). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQHHVWPLT (SEQ ID NO: 392).
- the invention relates to Clone RD-26576 CAR DNA H ⁇ L (SEQ ID NO: 393):
- the invention relates to Clone RD-26576 CAR H ⁇ L AA sequence (SEQ ID NO: 394):
- the invention relates to Clone RD-26576 CAR DNA L ⁇ H (SEQ ID NO: 395):
- the invention relates to Clone RD-26576 CAR L ⁇ H AA sequence (SEQ ID NO: 396):
- the invention relates to Clone RD-26578 HC DNA (SEQ ID NO: 397):
- the invention relates to Clone RD-26578 HC AA sequence (SEQ ID NO: 398):
- the invention relates to HC CDR1 AA sequence thereof: FTFSSRGMH (SEQ ID NO: 399). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: VIGYDGQEKYYADSVKG (SEQ ID NO: 400). In further embodiments, the invention relates to HC CDR3 thereof: VKGPLQEPPYDYGMDV (SEQ ID NO: 401).
- the invention relates to Clone RD-26578 LC DNA (SEQ ID NO: 402):
- the invention relates to Clone RD-26578 LC AA sequence (SEQ ID NO: 403):
- the invention relates to LC CDR1 AA sequence: RASQSVSSNLA (SEQ ID NO: 404). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: SASTRAT (SEQ ID NO: 405). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQHHVWPLT (SEQ ID NO: 406).
- the invention relates to Clone RD-26578 CAR DNA H ⁇ L (SEQ ID NO: 407):
- the invention relates to Clone RD-26578 CAR H ⁇ L AA sequence (SEQ ID NO: 408):
- the invention relates to Clone RD-26578 CAR DNA L ⁇ H (SEQ ID NO: 409):
- the invention relates to Clone RD-26578 CAR L ⁇ H AA sequence (SEQ ID NO: 410):
- additional on-off or other types of control switch techniques may be incorporated herein. These techniques may employ the use of dimerization domains and optional activators of such domain dimerization. These techniques include, e.g., those described by Wu et al., Science 2014 350 (6258) utilizing FKBP/Rapalog dimerization systems in certain cells, the contents of which are incorporated by reference herein in their entirety. Additional dimerization technology is described in, e.g., Fegan et al. Chem. Rev. 2010, 110, 3315-3336 as well as U.S. Pat. Nos.
- dimerization pairs may include cyclosporine-A/cyclophilin, receptor, estrogen/estrogen receptor (optionally using tamoxifen), glucocorticoids/glucocorticoid receptor, tetracycline/tetracycline receptor, vitamin D/vitamin D receptor.
- dimerization technology can be found in e.g., WO2014/127261, WO2015/090229, US2014/0286987, US2015/0266973, US2016/0046700, U.S. Pat. No. 8,486,693, US2014/0171649, and US2012/0130076, the contents of which are further incorporated by reference herein in their entirety.
- vectors comprising a polynucleotide of the present invention.
- the present invention is directed to a vector or a set of vectors comprising a polynucleotide encoding a CAR or a TCR, as described herein.
- the present invention is directed to a vector or a set of vectors comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- the vector is a viral vector.
- the vector is a retroviral vector (such as pMSVG1), a DNA vector, a murine leukemia virus vector, an SFG vector, a plasmid, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector (AAV), a lentiviral vector (such as pGAR), or any combination thereof.
- retroviral vector such as pMSVG1
- DNA vector such as pMSVG1
- a murine leukemia virus vector such as a murine leukemia virus vector, an SFG vector, a plasmid, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a her
- the pGAR sequence (SEQ ID NO: 413) is as follows:
- the pGAR vector map is set forth in FIG. 19 .
- Suitable additional exemplary vectors include e.g., pBABE-puro, pBABE-neo largeTcDNA, pBABE-hygro-hTERT, pMKO.1 GFP, MSCV-IRES-GFP, pMSCV PIG (Puro IRES GFP empty plasmid), pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE, MSCV IRES Luciferase, pMIG, MDH1-PGK-GFP_2.0, TtRMPVIR, pMSCV-IRES-mCherry FP, pRetroX GFP T2A Cre, pRXTN, pLncEXP, and pLXIN-Luc.
- cells comprising a polynucleotide or a vector of the present invention.
- the present invention is directed to cells, in vitro cells, comprising a polynucleotide encoding a CAR or a TCR, as described herein.
- the present invention is directed to cells, e.g., in vitro cells, comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- the present invention is directed to in vitro cells comprising a polypeptide encoded by a polynucleotide encoding a CAR or a TCR, as disclosed herein.
- the present invention is directed to cells, in vitro cells, comprising a polypeptide encoded by a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- any cell may be used as a host cell for the polynucleotides, the vectors, or the polypeptides of the present invention.
- the cell can be a prokaryotic cell, fungal cell, yeast cell, or higher eukaryotic cells such as a mammalian cell.
- Suitable prokaryotic cells include, without limitation, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobactehaceae such as Escherichia , e.g., E.
- the cell is a human cell. In some embodiments, the cell is an immune cell.
- the immune cell is selected from the group consisting of a T cell, a B cell, a tumor infiltrating lymphocyte (TIL), a TCR expressing cell, a natural killer (NK) cell, a dendritic cell, a granulocyte, an innate lymphoid cell, a megakaryocyte, a monocyte, a macrophage, a platelet, a thymocyte, and a myeloid cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- the T cell is a tumor-infiltrating lymphocyte (TIL), autologous T cell, engineered autologous T cell (eACTTM), an allogeneic T cell, a heterologous T cell, or any combination thereof.
- T cells can be differentiated in vitro from a hematopoietic stem cell population, or T cells can be obtained from a subject.
- T cells can be obtained from, e.g., peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors.
- the T cells can be derived from one or more T cell lines available in the art.
- T cells can also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLLTM separation and/or apheresis.
- the cells collected by apheresis are washed to remove the plasma fraction, and placed in an appropriate buffer or media for subsequent processing.
- the cells are washed with PBS.
- a washing step can be used, such as by using a semiautomated flowthrough centrifuge, e.g., the COBETM 2991 cell processor, the Baxter CYTOMATETM, or the like.
- the washed cells are resuspended in one or more biocompatible buffers, or other saline solution with or without buffer.
- the undesired components of the apheresis sample are removed. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety.
- T cells are isolated from PBMCs by lysing the red blood cells and depleting the monocytes, e.g., by using centrifugation through a PERCOLLTM gradient.
- a specific subpopulation of T cells such as CD28 + , CD4 + , CD8 + , CD45RA + , and CD45RO + T cells is further isolated by positive or negative selection techniques known in the art. For example, enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells.
- cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected can be used.
- a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8.
- flow cytometry and cell sorting are used to isolate cell populations of interest for use in the present invention.
- PBMCs are used directly for genetic modification with the immune cells (such as CARs or TCRs) using methods as described herein.
- T lymphocytes are further isolated, and both cytotoxic and helper T lymphocytes are sorted into naive, memory, and effector T cell subpopulations either before or after genetic modification and/or expansion.
- CD8 + cells are further sorted into naive, central memory, and effector cells by identifying cell surface antigens that are associated with each of these types of CD8 + cells.
- the expression of phenotypic markers of central memory T cells includes CD45RO, CD62L, CCR7, CD28, CD3, and CD127 and are negative for granzyme B.
- central memory T cells are CD45RO + , CD62L + , CD8 + T cells.
- effector T cells are negative for CD62L, CCR7, CD28, and CD127 and positive for granzyme B and perforin.
- CD4 + T cells are further sorted into subpopulations. For example, CD4 + T helper cells can be sorted into naive, central memory, and effector cells by identifying cell populations that have cell surface antigens.
- the immune cells e.g., T cells
- the immune cells are genetically modified following isolation using known methods, or the immune cells are activated and expanded (or differentiated in the case of progenitors) in vitro prior to being genetically modified.
- the immune cells e.g., T cells
- Methods for activating and expanding T cells are known in the art and are described, e.g., in U.S. Pat. Nos.
- Such methods include contacting PBMC or isolated T cells with a stimulatory agent and costimulatory agent, such as anti-CD3 and anti-CD28 antibodies, generally attached to a bead or other surface, in a culture medium with appropriate cytokines, such as IL-2.
- a stimulatory agent and costimulatory agent such as anti-CD3 and anti-CD28 antibodies
- cytokines such as IL-2.
- Anti-CD3 and anti-CD28 antibodies attached to the same bead serve as a “surrogate” antigen presenting cell (APC).
- APC antigen presenting cell
- One example is The Dynabeads® system, a CD3 CD28 activator/stimulator system for physiological activation of human T cells.
- the T cells are activated and stimulated to proliferate with feeder cells and appropriate antibodies and cytokines using methods such as those described in U.S. Pat. Nos. 6,040,177 and 5,827,642 and PCT Publication No. WO 2012/129514, the contents of which are hereby incorporated by reference in their entirety.
- the T cells are obtained from a donor subject.
- the donor subject is human patient afflicted with a cancer or a tumor.
- the donor subject is a human patient not afflicted with a cancer or a tumor.
- compositions comprising a polynucleotide described herein, a vector described herein, a polypeptide described herein, or an in vitro cell described herein.
- the composition comprises a pharmaceutically acceptable carrier, diluent, solubilizer, emulsifier, preservative and/or adjuvant.
- the composition comprises an excipient.
- the composition comprises a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA.
- the composition comprises a CAR or a TCR encoded by a polynucleotide of the present invention, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA.
- the composition comprises a T cell comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA.
- the composition comprises an antibody or an antigen binding molecule thereof encoded by a polynucleotide of the present invention.
- the composition comprises an in vitro cell comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof encoded by a polynucleotide of the present invention.
- the composition includes more than one different antigen binding molecule to BMCA. In some embodiments, the composition included more than one antigen binding molecule to BCMA, wherein the antigen binding molecules to BCMA bind more than one epitope. In some embodiments, the antigen binding molecules will not compete with one another for binding to BCMA. In some embodiments, any of the antigen binding molecules provided herein are combined together in a pharmaceutical composition.
- the composition is selected for parenteral delivery, for inhalation, or for delivery through the digestive tract, such as orally.
- the preparation of such pharmaceutically acceptable compositions is within the ability of one skilled in the art.
- buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.
- the composition when parenteral administration is contemplated, is in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising a desired antigen binding molecule to BCMA, with or without additional therapeutic agents, in a pharmaceutically acceptable vehicle.
- Another aspect of the invention is directed to a method of making a cell expressing a CAR or a TCR comprising transducing a cell with a polynucleotide disclosed herein under suitable conditions.
- the method comprises transducing a cell with a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein.
- the method comprises transducing a cell with a vector comprising the polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA.
- the method comprises transducing a cell with a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In some embodiments, the method comprises transducing a cell with a vector comprising the polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as described herein. In some embodiments, the method further comprises isolating the cell.
- Another aspect of the present invention is directed to a method of inducing an immunity against a tumor comprising administering to a subject an effective amount of a cell comprising a polynucleotide described herein, a vector described herein, or a CAR or a TCR described herein.
- the method comprises administering to a subject an effective amount of a cell comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein.
- the method comprises administering to a subject an effective amount of a cell comprising a vector comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein.
- the method comprises administering to a subject an effective amount of a cell comprising a CAR or a TCR encoded by a polynucleotide disclosed herein, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA.
- the method comprises administering to a subject an effective amount of a cell comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- the method comprises administering to a subject an effective amount of a cell comprising a vector comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- the method comprises administering to a subject an effective amount of a cell comprising an antibody or antigen binding molecule thereof encoded by a polynucleotide disclosed herein, wherein the antibody or antigen binding molecule thereof specifically binds to BCMA.
- Another aspect of the present invention is directed to a method of inducing an immune response in a subject comprising administering an effective amount of the engineered immune cells of the present application.
- the immune response is a T cell-mediated immune response.
- the T cell-mediated immune response is directed against one or more target cells.
- the engineered immune cell comprises a CAR or a TCR.
- the target cell is a tumor cell.
- Another aspect of the present invention is directed to a method for treating or preventing a malignancy, said method comprising administering to a subject in need thereof an effective amount of at least one isolated antigen binding molecule described herein or at least one immune cell, wherein the immune cell comprises at least one CAR, TCR, and/or an isolated antigen binding molecule as described herein.
- Another aspect of the present invention is directed to a method of treating a hyperproliferative disorder or an inflammatory disease in a subject in need thereof comprising administering to the subject a polynucleotide disclosed herein, a vector disclosed herein, a CAR or a TCR disclosed herein, a cell disclosed herein, or a composition disclosed herein.
- the inflammatory disease is selected from the group consisting of rheumatoid arthritis, psoriasis, allergies, asthma, autoimmune diseases such as Crohn's, IBD, fibromyalga, mastocytosis, Celiac disease, and any combination thereof.
- the present invention may be useful to treat diabetes, particularly Type 1 diabetes.
- Another aspect of the present invention is directed to a method of treating a cancer in a subject in need thereof comprising administering to the subject a polynucleotide disclosed herein, a vector disclosed herein, a CAR or a TCR disclosed herein, a cell disclosed herein, or a composition disclosed herein.
- the method comprises administering a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein.
- the method comprises administering a vector comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein.
- the method comprises administering a CAR or a TCR encoded by a polynucleotide disclosed herein, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA.
- the method comprises administering a cell comprising the polynucleotide, or a vector comprising the polynucleotide, encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein.
- the method comprises administering a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- the method comprises administering a vector comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- the method comprises administering an antibody or an antigen binding molecule thereof encoded by a polynucleotide disclosed herein, wherein the antibody or the antigen binding molecule thereof specifically binds to BCMA.
- the method comprises administering a cell comprising the polynucleotide, or a vector comprising the polynucleotide, encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- an antigen binding molecule to BCMA is administered alone.
- an antigen binding molecule to BCMA is administered as part of a CAR, TCR, or other immune cell.
- the antigen binding molecule to BCMA can be under the control of the same promoter region, or a separate promoter.
- the genes encoding protein agents and/or an antigen binding molecule to BCMA can be in separate vectors.
- the donor T cells for use in the T cell therapy are obtained from the patient (e.g., for an autologous T cell therapy). In other embodiments, the donor T cells for use in the T cell therapy are obtained from a subject that is not the patient.
- the T cells can be administered at a therapeutically effective amount.
- a therapeutically effective amount of the T cells can be at least about 10 4 cells, at least about 10 5 cells, at least about 10 6 cells, at least about 10 7 cells, at least about 10 8 cells, at least about 10 9 cells, at least about 10 10 cells, or at least about 10 11 cells.
- the therapeutically effective amount of the T cells is about 10 4 cells, about 10 5 cells, about 10 6 cells, about 10 7 cells, or about 10 8 cells.
- the therapeutically effective amount of the anti-BCMA CAR T cells is about 2 ⁇ 10 6 cells/kg, about 3 ⁇ 10 6 cells/kg, about 4 ⁇ 10 6 cells/kg, about 5 ⁇ 10 6 cells/kg, about 6 ⁇ 10 6 cells/kg, about 7 ⁇ 10 6 cells/kg, about 8 ⁇ 10 6 cells/kg, about 9 ⁇ 10 6 cells/kg, about 1 ⁇ 10 7 cells/kg, about 2 ⁇ 10 7 cells/kg, about 3 ⁇ 10 7 cells/kg, about 4 ⁇ 10 7 cells/kg, about 5 ⁇ 10 7 cells/kg, about 6 ⁇ 10 7 cells/kg, about 7 ⁇ 10 7 cells/kg, about 8 ⁇ 10 7 cells/kg, or about 9 ⁇ 10 7 cells/kg.
- the kit comprises an antigen binding molecule that binds BCMA, along with means for indicating the binding of the antigen binding molecule with BCMA, if present, and optionally BCMA protein levels.
- Various means for indicating the presence of an antigen binding molecule can be used.
- fluorophores, other molecular probes, or enzymes can be linked to the antigen binding molecule and the presence of the antigen binding molecule can be observed in a variety of ways.
- the degree of antigen binding molecule binding can be used to determine how much BCMA is in a sample.
- the methods of the invention can be used to treat a cancer in a subject, reduce the size of a tumor, kill tumor cells, prevent tumor cell proliferation, prevent growth of a tumor, eliminate a tumor from a patient, prevent relapse of a tumor, prevent tumor metastasis, induce remission in a patient, or any combination thereof.
- the methods induce a complete response. In other embodiments, the methods induce a partial response.
- Cancers that may be treated include tumors that are not vascularized, not yet substantially vascularized, or vascularized.
- the cancer may also include solid or non-solid tumors.
- the cancer is a hematologic cancer.
- the cancer is of the white blood cells.
- the cancer is of the plasma cells.
- the cancer is leukemia, lymphoma, or myeloma.
- the cancer is multiple myeloma, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), chronic or acute leukemia, myeloid diseases including but not limited to acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), T-cell lymphoma, one or more of B-cell acute lymphoid leukemia (“BALL”), T-cell acute lymphoid leukemia (“TALL”), acute lymphoid leukemia (ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blast
- the methods further comprise administering a chemotherapeutic.
- the chemotherapeutic selected is a lymphodepleting (preconditioning) chemotherapeutic.
- Beneficial preconditioning treatment regimens, along with correlative beneficial biomarkers are described in U.S. Provisional Patent Applications 62/262,143 and 62/167,750 which are hereby incorporated by reference in their entirety herein.
- methods of conditioning a patient in need of a T cell therapy comprising administering to the patient specified beneficial doses of cyclophosphamide (between 200 mg/m 2 /day and 2000 mg/m 2 /day) and specified doses of fludarabine (between 20 mg/m 2 /day and 900 mg/m 2 /day).
- a preferred dose regimen involves treating a patient comprising administering daily to the patient about 500 mg/m 2 /day of cyclophosphamide and about 60 mg/m 2 /day of fludarabine for three days prior to administration of a therapeutically effective amount of engineered T cells to the patient.
- the antigen binding molecule, transduced (or otherwise engineered) cells (such as CARs or TCRs), and the chemotherapeutic agent are administered each in an amount effective to treat the disease or condition in the subject.
- compositions comprising CAR- and/or TCR-expressing immune effector cells disclosed herein may be administered in conjunction with any number of chemotherapeutic agents.
- chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine resume; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
- paclitaxel (TAXOLTM, Bristol-Myers Squibb) and doxetaxel (TAXOTERE®, Rhone-Poulenc Rorer); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylomithine (DMFO); retinoic acid derivatives such as TargretinTM (bexarotene), PanretinTM, (alitretinoin); ONTAKTM (denileukin diftitox
- Combinations of chemotherapeutic agents are also administered where appropriate, including, but not limited to CHOP, i.e., Cyclophosphamide (Cytoxan®), Doxorubicin (hydroxydoxorubicin), Vincristine (Oncovin®), and Prednisone.
- CHOP Cyclophosphamide
- Doxorubicin hydroxydoxorubicin
- Vincristine Oncovin®
- Prednisone i.e., Cyclophosphamide (Cytoxan®)
- Doxorubicin hydroxydoxorubicin
- Vincristine Oncovin®
- Prednisone Prednisone
- additional therapeutic agents may be used in conjunction with the compositions described herein.
- additional therapeutic agents include PD-1 inhibitors such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), pembrolizumab, pidilizumab (CureTech), and atezolizumab (Roche).
- Additional therapeutic agents suitable for use in combination with the invention include, but are not limited to, ibrutinib (Imbruvica®), ofatumumab (Arzerra®), rituximab (Rituxan®), bevacizumab (Avastin®), trastuzumab (Herceptin®), trastuzumab emtansine (KADCYLA®), imatinib (Gleevec®), cetuximab (Erbitux®), panitumumab (Vectibix®), catumaxomab, ibritumomab, ofatumumab, tositumomab, brentuximab, alemtuzumab, gemtuzumab, erlotinib, gefitinib, vandetanib, afatinib, lapatinib, neratinib, axitinib, masitinib,
- the composition comprising CAR- and/or TCR-containing immune are administered with an anti-inflammatory agent.
- Anti-inflammatory agents or drugs can include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti-inflammatory drugs (NSAIDS) including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate.
- steroids and glucocorticoids including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, pre
- Exemplary NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors, and sialylates.
- Exemplary analgesics include acetaminophen, oxycodone, tramadol of proporxyphene hydrochloride.
- Exemplary glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone.
- Exemplary biological response modifiers include molecules directed against cell surface markers (e.g., CD4, CD5, etc.), cytokine inhibitors, such as the TNF antagonists, (e.g., etanercept (ENBREL®), adalimumab (HUMIRA®) and infliximab (REMICADE®), chemokine inhibitors and adhesion molecule inhibitors.
- TNF antagonists e.g., etanercept (ENBREL®), adalimumab (HUMIRA®) and infliximab (REMICADE®
- chemokine inhibitors esion molecule inhibitors.
- adhesion molecule inhibitors include monoclonal antibodies as well as recombinant forms of molecules.
- Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, Gold (oral (auranofin) and intramuscular), and minocycline.
- compositions described herein are administered in conjunction with a cytokine.
- cytokine as used herein is meant to refer to proteins released by one cell population that act on another cell as intercellular mediators. Examples of cytokines are lymphokines, monokines, and traditional polypeptide hormones.
- growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogen; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors (NGFs) such as NGF-beta; platelet-growth factor; transforming growth factors (TGFs) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoin
- FSH follicle
- BCMA expression was measured in various cell lines. BCMA was found to be expressed, with a fragments/kilobase of exon/million reads mapped (FPKM) greater than 35, in 99% of multiple myeloma tumor cell lines tested ( FIG. 2 A ). BCMA expression was greater than that of CD70, CS-1, CLL-1, DLL-1 and FLT3 ( FIG. 2 A ). To further characterize the expression of BCMA, EoL-1 (Sigma), NCI-H929 (Molecular Imaging), and MM1S (Molecular Imaging) cells were stained with an anti-BCMA antibody conjugated to PE (Biolegend, San Diego, Calif.) in stain buffer (BD Pharmingen, San Jose, Calif.) for 30 minutes at 4° C.
- PE Biolegend, San Diego, Calif.
- stain buffer BD Pharmingen, San Jose, Calif.
- FIGS. 2 B- 2 C BCMA expression was observed in the myeloma cell lines MM1S ( FIG. 2 C ) and NCI-H929 ( FIG. 2 D ), but not in the human eosinophil cell line EoL-1 ( FIG. 2 B ). In addition, little to no BCMA expression was observed in normal immune cells ( FIG. 2 E ).
- a third generation lentiviral transfer vector containing the BCMA CAR constructs was used along with the ViraPower Lentiviral Packaging Mix (Life Technologies, FIX′) to generate the lentiviral supernatants.
- a transfection mix was generated by mixing 15 ⁇ g of DNA and 22.5 ⁇ l of polyethileneimine (Polysciences, 1 mg/ml) in 600 ⁇ l of OptiMEM media. The transfection mix was incubated for 5 minutes at room temperature. Simultaneously, 293T cells (ATCC) were trypsinized and counted. A total of 10 ⁇ 10 6 total 293T cells were then plated in a T75 flask with the transfection mix. Following culture for three days, supernatants were collected and filtered through a 0.45 ⁇ m filter and stored at ⁇ 80° C.
- PBMCs Peripheral blood mononuclear cells
- Hemacare healthy donor leukopaks
- PBMCs peripheral blood mononuclear cells
- OKT3 Moromonab-CD3, 50 ng/ml, Miltenyi Biotec
- IL-2 300 IU/ml, Proleukin®, Prometheus® Therapeutics and Diagnostics
- MOI multiplicity of infection
- transduced T cells were stained with recombinant BCMA-Fc (R&D Systems) in stain buffer (BD Pharmingen) for 30 minutes at 4° C. Cells were then washed and stained with goat anti-human IgG Fc PE (Jackson ImmunoResearch, West Grove, Pa.) in stain buffer for 30 minutes at 4° C. Cells were then washed and resuspended in stain buffer with propidium iodide (BD Pharmingen) prior to data acquisition. All experiments were performed in two different donors. BCMA CAR expression was observed for each of the constructs in both Donor 1 ( FIG. 3 A ) and Donor 2 ( FIG. 3 B ) transduced cells.
- BCMA CAR expression was observed for each of the constructs in both Donor 1 ( FIG. 3 A ) and Donor 2 ( FIG. 3 B ) transduced cells.
- Effector cells e.g., anti-BCMA CAR T cells
- target cells were cultured with target cells at a 1:1 effector cell to target cell (E:T) ratio in R10 media 12 days after T cell stimulation.
- E:T effector cell to target cell
- Cell lines tested included EoL-1, NCI-H929 and MM1S.
- supernatants were analyzed by Luminex (EMD Millipore), according to the manufacturer's instructions, for production of the cytokines IFN ⁇ ( FIGS. 4 A- 4 B ), TNF ⁇ ( FIGS. 4 C- 4 D ), and IL-2 ( FIGS. 4 E- 4 F ).
- IFN ⁇ FIGS. 4 A- 4 B
- TNF ⁇ FIGS. 4 A- 4 B
- TNF ⁇ FIGS.
- FIGS. 4 E- 4 F were observed in the supernatant of NCI-H929 and MM1S target cell co-cultures for each anti-BCMA CAR T cell tested in both donors ( FIGS. 4 A- 4 B ); however, IFN ⁇ ( FIGS. 4 A- 4 B ), TNF ⁇ ( FIGS. 4 C- 4 D ), and IL-2 ( FIGS. 4 E- 4 F ) were only observed in the supernatant of EoL-1 target cell co-cultures above background for the IR negative control T cells ( FIG. 4 A ).
- Target cell viability was assessed by flow cytometric analysis of propidium iodide (PI) uptake of CD3 negative cells.
- the anti-BCMA CAR T cells were co-cultured with EoL1 ( FIGS. 5 A- 5 B ), NCI-H929 ( FIGS. 5 C- 5 D ), or MM1S ( FIGS. 5 E- 5 F ) target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours. Little cytolytic activity was observed in the EoL-1 co-cultures at any time period for the anti-BCMA CAR T cells ( FIG. 5 A- 5 B ). However, co-culture of the anti-BCMA CAR T cells and the NCI-H929 or MM1S target cells resulted in a decrease in the percentage of viable target cells at each time point measured for each of the anti-BCMA CAR T cells.
- anti-BCMA CAR T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) prior to co-culture with EoL-1, NCI-H929, or MM1S target cells at a 1:1 E:T ratio in R10 media.
- CFSE carboxyfluorescein succinimidyl ester
- Antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotinylation Kit from Pierce/ThermoFisher (Waltham, Mass.).
- Goat anti-human F(ab′)2 kappa-FITC (LC-FITC), Extravidin-PE (EA-PE) and streptavidin-633 (SA-633) were obtained from Southern Biotech (Birmingham, Ala.), Sigma (St. Louis, Mo.) and Molecular Probes/Invitrogen (Waltham, Mass.), respectively.
- Streptavidin MicroBeads and MACS LC separation columns were purchased from Miltenyi Biotec (Gladbachn, Germany).
- yeast cells ( ⁇ 1010 cells/library) were incubated with 3 ml of 100 nM biotinylated monomeric antigen or 10 nM biotinylated Fc fusion antigen for 15 minutes at room temperature in FACS wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)). After washing once with 50 ml ice-cold wash buffer, the cell pellet was resuspended in 40 mL wash buffer, and Streptavidin MicroBeads (500 ⁇ l) were added to the yeast and incubated for 15 minutes at 4° C.
- FACS wash buffer phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)
- PBS phosphate-buffered saline
- BSA bovine serum albumin
- yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL was loaded, the column was washed 3 times with 3 ml FACS wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight. The following rounds of sorting were performed using flow cytometry. Approximately 1 ⁇ 108 yeast were pelleted, washed three times with wash buffer, and incubated with decreasing concentrations of biotinylated monomeric or Fc fusion antigen (100 to 1 nM) under equilibrium conditions at room temperature.
- Yeast were then washed twice and stained with LC-FITC (diluted 1:100) and either SA-633 (diluted 1:500) or EA-PE (diluted 1:50) secondary reagents for 15 minutes at 4° C. After washing twice with ice-cold wash buffer, the cell pellets were resuspended in 0.4 mL wash buffer and transferred to strainer-capped sort tubes. Sorting was performed using a FACS ARIA sorter (BD Biosciences, San Jose, Calif.) and sort gates were assigned to select for specific binders relative to a background control. Subsequent rounds of selection were focused on reduction of non-specific reagent binders (utilizing soluble membrane proteins from CHO cell), as well as pressuring for affinity to BCMA. After the final round of sorting, yeast were plated and individual colonies were picked for characterization.
- LC-FITC diluted 1:100
- SA-633 diluted 1:500
- EA-PE diluted 1:50
- Binding optimization of na ⁇ ve clones was carried out using three maturation strategies: light chain diversification, diversification of VH CDRH1/CDRH2, and performing VHmut/VKmut selections.
- Light Chain Diversification Heavy chain plasmids were extracted and transformed into a light chain library with a diversity of 1 ⁇ 10 6 . Selections were performed as described above with one round of MACS sorting and two rounds of FACS sorting using 10 nM or 1 nM biotinylated antigen for respective rounds.
- CDRH1 and CDRH2 Selection A selected donor CDRH3 was recombined into a premade library with CDRH1 and CDRH2 variants of a diversity of 1 ⁇ 10 8 and selections were performed as described above. Affinity pressures were applied by incubating the biotinylated antigen-antibody yeast complex with unbiotinylated antigen for varying amounts of time to select for the highest affinity antibodies.
- VHmut/VKmut Selection This round of affinity maturation included error prone PCR-based mutagenesis of the heavy chain and/or light chain. Selections were performed similar to previous cycles, but employing FACS sorting for all selection rounds. Antigen concentration was reduced and cold antigen competition times were increased to pressure further for optimal affinity.
- Yeast clones were grown to saturation and then induced for 48 h at 30° C. with shaking. After induction, yeast cells were pelleted and the supernatants were harvested for purification. IgGs were purified using a Protein A column and eluted with acetic acid, pH 2.0. Fab fragments were generated by papain digestion and purified over KappaSelect (GE Healthcare LifeSciences, Pittsburgh, Pa.).
- ForteBio affinity measurements were performed generally as previously described (Estep et al., 2013). Briefly, ForteBio affinity measurements were performed by loading IgGs on-line onto AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 minutes and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded IgGs were exposed to 100 nM antigen for 5 minutes, afterwards they were transferred to assay buffer for 5 minutes for off-rate measurement. Kinetics were analyzed using the 1:1 binding model.
- Epitope binning/ligand blocking was performed using a standard sandwich format cross-blocking assay. Control anti-target IgG was loaded onto AHQ sensors and unoccupied Fc-binding sites on the sensor were blocked with an irrelevant human IgG1 antibody. The sensors were then exposed to 100 nM target antigen followed by a second anti-target antibody or ligand. Data was processed using ForteBio's Data Analysis Software 7.0. Additional binding by the second antibody or ligand after antigen association indicates an unoccupied epitope (non-competitor), while no binding indicates epitope blocking (competitor or ligand blocking).
- a TSKgel SuperSW mAb HTP column (22855) was used for fast SEC analysis of yeast produced mAbs at 0.4 mL/minute with a cycle time of 6 minutes/run. 200 mM Sodium Phosphate and 250 mM Sodium Chloride was used as the mobile phase.
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 272 EVQLLESGGGLVQPGGSLRL SCAASGFTFDDYAMA WVRQAPGKGLEWVS AISDAGDRTYY ADSVRG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARAEMGAVFDI WGQGTMVTVSS (SEQ ID NO: 273) SCAASGFTFDDYAMA [HC CDR1] (SEQ ID NO: 274) AISDAGDRTYYADSVRG [HC CDR2] (SEQ ID NO: 275) ARAEMGAVFDI [HC CDR3] Clone FS-26528 LC DNA (SEQ ID NO: 276) GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGG
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 277 EIVLTQSPATLSLSPGERATLSC RASQSVSRYLA WYQQKPGQAPRLLIY DASNRAT GIPARF SGSGSGTDFTLTISSLEPEDFAVYYC QQ RISWPFT FGGGTKVEIKR (SEQ ID NO: 278) RASQSVSRYLA [LC CDR1] (SEQ ID NO: 279) DASNRAT [LC CDR2] (SEQ ID NO: 280) QQRISWPFT [LC CDR3] Clone FS-26528 CAR DNA HxL (SEQ ID NO: 281) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAGGTGCAGCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT CCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGCCATGGCATGGGTC
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 286 QVQLVESGGGVVQPGRSLRLSCAASG FTFSEHGMH WVRQAPGKGLEWVA AISYDGRNKHY ADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARDGTYLGGLWYFDL WGRGTLVTVSS (SEQ ID NO: 287) FTFSEHGMH [HC CDR1] (SEQ ID NO: 288) AISYDGRNKHYADSVKG [HC CDR2] (SEQ ID NO: 289) ARDGTYLGGLWYFDL [HC CDR3] Clone PC-26534 LC DNA (SEQ ID NO: 290) GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC TGCAGAAGCCAGGGCAGTCTCCACAGCTC
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 291 DIVMTQSPLSLPVTPGEPASISC RSSQSLL H SNGYNYLD WYLQKPGQSPQLLIY LGSNRA S GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQGLGLPLT FGGGTKVEIKR (SEQ ID NO: 292) RSSQSLLHSNGYNYLD [LC CDR1] (SEQ ID NO: 293) LGSNRAS [LC CDR2] (SEQ ID NO: 294) MQGLGLPLT [LC CDR3] Clone PC-26534 CAR DNA HxL (SEQ ID NO: 295) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGGCAT
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 305 EIVMTQSPATLSVSPGERATLSC RASQSVSSNLA WYQQKPGQAPRLLIY GASTRAT GIPARF SGSGSGTEFTLTISSLQSEDFAVYYC QQYAAYPT FGGGTKVEIKR (SEQ ID NO: 306) RASQSVSSNLA (LC CDR1) (SEQ ID NO: 307) GASTRAT (LC CDR2) (SEQ ID NO: 308) QQYAAYPT (LC CDR3) Clone AJ-26545 CAR DNA HxL (SEQ ID NO: 309) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTT CCTGCAGGGCATCTGGATACACCTTCATGGAGCACTATATGCACTGGGTGCGACAGGCCCCT GG
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 314 QVQLVQSGAE VKKPGASVKV SCKASG YTFT EHYMH WVRQA PGQRLEWMG V IGPSGGKTSY AQKFQG RVTM TRDTSTSTVY MELSSLRSED TAVYYC ARES WPMDV WGQGT TVTVSS (SEQ ID NO: 315) YTFTEHYMH (HC CDR1) (SEQ ID NO: 316) VIGPSGGKTSYAQKFQG (HC CDR2) (SEQ ID NO: 317) ARESWPMDV (HC CDR3) Clone AJ-26554 LC DNA (SEQ ID NO: 318) GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGGTG
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 328 QVQLQESGPGLVKPSQTLSLTCTVSG GSIGSGGSYWS WIRQHPGKGLEWIG LIYYDGSTY YNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYC ARGRGYETSLAFDI WGQGTMVTVSS (SEQ ID NO: 329) GSIGSGGSYWS (HC CDR1) (SEQ ID NO: 330) LIYYDGSTYYNPSLKS (HC CDR2) (SEQ ID NO: 331) ARGRGYETSLAFDI (HC CDR3) Clone NM-26562 LC DNA (SEQ ID NO: 332) GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCT
- CDRs 1, 2, and 3 are underlined.
- EIVLTQSPATLSLSPGERATLSC RASQSVSSYLA WYQQKPGQAPRLLIY DASNRAT GIPA RFSGSGSGTDFTLTISSLEPEDFAVYYC QQRHVWPPT FGGGTKVEIKR (SEQ ID NO: 334) RASQSVSSYLA (LC CDR1) (SEQ ID NO: 335) DASNRAT (LC CDR2) (SEQ ID NO: 336) QQRHVWPPT (LC CDR3) Clone NM-26562 CAR DNA HxL (SEQ ID NO: 337) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCA CCTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCT
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 342 EVQLVESGGGLVQPGGSLRLSCAASG FTFSSYSMN WVRQAPGKGLEWVS TISSSSSIIYY ADSVKG RFTISRDNAKNSLYLQMNSLRAEDTAVYYC ARGSQEHLIFDY WGQGTLVTVSS (SEQ ID NO: 343) FTFSSYSMN (HC CDR1) (SEQ ID NO: 344) TISSSSSIIYYADSVKG (HC CDR2) (SEQ ID NO: 345) ARGSQEHLIFDY (HC CDR3) Clone TS-26564 LC DNA (SEQ ID NO: 346) GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACA
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 347 EIVLTQSPATLSLSPGERATLSC RASQSVSRYLA WYQQKPGQAPRLLIY DASNRAT GIPA RFSGSGSGTDFTLTISSLEPEDFAVYYC QQRFYYPWT FGGGTKVEIKR (SEQ ID NO: 348) RASQSVSRYLA (LC CDR1) (SEQ ID NO: 349) DASNRAT (LC CDR2) (SEQ ID NO: 350) QQRFYYPWT (LC CDR3) Clone TS-26564 CAR DNA HxL (SEQ ID NO: 351) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT CCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGG
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 356 QVQLVESGGG VVQPGRSLRL SCAASG FTFG SYGMH WVRQA PGKGLEWVAV I HYDGSVEYY ADSVKG RFTI SRDNSKDTLY LQMNSLRAED TAVYYC ARTD FWSGSPPSLD Y WGQGTLVTV SS
- SEQ ID NO: 357 FTFGSYGMH (HC CDR1) (SEQ ID NO: 358) VIHYDGSVEYYADSVKG (HC CDR2) (SEQ ID NO: 359) ARTDFWSGSPPSLDY (HC CDR3)
- Clone RY-26568 LC DNA (SEQ ID NO: 360) GACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGA AAGCC
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 361 DIQLTQSPSSVSASVGDRVTITC RASRGISSWLA WYQQKPGKAPKLLIY GASSLQS GVPSRF SGSGSGTDFTLTISSLQPEDFATYYC QQIYTFPFT FGGGTKVEIKR (SEQ ID NO: 362) RASRGISSWLA (LC CDR1) (SEQ ID NO: 363) GASSLQS (LC CDR2) (SEQ ID NO: 364) QQIYTFPFT (LC CDR3) Clone RY-26568 CAR DNA HxL (SEQ ID NO: 365) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACT
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 370 QVQLVQSGAEVKKPGSSVKVSCKASG GTLSSLAIS WVRQAPGQGLEWMG GVIPILGRANYAQ KFQG RVTITADESTSTAYMELSSLRSEDTAVYYC ARTPEYSSSIWHYYYGMDV WGQGTTVTV SS (SEQ ID NO: 371) GTLSSLAIS (HC CDR1) (SEQ ID NO: 372) GVIPILGRANYAQKFQG (HC CDR2) (SEQ ID NO: 373) ARTPEYSSSIWHYYYGMDV (HC CDR3) Clone PP-26575 LC DNA (SEQ ID NO: 374) GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT ACCAGCAGAAACCAGGACA
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 375 DIVMTQSPDSLAVSLGERATINC KSSQSVLYSSNNKNYLA WYQQKPGQPPKLLIY WASTR ES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQFAHTPFT FGGGTKVEIKR (SEQ ID NO: 376) KSSQSVLYSSNNKNYLA (LC CDR1) (SEQ ID NO: 377) WASTRES (LC CDR2) (SEQ ID NO: 378) QQFAHTPFT (LC CDR3) Clone PP-26575 CAR DNA HxL (SEQ ID NO: 379) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT CCTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCTA
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 384 QVRLVESGGGVVQPGRSLRLSCAASG FTFSSYGIH WVRQAPGKGLEWVA VIGYDGQEKYYAD SVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC VKGPLQEPPYAFGMDV WGQGTTVTVSS (SEQ ID NO: 385) FTFSSYGIH (HC CDR1) (SEQ ID NO: 386) VIGYDGQEKYYADSVKG (HC CDR2) (SEQ ID NO: 387) VKGPLQEPPYAFGMDV (HC CDR3) Clone RD-26576 LC DNA (SEQ ID NO: 388) GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC AGGCTCCCAGGCTCCT
- CDRs 1, 2, and 3 are underlined.
- EIVMTQSPATLSVSPGERATLSC RASQSVSSNLA WYQQKPGQAPRLLIY SASTRAT GIPA RFSGSGSGTEFTLTISSLQSEDFAVYYC QQHHVWPLT FGGGTKVEIKR (SEQ ID NO: 390) RASQSVSSNLA (LC CDR1) (SEQ ID NO: 391) SASTRAT (LC CDR2) (SEQ ID NO: 392) QQHHVWPLT (LC CDR3) Clone RD-26576 CAR DNA HxL (SEQ ID NO: 393) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGTCCGCCAG
- CDRs 1, 2, and 3 are underlined.
- SEQ ID NO: 403 EIVMTQSPATLSVSPGERATLSC RASQSVSSNLA WYQQKPGQAPRLLIY S ASTRAT GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC QQHHVWPLT FGGGTKVEIKR (SEQ ID NO: 404) RASQSVSSNLA (LC CDR1) (SEQ ID NO: 405) SASTRAT (LC CDR2) (SEQ ID NO: 406) QQHHVWPLT (LC CDR3) Clone RD-26578 CAR DNA HxL (SEQ ID NO: 407) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGGTCCGCC
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
Description
- This application is a continuation of U.S. application Ser. No. 16/569,341, filed Sep. 12, 2019, now U.S. Pat. No. 11,505,613, which is a continuation of U.S. application Ser. No. 15/476,309, filed Mar. 31, 2017, now U.S. Pat. No. 10,689,450, and claims the benefit of U.S. Provisional Patent Application No. 62/317,334, filed Apr. 1, 2016, all of which are hereby incorporated by reference in their entireties.
- The contents of the electronic sequence listing (76NT-353593-US3.xml; Size: 670,804 bytes; and Date of Creation: Jan. 12, 2023) is herein incorporated by reference in its entirety.
- This invention relates to chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule which binds to B-cell maturation antigen (BCMA), polynucleotides encoding the same, and methods of treating a cancer or other disease or disorder in a patient using the same.
- Human cancers are by their nature comprised of normal cells that have undergone a genetic or epigenetic conversion to become abnormal cancer cells. In doing so, cancer cells begin to express proteins and other antigens that are distinct from those expressed by normal cells. These aberrant tumor antigens can be used by the body's innate immune system to specifically target and kill cancer cells. However, cancer cells employ various mechanisms to prevent immune cells, such as T and B lymphocytes, from successfully targeting cancer cells.
- Human T cell therapies rely on enriched or modified human T cells to target and kill cancer cells in a patient. To increase the ability of T cells to target and kill a particular cancer cell, methods have been developed to engineer T cells to express constructs which direct T cells to a particular target cancer cell. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs), which comprise binding domains capable of interacting with a particular tumor antigen, allow T cells to target and kill cancer cells that express the particular tumor antigen.
- Current therapies for hematologic malignancies have shown varying levels of effectiveness with undesired side effects. Therefore, a need exists to identify novel and improved therapies for treating BCMA related diseases and disorders.
- The present invention is directed to an isolated polynucleotide encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) comprising a binding molecule that specifically binds to B-cell maturation antigen (BCMA), wherein the binding molecule comprises: (a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2X3X4X5X6X7SY (SEQ ID NO: 145) wherein: X2 is not present or G; X3 is not present or S; X4 is F, G, I, or Y; X5 is S or T; X6 is F or S; and X7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X11X3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is not present or G or S; X8 is N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17DX19 (SEQ ID NO: 147), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or A, D, G, P, R, or S; X5 is not present or E, F, G, L, Q, or T; X6 is not present or E, M, Q, W, or Y; X7 is not present or A, E, L, or S; X8 is not present or G, P, S, or T; X9 is not present or G, P, or S; X10 is not present or I, L, P, or Y; X11 is not present or W; X12 is not present or H; X13 is not present or E or Y; X14 is not present or D, G, H, P, S, W, or Y; X15 is A, G, L, W, or Y; X16 is not present or A, G, I, P, or V; X17 is F, L, or M; and X19 is I, L, V, or Y; and/or (d) a light chain variable region (VL) CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D; (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7(SEQ ID NO: 149), wherein X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In another embodiment, the invention is directed to an isolated polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, wherein the antibody or the antigen binding molecule thereof comprises: (a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2X3X4X5X6X7SY (SEQ ID NO: 145), wherein: X2 is not present or G; X3 is not present or S; X4 is F, G, I, or Y; X5 is S or T; X6 is F or S; and X7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is not present or G or S; X8 is N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17DX19 (SEQ ID NO: 147), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or A, D, G, P, R, or S; X5 is not present or E, F, G, L, Q, or T; X6 is not present or E, M, Q, W, or Y; X7 is not present or A, E, L, or S; X8 is not present or G, P, S, or T; X9 is not present or G, P, or S; X10 is not present or I, L, P, or Y; X11 is not present or W; X12 is not present or H; X13 is not present or E or Y; X14 is not present or D, G, H, P, S, W, or Y; X15 is A, G, L, W, or Y; X16 is not present or A, G, I, P, or V; X17 is F, L, or M; and X19 is I, L, V, or Y; and/or (d) a light chain variable region (VL) CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D; (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 149), wherein X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In some embodiments, the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9-16. In some embodiments, the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25-32. In some embodiments, the VL CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 81-88. In some embodiments, the VL CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 97-104. In some embodiments, the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 113-120.
- In some embodiments, the binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 9; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 25; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 41; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113; (b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 10; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 42; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114; (c) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 43; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115; (d) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 12; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 28; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 44; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116; (e) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 13; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 45; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117; (f) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 14; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 46; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118; (g) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 47; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119; or (h) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 16; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 32; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 48; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120.
- In some embodiments, the binding molecule is single chained. In some embodiments, the binding molecule comprises an scFv.
- In some embodiments, the CAR comprises a transmembrane domain. In some embodiments, the transmembrane domain is a transmembrane domain of CD28, 4-1BB/CD137, CD8 (e.g., CD8 alpha, CD4, CD19, CD3 epsilon, CD45, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, a zeta chain of a T cell receptor, or any combination thereof. In some embodiments, the CAR comprises a hinge region between the transmembrane domain and the binding molecule. In some embodiments, the hinge region is of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, CD28, or CD8 alpha. In some embodiments, the CAR or TCR comprises a costimulatory region. In some embodiments, the costimulatory region is a signaling region of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT (tumor necrosis
factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof. In some embodiments, the CAR or TCR comprises an activation domain. In some embodiments, the activation domain is a CD3 zeta domain. - In other embodiments, the invention is directed to a vector comprising the polynucleotide or a polypeptide encoded by the polynucleotide.
- In certain embodiments, the invention is directed to a cell comprising the polynucleotide, the vector, the polypeptide, or any combination thereof. In other embodiments, the invention is directed to a cell, e.g., an immune cell, e.g., a tumor-infiltrating lymphocyte (TIL), autologous T cell, engineered autologous T cell (eACT), an allogeneic T cell, or any combination thereof.
- In other embodiments, the invention is directed to a method of inducing an immunity against a tumor comprising administering to a subject an effective amount of a cell comprising the polynucleotide, the vector, the polypeptide, or any combination thereof. Other aspects of the invention include a method of treating a cancer in a subject in need thereof comprising administering to the subject the polynucleotide, the vector, the polypeptide, the cell, or the composition. The cancer treatable by the method can be a hematologic cancer.
-
FIG. 1A-1F show CLUTSTAL W (1.83) multiple sequence alignments of eight example anti-BCMA binding molecules disclosed herein.FIG. 1A shows a sequence alignment of example anti-BCMA binding molecules comprising a VH domain. Complementarity determining regions (CDRs) and framework regions (FRs) are shown, as determined by Chothia.FIG. 1B is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated inFIG. 1A .FIG. 1C shows a sequence alignment of example anti-BCMA binding molecules comprising a VH domain, with alternate CDRs and FRs shown.FIG. 1D is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated inFIG. 1C .FIG. 1E shows a sequence alignment of example anti-BCMA binding molecules comprising a VL domain. CDRs and FRs are shown, as determined by Chothia.FIG. 1F is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated inFIG. 1E . -
FIGS. 2A-2F show BCMA expression in various cells.FIG. 2A shows multiple myeloma cell expression of BCMA, CD138, CS-1, CD38, and CD19. Box-plot analysis shows the distribution of gene expression levels in the various multiple myeloma cell lines tested (FIG. 2A ).FIGS. 2B-2D show BCMA expression in EoL1 (FIG. 2B ), MM1S (FIG. 2C ), and NCI-H929 (FIG. 2D ) cancer cell lines as measured by flow cytometric analysis of BCMA cell surface expression on the respective cell lines.FIG. 2E shows the expression of BCMA, CS-1, CLL-1, DLL3, CD70, and FLT3 in alternatively activated macrophages; CD14-positive, CD16-negative cells; CD38-negative naïve B cells; CD4-positive, alpha-beta T cells; central memory CD4-positive cells; central memory CD8-positive cells; class switched memory B cells; cytotoxic CD56-dim natural killer cell; effector memory CD4-positive cells; effector memory CD8-positive cells; inflammatory macrophages; macrophages; mature neutrophils; memory B cells; monocytes; myeloid cells; and regulatory T cells.FIG. 2F shows the expression of BCMA, CD138, CS-1, CD38, and CD19 in the same cell types as inFIG. 2E . Gene expression is shown as fragments per kilobase of exon per million reads mapped (FPKM) (FIG. 2A ,FIG. 2E , andFIG. 2F ). -
FIG. 3A andFIG. 3B show CAR expression in lentivirus transduced primary human T cells from a first healthy donor (FIG. 3A ) and a second healthy donor (FIG. 3B ). -
FIGS. 4A-4F shows IFNγ, TNFα, and IL-2 production by lentivirus transduced CAR T cells from two healthy donors following 16 hours of co-cultured with EoL-1 (Black), NCI-H929 (light grey), or MM1S (grey) target cell lines.FIGS. 4A and 4B show the IFNγ (pg/ml; y-axis) production in lentivirus transduced CAR T cells from a first donor (FIG. 4A ) and a second donor (FIG. 4B ).FIGS. 4C and 4D show the TNFα (pg/ml; y-axis) production in lentivirus transduced CAR T cells from a first donor (FIG. 4C ) and a second donor (FIG. 4D ).FIGS. 4E and 4F show the IL-2 production (pg/ml; y-axis) in lentivirus transduced CAR T cells from a first donor (FIG. 4E ) and a second donor (FIG. 4F ). -
FIGS. 5A-5F show the average cytolytic activity (as a percentage of viable target cells remaining; y-axis) over time from two healthy donors expressing the indicated CARs co-cultured with EoL1 (FIGS. 5A and 5B ), NCI-H929 (FIGS. 5C and 5D ), or MM1S (FIGS. 5E and 5F ) target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.FIGS. 5A and 5B show the average cytolytic activity of transduced CART cells from a first donor (FIG. 5A ) and a second donor (FIG. 5B ) co-cultured with EoL1 target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.FIGS. 5C and 5D show the average cytolytic activity of transduced CAR T cells from a first donor (FIG. 5C ) and a second donor (FIG. 5D ) co-cultured with NCI-H929 target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.FIGS. 5E and 5F show the average cytolytic activity of transduced CART cells from a first donor (FIG. 5E ) and a second donor (FIG. 5F ) co-cultured with MM1S target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours. -
FIGS. 6A and 6B show proliferation of CFSE-labeled lentivirus transduced CART cells from a first healthy donor (FIG. 6A ) and a second healthy donor (FIG. 6B ) following 5 days of co-culture with CD3-CD28 beads (top row), EoL-1 (second row), NCI-H929 (third row), or MM1S (bottom row) target cell lines. - In the Figure descriptions below, underlined sequences denote CDR regions calculated using Chothia.
-
FIG. 7A shows Clone FS-26528 HC DNA sequence (SEQ ID NO: 271) -
FIG. 7B shows Clone FS-26528 HC AA sequence (SEQ ID NO: 272) -
FIG. 7C shows HC CDR sequences for clone FS-26528. -
FIG. 7D shows Clone FS-26528 LC DNA sequence (SEQ ID NO: 276). -
FIG. 7E shows Clone FS-26528 LC AA sequence (SEQ ID NO: 277). -
FIG. 7F shows LC CDR sequences for clone FS-26528. -
FIG. 7G shows Clone FS-26528 CAR DNA H×L sequences (SEQ ID NO: 281) -
FIG. 7H shows Clone FS-26528 CAR H×L AA sequences (SEQ ID NO: 282) -
FIG. 7I shows Clone FS-26528 CAR DNA L×H sequences (SEQ ID NO: 283). -
FIG. 7J shows Clone FS-26528 CAR L×H sequences (SEQ ID NO: 284). -
FIG. 8A shows Clone PC-26534 HC DNA sequence (SEQ ID NO: 285). -
FIG. 8B shows Clone PC-26534 HC sequence (SEQ ID NO: 286). -
FIG. 8C shows HC CDR sequences for clone FS-26528. -
FIG. 8D shows Clone PC-26534 LC DNA sequences (SEQ ID NO: 290). -
FIG. 8E shows the Clone PC-26534 LC sequence (SEQ ID NO: 291). -
FIG. 8F shows LC CDR sequences for Clone PC-26534. -
FIG. 8G shows the Clone PC-26534 CAR DNA H×L sequence (SEQ ID NO: 295). -
FIG. 8H shows the Clone PC-26534 CAR H×L AA sequence (SEQ ID NO: 296) -
FIG. 8I shows the Clone PC-26534 CAR DNA L×H sequence (SEQ ID NO: 297). -
FIG. 8J shows Clone PC-26534 CAR L×H sequence (SEQ ID NO: 298). -
FIG. 9A shows Clone AJ-26545 HC DNA sequence (SEQ ID NO: 299). -
FIG. 9B shows Clone AJ-26545 variable HC sequence (SEQ ID NO: 300). -
FIG. 9C shows HC CDR sequences for Clone AJ-26545. -
FIG. 9D shows Clone AJ-26545 variable LC DNA sequence (SEQ ID NO: 304). -
FIG. 9E shows Clone AJ-26545 variable LC AA sequence (SEQ ID NO: 305) -
FIG. 9F shows Clone AJ-26545 LC CDR sequences. -
FIG. 9G shows Clone AJ-26545 CAR DNA H×L sequence (SEQ ID NO: 309). -
FIG. 9H shows Clone AJ-26545 CAR H×L AA sequence (SEQ ID NO: 310) -
FIG. 9I shows Clone AJ-26545 CAR DNA L×H sequence (SEQ ID NO: 311) -
FIG. 9J shows Clone AJ-26545 CAR L×H sequence (SEQ ID NO: 312). -
FIG. 10A shows Clone AJ-26554 HC DNA sequence (SEQ ID NO: 313) -
FIG. 10B shows Clone AJ-26554 HC AA sequence (SEQ ID NO: 314). -
FIG. 10C shows Clone AJ-26554 HC CDR sequences -
FIG. 10D shows Clone AJ-26554 LC DNA sequence (SEQ ID NO: 318). -
FIG. 10E shows Clone AJ-26554 LC AA sequence (SEQ ID NO: 319). -
FIG. 10F shows Clone AJ-26554 LC CDR sequences. -
FIG. 10G shows Clone AJ-26554 CAR DNA H×L chain sequences (SEQ ID NO: 323). -
FIG. 10H shows Clone AJ-26554 CAR H×L chain AA sequences (SEQ ID NO: 324). -
FIG. 10I shows Clone AJ-26554 CAR DNA L×H chain sequences (SEQ ID NO: 325). -
FIG. 10J shows Clone AJ-26554 CAR L×H AA sequences (SEQ ID NO: 326). -
FIG. 11A shows Clone NM-26562 HC DNA sequence (SEQ ID NO: 327). -
FIG. 11B shows Clone NM-26562 HC AA sequence (SEQ ID NO: 328). -
FIG. 11C shows Clone NM-26562 HC CDR sequences. -
FIG. 11D shows Clone NM-26562 LC DNA sequence (SEQ ID NO: 332). -
FIG. 11E shows Clone NM-26562 LC AA sequence (SEQ ID NO: 333). -
FIG. 11F shows the Clone NM-26562 LC CDR sequences. -
FIG. 11G shows the Clone NM-26562 CAR DNA H×L sequences (SEQ ID NO: 337) -
FIG. 11H shows Clone NM-26562 CAR H×L AA sequences (SEQ ID NO: 338). -
FIG. 11I shows Clone NM-26562 CAR DNA L×H sequences (SEQ ID NO: 339). -
FIG. 11J shows Clone NM-26562 CAR L×H AA sequences (SEQ ID NO: 340). -
FIG. 12A shows Clone TS-26564 HC DNA sequence (SEQ ID NO: 341). -
FIG. 12B shows Clone TS-26564 HC AA sequence (SEQ ID NO: 342). -
FIG. 12C shows the Clone TS-26564 HC CDR sequences. -
FIG. 12D shows the Clone TS-26564 LC DNA sequence (SEQ ID NO: 346). -
FIG. 12E shows the Clone TS-26564 LC AA sequence (SEQ ID NO: 347). -
FIG. 12F shows the Clone TS-26564 LC CDR sequences. -
FIG. 12G shows the Clone TS-26564 CAR DNA H×L sequences (SEQ ID NO: 351). -
FIG. 12H shows the Clone TS-26564 CAR H×L chain AA sequences (SEQ ID NO: 352). -
FIG. 12I shows the Clone TS-26564 CAR DNA L×H sequences (SEQ ID NO: 353) -
FIG. 12J shows the Clone TS-26564 CAR L×H AA sequences (SEQ ID NO: 354) -
FIG. 13A shows the Clone RY-26568 HC DNA sequence (SEQ ID NO: 355) -
FIG. 13B shows the Clone RY-26568 HC AA sequence (SEQ ID NO: 356). -
FIG. 13C shows the Clone RY-26568 HC CDR sequences. -
FIG. 13D shows the Clone RY-26568 LC DNA sequence (SEQ ID NO: 360). -
FIG. 13E shows the Clone RY-26568 LC AA sequence (SEQ ID NO: 361). -
FIG. 13F shows the Clone RY-26568 LC CDR AA sequences. -
FIG. 13G shows the Clone RY-26568 CAR DNA H×L sequences (SEQ ID NO: 365) -
FIG. 13H shows the Clone RY-26568 CAR H×L AA sequences (SEQ ID NO: 366). -
FIG. 13I shows the Clone RY-26568 CAR DNA L×H sequences (SEQ ID NO: 367). -
FIG. 13J shows the Clone RY-26568 CAR L×H AA sequences (SEQ ID NO: 368). -
FIG. 14A shows the Clone PP-26575 HC DNA sequence (SEQ ID NO: 369). -
FIG. 14B shows the Clone PP-26575 HC AA sequence (SEQ ID NO: 370). -
FIG. 14C shows the Clone PP-26575 HC CDR AA sequences. -
FIG. 14D shows the Clone PP-26575 LC DNA sequence (SEQ ID NO: 374). -
FIG. 14E shows the Clone PP-26575 LC AA sequence (SEQ ID NO: 375). -
FIG. 14F shows the Clone PP-26575 LC CDR AA sequences. -
FIG. 14G shows the Clone PP-26575 CAR DNA H×L sequences (SEQ ID NO: 379). -
FIG. 14H shows Clone PP-26575 CAR H×L AA sequences (SEQ ID NO: 380). -
FIG. 14I shows Clone PP-26575 CAR DNA L×H sequence (SEQ ID NO: 381). -
FIG. 14J shows the Clone PP-26575 CAR L×H AA sequence (SEQ ID NO: 382). -
FIG. 15A shows the Clone RD-26576 HC DNA sequence (SEQ ID NO: 383) -
FIG. 15B shows Clone RD-26576 HC AA sequence (SEQ ID NO: 384). -
FIG. 15C shows the Clone RD-26576 HC CDR sequences. -
FIG. 15D shows the Clone RD-26576 LC DNA sequence (SEQ ID NO: 388) -
FIG. 15E shows the Clone RD-26576 LC AA sequence (SEQ ID NO: 389). -
FIG. 15F shows the Clone RD-26576 LC CDR sequences. -
FIG. 15G shoes the Clone RD-26576 CAR DNA H×L sequences (SEQ ID NO: 393). -
FIG. 15H shows the Clone RD-26576 CAR H×L chain AA sequences (SEQ ID NO: 394). -
FIG. 15I shows the Clone RD-26576 CAR DNA L×H sequences (SEQ ID NO: 395). -
FIG. 15J shows the Clone RD-26576 CAR L×H AA sequences (SEQ ID NO: 396). -
FIG. 16A shows the Clone RD-26578 HC DNA sequences (SEQ ID NO: 397). -
FIG. 16B shows the Clone RD-26578 HC AA sequence (SEQ ID NO: 398). -
FIG. 16C shows the Clone RD-26578 HC CDR AA sequences. -
FIG. 16D shows the Clone RD-26578 LC DNA sequence (SEQ ID NO: 402). -
FIG. 16E shows the Clone RD-26578 LC AA sequence (SEQ ID NO: 403) -
FIG. 16F shows the Clone RD-26578 LC CDR sequences. -
FIG. 16G shows the Clone RD-26578 CAR DNA H×L chain sequence (SEQ ID NO: 407). -
FIG. 16H shows the Clone RD-26578 CAR H×L AA sequence (SEQ ID NO: 408). -
FIG. 16I shows the Clone RD-26578 CAR DNA L×H sequences (SEQ ID NO: 409). -
FIG. 16J shows the Clone RD-26578 CAR L×H AA sequence (SEQ ID NO: 410). -
FIG. 17 shows the outcome of an in vivo study examining the efficacy of clone RD-21530 in a subcutaneous RPMI-8226 mouse model. Cohorts of 10 mice each were tested for the CAR (dashed lines) and mock transduced (bolded lines) T cells. -
FIG. 18A andFIG. 18B show the outcome of an in vitro cytotoxicity assay using the optimized BCMA scFv variants cocultured with NCI-H929 and MM.1S cells, respectively. CAR T cells using these optimized scFvs were incubated overnight with luciferase labeled target cells in 3:1 and 1:1 effector to target cell ratios. -
FIG. 19 shows the pGAR vector map. - The present invention relates to antibodies, antigen binding molecules thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, which bind BCMA, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy, e.g., an autologous cell therapy (eACT™), for the treatment of a patient suffering from a cancer. In particular, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
- In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application.
- The term “and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
- It is understood that wherever aspects are described herein with the language “comprising,” otherwise analogous aspects described in terms of “consisting of” and/or “consisting essentially of” are also provided.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.
- Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
- “Administering” refers to the physical introduction of an agent to a subject, using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes of administration for the formulations disclosed herein include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase “parenteral administration” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation. In some embodiments, the formulation is administered via a non-parenteral route, e.g., orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
- The term “antibody” (Ab) includes, without limitation, a glycoprotein immunoglobulin which binds specifically to an antigen. In general, and antibody can comprise at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen binding molecule thereof. Each H chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region comprises three constant domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprises one constant domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the Abs may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
- Antibodies can include, for example, monoclonal antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain-antibody heavy chain pair, intrabodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), heteroconjugate antibodies, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain Fvs (scFv), camelized antibodies, affybodies, Fab fragments, F(ab′)2 fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (including, e.g., anti-anti-Id antibodies), minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), and antigen-binding fragments of any of the above. In certain embodiments, antibodies described herein refer to polyclonal antibody populations.
- An immunoglobulin may derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM. IgG subclasses are also well known to those in the art and include but are not limited to human IgG1, IgG2, IgG3 and IgG4. “Isotype” refers to the Ab class or subclass (e.g., IgM or IgG1) that is encoded by the heavy chain constant region genes. The term “antibody” includes, by way of example, both naturally occurring and non-naturally occurring Abs; monoclonal and polyclonal Abs; chimeric and humanized Abs; human or nonhuman Abs; wholly synthetic Abs; and single chain Abs. A nonhuman Ab may be humanized by recombinant methods to reduce its immunogenicity in man. Where not expressly stated, and unless the context indicates otherwise, the term “antibody” also includes an antigen-binding fragment or an antigen binding molecule of any of the aforementioned immunoglobulins, and includes a monovalent and a divalent fragment or portion, and a single chain Ab.
- An “antigen binding molecule,” “antigen binding portion,” or “antibody fragment” refers to any molecule that comprises the antigen binding parts (e.g., CDRs) of the antibody from which the molecule is derived. An antigen binding molecule can include the antigenic complementarity determining regions (CDRs). Examples of antibody fragments include, but are not limited to, Fab, Fab′, F(ab′)2, and Fv fragments, dAb, linear antibodies, scFv antibodies, and multispecific antibodies formed from antigen binding molecules. Peptibodies (i.e., Fc fusion molecules comprising peptide binding domains) are another example of suitable antigen binding molecules. In some embodiments, the antigen binding molecule binds to an antigen on a tumor cell. In some embodiments, the antigen binding molecule binds to an antigen on a cell involved in a hyperproliferative disease or to a viral or bacterial antigen. In certain embodiments, the antigen binding molecule binds to BCMA. In further embodiments, the antigen binding molecule is an antibody of fragment thereof, including one or more of the complementarity determining regions (CDRs) thereof. In further embodiments, the antigen binding molecule is a single chain variable fragment (scFv). In some embodiments, the antigen binding molecule comprises or consists of avimers.
- As used herein, the terms “variable region” or “variable domain” are used interchangeably and are common in the art. The variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-
terminal 110 to 120 amino acids in the mature heavy chain and about 90 to 115 amino acids in the mature light chain, which differ extensively in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR). Without wishing to be bound by any particular mechanism or theory, it is believed that the CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with antigen. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and human framework regions (FRs). In particular embodiments, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FRs). - The terms “VL” and “VL domain” are used interchangeably to refer to the light chain variable region of an antibody or an antigen-binding fragment thereof.
- The terms “VH” and “VH domain” are used interchangeably to refer to the heavy chain variable region of an antibody or an antigen-binding fragment thereof.
- A number of definitions of the CDRs are commonly in use: Kabat numbering, Chothia numbering, AbM numbering, or contact numbering. The AbM definition is a compromise between the two used by Oxford Molecular's AbM antibody modelling software. The contact definition is based on an analysis of the available complex crystal structures.
-
TABLE 1 CDR Numbering Loop Kabat AbM Chothia Contact L1 L24 - - - L34 L24 - - - L34 L24 - - - L34 L30 - - - L36 L2 L50 - - - L56 L50 - - - L56 L50 - - - L56 L46 - - - L55 L3 L89 - - - L97 L89 - - - L97 L89 - - - L97 L89 - - - L96 H1 H31 - - - H35B H26 - - - H35B H26 - - - H32 . . . 34 H30 - - - H35B (Kabat Numbering) H1 H31 - - - H35 H26 - - - H35 H26 - - - H32 H30 - - - H35 (Chothia Numbering) H2 H50 - - - H65 H50 - - - H58 H52 - - - H56 H47 - - - H58 H3 H95 - - - H102 H95 - - - H102 H95 - - - H102 H93 - - - H101 - The term “Kabat numbering” and like terms are recognized in the art and refer to a system of numbering amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding molecule thereof. In certain aspects, the CDRs of an antibody can be determined according to the Kabat numbering system (see, e.g., Kabat EA & Wu TT (1971) Ann NY Acad Sci 190: 382-391 and Kabat E A et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Using the Kabat numbering system, CDRs within an antibody heavy chain molecule are typically present at amino acid positions 31 to 35, which optionally can include one or two additional amino acids, following 35 (referred to in the Kabat numbering scheme as 35A and 35B) (CDR1), amino acid positions 50 to 65 (CDR2), and amino acid positions 95 to 102 (CDR3). Using the Kabat numbering system, CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3). In a specific embodiment, the CDRs of the antibodies described herein have been determined according to the Kabat numbering scheme.
- In certain aspects, the CDRs of an antibody can be determined according to the Chothia numbering scheme, which refers to the location of immunoglobulin structural loops (see, e.g., Chothia C & Lesk AM, (1987), J Mol Biol 196: 901-917; Al-Lazikani B et al., (1997) J Mol Biol 273: 927-948; Chothia C et al., (1992) J Mol Biol 227: 799-817; Tramontano A et al., (1990) J Mol Biol 215(1): 175-82; and U.S. Pat. No. 7,709,226). Typically, when using the Kabat numbering convention, the Chothia CDR-H1 loop is present at heavy
chain amino acids 26 to 32, 33, or 34, the Chothia CDR-H2 loop is present at heavychain amino acids 52 to 56, and the Chothia CDR-H3 loop is present at heavychain amino acids 95 to 102, while the Chothia CDR-L1 loop is present at lightchain amino acids 24 to 34, the Chothia CDR-L2 loop is present at lightchain amino acids 50 to 56, and the Chothia CDR-L3 loop is present at lightchain amino acids 89 to 97. The end of the Chothia CDR-HI loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). In a specific embodiment, the CDRs of the antibodies described herein have been determined according to the Chothia numbering scheme. - As used herein, the terms “constant region” and “constant domain” are interchangeable and have a meaning common in the art. The constant region is an antibody portion, e.g., a carboxyl terminal portion of a light and/or heavy chain which is not directly involved in binding of an antibody to antigen but which can exhibit various effector functions, such as interaction with the Fc receptor. The constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence relative to an immunoglobulin variable domain.
- As used herein, the term “heavy chain” when used in reference to an antibody can refer to any distinct type, e.g., alpha (α), delta (δ), epsilon (ε), gamma (γ) and mu (μ), based on the amino acid sequence of the constant domain, which give rise to IgA, IgD, IgE, IgG and IgM classes of antibodies, respectively, including subclasses of IgG, e.g., IgG1, IgG2, IgG3 and IgG4.
- As used herein, the term “light chain” when used in reference to an antibody can refer to any distinct type, e.g., kappa (κ) or lambda (λ) based on the amino acid sequence of the constant domains. Light chain amino acid sequences are well known in the art. In specific embodiments, the light chain is a human light chain.
- “Binding affinity” generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (KD), and equilibrium association constant (KA). The KD is calculated from the quotient of koff/kon, whereas KA is calculated from the quotient of kon/koff. kon refers to the association rate constant of, e.g., an antibody to an antigen, and koff refers to the dissociation of, e.g., an antibody to an antigen. The kon and koff can be determined by techniques known to one of ordinary skill in the art, such as BIAcore® or KinExA.
- As used herein, a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In certain embodiments, one or more amino acid residues within a CDR(s) or within a framework region(s) of an antibody or antigen-binding fragment thereof can be replaced with an amino acid residue with a similar side chain.
- As used herein, an “epitope” is a term in the art and refers to a localized region of an antigen to which an antibody can specifically bind. An epitope can be, for example, contiguous amino acids of a polypeptide (linear or contiguous epitope) or an epitope can, for example, come together from two or more non-contiguous regions of a polypeptide or polypeptides (conformational, non-linear, discontinuous, or non-contiguous epitope). In certain embodiments, the epitope to which an antibody binds can be determined by, e.g., NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization may be accomplished using any of the known methods in the art (e.g., Giegé R et al., (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189: 1-23; Chayen N E (1997) Structure 5: 1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303). Antibody:antigen crystals may be studied using well known X-ray diffraction techniques and may be refined using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see e.g. Meth Enzymol (1985)
volumes 114 & 115, eds Wyckoff H W et al.; U.S. 2004/0014194), and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49(Pt 1): 37-60; Bricogne G (1997) Meth Enzymol 276A: 361-423, ed Carter C W; Roversi P et al., (2000) Acta Crystallogr D Biol Crystallogr 56(Pt 10): 1316-1323). Mutagenesis mapping studies may be accomplished using any method known to one of skill in the art. See, e.g., Champe M et al., (1995) J Biol Chem 270: 1388-1394 and Cunningham B C & Wells J A (1989) Science 244: 1081-1085 for a description of mutagenesis techniques, including alanine scanning mutagenesis techniques. - As used herein, an antigen binding molecule, an antibody, or an antigen binding molecule thereof “cross competes” with a reference antibody or an antigen binding molecule thereof if the interaction between an antigen and the first binding molecule, an antibody, or an antigen binding molecule thereof blocks, limits, inhibits, or otherwise reduces the ability of the reference binding molecule, reference antibody, or an antigen binding molecule thereof to interact with the antigen. Cross competition can be complete, e.g., binding of the binding molecule to the antigen completely blocks the ability of the reference binding molecule to bind the antigen, or it can be partial, e.g., binding of the binding molecule to the antigen reduces the ability of the reference binding molecule to bind the antigen. In certain embodiments, an antigen binding molecule that cross competes with a reference antigen binding molecule binds the same or an overlapping epitope as the reference antigen binding molecule. In other embodiments, the antigen binding molecule that cross competes with a reference antigen binding molecule binds a different epitope as the reference antigen binding molecule. Numerous types of competitive binding assays can be used to determine if one antigen binding molecule competes with another, for example: solid phase direct or indirect radioimmunoassay (RIA); solid phase direct or indirect enzyme immunoassay (EIA); sandwich competition assay (Stahli et al., 1983, Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (Kirkland et al., 1986, J. Immunol. 137:3614-3619); solid phase direct labeled assay, solid phase direct labeled sandwich assay (Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using 1-125 label (Morel et al., 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (Cheung, et al., 1990, Virology 176:546-552); and direct labeled RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82).
- As used herein, the terms “immunospecifically binds,” “immunospecifically recognizes,” “specifically binds,” and “specifically recognizes” are analogous terms in the context of antibodies and refer to molecules that bind to an antigen (e.g., epitope or immune complex) as such binding is understood by one skilled in the art. For example, a molecule that specifically binds to an antigen may bind to other peptides or polypeptides, generally with lower affinity as determined by, e.g., immunoassays, BIAcore®,
KinExA 3000 instrument (Sapidyne Instruments, Boise, Id.), or other assays known in the art. In a specific embodiment, molecules that specifically bind to an antigen bind to the antigen with a KA that is at least 2 logs, 2.5 logs, 3 logs, 4 logs or greater than the KA when the molecules bind to another antigen. - In another embodiment, specific embodiment, molecules that specifically bind to an antigen bind with a dissociation constant (Kd) of about 1×10−7 M. In some embodiments, the antigen binding molecule specifically binds an antigen with “high affinity” when the Kd is about 1×10−9 M to about 5×10−9 M. In some embodiments, the antigen binding molecule specifically binds an antigen with “very high affinity” when the Kd is 1×10−10 M to about 5×10−10 M. In one embodiment, the antigen binding molecule has a Kd of 10−9 M. In one embodiment, the off-rate is less than about 1×10−5. In other embodiments, the antigen binding molecule binds human BCMA with a Kd of between about 1×10−7 M and about 1×10−13 M. In yet another embodiment, the antigen binding molecule binds human BCMA with a Kd of about 1×10−10 M to about 5×10−10 M.
- In another specific embodiment, molecules that specifically bind to an antigen do not cross react with other proteins under similar binding conditions. In another specific embodiment, molecules that specifically bind to an antigen do not cross react with other non-BCMA proteins. In a specific embodiment, provided herein is an antibody or fragment thereof that binds to BCMA with higher affinity than to another unrelated antigen. In certain embodiments, provided herein is an antibody or fragment thereof that binds to BCMA (e.g., human BCMA) with a 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher affinity than to another, unrelated antigen as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay. In a specific embodiment, the extent of binding of an anti-BCMA antibody or antigen-binding fragment thereof described herein to an unrelated, non-BCMA protein is less than 10%, 15%, or 20% of the binding of the antibody to BCMA protein as measured by, e.g., a radioimmunoassay.
- In a specific embodiment, provided herein is an antibody or fragment thereof that binds to human BCMA with higher affinity than to another species of BCMA. In certain embodiments, provided herein is an antibody or fragment thereof that binds to human BCMA with a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or higher affinity than to another species of BCMA as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay. In a specific embodiment, an antibody or fragment thereof described herein, which binds to human BCMA, will bind to another species of BCMA protein with less than 10%, 15%, or 20% of the binding of the antibody or fragment thereof to the human BCMA protein as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay.
- An “antigen” refers to any molecule that provokes an immune response or is capable of being bound by an antibody or an antigen binding molecule. The immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. A person of skill in the art would readily understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. An antigen can be endogenously expressed, i.e. expressed by genomic DNA, or can be recombinantly expressed. An antigen can be specific to a certain tissue, such as a cancer cell, or it can be broadly expressed. In addition, fragments of larger molecules can act as antigens. In one embodiment, antigens are tumor antigens. In one particular embodiment, the antigen is BCMA.
- The term “neutralizing” refers to an antigen binding molecule, scFv, antibody, or a fragment thereof that binds to a ligand and prevents or reduces the biological effect of that ligand. In some embodiments, the antigen binding molecule, scFv, antibody, or a fragment thereof, directly blocking a binding site on the ligand or otherwise alters the ligand's ability to bind through indirect means (such as structural or energetic alterations in the ligand). In some embodiments, the antigen binding molecule, scFv, antibody, or a fragment thereof prevents the protein to which it is bound from performing a biological function.
- As used herein, the term “BCMA” refers to B cell maturation antigen, which can include, but is not limited to, native BCMA, an isoform of BCMA, or an interspecies BCMA homolog of BCMA. BCMA (also known as TNFRSF17, CD269, and TNFRSF13A) is a member of the tumor necrosis factor (TNF)-receptor superfamily. BCMA is expressed on the surface of multiple myeloma cells, while highly restricted to plasma cells and a subset of mature B cells in healthy tissue (
FIG. 2A andFIG. 2C ). The amino acid sequence of human BCMA (hBCMA) is provided in NCBI Accession Q02223.2 (GI:313104029) (SEQ ID NO: 163). As used herein, BCMA includes human BCMA and non-human BCMA homologs, as well as variants, fragments, or post-transnationally modified forms thereof, including, but not limited to, N- and O-linked glycosylated forms of BCMA. BCMA proteins may further include fragments comprising all or a portion of the extracellular domain of BCMA (e.g., all or a portion of amino acids 1-54 of hBCMA). - The term “autologous” refers to any material derived from the same individual to which it is later to be re-introduced. For example, the engineered autologous cell therapy (eACT™) method described herein involves collection of lymphocytes from a patient, which are then engineered to express, e.g., a CAR construct, and then administered back to the same patient.
- The term “allogeneic” refers to any material derived from one individual which is then introduced to another individual of the same species, e.g., allogeneic T cell transplantation.
- The terms “transduction” and “transduced” refer to the process whereby foreign DNA is introduced into a cell via viral vector (see Jones et al., “Genetics: principles and analysis,” Boston: Jones & Bartlett Publ. (1998)). In some embodiments, the vector is a retroviral vector, a DNA vector, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector, a lentiviral vector, or any combination thereof.
- A “cancer” refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and may also metastasize to distant parts of the body through the lymphatic system or bloodstream. A “cancer” or “cancer tissue” can include a tumor. Examples of cancers that can be treated by the methods of the present invention include, but are not limited to, cancers of the immune system including lymphoma, leukemia, myeloma, and other leukocyte malignancies. In some embodiments, the methods of the present invention can be used to reduce the tumor size of a tumor derived from, for example, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, multiple myeloma, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, other B cell malignancies, and combinations of said cancers. In one particular embodiment, the cancer is multiple myeloma. The particular cancer can be responsive to chemo- or radiation therapy or the cancer can be refractory. A refractor cancer refers to a cancer that is not amendable to surgical intervention and the cancer is either initially unresponsive to chemo- or radiation therapy or the cancer becomes unresponsive over time.
- An “anti-tumor effect” as used herein, refers to a biological effect that can present as a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in tumor cell proliferation, a decrease in the number of metastases, an increase in overall or progression-free survival, an increase in life expectancy, or amelioration of various physiological symptoms associated with the tumor. An anti-tumor effect can also refer to the prevention of the occurrence of a tumor, e.g., a vaccine.
- A “cytokine,” as used herein, refers to a non-antibody protein that is released by one cell in response to contact with a specific antigen, wherein the cytokine interacts with a second cell to mediate a response in the second cell. A cytokine can be endogenously expressed by a cell or administered to a subject. Cytokines may be released by immune cells, including macrophages, B cells, T cells, and mast cells to propagate an immune response. Cytokines can induce various responses in the recipient cell. Cytokines can include homeostatic cytokines, chemokines, pro-inflammatory cytokines, effectors, and acute-phase proteins. For example, homeostatic cytokines, including interleukin (IL) 7 and IL-15, promote immune cell survival and proliferation, and pro-inflammatory cytokines can promote an inflammatory response. Examples of homeostatic cytokines include, but are not limited to, IL-2, IL-4, IL-5, IL-7, IL-10, IL-12p40, IL-12p70, IL-15, and interferon (IFN) gamma. Examples of pro-inflammatory cytokines include, but are not limited to, IL-1a, IL-1b, IL-6, IL-13, IL-17a, tumor necrosis factor (TNF)-alpha, TNF-beta, fibroblast growth factor (FGF) 2, granulocyte macrophage colony-stimulating factor (GM-CSF), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular adhesion molecule 1 (sVCAM-1), vascular endothelial growth factor (VEGF), VEGF-C, VEGF-D, and placental growth factor (PLGF). Examples of effectors include, but are not limited to, granzyme A, granzyme B, soluble Fas ligand (sFasL), and perforin. Examples of acute phase-proteins include, but are not limited to, C-reactive protein (CRP) and serum amyloid A (SAA).
- “Chemokines” are a type of cytokine that mediates cell chemotaxis, or directional movement. Examples of chemokines include, but are not limited to, IL-8, IL-16, eotaxin, eotaxin-3, macrophage-derived chemokine (MDC or CCL22), monocyte chemotactic protein 1 (MCP-1 or CCL2), MCP-4, macrophage inflammatory protein 1α (MIP-1α, MIP-1α), MIP-1β (MIP-1b), gamma-induced protein 10 (IP-10), and thymus and activation regulated chemokine (TARC or CCL17).
- A “therapeutically effective amount,” “effective dose,” “effective amount,” or “therapeutically effective dosage” of a therapeutic agent, e.g., engineered CAR T cells, is any amount that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
- The term “lymphocyte” as used herein includes natural killer (NK) cells, T cells, or B cells. NK cells are a type of cytotoxic (cell toxic) lymphocyte that represent a major component of the inherent immune system. NK cells reject tumors and cells infected by viruses. It works through the process of apoptosis or programmed cell death. They were termed “natural killers” because they do not require activation in order to kill cells. T-cells play a major role in cell-mediated-immunity (no antibody involvement). Its T-cell receptors (TCR) differentiate themselves from other lymphocyte types. The thymus, a specialized organ of the immune system, is primarily responsible for the T cell's maturation. There are six types of T-cells, namely: Helper T-cells (e.g., CD4+ cells), Cytotoxic T-cells (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CD8+ T-cells or killer T cell), Memory T-cells ((i) stem memory TSCM cells, like naive cells, are CD45RO−, CCR7+, CD45RA+, CD62L+(L-selectin), CD27+, CD28+ and IL-7Rα+, but they also express large amounts of CD95, IL-2Rβ, CXCR3, and LFA-1, and show numerous functional attributes distinctive of memory cells); (ii) central memory TCM cells express L-selectin and the CCR7, they secrete IL-2, but not IFNγ or IL-4, and (iii) effector memory TEM cells, however, do not express L-selectin or CCR7 but produce effector cytokines like IFNγ and IL-4), Regulatory T-cells (Tregs, suppressor T cells, or CD4+CD25+ regulatory T cells), Natural Killer T-cells (NKT) and Gamma Delta T-cells. B-cells, on the other hand, play a principal role in humoral immunity (with antibody involvement). It makes antibodies and antigens and performs the role of antigen-presenting cells (APCs) and turns into memory B-cells after activation by antigen interaction. In mammals, immature B-cells are formed in the bone marrow, where its name is derived from.
- The term “genetically engineered” or “engineered” refers to a method of modifying the genome of a cell, including, but not limited to, deleting a coding or non-coding region or a portion thereof or inserting a coding region or a portion thereof. In some embodiments, the cell that is modified is a lymphocyte, e.g., a T cell, which can either be obtained from a patient or a donor. The cell can be modified to express an exogenous construct, such as, e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR), which is incorporated into the cell's genome.
- An “immune response” refers to the action of a cell of the immune system (for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils) and soluble macromolecules produced by any of these cells or the liver (including Abs, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and/or elimination from a vertebrate's body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues.
- The term “immunotherapy” refers to the treatment of a subject afflicted with, or at risk of contracting or suffering a recurrence of, a disease by a method comprising inducing, enhancing, suppressing or otherwise modifying an immune response. Examples of immunotherapy include, but are not limited to, T cell therapies. T cell therapy can include adoptive T cell therapy, tumor-infiltrating lymphocyte (TIL) immunotherapy, autologous cell therapy, engineered autologous cell therapy (eACT), and allogeneic T cell transplantation. However, one of skill in the art would recognize that the conditioning methods disclosed herein would enhance the effectiveness of any transplanted T cell therapy. Examples of T cell therapies are described in U.S. Patent Publication Nos. 2014/0154228 and 2002/0006409, U.S. Pat. No. 5,728,388, and International Publication No. WO 2008/081035.
- The T cells of the immunotherapy can come from any source known in the art. For example, T cells can be differentiated in vitro from a hematopoietic stem cell population, or T cells can be obtained from a subject. T cells can be obtained from, e.g., peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In addition, the T cells can be derived from one or more T cell lines available in the art. T cells can also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLL™ separation and/or apheresis. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety.
- The term “engineered Autologous Cell Therapy,” which can be abbreviated as “eACT™,” also known as adoptive cell transfer, is a process by which a patient's own T cells are collected and subsequently genetically altered to recognize and target one or more antigens expressed on the cell surface of one or more specific tumor cells or malignancies. T cells can be engineered to express, for example, chimeric antigen receptors (CAR) or T cell receptor (TCR). CAR positive (+) T cells are engineered to express an extracellular single chain variable fragment (scFv) with specificity for a particular tumor antigen linked to an intracellular signaling part comprising at least one costimulatory domain and at least one activating domain. The costimulatory domain can be derived from, e.g., CD28, and the activating domain can be derived from, e.g., CD3-zeta. In certain embodiments, the CAR is designed to have two, three, four, or more costimulatory domains. The CAR scFv can be designed to target, for example, CD19, which is a transmembrane protein expressed by cells in the B cell lineage, including all normal B cells and B cell malignances, including but not limited to NHL, CLL, and non-T cell ALL. In some embodiments, the CAR is engineered such that the costimulatory domain is expressed as a separate polypeptide chain. Example CAR T cell therapies and constructs are described in U.S. Patent Publication Nos. 2013/0287748, 2014/0227237, 2014/0099309, and 2014/0050708, and these references are incorporated by reference in their entirety.
- A “patient” as used herein includes any human who is afflicted with a cancer (e.g., a lymphoma or a leukemia). The terms “subject” and “patient” are used interchangeably herein.
- As used herein, the term “in vitro cell” refers to any cell which is cultured ex vivo. In particular, an in vitro cell can include a T cell.
- The terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
- In some aspects, the polypeptides and/or proteins have deletions from, additions to, and/or substitutions of one or more amino acid of antigen-binding protein, and in some embodiments preferably no more than 8 amino acid substitutions therein. Useful polypeptide fragments may include immunologically functional fragments of antigen binding molecules, including not limited to one or more CDR regions, variable domains of a heavy and/or light chain, a portion of other portions of an antibody chain, and the like. Additionally, polypeptide fragments of activating and/or costimulatory molecules and the like are within the scope of the invention.
- “Activation” or “Stimulation” as used herein, refers to a primary response induced by binding of an activating molecule with its cognate ligand, wherein the binding mediates a signal transduction event. An “activating molecule” or “stimulating molecule” refers to a molecule on a T cell, e.g., the TCR/CD3 complex that specifically binds with a cognate stimulatory ligand present on an antigen present cell. Suitable activating molecules are described herein.
- A “stimulatory ligand” is a ligand that when present on an antigen presenting cell (e.g., an aAPC, a dendritic cell, a B-cell, and the like) can specifically bind with a stimulatory molecule on a T cell, thereby mediating a primary response by the T cell, including, but not limited to, activation, initiation of an immune response, proliferation, and the like. Stimulatory ligands include, but are not limited to, an MHC Class I molecule loaded with a peptide, an anti-CD3 antibody, a superagonist anti-CD28 antibody, and a superagonist anti-CD2 antibody.
- A “costimulatory signal,” as used herein, refers to a signal, which in combination with a primary signal, such as TCR/CD3 ligation, leads to a T cell response, such as, but not limited to, proliferation and/or upregulation or down regulation of key molecules.
- A “costimulatory ligand” as used herein, includes a molecule on an antigen presenting cell that specifically binds a cognate co-stimulatory molecule on a T cell. Binding of the costimulatory ligand provides a signal that mediates a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. A costimulatory ligand induces a signal that is in addition to the primary signal provided by a stimulatory molecule, for instance, by binding of a T cell receptor (TCR)/CD3 complex with a major histocompatibility complex (MHC) molecule loaded with peptide. A co-stimulatory ligand can include, but is not limited to, CD7, B7-1 (CD80), B7-2 (CD86), programmed death (PD) L1, PD-L2, 4-1BB ligand, OX40 ligand, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30 ligand, CD40, CD70, CD83, human leukocyte antigen G (HLA-G), MHC class I chain-related protein A (MICA), MHC class I chain-related protein B (MICB), herpes virus entry mediator (HVEM), lymphotoxin beta receptor, 3/TR6, immunoglobulin-like transcript (ILT) 3, ILT4, an agonist or antibody that binds Toll ligand receptor and a ligand that specifically binds with B7-H3. A co-stimulatory ligand includes, without limitation, an antibody that specifically binds with a co-stimulatory molecule present on a T cell, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, tumor necrosis factor superfamily member 14 (TNFSF14 or LIGHT), natural killer cell receptor C (NKG2C), B7-H3, and a ligand that specifically binds with CD83.
- A “costimulatory molecule” is a cognate binding partner on a T cell that specifically binds with a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules include, but are not limited to, CD28, CD28T, OX40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF, TNFr, integrin, signaling lymphocytic activation molecule, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, CD83 ligand, or fragments or combinations thereof.
- The terms “reducing” and “decreasing” are used interchangeably herein and indicate any change that is less than the original. “Reducing” and “decreasing” are relative terms, requiring a comparison between pre- and post-measurements. “Reducing” and “decreasing” include complete depletions.
- “Treatment” or “treating” of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease. In one embodiment, “treatment” or “treating” includes a partial remission. In another embodiment, “treatment” or “treating” includes a complete remission.
- To calculate percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). In certain embodiments, a standard comparison matrix (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the
PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for theBLOSUM 62 comparison matrix) is also used by the algorithm. - The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the indefinite articles “a” or “an” should be understood to refer to “one or more” of any recited or enumerated component.
- The terms “about” or “comprising essentially of” refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, “about” or “comprising essentially of” can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, “about” or “comprising essentially of” can mean a range of up to 10% (i.e., ±10%). For example, about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%). Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of “about” or “comprising essentially of” should be assumed to be within an acceptable error range for that particular value or composition.
- As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
- Various aspects of the invention are described in further detail in the following subsections.
- The present invention is directed to a polynucleotide encoding an anti-BCMA antibody or antigen binding molecule thereof which cross competes with one or more antibodies described herein (i.e., one or more described in
FIG. 1 ) or an antibody or antigen binding molecule thereof encoded by the polynucleotide. In one embodiment, the invention is directed to a polynucleotide encoding an anti-BCMA antibody or antigen binding molecule thereof which binds to the same epitope as one or more antibodies described inFIG. 1 or an antibody or antigen binding molecule thereof encoded by the polynucleotide. In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule thereof that specifically binds to BCMA, wherein the antibody or binding molecule comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2X3X4X5X6X7SY (SEQ ID NO: 145), wherein: X2 is not present or G; X3 is not present or S; X4 is F, G, I, or Y; X5 is S or T; X6 is F or S; and X7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is not present or G or S; X8 is N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17DX19 (SEQ ID NO: 147), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or A, D, G, P, R, or S; X5 is not present or E, F, G, L, Q, or T; X6 is not present or E, M, Q, W, or Y; X7 is not present or A, E, L, or S; X8 is not present or G, P, S, or T; X9 is not present or G, P, or S; X10 is not present or I, L, P, or Y; X11 is not present or W; X12 is not present or H; X13 is not present or E or Y; X14 is not present or D, G, H, P, S, W, or Y; X15 is A, G, L, W, or Y; X16 is not present or A, G, I, P, or V; X17 is F, L, or M; and X19 is I, L, V, or Y. - In one particular embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6SYX9X10X11 (SEQ ID NO: 263), wherein: X1 is not present or G; X2 is not present or S X3 is F, G, I, or Y; X4 is S or T; X5 is F or S; X6 is S or T; X9 is A, G, S, or Y; X10 is I, M, or W; and X11 is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is G or S; X8 is not present or N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19DX21 (SEQ ID NO: 264), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or D, G, or P; X5 is not present or F, L, or T; X6 is not present or P, Q, R, W, or Y; X7 is not present or E, G, L, or S; X8 is not present or A, G, P, S, or Y; X9 is not present or A, E, G, P, Q, or S; X10 is not present or E, L, M, PS, T, or Y; X11 is not present or D, G, H, P, S or W; X12 is not present or A, G, I, L, or Y; X13 is not present or A, G, I, V, or W; X14 is not present or H; X15 is not present or Y; X16 is not present or Y; X17 is not present or W or Y; X18 is not present or P or G; X19 is F, L, or M; and X21 is I, L, V, or Y.
- In another embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D; and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 149), wherein X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T; and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In one particular embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2X3X4X5X6X7SY (SEQ ID NO: 145), wherein: X2 is not present or G; X3 is not present or S; X4 is F, G, I, or Y; X5 is S or T; X6 is F or S; and X7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is not present or G or S; X8 is N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17DX19 (SEQ ID NO: 147), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or A, D, G, P, R, or S; X5 is not present or E, F, G, L, Q, or T; X6 is not present or E, M, Q, W, or Y; X7 is not present or A, E, L, or S; X8 is not present or G, P, S, or T; X9 is not present or G, P, or S; X10 is not present or I, L, P, or Y; X11 is not present or W; X12 is not present or H; X13 is not present or E or Y; X14 is not present or D, G, H, P, S, W, or Y; X15 is A, G, L, W, or Y; X16 is not present or A, G, I, P, or V; X17 is F, L, or M; and X19 is I, L, V, or Y; and/or (d) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D; and/or (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 149), wherein X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In one particular embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6SYX9X10X11 (SEQ ID NO: 263), wherein: X1 is not present or G; X2 is not present or S X3 is F, G, I, or Y; X4 is S or T; X5 is F or S; X6 is S or T; X9 is A, G, S, or Y; X10 is I, M, or W; and X11 is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is G or S; X8 is not present or N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19DX21 (SEQ ID NO: 264), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or D, G, or P; X5 is not present or F, L, or T; X6 is not present or P, Q, R, W, or Y; X7 is not present or E, G, L, or S; X8 is not present or A, G, P, S, or Y; X9 is not present or A, E, G, P, Q, or S; X10 is not present or E, L, M, PS, T, or Y; X11 is not present or D, G, H, P, S or W; X12 is not present or A, G, I, L, or Y; X13 is not present or A, G, I, V, or W; X14 is not present or H; X15 is not present or Y; X16 is not present or Y; X17 is not present or W or Y; X18 is not present or P or G; X19 is F, L, or M; and X21 is I, L, V, or Y; and/or (d) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D; and/or (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 149), wherein X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In another embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH and a VL, wherein: (i) the VH comprises: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2X3X4X5X6X7SY (SEQ ID NO: 145), wherein: X2 is not present or G; X3 is not present or S; X4 is F, G, I, or Y; X5 is S or T; X6 is F or S; and X7 is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is not present or G or S; X8 is N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17DX19 (SEQ ID NO: 147), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or A, D, G, P, R, or S; X5 is not present or E, F, G, L, Q, or T; X6 is not present or E, M, Q, W, or Y; X7 is not present or A, E, L, or S; X8 is not present or G, P, S, or T; X9 is not present or G, P, or S; X10 is not present or I, L, P, or Y; X11 is not present or W; X12 is not present or H; X13 is not present or E or Y; X14 is not present or D, G, H, P, S, W, or Y; X15 is A, G, L, W, or Y; X16 is not present or A, G, I, P, or V; X17 is F, L, or M; and X19 is I, L, V, or Y; and (ii) the VL comprises: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D; and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 149), wherein X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T; and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In another embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH and a VL, wherein: (i) the VH comprises: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6SYX9X10X11 (SEQ ID NO: 263), wherein: X1 is not present or G; X2 is not present or S X3 is F, G, I, or Y; X4 is S or T; X5 is F or S; X6 is S or T; X9 is A, G, S, or Y; X10 is I, M, or W; and X11 is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is G or S; X8 is not present or N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19DX21 (SEQ ID NO: 264), wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or D, G, or P; X5 is not present or F, L, or T; X6 is not present or P, Q, R, W, or Y; X7 is not present or E, G, L, or S; X8 is not present or A, G, P, S, or Y; X9 is not present or A, E, G, P, Q, or S; X10 is not present or E, L, M, P, S, T, or Y; X11 is not present or D, G, H, P, S or W; X12 is not present or A, G, I, L, or Y; X13 is not present or A, G, I, V, or W; X14 is not present or H; X15 is not present or Y; X16 is not present or Y; X17 is not present or W or Y; X18 is not present or P or G; X19 is F, L, or M; and X21 is I, L, V, or Y; and (ii) the VL comprises: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D; and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 149), wherein X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T; and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2X3X4X5X6X7SY (SEQ ID NO: 145), wherein: X2 is not present or G; X3 is not present or S; X4 is F, G, I, or Y; X5 is S or T; X6 is F or S; and X7 is S or T.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2TFSSY (SEQ ID NO: 151), wherein: X2 is F or G.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX2X3X4X5X6SSY (SEQ ID NO: 152), wherein: X2 is not present or G; X3 is not present or S; X4 is F, G, or I; X5 is S or T; and X6 is F or S.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6SYX9X10X11 (SEQ ID NO: 263), wherein: X1 is not present or G; X2 is not present or S X3 is F, G, I, or Y; X4 is S or T; X5 is F or S; X6 is S or T; X9 is A, G, S, or Y; X10 is I, M, or W; and X11 is G, H, N, or S.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1TFX4SYX7X8X9 (SEQ ID NO: 265), wherein: X1 is F, G, or Y; X4 is S or T; X7 is A, G, S, or Y; X8 is I or M; and X9 is H, N, or S.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence FTFSSYX7MX9 (SEQ ID NO: 266), wherein: X7 is A, G, or S; and X9 is H, N, or S.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YX12X13X14X15X16X17 (SEQ ID NO: 146), wherein: X1 is A, G, I, S, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is G or S; X8 is not present or N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X12 is A or N; X13 is D, P, or Q; X14 is K or S; X15 is F, L, or V; X16 is K or Q; and X17 is G or S.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3X4X5X6X7X8X9X10YAX13X14X15X16G (SEQ ID NO: 153), wherein: X1 is A, G, I, T, or V; X3 is I, N, or S; X4 is G, P, S, or Y; X5 is D, G, I, or S; X6 is F, G, or S; X7 is G or S; X8 is N, S, or T; X9 is A, I, K, or T; X10 is N, S, or Y; X13 is D or Q; X14 is K or S; X15 is F or V; and X16 is K or Q.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1ISX4X5X6X7X8X9YYADSVKG (SEQ ID NO: 154), wherein: X1 is A, T, or V; X4 is G, S, or Y; X5 is D or S; X6 is G or S; X7 is G or S; X8 is N, S, or T; and X9 is I, K, or T.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1IX3PX5X6GX8X9X10YAQKFQG (SEQ ID NO: 155), wherein: X1 is G or I; X3 is I or N; X5 is G or I; X6 is F or G; X8 is S or T; X9 is A or T; and X10 is N or S.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17DX19 (SEQ ID NO: 147) and wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or A, D, G, P, R, or S; X5 is not present or E, F, G, L, Q, or T; X6 is not present or E, M, Q, W, or Y; X7 is not present or A, E, L, or S; X8 is not present or G, P, S, or T; X9 is not present or G, P, or S; X10 is not present or I, L, P, or Y; X11 is not present or W; X12 is not present or H; X13 is not present or E or Y; X14 is not present or D, G, H, P, S, W, or Y; X15 is A, G, L, W, or Y; X16 is not present or A, G, I, P, or V; X17 is F, L, or M; and X19 is I, L, V, or Y.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence ARX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17DX19 (SEQ ID NO: 156) and wherein: X3 is not present or D, G, or T; X4 is not present or A, D, G, P, R, or S; X5 is not present or E, F, G, Q, or T; X6 is not present or E, M, W, or Y; X7 is not present or A, L, or S; X8 is not present or G, S, or T; X9 is not present or G or S; X10 is not present or I, L, or P; X11 is not present or W; X12 is not present or H; X13 is not present or E or Y; X14 is not present or G, H, P, S, W, or Y; X15 is A, G, L, W, or Y; X16 is not present or A, G, I, P, or V; X17 is F, L, or M; and X19 is I, L, V, or Y.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19DX21 (SEQ ID NO: 264) and wherein: X1 is A or V; X2 is K or R; X3 is not present or D, G, or T; X4 is not present or D, G, or P; X5 is not present or F, L, or T; X6 is not present or P, Q, R, W, or Y; X7 is not present or E, G, L, or S; X8 is not present or A, G, P, S, or Y; X9 is A, E, G, P, Q, or S; X10 is E, L, M, P, S, T, or Y; X11 is not present or D, G, H, P, S or W; X12 is not present or A, G, I, L, or Y; X13 is not present or A, G, I, V, or W; X14 is not present or H; X15 is not present or Y; X16 is not present or Y; X17 is not present or W or Y; X18 is not present or P or G; X19 is F, L, or M; and X21 is I, L, V, or Y.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence ARX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19DX21 (SEQ ID NO: 267), wherein: X3 is not present or D or T; X4 is not present or D or G; X5 is not present or F or T; X6 is not present or P, R, W, or Y; X7 is not present or E, G, L, or S; X8 is not present or A, G, S, or Y; X9 is A, E, G, Q, or S; X10 is E, L, M, P, S, or T; X11 is not present or G, H, P, S or W; X12 is not present or A, G, I, L, or Y; X13 is not present or A, I, V, or W; X14 is not present or H; X15 is not present or Y; X16 is not present or Y; X17 is not present or W or Y; X18 is not present or P or G; X19 is F, L, or M; and X21 is I, L, V, or Y.
- In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises one, two, or all three of any of the VH CDRs listed above or described in
FIG. 1A orFIG. 1B . In some embodiments, the antibody or antigen binding molecule comprises the VH framework regions (FRs) described herein. In specific embodiments, the antibody or antigen binding molecule comprises the VH FRs of an antibody set forth inFIG. 1A orFIG. 1B (e.g., one, two, three, or four of the FRs in one sequence ofFIG. 1A ). - In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SQX5X6X7X8X9X10X11X12X13X14X15LX17 (SEQ ID NO: 148), wherein: X1 is K or R; X2 is A or S; X5 is G or S; X6 is I, L, or V; X7 is L or S; X8 is not present or H or Y; X9 is not present or S; X10 is not present or N or S; X11 is not present or G or N; X12 is not present or N; X13 is not present or K or Y; X14 is N, R, or S; X15 is N, W, or Y; and X17 is A or D.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence RASQX5X6SX8X9LA (SEQ ID NO: 157), wherein: X5 is G or S; X6 is I or V; X8 is R or S; and X9 is N, W, or Y.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X1SSQSX6LX8SX10X11X12X13NYLX17 (SEQ ID NO: 158), wherein: X1 is K or R; X6 is L or V; X8 is H or Y; X10 is N or S; X11 is G or N; X12 is not present or N; X13 is K or Y; and X17 is A or D.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 149), wherein: X1 is D, G, L, S, or W; X2 is A or G; X4 is N, S, or T; X5 is L or R; X6 is A, E, or Q; and X7 is S or T.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1ASX4RAT (SEQ ID NO: 159), wherein: X1 is D, G, or S; and X4 is N or T.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1ASX4X5X6X7 (SEQ ID NO: 160), wherein: X1 is D, G, or S; X4 is N, S, or T; X5 is L or R; X6 is A or Q; and X7 is S or T.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X1X2SX4RX6S (SEQ ID NO: 161), wherein X1 is L or W; X2 is A or G; X4 is N or T; and X6 is A or E.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X1QX3X4X5X6PX8T (SEQ ID NO: 150), wherein: X1 is M or Q; X3 is F, G, H, I, R, or Y; X4 is A, F, H, I, L, or Y; X5 is A, G, H, S, T, V, or Y; X6 is F, L, T, W, or Y; and X8 is not present or F, L, P, or W.
- In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QQX3X4X5X6PX8T (SEQ ID NO: 162), wherein: X3 is H, I, R, or Y; X4 is A, F, H, I, or Y; X5 is A, S, T, V, or Y; X6 is F, W, or Y; and X8 is not present or F, L, P, or W.
- In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises one, two, or all three of any of the VL CDRs listed above or described in
FIG. 2 . In some embodiments, the antibody or antigen binding molecule comprises the VL framework regions (FRs) described herein. In specific embodiments, the antibody or antigen binding molecule comprises the VL FRs of an antibody set forth inFIG. 4 (e.g., one, two, three, or four of the FRs in one row ofFIG. 4 ). - In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH CDR1, wherein the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9-16. In other embodiments, the antibody or antigen binding molecule comprises a VH CDR1, wherein the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 215-222. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR2, wherein the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25-32. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR2, wherein the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 231-238. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR3, wherein the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 41-48. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR3, wherein the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 247-254.
- In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH CDR1, a VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprise the amino acid sequence of the VH CDR1, VH CDR2, and VH CDR3 of an antibody in
FIG. 1A orFIG. 1B , respectively. - In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL CDR1, wherein the VL CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 81-88. In some embodiments, the antibody or antigen binding molecule comprises a VL CDR2, wherein the VL CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 97-104. In some embodiments, the antibody or antigen binding molecule comprises a VL CDR3, wherein the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 113-120.
- In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL CDR1, a VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprise the amino acid sequence of the VL CDR1, VL CDR2, and VL CDR3 of an antibody in
FIG. 1C , respectively. - In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH framework region 1 (FR1), wherein the VH FR1 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 1-8 and 207-214. In some embodiments, the antibody or antigen binding molecule comprises a VH FR2, wherein the VH FR2 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 17-24 and 223-23. In some embodiments, the antibody or antigen binding molecule comprises a VH FR3, wherein the VH FR3 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 33-40 and 239-246. In some embodiments, the antibody or antigen binding molecule comprises a VH FR4, wherein the VH FR4 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 49-56 and 255-262.
- In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR1, wherein the VL FR1 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 73-80. In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR2, wherein the VL FR2 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 89-96. In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR3, wherein the VL FR3 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 105-112. In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR4, wherein the VL FR4 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 121-128.
- In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises any one, two, and/or three VH CDR sequences disclosed herein. In certain embodiments, the antibody or antigen binding molecule comprises a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of any VH CDR1, VH CDR2, and VH CDR3 disclosed herein, respectively. In some embodiments, the antibody or antigen binding molecule comprises any one, two, and/or three VL CDR sequences disclosed herein. In certain embodiments, the antibody or antigen binding molecule comprises a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of any VL CDR1, VL CDR2, and VL CDR3 disclosed herein, respectively.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 9; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 25; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 41; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 10; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 42; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 43; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 28; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 44; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 13; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 45; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 14; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 46; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 47; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 16; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 32; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 48; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 215; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 231; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 247; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 216; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 232; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 248; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 217; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 233; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 249; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:218; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 234; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 250; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 219; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 235; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 251; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 220; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 236; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 252; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 221; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 237; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 253; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119.
- In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 222; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 238; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 254; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120.
- In some embodiments, the antibody or antigen binding molecule comprises a heavy chain variable region sequence comprising an amino acid sequence of
FIG. 1A orFIG. 1B . In some embodiments, the antibody or antigen binding molecule comprises a heavy chain variable region sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72. In some embodiments, the antibody or antigen binding molecule comprises a light chain variable region sequence comprising an amino acid sequence selected fromFIG. 1C . In some embodiments, the antibody or antigen binding molecule comprises a light chain variable region sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-144. - In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 65; and (b) a light chain variable region comprising the amino acid sequence of
SEQ ID NO 137. - In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 66; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 138.
- In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 67; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 139.
- In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 68; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 140.
- In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 69; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 141.
- In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 70; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 142.
- In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 71; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 143.
- In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 72; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 144.
- In one particular embodiment, the polynucleotide of the present invention comprises a nucleotide sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a nucleotide sequence selected form the group consisting of SEQ ID NOs: 57-64. In another embodiment, the polynucleotide of the present invention comprises a nucleotide sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a nucleotide sequence selected form the group consisting of SEQ ID NOs: 129-136.
- The antibody or antigen binding molecule encoded by the polypeptide of the present invention can be single chained or double chained. In some embodiments, the antibody or antigen binding molecule comprises is single chained. In certain embodiments, the antigen binding molecule is selected from the group consisting of an scFv, an Fab, an Fab′, an Fv, an F(ab′)2, a dAb, and any combination thereof. In one particular embodiment, the antibody or antigen binding molecule comprises an scFv.
- In certain embodiments, the antibody or antigen binding molecule comprises a single chain, wherein the heavy chain variable region and the light chain variable region are connected by a linker. In some embodiments, the VH is located at the N terminus of the linker and the VL is located at the C terminus of the linker. In other embodiments, the VL is located at the N terminus of the linker and the VH is located at the C terminus of the linker. In some embodiments, the linker comprises at least about 5, at least about 8, at least about 10, at least about 13, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 amino acids. In some embodiments, the linker comprises at least about 18 amino acids. In certain embodiments, the linker comprises an amino acid sequence that is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence GSTSGSGKPGSGEGSTKG (SEQ ID NO: 174) or a poly-Gly linker such as the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO: 268). Or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 411). In one embodiment, the linker is a Whitlow linker. In certain embodiments, the antibody or antigen binding molecule comprises a single chain, wherein the heavy chain variable region and the light chain variable region are connected by a linker, wherein the linker comprises the amino acid sequence of SEQ ID NO: 174.
- In some embodiments, the antibody or antigen binding molecules of the present invention specifically bind BCMA (e.g., hBCMA). In certain embodiments, an anti-BCMA antibody or antigen binding molecule of the present invention binds human BCMA with a KD of less than 1×10−6 M, less than 1×10−7 M, less than 1×10−8M, or less than 1×10−9 M. In one particular embodiment, the anti-BCMA antibody or antigen binding molecules binds human BCMA with a KD of less than 1×10−7 M. In another embodiment, the anti-BCMA antibody or antigen binding molecules binds human BCMA with a KD of less than 1×10−8 M. In some embodiments, the anti-BCMA antibody or antigen binding molecules binds human BCMA with a KD of about 1×10−7 M, about 2×10−7 M, about 3×10−7 M, about 4×10−7 M, about 5×10−7 M, about 6×10−7 M, about 7×10−7 M, about 8×10−7 M, about 9×10−7 M, about 1×10−8 M, about 2×10−8 M, about 3×10−8M, about 4×10−8M, about 5×10−8 M, about 6×10−8 M, about 7×10−8 M, about 8×10−8 M, about 9×10−8 M, about 1×10−9M, about 2×10−9M, about 3×10−9 M, about 4×10−9M, about 5×10−9 M, about 6×10−9 M, about 7×10−9 M, about 8×10−9M, about 9×10−9M, about 1×10−10 M, or about 5×10−10 M. In certain embodiments, the KD is calculated as the quotient of koff/kon, and the kon and koff are determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the KD is calculated as the quotient of koff/kon, and the kon and koff are determined using a bivalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology.
- In other embodiments, the anti-BCMA antibody or antigen binding molecule binds human BCMA-Fc with a KD of less than 1×10−9M, less than 3×10−9M, less than 5×10−9M, less than 1×10−10M, less than 3×10−10M, or less than 5×10−10M. In other embodiments, the anti-BCMA antibody or antigen binding molecules binds cyno BCMA-Fc with a KD of less than 1×10−5M, less than 1×10−6 M, less than 1×10−7M, less than 1×10−8 M, less than 1×10−9M, or less than 1×10−10 M.
- In some embodiments, the anti-BCMA antibody or antigen binding molecule binds human BCMA with an association rate (kon) of less than 1×10−4M−1 s−1, less than 2×10−4M−1 s−1, less than 3×10−4 M−1 s−1, less than 4×10−4M−1 s−1, less than 5×10−4M−1 s−1, less than 6×10−4 M−1 s−1, less than 7×10−4 M−1 s−1, less than 8×10−4M−1 s−1, less than 9×10−4 M−1 s−1, less than 1×10−5M−1 s−1, less than 2×10−5 M−1 s−1, less than 3×10−5M−1 s−1, less than 4×10−5 M−1 s−1, less than 5×10−5 M−1 s−1, less than 6×10−5M−1 s−1, less than 7×10−5M−1 s−1, less than 8×10−5 M−1 s−1, less than 9×10−5 M−1 s−1, less than 1×10−6M−1 s−1, less than 2×10−6 M−1 s−1, less than 3×10−6M−1 s−1, less than 4×10−6 M−1 s−1, less than 5×10−6M−1 s−1, less than 6×10−6 M−1 s−1, less than 7×10−6 M−1 s−1, less than 8×10−6M−1 s−1, less than 9×10−6M−1 s−1, or less than 1×10−7M−1s−1. In certain embodiments, the kon is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the kon is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
- In some embodiments, the anti-BCMA antibody or antigen binding molecule binds human BCMA with an dissociation rate (koff) of less than 1×10−2 s−1, less than 2×10−2 s−1, less than 3×10−2 s−1, less than 4×10−2 s−1, less than 5×10−2 s−1, less than 6×10−2 s−1, less than 7×10−2 s−1, less than 8×10−2 s−1, less than 9×10−2 s−1, less than 1×10−3 s−1, less than 2×10−3 s−1, less than 3×10−3 s−1, less than 4×10−3 s−1, less than 5×10−3 s−1, less than 6×10−3 s−1, less than 7×10−3 s−1, less than 8×10−3 s−1, less than 9×10−3 s−1, less than 1×10−4 s−1, less than 2×10−4 s−1, less than 3×10−4 s−1, less than 4×10−4 s−1, less than 5×10−4s−1, less than 6×10−4 s−1, less than 7×10−4 s−1, less than 8×10−4 s−1, less than 9×10−4 s−1, less than 1×10−4 s−1, or less than 5×10−4 s−1. In certain embodiments, the koff is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the koff is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
- In some embodiments, the polynucleotide of the present invention encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule cross competes with a reference antibody disclosed herein. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-56, 65-128, and 137-144. In some embodiments, the antibody or antigen binding molecule cross competes with a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72 and 137-144. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-16. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 25-32. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-48. In some embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 89-96. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-112. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 121-128. In one embodiment, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72. In another embodiment, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-144.
- In some embodiments, the polynucleotide of the present invention encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody disclosed herein (e.g.,
FIG. 1 ). In certain embodiments, the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-56, 65-128, and 137-144. In some embodiments, the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72 and 137-144. - The present invention is also directed to polynucleotides encoding chimeric antigen receptors (CARs) or T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to BCMA described in Section II, and engineered T cells comprising an antigen binding molecule that specifically binds to BCMA described in Section II. In some embodiments, an anti-BCMA CAR or TCR encoded by the polynucleotide of the present invention comprises an antigen binding molecule that specifically binds to BCMA. In some embodiments, the anti-BCMA CAR or TCR encoded by the polynucleotide further comprises a costimulatory domain. In some embodiments, the costimulatory domain in the anti-BCMA CAR or TCR encoded by the polynucleotide comprises an extracellular domain (i.e., a hinge region), a transmembrane domain, and/or an intracellular (signaling) domain. In some embodiments, the anti-BCMA CAR or TCR encoded by the polynucleotide further comprises a CD3 zeta activating domain. In one particular embodiment, the anti-BCMA CAR or TCR encoded by the polynucleotide comprises an antigen binding molecule that specifically binds BCMA (e.g., hBCMA), a costimulatory domain comprising an extracellular domain, a transmembrane domain, and an intracellular domain, and a CD3 zeta activating domain.
- In some embodiments, the polynucleotide of the present invention encodes a TCR, wherein the TCR comprises an antigen binding molecule that specifically binds to BCMA, and wherein the TCR further comprises a fourth complementarity determining region (CDR4). In certain embodiments, the polynucleotide encodes a TCR, wherein the TCR comprises an antigen binding molecule that specifically binds to BCMA, and a constant region. In some embodiments, the constant region is selected from a constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM.
- III.A. Costimulatory Domain
- In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an antigen binding molecule that specifically binds to BCMA (one or more antigen binding molecules in Section II), and wherein the CAR further comprises a costimulatory domain. In some embodiments, the costimulatory domain is positioned between the antigen binding molecule and an activating domain. In certain embodiments, the costimulatory domain can comprise an extracellular domain, a transmembrane domain, and an intracellular signaling domain.
- Extracellular Domain: In one embodiment, the extracellular domain comprises a hinge region (e.g., a spacer region). In another embodiment, the extracellular domain is from or derived from (e.g., comprises) CD28, CD28T, OX40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), ICOS, April, BAFF, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNFγ, integrin, signaling lymphocytic activation molecule, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, CD83 ligand, or fragments or combinations thereof. The extracellular domain can be derived either from a natural or from a synthetic source.
- In some embodiments, the extracellular domain in the costimulatory domain is positioned between the antigen binding molecule and the transmembrane domain. In certain embodiments, the extracellular domain in the costimulatory domain is from or derived from an immunoglobulin. In some embodiments, the extracellular domain in the costimulatory domain is selected from the hinge regions of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM, or a fragment thereof. In other embodiments, the extracellular domain in the costimulatory domain is from or derived from the hinge region of CD8 alpha. In one particular embodiment, the extracellular domain in the costimulatory domain is from or derived from the hinge region of CD28. In certain embodiments, the extracellular domain in the costimulatory domain comprises a fragment of the hinge region of CD8 alpha or a fragment of the hinge region of CD28, wherein the fragment is anything less than the whole hinge region. In some embodiments, the fragment of the CD8 alpha hinge region or the fragment of the CD28 hinge region comprises an amino acid sequence that excludes at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 amino acids at the N-terminus or C-Terminus, or both, of the CD8 alpha hinge region of the CD28 hinge region.
- In certain embodiments, the extracellular domain in the costimulatory domain comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence LDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 167) or a fragment thereof. In some embodiments, the extracellular domain in the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 167 or a fragment thereof.
- In certain embodiments, the extracellular domain in the costimulatory domain is encoded by a nucleotide sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the nucleotide sequence CTTGATAATGAAAAGTCAAACGGAACAATCATT CACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCA (SEQ ID NO: 166) or a fragment thereof. In some embodiments, the extracellular domain in the costimulatory domain is encoded by a nucleotide sequence that comprises the nucleotide sequence of SEQ ID NO: 166 or a fragment thereof.
- In some embodiments, the CD28T domain is derived from a human CD28 hinge region. In other embodiments, the CD28T domain is derived from a rodent, murine, or primate (e.g., non-human primate) CD28 hinge region. In some embodiments, the CD28T domain is derived from a chimeric CD28 hinge region.
- In some embodiments, the extracellular domain comprises some or all of a member of the immunoglobulin family such as IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, or fragment thereof.
- Transmembrane Domain: The costimulatory domain for the CAR or TCR of the invention can further comprise a transmembrane domain. The transmembrane domain can be designed to be fused to the extracellular domain in the costimulatory domain. It can similarly be fused to the intracellular domain in the costimulatory domain. In one embodiment, the transmembrane domain that naturally is associated with one of the domains in a CAR is used. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex. The transmembrane domain may be derived either from a natural or from a synthetic source. Where the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. In some embodiments, the transmembrane domain is derived from CD28, OX-40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, zeta), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD3 gamma, CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNFγ, integrin, signaling lymphocytic activation molecule, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, CD83 ligand, or a fragment thereof.
- Optionally, a short oligo or polypeptide linker, preferably between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic signaling domain of the CAR. A glycine-serine doublet provides a particularly suitable linker.
- In one embodiment, the transmembrane domain in the CAR of the invention comprises the CD8 transmembrane domain. In one embodiment, the CD8 transmembrane domain comprises the transmembrane portion of the nucleic acid sequence of GCTGCAGCATTGAGCAACTCAATAATGTATTTTAGTCACTTTGTACCAGTGTTCTTGCCGGC TAAGCCTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGC CTCTGTCCCTGCGCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGA CTGGATTTCGCCTGCGATATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCT GCTGTCCCTGGTCATCACGCTCTATTGTAATCACAGGAAC (SEQ ID NO: 269). In one embodiment, the CD8 transmembrane domain comprises the nucleic acid sequence that encodes the transmembrane amino acid sequence contained within
-
(SEQ ID NO: 270) AAALSNSIMYFSHEVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEA CRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRN. - In another embodiment, the transmembrane domain in the costimulating domain is a CD28 transmembrane domain. In some embodiments, the transmembrane domain comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 169). In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 169.
- In some embodiments, the transmembrane domain is encoded by a nucleotide sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the nucleotide sequence TTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGC TTTTATAATCTTCTGGGTT (SEQ ID NO: 168). In some embodiments, the transmembrane domain is encoded by a nucleotide sequence that comprises the nucleotide sequence of SEQ ID NO: 168.
- Intracellular (signaling) Domain: The intracellular (signaling) domain of the engineered T cells of the invention can provide signaling to an activating domain, which then activates at least one of the normal effector functions of the immune cell. Effector function of a T cell, for example, can be cytolytic activity or helper activity including the secretion of cytokines.
- In certain embodiments, suitable intracellular signaling domain include (i.e., comprise), but are not limited to CD28, CD28T, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof.
- An example of a nucleotide sequence encoding the intracellular signaling domain is set forth in SEQ ID NO. 170:
-
AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACC TAGAGATTTCGCTGCCTATCGGAGC. - In one embodiment, the polynucleotide encoding an intracellular signaling domain within a costimulatory domain comprises a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the nucleotide sequence of SEQ ID NO: 170.
- An example of an intracellular signaling domain is set forth in SEQ ID NO. 171:
-
RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS - In one particular embodiment, the intracellular signaling domain within a costimulatory domain comprises an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of SEQ ID NO: 171.
- The intracellular signaling sequences within the CAR of the invention can be linked to each other or to an activating domain in a random or specified order. Optionally, a short oligo- or polypeptide linker, preferably between 2 and 10 amino acids in length may form the linkage. A glycine-serine doublet provides a particularly suitable linker.
- It will further be appreciated that where desired, the costimulatory regions described herein can be expressed in a separate chain from the antigen binding molecule (e.g., scFv) and activating domains, in so-called “trans” configuration.
- III.B Activating Domain
- In some embodiments, intracellular domains for use in the engineered T cell of the invention include cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen/receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability. CD3 is an element of the T cell receptor on native T cells, and has been shown to be an important intracellular activating element in CARs. In one embodiment, the activating domain is CD3, e.g., CD3 zeta, the nucleotide sequence of which is set forth in SEQ ID NO. 172:
-
AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCC AGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGA CGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCA AGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATA AGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAG GGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAG GATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In some embodiments, the polynucleotide encoding an activating domain comprises a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the nucleotide sequence of SEQ ID NO: 172.
- The corresponding amino acid of intracellular CD3 zeta is set forth in SEQ ID NO. 173:
-
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP RRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR. - In some embodiments, the activating domain comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of SEQ ID NO: 173.
- Additionally, in certain embodiments the activating domain comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of a CD3 zeta variant as set forth in SEQ ID NO: 412:
-
RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATK DTYDALHMQALPPR. - III.C. Leader Peptide
- In some embodiments, the polynucleotide of the present invention encodes a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, and wherein the CAR or the TCR further comprises a leader peptide (also referred to herein as a “signal peptide”). In certain embodiments, the leader peptide comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 165). In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 165. In some embodiments, the leader peptide is encoded by a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 164.
- In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises a leader peptide (P), an antigen binding molecule (B), a hinge domain (H), a transmembrane domain (T), a costimulatory region (C), and an activation domain (A), wherein the CAR is configured according to the following: P-B-H-T-C-A. In some embodiments, the antigen binding molecule comprises a VH and a VL, wherein the CAR is configured according to the following: P-VH-VL-H-T-C-A or P-VL-VH-H-T-C-A. In some embodiments, the VH and the VL are connected by a linker (L), wherein the anti-BCMA CAR is configured according to the following, from N-terminus to C-terminus: P-VH-L-VL-H-T-C-A or P-VH-L-VL-H-T-C-A.
- In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from Table 2. In certain embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence selected from Table 2.
-
TABLE 2 Example CAR Sequences SEQ SEQ Anti- ID ID BCMA CAR Nucleotide Sequence NO: Amino Acid Sequence NO: FS- ATGGCACTCCCCGTAACTGCTCTGCTGC 175 MALPVTALLLPLALLLHAARP 176 21495CAR TGCCGTTGGCATTGCTCCTGCACGCCGC EVQLLESGGGLVQPGGSLRLS HxL ACGCCCGGAGGTGCAGCTGTTGGAGTCT CAASGFTFSSYAMSWVRQAPG GGGGGAGGCTTGGTACAGCCTGGGGGGT KGLEWVSAISGSGGSTYYADS CCCTGAGACTCTCCTGTGCAGCCTCTGG VKGRFTISRDNSKNTLYLQMN ATTCACCTTTAGCAGCTATGCCATGAGC SLRAEDTAVYYCARAEMGAVF TGGGTCCGCCAGGCTCCAGGGAAGGGGC DIWGQGTMVTVSSGSTSGSGK TGGAGTGGGTCTCAGCTATTAGTGGTAG PGSGEGSTKGEIVLTQSPATL TGGTGGTAGCACATACTACGCAGACTCC SLSPGERATLSCRASQSVSRY GTGAAGGGCCGGTTCACCATCTCCAGAG LAWYQQKPGQAPRLLIYDASN ACAATTCCAAGAACACGCTGTATCTGCA RATGIPARFSGSGSGTDFTLT AATGAACAGCCTGAGAGCCGAGGACACG ISSLEPEDFAVYYCQQRISWP GCGGTGTACTACTGCGCAAGAGCCGAGA FTFGGGTKVEIKRAAALDNEK TGGGAGCCGTATTCGACATATGGGGTCA SNGTIIHVKGKHLCPSPLFPG GGGTACAATGGTCACCGTCTCCTCAGGG PSKPFWVLVVVGGVLACYSLL TCTACATCCGGCTCCGGGAAGCCCGGAA VTVAFIIFWVRSKRSRLLHSD GTGGCGAAGGTAGTACAAAGGGGGAAAT YMNMTPRRPGPTRKHYQPYAP TGTGTTGACACAGTCTCCAGCCACCCTG PRDFAAYRSRVKFSRSADAPA TCTTTGTCTCCAGGGGAAAGAGCCACCC YQQGQNQLYNELNLGRREEYD TCTCCTGCAGGGCCAGTCAGAGTGTTAG VLDKRRGRDPEMGGKPRRKNP CAGGTACTTAGCCTGGTACCAACAGAAA QEGLYNELQKDKMAEAYSEIG CCTGGCCAGGCTCCCAGGCTCCTCATCT MKGERRRGKGHDGLYQGLSTA ATGATGCATCCAACAGGGCCACTGGCAT TKDTYDALHMQALPPR CCCAGCCAGGTTCAGTGGCAGTGGGTCT GGGACAGACTTCACTCTCACCATCAGCA GCCTAGAGCCTGAAGATTTTGCAGTTTA TTACTGTCAGCAGAGAATCTCCTGGCCT TTCACTTTTGGCGGAGGGACCAAGGTTG AGATCAAACGGGCCGCTGCCCTTGATAA TGAAAAGTCAAACGGAACAATCATTCAC GTGAAGGGCAAGCACCTCTGTCCGTCAC CCTTGTTCCCTGGTCCATCCAAGCCATT CTGGGTGTTGGTCGTAGTGGGTGGAGTC CTCGCTTGTTACTCTCTGCTCGTCACCG TGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGAT TACATGAATATGACTCCACGCCGCCCTG GCCCCACAAGGAAACACTACCAGCCTTA CGCACCACCTAGAGATTTCGCTGCCTAT CGGAGCAGGGTGAAGTTTTCCAGATCTG CAGATGCACCAGCGTATCAGCAGGGCCA GAACCAACTGTATAACGAGCTCAACCTG GGACGCAGGGAAGAGTATGACGTTTTGG ACAAGCGCAGAGGACGGGACCCTGAGAT GGGTGGCAAACCAAGACGAAAAAACCCC CAGGAGGGTCTCTATAATGAGCTGCAGA AGGATAAGATGGCTGAAGCCTATTCTGA AATAGGCATGAAAGGAGAGCGGAGAAGG GGAAAAGGGCACGACGGTTTGTACCAGG GACTCAGCACTGCTACGAAGGATACTTA TGACGCTCTCCACATGCAAGCCCTGCCA CCTAGGTAA FS- ATGGCACTCCCCGTAACTGCTCTGCTGC 177 MALPVTALLLPLALLLHAARP 178 21495CAR TGCCGTTGGCATTGCTCCTGCACGCCGC EIVLTQSPATLSLSPGERATL LxH ACGCCCGGAAATTGTGTTGACACAGTCT SCRASQSVSRYLAWYQQKPGQ CCAGCCACCCTGTCTTTGTCTCCAGGGG APRLLIYDASNRATGIPARES AAAGAGCCACCCTCTCCTGCAGGGCCAG GSGSGTDFTLTISSLEPEDFA TCAGAGTGTTAGCAGGTACTTAGCCTGG VYYCQQRISWPFTFGGGTKVE TACCAACAGAAACCTGGCCAGGCTCCCA IKRGSTSGSGKPGSGEGSTKG GGCTCCTCATCTATGATGCATCCAACAG EVQLLESGGGLVQPGGSLRLS GGCCACTGGCATCCCAGCCAGGTTCAGT CAASGFTFSSYAMSWVRQAPG GGCAGTGGGTCTGGGACAGACTTCACTC KGLEWVSAISGSGGSTYYADS TCACCATCAGCAGCCTAGAGCCTGAAGA VKGRFTISRDNSKNTLYLQMN TTTTGCAGTTTATTACTGTCAGCAGAGA SLRAEDTAVYYCARAEMGAVF ATCTCCTGGCCTTTCACTTTTGGCGGAG DIWGQGTMVTVSSAAALDNEK GGACCAAGGTTGAGATCAAACGGGGGTC SNGTIIHVKGKHLCPSPLFPG TACATCCGGCTCCGGGAAGCCCGGAAGT PSKPFWVLVVVGGVLACYSLL GGCGAAGGTAGTACAAAGGGGGAGGTGC VTVAFIIFWVRSKRSRLLHSD AGCTGTTGGAGTCTGGGGGAGGCTTGGT YMNMTPRRPGPTRKHYQPYAP ACAGCCTGGGGGGTCCCTGAGACTCTCC PRDFAAYRSRVKFSRSADAPA TGTGCAGCCTCTGGATTCACCTTTAGCA YQQGQNQLYNELNLGRREEYD GCTATGCCATGAGCTGGGTCCGCCAGGC VLDKRRGRDPEMGGKPRRKNP TCCAGGGAAGGGGCTGGAGTGGGTCTCA QEGLYNELQKDKMAEAYSEIG GCTATTAGTGGTAGTGGTGGTAGCACAT MKGERRRGKGHDGLYQGLSTA ACTACGCAGACTCCGTGAAGGGCCGGTT TKDTYDALHMQALPPR CACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGA GAGCCGAGGACACGGCGGTGTACTACTG CGCAAGAGCCGAGATGGGAGCCGTATTC GACATATGGGGTCAGGGTACAATGGTCA CCGTCTCCTCAGCCGCTGCCCTTGATAA TGAAAAGTCAAACGGAACAATCATTCAC GTGAAGGGCAAGCACCTCTGTCCGTCAC CCTTGTTCCCTGGTCCATCCAAGCCATT CTGGGTGTTGGTCGTAGTGGGTGGAGTC CTCGCTTGTTACTCTCTGCTCGTCACCG TGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGAT TACATGAATATGACTCCACGCCGCCCTG GCCCCACAAGGAAACACTACCAGCCTTA CGCACCACCTAGAGATTTCGCTGCCTAT CGGAGCAGGGTGAAGTTTTCCAGATCTG CAGATGCACCAGCGTATCAGCAGGGCCA GAACCAACTGTATAACGAGCTCAACCTG GGACGCAGGGAAGAGTATGACGTTTTGG ACAAGCGCAGAGGACGGGACCCTGAGAT GGGTGGCAAACCAAGACGAAAAAACCCC CAGGAGGGTCTCTATAATGAGCTGCAGA AGGATAAGATGGCTGAAGCCTATTCTGA AATAGGCATGAAAGGAGAGCGGAGAAGG GGAAAAGGGCACGACGGTTTGTACCAGG GACTCAGCACTGCTACGAAGGATACTTA TGACGCTCTCCACATGCAAGCCCTGCCA CCTAGGTAA PC- ATGGCACTCCCCGTAACTGCTCTGCTGC 179 MALPVTALLLPLALLLHAARP 180 21497CAR TGCCGTTGGCATTGCTCCTGCACGCCGC QVQLVESGGGVVQPGRSLRLS HxL ACGCCCGCAGGTGCAGCTGGTGGAGTCT CAASGFTFSSYGMHWVRQAPG GGGGGAGGCGTGGTCCAGCCTGGGAGGT KGLEWVAVISYDGSNKYYADS CCCTGAGACTCTCCTGTGCAGCGTCTGG VKGRFTISRDNSKNTLYLQMN ATTCACCTTCAGTAGCTATGGCATGCAC SLRAEDTAVYYCARDGTYLGG TGGGTCCGCCAGGCTCCAGGCAAGGGGC LWYFDLWGRGTLVTVSSGSTS TGGAGTGGGTGGCAGTTATATCGTATGA GSGKPGSGEGSTKGDIVMTQS TGGAAGTAATAAATACTATGCAGACTCC PLSLPVTPGEPASISCRSSQS GTGAAGGGCCGATTCACCATCTCCAGAG LLHSNGYNYLDWYLQKPGQSP ACAATTCCAAGAACACGCTGTATCTGCA QLLIYLGSNRASGVPDRFSGS AATGAACAGCCTGAGAGCCGAGGACACG GSGTDFTLKISRVEAEDVGVY GCGGTGTACTACTGCGCCAGAGACGGTA YCMQGLGLPLTFGGGTKVEIK CTTATCTAGGTGGTCTCTGGTACTTCGA RAAALDNEKSNGTIIHVKGKH CTTATGGGGGAGAGGTACCTTGGTCACC LCPSPLFPGPSKPFWVLVVVG GTCTCCTCAGGGTCTACATCCGGCTCCG GVLACYSLLVTVAFIIFWVRS GGAAGCCCGGAAGTGGCGAAGGTAGTAC KRSRLLHSDYMNMTPRRPGPT AAAGGGGGATATTGTGATGACTCAGTCT RKHYQPYAPPRDFAAYRSRVK CCACTCTCCCTGCCCGTCACCCCTGGAG FSRSADAPAYQQGQNQLYNEL AGCCGGCCTCCATCTCCTGCAGGTCTAG NLGRREEYDVLDKRRGRDPEM TCAGAGCCTCCTGCATAGTAATGGATAC GGKPRRKNPQEGLYNELQKDK AACTATTTGGATTGGTACCTGCAGAAGC MAEAYSEIGMKGERRRGKGHD CAGGGCAGTCTCCACAGCTCCTGATCTA GLYQGLSTATKDTYDALHMQA TTTGGGTTCTAATCGGGCCTCCGGGGTC LPPR CCTGACAGGTTCAGTGGCAGTGGATCAG GCACAGATTTTACACTGAAAATCAGCAG AGTGGAGGCTGAGGATGTTGGGGTTTAT TACTGCATGCAGGGACTCGGCCTCCCTC TCACTTTTGGCGGAGGGACCAAGGTTGA GATCAAACGGGCCGCTGCCCTTGATAAT GAAAAGTCAAACGGAACAATCATTCACG TGAAGGGCAAGCACCTCTGTCCGTCACC CTTGTTCCCTGGTCCATCCAAGCCATTC TGGGTGTTGGTCGTAGTGGGTGGAGTCC TCGCTTGTTACTCTCTGCTCGTCACCGT GGCTTTTATAATCTTCTGGGTTAGATCC AAAAGAAGCCGCCTGCTCCATAGCGATT ACATGAATATGACTCCACGCCGCCCTGG CCCCACAAGGAAACACTACCAGCCTTAC GCACCACCTAGAGATTTCGCTGCCTATC GGAGCAGGGTGAAGTTTTCCAGATCTGC AGATGCACCAGCGTATCAGCAGGGCCAG AACCAACTGTATAACGAGCTCAACCTGG GACGCAGGGAAGAGTATGACGTTTTGGA CAAGCGCAGAGGACGGGACCCTGAGATG GGTGGCAAACCAAGACGAAAAAACCCCC AGGAGGGTCTCTATAATGAGCTGCAGAA GGATAAGATGGCTGAAGCCTATTCTGAA ATAGGCATGAAAGGAGAGCGGAGAAGGG GAAAAGGGCACGACGGTTTGTACCAGGG ACTCAGCACTGCTACGAAGGATACTTAT GACGCTCTCCACATGCAAGCCCTGCCAC CTAGGTAA PC- ATGGCACTCCCCGTAACTGCTCTGCTGC 181 MALPVTALLLPLALLLHAARP 182 21497CAR TGCCGTTGGCATTGCTCCTGCACGCCGC DIVMTQSPLSLPVTPGEPASI HxL ACGCCCGGATATTGTGATGACTCAGTCT SCRSSQSLLHSNGYNYLDWYL CCACTCTCCCTGCCCGTCACCCCTGGAG QKPGQSPQLLIYLGSNRASGV AGCCGGCCTCCATCTCCTGCAGGTCTAG PDRFSGSGSGTDFTLKISRVE TCAGAGCCTCCTGCATAGTAATGGATAC AEDVGVYYCMQGLGLPLTFGG AACTATTTGGATTGGTACCTGCAGAAGC GTKVEIKRGSTSGSGKPGSGE CAGGGCAGTCTCCACAGCTCCTGATCTA GSTKGQVQLVESGGGVVQPGR TTTGGGTTCTAATCGGGCCTCCGGGGTC SLRLSCAASGFTFSSYGMHWV CCTGACAGGTTCAGTGGCAGTGGATCAG RQAPGKGLEWVAVISYDGSNK GCACAGATTTTACACTGAAAATCAGCAG YYADSVKGRFTISRDNSKNTL AGTGGAGGCTGAGGATGTTGGGGTTTAT YLQMNSLRAEDTAVYYCARDG TACTGCATGCAGGGACTCGGCCTCCCTC TYLGGLWYFDLWGRGTLVTVS TCACTTTTGGCGGAGGGACCAAGGTTGA SAAALDNEKSNGTIIHVKGKH GATCAAACGGGGGTCTACATCCGGCTCC LCPSPLFPGPSKPFWVLVVVG GGGAAGCCCGGAAGTGGCGAAGGTAGTA GVLACYSLLVTVAFIIFWVRS CAAAGGGGCAGGTGCAGCTGGTGGAGTC KRSRLLHSDYMNMTPRRPGPT TGGGGGAGGCGTGGTCCAGCCTGGGAGG RKHYQPYAPPRDFAAYRSRVK TCCCTGAGACTCTCCTGTGCAGCGTCTG FSRSADAPAYQQGQNQLYNEL GATTCACCTTCAGTAGCTATGGCATGCA NLGRREEYDVLDKRRGRDPEM CTGGGTCCGCCAGGCTCCAGGCAAGGGG GGKPRRKNPQEGLYNELQKDK CTGGAGTGGGTGGCAGTTATATCGTATG MAEAYSEIGMKGERRRGKGHD ATGGAAGTAATAAATACTATGCAGACTC GLYQGLSTATKDTYDALHMQA CGTGAAGGGCCGATTCACCATCTCCAGA LPPR GACAATTCCAAGAACACGCTGTATCTGC AAATGAACAGCCTGAGAGCCGAGGACAC GGCGGTGTACTACTGCGCCAGAGACGGT ACTTATCTAGGTGGTCTCTGGTACTTCG ACTTATGGGGGAGAGGTACCTTGGTCAC CGTCTCCTCAGCCGCTGCCCTTGATAAT GAAAAGTCAAACGGAACAATCATTCACG TGAAGGGCAAGCACCTCTGTCCGTCACC CTTGTTCCCTGGTCCATCCAAGCCATTC TGGGTGTTGGTCGTAGTGGGTGGAGTCC TCGCTTGTTACTCTCTGCTCGTCACCGT GGCTTTTATAATCTTCTGGGTTAGATCC AAAAGAAGCCGCCTGCTCCATAGCGATT ACATGAATATGACTCCACGCCGCCCTGG CCCCACAAGGAAACACTACCAGCCTTAC GCACCACCTAGAGATTTCGCTGCCTATC GGAGCAGGGTGAAGTTTTCCAGATCTGC AGATGCACCAGCGTATCAGCAGGGCCAG AACCAACTGTATAACGAGCTCAACCTGG GACGCAGGGAAGAGTATGACGTTTTGGA CAAGCGCAGAGGACGGGACCCTGAGATG GGTGGCAAACCAAGACGAAAAAACCCCC AGGAGGGTCTCTATAATGAGCTGCAGAA GGATAAGATGGCTGAAGCCTATTCTGAA ATAGGCATGAAAGGAGAGCGGAGAAGGG GAAAAGGGCACGACGGTTTGTACCAGGG ACTCAGCACTGCTACGAAGGATACTTAT GACGCTCTCCACATGCAAGCCCTGCCAC CTAGGTAA AJ- ATGGCACTCCCCGTAACTGCTCTGCTGC 183 MALPVTALLLPLALLLHAARP 184 21508CAR TGCCGTTGGCATTGCTCCTGCACGCCGC QVQLVQSGAEVKKPGASVKVS HxL ACGCCCGCAGGTGCAGCTGGTGCAGTCT CKASGYTFTSYYMHWVRQAPG GGGGCTGAGGTGAAGAAGCCTGGGGCCT QGLEWMGIINPGGGSTSYAQK CAGTGAAGGTTTCCTGCAAGGCATCTGG FQGRVTMTRDTSTSTVYMELS ATACACCTTCACCAGCTACTATATGCAC SLRSEDTAVYYCARESWPMDV TGGGTGCGACAGGCCCCTGGACAAGGGC WGQGTTVTVSSGSTSGSGKPG TTGAGTGGATGGGAATAATCAACCCTGG SGEGSTKGEIVMTQSPATLSV TGGTGGTAGCACAAGCTACGCACAGAAG SPGERATLSCRASQSVSSNLA TTCCAGGGCAGAGTCACCATGACCAGGG WYQQKPGQAPRLLIYGASTRA ACACGTCCACGAGCACAGTCTACATGGA TGIPARFSGSGSGTEFTLTIS GCTGAGCAGCCTGAGATCTGAGGACACG SLQSEDFAVYYCQQYAAYPTF GCGGTGTACTACTGCGCCAGAGAGAGTT GGGTKVEIKRAAALDNEKSNG GGCCAATGGACGTATGGGGCCAGGGAAC TIIHVKGKHLCPSPLFPGPSK AACTGTCACCGTCTCCTCAGGGTCTACA PFWVLVVVGGVLACYSLLVTV TCCGGCTCCGGGAAGCCCGGAAGTGGCG AFIIFWVRSKRSRLLHSDYMN AAGGTAGTACAAAGGGGGAAATAGTGAT MTPRRPGPTRKHYQPYAPPRD GACGCAGTCTCCAGCCACCCTGTCTGTG FAAYRSRVKFSRSADAPAYQQ TCTCCAGGGGAAAGAGCCACCCTCTCCT GQNQLYNELNLGRREEYDVLD GCAGGGCCAGTCAGAGTGTTAGCAGCAA KRRGRDPEMGGKPRRKNPQEG CTTAGCCTGGTACCAGCAGAAACCTGGC LYNELQKDKMAEAYSEIGMKG CAGGCTCCCAGGCTCCTCATCTATGGTG ERRRGKGHDGLYQGLSTATKD CATCCACCAGGGCCACTGGTATCCCAGC TYDALHMQALPPR CAGGTTCAGTGGCAGTGGGTCTGGGACA GAGTTCACTCTCACCATCAGCAGCCTGC AGTCTGAAGATTTTGCAGTTTATTACTG TCAGCAGTACGCCGCCTACCCTACTTTT GGCGGAGGGACCAAGGTTGAGATCAAAC GGGCCGCTGCCCTTGATAATGAAAAGTC AAACGGAACAATCATTCACGTGAAGGGC AAGCACCTCTGTCCGTCACCCTTGTTCC CTGGTCCATCCAAGCCATTCTGGGTGTT GGTCGTAGTGGGTGGAGTCCTCGCTTGT TACTCTCTGCTCGTCACCGTGGCTTTTA TAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAAT ATGACTCCACGCCGCCCTGGCCCCACAA GGAAACACTACCAGCCTTACGCACCACC TAGAGATTTCGCTGCCTATCGGAGCAGG GTGAAGTTTTCCAGATCTGCAGATGCAC CAGCGTATCAGCAGGGCCAGAACCAACT GTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCA GAGGACGGGACCCTGAGATGGGTGGCAA ACCAAGACGAAAAAACCCCCAGGAGGGT CTCTATAATGAGCTGCAGAAGGATAAGA TGGCTGAAGCCTATTCTGAAATAGGCAT GAAAGGAGAGCGGAGAAGGGGAAAAGGG CACGACGGTTTGTACCAGGGACTCAGCA CTGCTACGAAGGATACTTATGACGCTCT CCACATGCAAGCCCTGCCACCTAGGTAA AJ- ATGGCACTCCCCGTAACTGCTCTGCTGC 185 MALPVTALLLPLALLLHAARP 186 21508CAR TGCCGTTGGCATTGCTCCTGCACGCCGC EIVMTQSPATLSVSPGERATL LxH ACGCCCGGAAATAGTGATGACGCAGTCT SCRASQSVSSNLAWYQQKPGQ CCAGCCACCCTGTCTGTGTCTCCAGGGG APRLLIYGASTRATGIPARFS AAAGAGCCACCCTCTCCTGCAGGGCCAG GSGSGTEFTLTISSLQSEDFA TCAGAGTGTTAGCAGCAACTTAGCCTGG VYYCQQYAAYPTFGGGTKVEI TACCAGCAGAAACCTGGCCAGGCTCCCA KRGSTSGSGKPGSGEGSTKGQ GGCTCCTCATCTATGGTGCATCCACCAG VQLVQSGAEVKKPGASVKVSC GGCCACTGGTATCCCAGCCAGGTTCAGT KASGYTFTSYYMHWVRQAPGQ GGCAGTGGGTCTGGGACAGAGTTCACTC GLEWMGIINPGGGSTSYAQKF TCACCATCAGCAGCCTGCAGTCTGAAGA QGRVTMTRDTSTSTVYMELSS TTTTGCAGTTTATTACTGTCAGCAGTAC LRSEDTAVYYCARESWPMDVW GCCGCCTACCCTACTTTTGGCGGAGGGA GQGTTVTVSSAAALDNEKSNG CCAAGGTTGAGATCAAACGGGGGTCTAC TIIHVKGKHLCPSPLFPGPSK ATCCGGCTCCGGGAAGCCCGGAAGTGGC PFWVLVVVGGVLACYSLLVTV GAAGGTAGTACAAAGGGGCAGGTGCAGC AFIIFWVRSKRSRLLHSDYMN TGGTGCAGTCTGGGGCTGAGGTGAAGAA MTPRRPGPTRKHYQPYAPPRD GCCTGGGGCCTCAGTGAAGGTTTCCTGC FAAYRSRVKFSRSADAPAYQQ AAGGCATCTGGATACACCTTCACCAGCT GQNQLYNELNLGRREEYDVLD ACTATATGCACTGGGTGCGACAGGCCCC KRRGRDPEMGGKPRRKNPQEG TGGACAAGGGCTTGAGTGGATGGGAATA LYNELQKDKMAEAYSEIGMKG ATCAACCCTGGTGGTGGTAGCACAAGCT ERRRGKGHDGLYQGLSTATKD ACGCACAGAAGTTCCAGGGCAGAGTCAC TYDALHMQALPPR CATGACCAGGGACACGTCCACGAGCACA GTCTACATGGAGCTGAGCAGCCTGAGAT CTGAGGACACGGCGGTGTACTACTGCGC CAGAGAGAGTTGGCCAATGGACGTATGG GGCCAGGGAACAACTGTCACCGTCTCCT CAGCCGCTGCCCTTGATAATGAAAAGTC AAACGGAACAATCATTCACGTGAAGGGC AAGCACCTCTGTCCGTCACCCTTGTTCC CTGGTCCATCCAAGCCATTCTGGGTGTT GGTCGTAGTGGGTGGAGTCCTCGCTTGT TACTCTCTGCTCGTCACCGTGGCTTTTA TAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAAT ATGACTCCACGCCGCCCTGGCCCCACAA GGAAACACTACCAGCCTTACGCACCACC TAGAGATTTCGCTGCCTATCGGAGCAGG GTGAAGTTTTCCAGATCTGCAGATGCAC CAGCGTATCAGCAGGGCCAGAACCAACT GTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCA GAGGACGGGACCCTGAGATGGGTGGCAA ACCAAGACGAAAAAACCCCCAGGAGGGT CTCTATAATGAGCTGCAGAAGGATAAGA TGGCTGAAGCCTATTCTGAAATAGGCAT GAAAGGAGAGCGGAGAAGGGGAAAAGGG CACGACGGTTTGTACCAGGGACTCAGCA CTGCTACGAAGGATACTTATGACGCTCT CCACATGCAAGCCCTGCCACCTAGGTAA NM- ATGGCACTCCCCGTAACTGCTCTGCTGC 187 MALPVTALLLPLALLLHAARP 188 21517CAR TGCCGTTGGCATTGCTCCTGCACGCCGC QLQLQESGPGLVKPSETLSLT HxL ACGCCCGCAGCTGCAGCTGCAGGAGTCG CTVSGGSISSSSYYWGWIRQP GGCCCAGGACTGGTGAAGCCTTCGGAGA PGKGLEWIGSISYSGSTYYNP CCCTGTCCCTCACCTGCACTGTCTCTGG SLKSRVTISVDTSKNQFSLKL TGGCTCCATCAGCAGTAGTAGTTACTAC SSVTAADTAVYYCARGRGYAT TGGGGCTGGATCCGCCAGCCCCCAGGGA SLAFDIWGQGTMVTVSSGSTS AGGGGCTGGAGTGGATTGGGAGTATCTC GSGKPGSGEGSTKGEIVLTQS CTATAGTGGGAGCACCTACTACAACCCG PATLSLSPGERATLSCRASQS TCCCTCAAGAGTCGAGTCACCATATCCG VSSYLAWYQQKPGQAPRLLIY TAGACACGTCCAAGAACCAGTTCTCCCT DASNRATGIPARFSGSGSGTD GAAGCTGAGTTCTGTGACCGCCGCAGAC FTLTISSLEPEDFAVYYCQQR ACGGCGGTGTACTACTGCGCCAGAGGCA HVWPPTFGGGTKVEIKRAAAL GGGGATATGCAACCAGCTTAGCCTTCGA DNEKSNGTIIHVKGKHLCPSP TATCTGGGGTCAGGGTACAATGGTCACC LFPGPSKPFWVLVVVGGVLAC GTCTCCTCAGGGTCTACATCCGGCTCCG YSLLVTVAFIIFWVRSKRSRL GGAAGCCCGGAAGTGGCGAAGGTAGTAC LHSDYMNMTPRRPGPTRKHYQ AAAGGGGGAAATTGTGTTGACACAGTCT PYAPPRDFAAYRSRVKFSRSA CCAGCCACCCTGTCTTTGTCTCCAGGGG DAPAYQQGQNQLYNELNLGRR AAAGAGCCACCCTCTCCTGCAGGGCCAG EEYDVLDKRRGRDPEMGGKPR TCAGAGTGTTAGCAGCTACTTAGCCTGG RKNPQEGLYNELQKDKMAEAY TACCAACAGAAACCTGGCCAGGCTCCCA SEIGMKGERRRGKGHDGLYQG GGCTCCTCATCTATGATGCATCCAACAG LSTATKDTYDALHMQALPPR GGCCACTGGCATCCCAGCCAGGTTCAGT GGCAGTGGGTCTGGGACAGACTTCACTC TCACCATCAGCAGCCTAGAGCCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGAGA CACGTCTGGCCTCCTACTTTTGGCGGAG GGACCAAGGTTGAGATCAAACGGGCCGC TGCCCTTGATAATGAAAAGTCAAACGGA ACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCC ATCCAAGCCATTCTGGGTGTTGGTCGTA GTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTT CTGGGTTAGATCCAAAAGAAGCCGCCTG CTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACA CTACCAGCCTTACGCACCACCTAGAGAT TTCGCTGCCTATCGGAGCAGGGTGAAGT TTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAAC GAGCTCAACCTGGGACGCAGGGAAGAGT ATGACGTTTTGGACAAGCGCAGAGGACG GGACCCTGAGATGGGTGGCAAACCAAGA CGAAAAAACCCCCAGGAGGGTCTCTATA ATGAGCTGCAGAAGGATAAGATGGCTGA AGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACG GTTTGTACCAGGGACTCAGCACTGCTAC GAAGGATACTTATGACGCTCTCCACATG CAAGCCCTGCCACCTAGGTAA NM- ATGGCACTCCCCGTAACTGCTCTGCTGC 189 MALPVTALLLPLALLLHAARP 190 21517CAR TGCCGTTGGCATTGCTCCTGCACGCCGC EIVLTQSPATLSLSPGERATL LxH ACGCCCGGAAATTGTGTTGACACAGTCT SCRASQSVSSYLAWYQQKPGQ CCAGCCACCCTGTCTTTGTCTCCAGGGG APRLLIYDASNRATGIPARES AAAGAGCCACCCTCTCCTGCAGGGCCAG GSGSGTDFTLTISSLEPEDFA TCAGAGTGTTAGCAGCTACTTAGCCTGG VYYCQQRHVWPPTFGGGTKVE TACCAACAGAAACCTGGCCAGGCTCCCA IKRGSTSGSGKPGSGEGSTKG GGCTCCTCATCTATGATGCATCCAACAG QLQLQESGPGLVKPSETLSLT GGCCACTGGCATCCCAGCCAGGTTCAGT CTVSGGSISSSSYYWGWIRQP GGCAGTGGGTCTGGGACAGACTTCACTC PGKGLEWIGSISYSGSTYYNP TCACCATCAGCAGCCTAGAGCCTGAAGA SLKSRVTISVDTSKNQFSLKL TTTTGCAGTTTATTACTGTCAGCAGAGA SSVTAADTAVYYCARGRGYAT CACGTCTGGCCTCCTACTTTTGGCGGAG SLAFDIWGQGTMVTVSSAAAL GGACCAAGGTTGAGATCAAACGGGGGTC DNEKSNGTIIHVKGKHLCPSP TACATCCGGCTCCGGGAAGCCCGGAAGT LFPGPSKPFWVLVVVGGVLAC GGCGAAGGTAGTACAAAGGGGCAGCTGC YSLLVTVAFIIFWVRSKRSRL AGCTGCAGGAGTCGGGCCCAGGACTGGT LHSDYMNMTPRRPGPTRKHYQ GAAGCCTTCGGAGACCCTGTCCCTCACC PYAPPRDFAAYRSRVKFSRSA TGCACTGTCTCTGGTGGCTCCATCAGCA DAPAYQQGQNQLYNELNLGRR GTAGTAGTTACTACTGGGGCTGGATCCG EEYDVLDKRRGRDPEMGGKPR CCAGCCCCCAGGGAAGGGGCTGGAGTGG RKNPQEGLYNELQKDKMAEAY ATTGGGAGTATCTCCTATAGTGGGAGCA SEIGMKGERRRGKGHDGLYQG CCTACTACAACCCGTCCCTCAAGAGTCG LSTATKDTYDALHMQALPPR AGTCACCATATCCGTAGACACGTCCAAG AACCAGTTCTCCCTGAAGCTGAGTTCTG TGACCGCCGCAGACACGGCGGTGTACTA CTGCGCCAGAGGCAGGGGATATGCAACC AGCTTAGCCTTCGATATCTGGGGTCAGG GTACAATGGTCACCGTCTCCTCAGCCGC TGCCCTTGATAATGAAAAGTCAAACGGA ACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCC ATCCAAGCCATTCTGGGTGTTGGTCGTA GTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTT CTGGGTTAGATCCAAAAGAAGCCGCCTG CTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACA CTACCAGCCTTACGCACCACCTAGAGAT TTCGCTGCCTATCGGAGCAGGGTGAAGT TTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAAC GAGCTCAACCTGGGACGCAGGGAAGAGT ATGACGTTTTGGACAAGCGCAGAGGACG GGACCCTGAGATGGGTGGCAAACCAAGA CGAAAAAACCCCCAGGAGGGTCTCTATA ATGAGCTGCAGAAGGATAAGATGGCTGA AGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACG GTTTGTACCAGGGACTCAGCACTGCTAC GAAGGATACTTATGACGCTCTCCACATG CAAGCCCTGCCACCTAGGTAA TS- ATGGCACTCCCCGTAACTGCTCTGCTGC 191 MALPVTALLLPLALLLHAARP 192 21522CAR TGCCGTTGGCATTGCTCCTGCACGCCGC EVQLVESGGGLVQPGGSLRLS HxL ACGCCCGGAGGTGCAGCTGGTGGAGTCT CAASGFTFSSYSMNWVRQAPG GGGGGAGGCTTGGTACAGCCTGGGGGGT KGLEWVSTISSSSSTIYYADS CCCTGAGACTCTCCTGTGCAGCCTCTGG VKGRFTISRDNAKNSLYLQMN ATTCACCTTCAGTAGCTATAGCATGAAC SLRAEDTAVYYCARGSQEHLI TGGGTCCGCCAGGCTCCAGGGAAGGGGC FDYWGQGTLVTVSSGSTSGSG TGGAGTGGGTTTCAACCATTAGTAGTAG KPGSGEGSTKGEIVLTQSPAT TAGTAGTACCATATACTACGCAGACTCT LSLSPGERATLSCRASQSVSR GTGAAGGGCCGATTCACCATCTCCAGAG YLAWYQQKPGQAPRLLIYDAS ACAATGCCAAGAACTCACTGTATCTGCA NRATGIPARFSGSGSGTDFTL AATGAACAGCCTGAGAGCTGAGGACACG TISSLEPEDFAVYYCQQRFYY GCGGTGTACTACTGCGCCAGAGGTTCTC PWTFGGGTKVEIKRAAALDNE AGGAGCACCTGATTTTCGATTATTGGGG KSNGTIIHVKGKHLCPSPLFP ACAGGGTACATTGGTCACCGTCTCCTCA GPSKPFWVLVVVGGVLACYSL GGGTCTACATCCGGCTCCGGGAAGCCCG LVTVAFIIFWVRSKRSRLLHS GAAGTGGCGAAGGTAGTACAAAGGGGGA DYMNMTPRRPGPTRKHYQPYA AATTGTGTTGACACAGTCTCCAGCCACC PPRDFAAYRSRVKFSRSADAP CTGTCTTTGTCTCCAGGGGAAAGAGCCA AYQQGQNQLYNELNLGRREEY CCCTCTCCTGCAGGGCCAGTCAGAGTGT DVLDKRRGRDPEMGGKPRRKN TAGCAGGTACTTAGCCTGGTACCAACAG PQEGLYNELQKDKMAEAYSEI AAACCTGGCCAGGCTCCCAGGCTCCTCA GMKGERRRGKGHDGLYQGLST TCTATGATGCATCCAACAGGGCCACTGG ATKDTYDALHMQALPPR CATCCCAGCCAGGTTCAGTGGCAGTGGG TCTGGGACAGACTTCACTCTCACCATCA GCAGCCTAGAGCCTGAAGATTTTGCAGT TTATTACTGTCAGCAGAGATTCTACTAC CCTTGGACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGGGCCGCTGCCCTTGA TAATGAAAAGTCAAACGGAACAATCATT CACGTGAAGGGCAAGCACCTCTGTCCGT CACCCTTGTTCCCTGGTCCATCCAAGCC ATTCTGGGTGTTGGTCGTAGTGGGTGGA GTCCTCGCTTGTTACTCTCTGCTCGTCA CCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGC GATTACATGAATATGACTCCACGCCGCC CTGGCCCCACAAGGAAACACTACCAGCC TTACGCACCACCTAGAGATTTCGCTGCC TATCGGAGCAGGGTGAAGTTTTCCAGAT CTGCAGATGCACCAGCGTATCAGCAGGG CCAGAACCAACTGTATAACGAGCTCAAC CTGGGACGCAGGGAAGAGTATGACGTTT TGGACAAGCGCAGAGGACGGGACCCTGA GATGGGTGGCAAACCAAGACGAAAAAAC CCCCAGGAGGGTCTCTATAATGAGCTGC AGAAGGATAAGATGGCTGAAGCCTATTC TGAAATAGGCATGAAAGGAGAGCGGAGA AGGGGAAAAGGGCACGACGGTTTGTACC AGGGACTCAGCACTGCTACGAAGGATAC TTATGACGCTCTCCACATGCAAGCCCTG CCACCTAGGTAA TS- ATGGCACTCCCCGTAACTGCTCTGCTGC 193 MALPVTALLLPLALLLHAARP 194 21522CAR TGCCGTTGGCATTGCTCCTGCACGCCGC EIVLTQSPATLSLSPGERATL LxH ACGCCCGGAAATTGTGTTGACACAGTCT SCRASQSVSRYLAWYQQKPGQ CCAGCCACCCTGTCTTTGTCTCCAGGGG APRLLIYDASNRATGIPARES AAAGAGCCACCCTCTCCTGCAGGGCCAG GSGSGTDFTLTISSLEPEDFA TCAGAGTGTTAGCAGGTACTTAGCCTGG VYYCQQRFYYPWTFGGGTKVE TACCAACAGAAACCTGGCCAGGCTCCCA IKRGSTSGSGKPGSGEGSTKG GGCTCCTCATCTATGATGCATCCAACAG EVQLVESGGGLVQPGGSLRLS GGCCACTGGCATCCCAGCCAGGTTCAGT CAASGFTFSSYSMNWVRQAPG GGCAGTGGGTCTGGGACAGACTTCACTC KGLEWVSTISSSSSTIYYADS TCACCATCAGCAGCCTAGAGCCTGAAGA VKGRFTISRDNAKNSLYLQMN TTTTGCAGTTTATTACTGTCAGCAGAGA SLRAEDTAVYYCARGSQEHLI TTCTACTACCCTTGGACTTTTGGCGGAG FDYWGQGTLVTVSSAAALDNE GGACCAAGGTTGAGATCAAACGGGGGTC KSNGTIIHVKGKHLCPSPLFP TACATCCGGCTCCGGGAAGCCCGGAAGT GPSKPFWVLVVVGGVLACYSL GGCGAAGGTAGTACAAAGGGGGAGGTGC LVTVAFIIFWVRSKRSRLLHS AGCTGGTGGAGTCTGGGGGAGGCTTGGT DYMNMTPRRPGPTRKHYQPYA ACAGCCTGGGGGGTCCCTGAGACTCTCC PPRDFAAYRSRVKFSRSADAP TGTGCAGCCTCTGGATTCACCTTCAGTA AYQQGQNQLYNELNLGRREEY GCTATAGCATGAACTGGGTCCGCCAGGC DVLDKRRGRDPEMGGKPRRKN TCCAGGGAAGGGGCTGGAGTGGGTTTCA PQEGLYNELQKDKMAEAYSEI ACCATTAGTAGTAGTAGTAGTACCATAT GMKGERRRGKGHDGLYQGLST ACTACGCAGACTCTGTGAAGGGCCGATT ATKDTYDALHMQALPPR CACCATCTCCAGAGACAATGCCAAGAAC TCACTGTATCTGCAAATGAACAGCCTGA GAGCTGAGGACACGGCGGTGTACTACTG CGCCAGAGGTTCTCAGGAGCACCTGATT TTCGATTATTGGGGACAGGGTACATTGG TCACCGTCTCCTCAGCCGCTGCCCTTGA TAATGAAAAGTCAAACGGAACAATCATT CACGTGAAGGGCAAGCACCTCTGTCCGT CACCCTTGTTCCCTGGTCCATCCAAGCC ATTCTGGGTGTTGGTCGTAGTGGGTGGA GTCCTCGCTTGTTACTCTCTGCTCGTCA CCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGC GATTACATGAATATGACTCCACGCCGCC CTGGCCCCACAAGGAAACACTACCAGCC TTACGCACCACCTAGAGATTTCGCTGCC TATCGGAGCAGGGTGAAGTTTTCCAGAT CTGCAGATGCACCAGCGTATCAGCAGGG CCAGAACCAACTGTATAACGAGCTCAAC CTGGGACGCAGGGAAGAGTATGACGTTT TGGACAAGCGCAGAGGACGGGACCCTGA GATGGGTGGCAAACCAAGACGAAAAAAC CCCCAGGAGGGTCTCTATAATGAGCTGC AGAAGGATAAGATGGCTGAAGCCTATTC TGAAATAGGCATGAAAGGAGAGCGGAGA AGGGGAAAAGGGCACGACGGTTTGTACC AGGGACTCAGCACTGCTACGAAGGATAC TTATGACGCTCTCCACATGCAAGCCCTG CCACCTAGGTAA RY- ATGGCACTCCCCGTAACTGCTCTGCTGC 195 MALPVTALLLPLALLLHAARP 196 21527CAR TGCCGTTGGCATTGCTCCTGCACGCCGC QVQLVESGGGVVQPGRSLRLS HxL ACGCCCGCAGGTGCAGCTGGTGGAGTCT CAASGFTFSSYGMHWVRQAPG GGGGGAGGCGTGGTCCAGCCTGGGAGGT KGLEWVAVISYDGSNKYYADS CCCTGAGACTCTCCTGTGCAGCGTCTGG VKGRFTISRDNSKNTLYLQMN ATTCACCTTCAGTAGCTATGGCATGCAC SLRAEDTAVYYCARTDFWSGS TGGGTCCGCCAGGCTCCAGGCAAGGGGC PPGLDYWGQGTLVTVSSGSTS TGGAGTGGGTGGCAGTTATATCGTATGA GSGKPGSGEGSTKGDIQLTQS TGGAAGTAATAAATACTATGCAGACTCC PSSVSASVGDRVTITCRASQG GTGAAGGGCCGATTCACCATCTCCAGAG ISSWLAWYQQKPGKAPKLLIY ACAATTCCAAGAACACGCTGTATCTGCA GASSLQSGVPSRFSGSGSGTD AATGAACAGCCTGAGAGCCGAGGACACG FTLTISSLQPEDFATYYCQQI GCGGTGTACTACTGCGCCAGAACTGACT YTFPFTFGGGTKVEIKRAAAL TCTGGAGCGGATCCCCTCCAGGCTTAGA DNEKSNGTIIHVKGKHLCPSP TTACTGGGGACAGGGTACATTGGTCACC LFPGPSKPFWVLVVVGGVLAC GTCTCCTCAGGGTCTACATCCGGCTCCG YSLLVTVAFIIFWVRSKRSRL GGAAGCCCGGAAGTGGCGAAGGTAGTAC LHSDYMNMTPRRPGPTRKHYQ AAAGGGGGACATCCAGTTGACCCAGTCT PYAPPRDFAAYRSRVKFSRSA CCATCTTCCGTGTCTGCATCTGTAGGAG DAPAYQQGQNQLYNELNLGRR ACAGAGTCACCATCACTTGTCGGGCGAG EEYDVLDKRRGRDPEMGGKPR TCAGGGTATTAGCAGCTGGTTAGCCTGG RKNPQEGLYNELQKDKMAEAY TATCAGCAGAAACCAGGGAAAGCCCCTA SEIGMKGERRRGKGHDGLYQG AGCTCCTGATCTATGGTGCATCCAGTTT LSTATKDTYDALHMQALPPR GCAAAGTGGGGTCCCATCAAGGTTCAGC GGCAGTGGATCTGGGACAGATTTCACTC TCACCATCAGCAGCCTGCAGCCTGAAGA TTTTGCAACTTATTACTGTCAGCAGATA TACACCTTCCCTTTCACTTTTGGCGGAG GGACCAAGGTTGAGATCAAACGGGCCGC TGCCCTTGATAATGAAAAGTCAAACGGA ACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCC ATCCAAGCCATTCTGGGTGTTGGTCGTA GTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTT CTGGGTTAGATCCAAAAGAAGCCGCCTG CTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACA CTACCAGCCTTACGCACCACCTAGAGAT TTCGCTGCCTATCGGAGCAGGGTGAAGT TTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAAC GAGCTCAACCTGGGACGCAGGGAAGAGT ATGACGTTTTGGACAAGCGCAGAGGACG GGACCCTGAGATGGGTGGCAAACCAAGA CGAAAAAACCCCCAGGAGGGTCTCTATA ATGAGCTGCAGAAGGATAAGATGGCTGA AGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACG GTTTGTACCAGGGACTCAGCACTGCTAC GAAGGATACTTATGACGCTCTCCACATG CAAGCCCTGCCACCTAGGTAA RY- ATGGCACTCCCCGTAACTGCTCTGCTGC 197 MALPVTALLLPLALLLHAARP 198 21527CAR TGCCGTTGGCATTGCTCCTGCACGCCGC DIQLTQSPSSVSASVGDRVTI LxH ACGCCCGGACATCCAGTTGACCCAGTCT TCRASQGISSWLAWYQQKPGK CCATCTTCCGTGTCTGCATCTGTAGGAG APKLLIYGASSLQSGVPSRFS ACAGAGTCACCATCACTTGTCGGGCGAG GSGSGTDFTLTISSLQPEDFA TCAGGGTATTAGCAGCTGGTTAGCCTGG TYYCQQIYTFPFTFGGGTKVE TATCAGCAGAAACCAGGGAAAGCCCCTA IKRGSTSGSGKPGSGEGSTKG AGCTCCTGATCTATGGTGCATCCAGTTT QVQLVESGGGVVQPGRSLRLS GCAAAGTGGGGTCCCATCAAGGTTCAGC CAASGFTFSSYGMHWVRQAPG GGCAGTGGATCTGGGACAGATTTCACTC KGLEWVAVISYDGSNKYYADS TCACCATCAGCAGCCTGCAGCCTGAAGA VKGRFTISRDNSKNTLYLQMN TTTTGCAACTTATTACTGTCAGCAGATA SLRAEDTAVYYCARTDFWSGS TACACCTTCCCTTTCACTTTTGGCGGAG PPGLDYWGQGTLVTVSSAAAL GGACCAAGGTTGAGATCAAACGGGGGTC DNEKSNGTIIHVKGKHLCPSP TACATCCGGCTCCGGGAAGCCCGGAAGT LFPGPSKPFWVLVVVGGVLAC GGCGAAGGTAGTACAAAGGGGCAGGTGC YSLLVTVAFIIFWVRSKRSRL AGCTGGTGGAGTCTGGGGGAGGCGTGGT LHSDYMNMTPRRPGPTRKHYQ CCAGCCTGGGAGGTCCCTGAGACTCTCC PYAPPRDFAAYRSRVKFSRSA TGTGCAGCGTCTGGATTCACCTTCAGTA DAPAYQQGQNQLYNELNLGRR GCTATGGCATGCACTGGGTCCGCCAGGC EEYDVLDKRRGRDPEMGGKPR TCCAGGCAAGGGGCTGGAGTGGGTGGCA RKNPQEGLYNELQKDKMAEAY GTTATATCGTATGATGGAAGTAATAAAT SEIGMKGERRRGKGHDGLYQG ACTATGCAGACTCCGTGAAGGGCCGATT LSTATKDTYDALHMQALPPR CACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGA GAGCCGAGGACACGGCGGTGTACTACTG CGCCAGAACTGACTTCTGGAGCGGATCC CCTCCAGGCTTAGATTACTGGGGACAGG GTACATTGGTCACCGTCTCCTCAGCCGC TGCCCTTGATAATGAAAAGTCAAACGGA ACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCC ATCCAAGCCATTCTGGGTGTTGGTCGTA GTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTT CTGGGTTAGATCCAAAAGAAGCCGCCTG CTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACA CTACCAGCCTTACGCACCACCTAGAGAT TTCGCTGCCTATCGGAGCAGGGTGAAGT TTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAAC GAGCTCAACCTGGGACGCAGGGAAGAGT ATGACGTTTTGGACAAGCGCAGAGGACG GGACCCTGAGATGGGTGGCAAACCAAGA CGAAAAAACCCCCAGGAGGGTCTCTATA ATGAGCTGCAGAAGGATAAGATGGCTGA AGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACG GTTTGTACCAGGGACTCAGCACTGCTAC GAAGGATACTTATGACGCTCTCCACATG CAAGCCCTGCCACCTAGGTAA PP- ATGGCACTCCCCGTAACTGCTCTGCTGC 199 MALPVTALLLPLALLLHAARP 200 21528CAR TGCCGTTGGCATTGCTCCTGCACGCCGC QVQLVQSGAEVKKPGSSVKVS HxL ACGCCCGCAGGTGCAGCTGGTGCAGTCT CKASGGTFSSYAISWVRQAPG GGGGCTGAGGTGAAGAAGCCTGGGTCCT QGLEWMGGIIPIFGTANYAQK CGGTGAAGGTCTCCTGCAAGGCTTCTGG FQGRVTITADESTSTAYMELS AGGCACCTTCAGCAGCTATGCTATCAGC SLRSEDTAVYYCARTPEYSSS TGGGTGCGACAGGCCCCTGGACAAGGGC IWHYYYGMDVWGQGTTVTVSS TTGAGTGGATGGGAGGGATCATCCCTAT GSTSGSGKPGSGEGSTKGDIV CTTTGGTACAGCAAACTACGCACAGAAG MTQSPDSLAVSLGERATINCK TTCCAGGGCAGAGTCACGATTACCGCGG SSQSVLYSSNNKNYLAWYQQK ACGAATCCACGAGCACAGCCTACATGGA PGQPPKLLIYWASTRESGVPD GCTGAGCAGCCTGAGATCTGAGGACACG RFSGSGSGTDFTLTISSLQAE GCGGTGTACTACTGCGCCAGAACTCCTG DVAVYYCQQFAHTPFTFGGGT AATACTCCTCCAGCATATGGCACTATTA KVEIKRAAALDNEKSNGTIIH CTACGGCATGGACGTATGGGGCCAGGGA VKGKHLCPSPLFPGPSKPFWV ACAACTGTCACCGTCTCCTCAGGGTCTA LVVVGGVLACYSLLVTVAFII CATCCGGCTCCGGGAAGCCCGGAAGTGG FWVRSKRSRLLHSDYMNMTPR CGAAGGTAGTACAAAGGGGGACATCGTG RPGPTRKHYQPYAPPRDFAAY ATGACCCAGTCTCCAGACTCCCTGGCTG RSRVKFSRSADAPAYQQGQNQ TGTCTCTGGGCGAGAGGGCCACCATCAA LYNELNLGRREEYDVLDKRRG CTGCAAGTCCAGCCAGAGTGTTTTATAC RDPEMGGKPRRKNPQEGLYNE AGCTCCAACAATAAGAACTACTTAGCTT LQKDKMAEAYSEIGMKGERRR GGTACCAGCAGAAACCAGGACAGCCTCC GKGHDGLYQGLSTATKDTYDA TAAGCTGCTCATTTACTGGGCATCTACC LHMQALPPR CGGGAATCCGGGGTCCCTGACCGATTCA GTGGCAGCGGGTCTGGGACAGATTTCAC TCTCACCATCAGCAGCCTGCAGGCTGAA GATGTGGCAGTTTATTACTGTCAGCAGT TCGCCCACACTCCTTTCACTTTTGGCGG AGGGACCAAGGTTGAGATCAAACGGGCC GCTGCCCTTGATAATGAAAAGTCAAACG GAACAATCATTCACGTGAAGGGCAAGCA CCTCTGTCCGTCACCCTTGTTCCCTGGT CCATCCAAGCCATTCTGGGTGTTGGTCG TAGTGGGTGGAGTCCTCGCTTGTTACTC TCTGCTCGTCACCGTGGCTTTTATAATC TTCTGGGTTAGATCCAAAAGAAGCCGCC TGCTCCATAGCGATTACATGAATATGAC TCCACGCCGCCCTGGCCCCACAAGGAAA CACTACCAGCCTTACGCACCACCTAGAG ATTTCGCTGCCTATCGGAGCAGGGTGAA GTTTTCCAGATCTGCAGATGCACCAGCG TATCAGCAGGGCCAGAACCAACTGTATA ACGAGCTCAACCTGGGACGCAGGGAAGA GTATGACGTTTTGGACAAGCGCAGAGGA CGGGACCCTGAGATGGGTGGCAAACCAA GACGAAAAAACCCCCAGGAGGGTCTCTA TAATGAGCTGCAGAAGGATAAGATGGCT GAAGCCTATTCTGAAATAGGCATGAAAG GAGAGCGGAGAAGGGGAAAAGGGCACGA CGGTTTGTACCAGGGACTCAGCACTGCT ACGAAGGATACTTATGACGCTCTCCACA TGCAAGCCCTGCCACCTAGGTAA PP- ATGGCACTCCCCGTAACTGCTCTGCTGC 201 MALPVTALLLPLALLLHAARP 202 21528CAR TGCCGTTGGCATTGCTCCTGCACGCCGC DIVMTQSPDSLAVSLGERATI LxH ACGCCCGGACATCGTGATGACCCAGTCT NCKSSQSVLYSSNNKNYLAWY CCAGACTCCCTGGCTGTGTCTCTGGGCG QQKPGQPPKLLIYWASTRESG AGAGGGCCACCATCAACTGCAAGTCCAG VPDRFSGSGSGTDFTLTISSL CCAGAGTGTTTTATACAGCTCCAACAAT QAEDVAVYYCQQFAHTPFTFG AAGAACTACTTAGCTTGGTACCAGCAGA GGTKVEIKRGSTSGSGKPGSG AACCAGGACAGCCTCCTAAGCTGCTCAT EGSTKGQVQLVQSGAEVKKPG TTACTGGGCATCTACCCGGGAATCCGGG SSVKVSCKASGGTFSSYAISW GTCCCTGACCGATTCAGTGGCAGCGGGT VRQAPGQGLEWMGGIIPIFGT CTGGGACAGATTTCACTCTCACCATCAG ANYAQKFQGRVTITADESTST CAGCCTGCAGGCTGAAGATGTGGCAGTT AYMELSSLRSEDTAVYYCART TATTACTGTCAGCAGTTCGCCCACACTC PEYSSSIWHYYYGMDVWGQGT CTTTCACTTTTGGCGGAGGGACCAAGGT TVTVSSAAALDNEKSNGTIIH TGAGATCAAACGGGGGTCTACATCCGGC VKGKHLCPSPLFPGPSKPFWV TCCGGGAAGCCCGGAAGTGGCGAAGGTA LVVVGGVLACYSLLVTVAFII GTACAAAGGGGCAGGTGCAGCTGGTGCA FWVRSKRSRLLHSDYMNMTPR GTCTGGGGCTGAGGTGAAGAAGCCTGGG RPGPTRKHYQPYAPPRDFAAY TCCTCGGTGAAGGTCTCCTGCAAGGCTT RSRVKFSRSADAPAYQQGQNQ CTGGAGGCACCTTCAGCAGCTATGCTAT LYNELNLGRREEYDVLDKRRG CAGCTGGGTGCGACAGGCCCCTGGACAA RDPEMGGKPRRKNPQEGLYNE GGGCTTGAGTGGATGGGAGGGATCATCC LQKDKMAEAYSEIGMKGERRR CTATCTTTGGTACAGCAAACTACGCACA GKGHDGLYQGLSTATKDTYDA GAAGTTCCAGGGCAGAGTCACGATTACC LHMQALPPR GCGGACGAATCCACGAGCACAGCCTACA TGGAGCTGAGCAGCCTGAGATCTGAGGA CACGGCGGTGTACTACTGCGCCAGAACT CCTGAATACTCCTCCAGCATATGGCACT ATTACTACGGCATGGACGTATGGGGCCA GGGAACAACTGTCACCGTCTCCTCAGCC GCTGCCCTTGATAATGAAAAGTCAAACG GAACAATCATTCACGTGAAGGGCAAGCA CCTCTGTCCGTCACCCTTGTTCCCTGGT CCATCCAAGCCATTCTGGGTGTTGGTCG TAGTGGGTGGAGTCCTCGCTTGTTACTC TCTGCTCGTCACCGTGGCTTTTATAATC TTCTGGGTTAGATCCAAAAGAAGCCGCC TGCTCCATAGCGATTACATGAATATGAC TCCACGCCGCCCTGGCCCCACAAGGAAA CACTACCAGCCTTACGCACCACCTAGAG ATTTCGCTGCCTATCGGAGCAGGGTGAA GTTTTCCAGATCTGCAGATGCACCAGCG TATCAGCAGGGCCAGAACCAACTGTATA ACGAGCTCAACCTGGGACGCAGGGAAGA GTATGACGTTTTGGACAAGCGCAGAGGA CGGGACCCTGAGATGGGTGGCAAACCAA GACGAAAAAACCCCCAGGAGGGTCTCTA TAATGAGCTGCAGAAGGATAAGATGGCT GAAGCCTATTCTGAAATAGGCATGAAAG GAGAGCGGAGAAGGGGAAAAGGGCACGA CGGTTTGTACCAGGGACTCAGCACTGCT ACGAAGGATACTTATGACGCTCTCCACA TGCAAGCCCTGCCACCTAGGTAA RD- ATGGCACTCCCCGTAACTGCTCTGCTGC 203 MALPVTALLLPLALLLHAARP 204 21530CAR TGCCGTTGGCATTGCTCCTGCACGCCGC QVQLVESGGGVVQPGRSLRLS HxL ACGCCCGCAGGTGCAGCTGGTGGAGTCT CAASGFTFSSYGMHWVRQAPG GGGGGAGGCGTGGTCCAGCCTGGGAGGT KGLEWVAVISYDGSNKYYADS CCCTGAGACTCTCCTGTGCAGCGTCTGG VKGRFTISRDNSKNTLYLQMN ATTCACCTTCAGTAGCTATGGCATGCAC SLRAEDTAVYYCVKGPLQEPP TGGGTCCGCCAGGCTCCAGGCAAGGGGC YDYGMDVWGQGTTVTVSSGST TGGAGTGGGTGGCAGTTATATCGTATGA SGSGKPGSGEGSTKGEIVMTQ TGGAAGTAATAAATACTATGCAGACTCC SPATLSVSPGERATLSCRASQ GTGAAGGGCCGATTCACCATCTCCAGAG SVSSNLAWYQQKPGQAPRLLI ACAATTCCAAGAACACGCTGTATCTGCA YSASTRATGIPARFSGSGSGT AATGAACAGCCTGAGAGCCGAGGACACG EFTLTISSLQSEDFAVYYCQQ GCGGTGTACTACTGCGTCAAGGGGCCGT HHVWPLTFGGGTKVEIKRAAA TGCAGGAGCCGCCATACGATTATGGAAT LDNEKSNGTIIHVKGKHLCPS GGACGTATGGGGCCAGGGAACAACTGTC PLFPGPSKPFWVLVVVGGVLA ACCGTCTCCTCAGGGTCTACATCCGGCT CYSLLVTVAFIIFWVRSKRSR CCGGGAAGCCCGGAAGTGGCGAAGGTAG LLHSDYMNMTPRRPGPTRKHY TACAAAGGGGGAAATAGTGATGACGCAG QPYAPPRDFAAYRSRVKFSRS TCTCCAGCCACCCTGTCTGTGTCTCCAG ADAPAYQQGQNQLYNELNLGR GGGAAAGAGCCACCCTCTCCTGCAGGGC REEYDVLDKRRGRDPEMGGKP CAGTCAGAGTGTTAGCAGCAACTTAGCC RRKNPQEGLYNELQKDKMAEA TGGTACCAGCAGAAACCTGGCCAGGCTC YSEIGMKGERRRGKGHDGLYQ CCAGGCTCCTCATCTATAGCGCATCCAC GLSTATKDTYDALHMQALPPR CAGGGCCACTGGTATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGAGTTCA CTCTCACCATCAGCAGCCTGCAGTCTGA AGATTTTGCAGTTTATTACTGTCAGCAG CACCACGTCTGGCCTCTCACTTTTGGCG GAGGGACCAAGGTTGAGATCAAACGGGC CGCTGCCCTTGATAATGAAAAGTCAAAC GGAACAATCATTCACGTGAAGGGCAAGC ACCTCTGTCCGTCACCCTTGTTCCCTGG TCCATCCAAGCCATTCTGGGTGTTGGTC GTAGTGGGTGGAGTCCTCGCTTGTTACT CTCTGCTCGTCACCGTGGCTTTTATAAT CTTCTGGGTTAGATCCAAAAGAAGCCGC CTGCTCCATAGCGATTACATGAATATGA CTCCACGCCGCCCTGGCCCCACAAGGAA ACACTACCAGCCTTACGCACCACCTAGA GATTTCGCTGCCTATCGGAGCAGGGTGA AGTTTTCCAGATCTGCAGATGCACCAGC GTATCAGCAGGGCCAGAACCAACTGTAT AACGAGCTCAACCTGGGACGCAGGGAAG AGTATGACGTTTTGGACAAGCGCAGAGG ACGGGACCCTGAGATGGGTGGCAAACCA AGACGAAAAAACCCCCAGGAGGGTCTCT ATAATGAGCTGCAGAAGGATAAGATGGC TGAAGCCTATTCTGAAATAGGCATGAAA GGAGAGCGGAGAAGGGGAAAAGGGCACG ACGGTTTGTACCAGGGACTCAGCACTGC TACGAAGGATACTTATGACGCTCTCCAC ATGCAAGCCCTGCCACCTAGGTAA RD- ATGGCACTCCCCGTAACTGCTCTGCTGC 205 MALPVTALLLPLALLLHAARP 206 21530CAR TGCCGTTGGCATTGCTCCTGCACGCCGC EIVMTQSPATLSVSPGERATL LxH ACGCCCGGAAATAGTGATGACGCAGTCT SCRASQSVSSNLAWYQQKPGQ CCAGCCACCCTGTCTGTGTCTCCAGGGG APRLLIYSASTRATGIPARFS AAAGAGCCACCCTCTCCTGCAGGGCCAG GSGSGTEFTLTISSLQSEDFA TCAGAGTGTTAGCAGCAACTTAGCCTGG VYYCQQHHVWPLTFGGGTKVE TACCAGCAGAAACCTGGCCAGGCTCCCA IKRGSTSGSGKPGSGEGSTKG GGCTCCTCATCTATAGCGCATCCACCAG QVQLVESGGGVVQPGRSLRLS GGCCACTGGTATCCCAGCCAGGTTCAGT CAASGFTFSSYGMHWVRQAPG GGCAGTGGGTCTGGGACAGAGTTCACTC KGLEWVAVISYDGSNKYYADS TCACCATCAGCAGCCTGCAGTCTGAAGA VKGRFTISRDNSKNTLYLQMN TTTTGCAGTTTATTACTGTCAGCAGCAC SLRAEDTAVYYCVKGPLQEPP CACGTCTGGCCTCTCACTTTTGGCGGAG YDYGMDVWGQGTTVTVSSAAA GGACCAAGGTTGAGATCAAACGGGGGTC LDNEKSNGTIIHVKGKHLCPS TACATCCGGCTCCGGGAAGCCCGGAAGT PLFPGPSKPFWVLVVVGGVLA GGCGAAGGTAGTACAAAGGGGCAGGTGC CYSLLVTVAFIIFWVRSKRSR AGCTGGTGGAGTCTGGGGGAGGCGTGGT LLHSDYMNMTPRRPGPTRKHY CCAGCCTGGGAGGTCCCTGAGACTCTCC QPYAPPRDFAAYRSRVKFSRS TGTGCAGCGTCTGGATTCACCTTCAGTA ADAPAYQQGQNQLYNELNLGR GCTATGGCATGCACTGGGTCCGCCAGGC REEYDVLDKRRGRDPEMGGKP TCCAGGCAAGGGGCTGGAGTGGGTGGCA RRKNPQEGLYNELQKDKMAEA GTTATATCGTATGATGGAAGTAATAAAT YSEIGMKGERRRGKGHDGLYQ ACTATGCAGACTCCGTGAAGGGCCGATT GLSTATKDTYDALHMQALPPR CACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGA GAGCCGAGGACACGGCGGTGTACTACTG CGTCAAGGGGCCGTTGCAGGAGCCGCCA TACGATTATGGAATGGACGTATGGGGCC AGGGAACAACTGTCACCGTCTCCTCAGC CGCTGCCCTTGATAATGAAAAGTCAAAC GGAACAATCATTCACGTGAAGGGCAAGC ACCTCTGTCCGTCACCCTTGTTCCCTGG TCCATCCAAGCCATTCTGGGTGTTGGTC GTAGTGGGTGGAGTCCTCGCTTGTTACT CTCTGCTCGTCACCGTGGCTTTTATAAT CTTCTGGGTTAGATCCAAAAGAAGCCGC CTGCTCCATAGCGATTACATGAATATGA CTCCACGCCGCCCTGGCCCCACAAGGAA ACACTACCAGCCTTACGCACCACCTAGA GATTTCGCTGCCTATCGGAGCAGGGTGA AGTTTTCCAGATCTGCAGATGCACCAGC GTATCAGCAGGGCCAGAACCAACTGTAT AACGAGCTCAACCTGGGACGCAGGGAAG AGTATGACGTTTTGGACAAGCGCAGAGG ACGGGACCCTGAGATGGGTGGCAAACCA AGACGAAAAAACCCCCAGGAGGGTCTCT ATAATGAGCTGCAGAAGGATAAGATGGC TGAAGCCTATTCTGAAATAGGCATGAAA GGAGAGCGGAGAAGGGGAAAAGGGCACG ACGGTTTGTACCAGGGACTCAGCACTGC TACGAAGGATACTTATGACGCTCTCCAC ATGCAAGCCCTGCCACCTAGGTAA - In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206. In certain embodiments, the CAR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206. In one embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 176. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 178. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 180. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 182. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 184. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 186. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 188. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 190. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 192. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 194. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 196. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 198. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 200. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 202. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 204. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 206.
- In some embodiments, the polynucleotide of the present invention comprises an nucleotide sequence at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, and 205. In certain embodiments, the polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, and 205. In one embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 175. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 177. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 179. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 181. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 183. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 185. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 187. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 189. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 191. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 193. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 195. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 197. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 199. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 201. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 203. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 205.
- In further embodiments, the invention relates to Clone FS-26528 HC DNA (SEQ ID NO: 271) as follows:
-
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGC CATGGCATGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCA GCTATTAGTGATGCAGGTGACAGAACATACTACGCAGACTCCGTGAGGG GCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCA AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGA GCCGAGATGGGAGCCGTATTCGACATATGGGGTCAGGGTACAATGGTCA CCGTCTCCTCA. - In further embodiments, the invention relates to the Clone FS-26528 HC amino acid sequence (SEQ ID NO: 272):
-
EVQLLESGGG LVQPGGSLRL SCAASGFTFD DYAMAWVRQA PGKGLEWVSA ISDAGDRTYY ADSVRGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARAE MGAVFDIWGQ GTMVTVSS. - In further embodiments, the invention relates to HC CDR1 thereof: SCAASGFTFDDYAMA (SEQ ID NO: 273). In further embodiments, the invention relates to HC CDR2 thereof: AISDAGDRTYYADSVRG (SEQ ID NO: 274). In further embodiments, the invention relates to HC CDR3 thereof: ARAEMGAVFDI (SEQ ID NO: 275) [HC CDR3]
- In further embodiments, the invention relates to Clone FS-26528 LC DNA (SEQ ID NO: 276):
-
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGG AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTT AGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGAGAATCTCCTGGCCTTTCACTTTT GGCGGAGGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone FS-26528 LC AA sequence (SEQ ID NO: 277):
-
EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RISWPFTFGG GTKVEIKR. - In further embodiments, the invention relates to LC CDR1 thereof: RASQSVSRYLA (SEQ ID NO: 278). In further embodiments, the invention relates to LC CDR2 thereof: DASNRAT (SEQ ID NO: 279). In further embodiments, the invention relates to the LC CDR3 thereof: QQRISWPFT (SEQ ID NO: 280).
- In further embodiments, the invention relates to Clone FS-26528 CAR DNA H×L (SEQ ID NO: 281):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGT ACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACC TTTGACGACTATGCCATGGCATGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTACGC AGACTCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC ACACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGT ACTACTGCGCAAGAGCCGAGATGGGAGCCGTATTCGACATATGGGGTCA GGGTACAATGGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAAG CCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACACAGT CTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTG CAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAA CCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCA CTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC TCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGT CAGCAGAGAATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAGGTTG AGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAAT CATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGT CCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTT GTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGC CGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAG ATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGC ACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTG GGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTA TAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGC ATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGG GACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGC CCTGCCACCTAGG. - In further embodiments, the invention relates to Clone FS-26528 CAR H×L AA sequence (SEQ ID NO: 282):
-
MALPVTALLL PLALLLHAAR PEVQLLESGG GLVQPGGSLR LSCAASGFTF DDYAMAWVRQ APGKGLEWVS AISDAGDRTY YADSVRGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCARA EMGAVFDIWG QGTMVTVSSG STSGSGKPGS GEGSTKGEIV LTQSPATLSL SPGERATLSC RASQSVSRYL AWYQQKPGQA PRLLIYDASN RATGIPARFS GSGSGTDFTL TISSLEPEDF AVYYCQQRIS WPFTFGGGTK VEIKRAAALD NEKSNGTIIH VKGKHLCPSP LFPGPSKPFW VLVVVGGVLA CYSLLVTVAF IIFWVRSKRS RLLHSDYMNM TPRRPGPTRK HYQPYAPPRD FAAYRSRVKF SRSADAPAYQ QGQNQLYNEL NLGRREEYDV LDKRRGRDPE MGGKPRRKNP QEGLYNELQK DKMAEAYSEI GMKGERRRGK GHDGLYQGLS TATKDTYDAL HMQALPPR. - In further embodiments, the invention relates to Clone FS-26528 CAR DNA L×H (SEQ ID NO: 283):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTC TTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT GTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCA GGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAG GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGC CTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGAGAATCTCCT GGCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTC TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGG GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGC CATGGCATGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCA GCTATTAGTGATGCAGGTGACAGAACATACTACGCAGACTCCGTGAGGG GCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCA AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGA GCCGAGATGGGAGCCGTATTCGACATATGGGGTCAGGGTACAATGGTCA CCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAAT CATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGT CCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTT GTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGC CGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAG ATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGC ACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTG GGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTA TAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGC ATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGG GACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGC CCTGCCACCTAGG. - In further embodiments, the invention relates to the Clone FS-26528 CAR L×H AA sequence (SEQ ID NO: 284):
-
MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA TLSCRASQSV SRYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRISWPFTFG GGTKVEIKRG STSGSGKPGS GEGSTKGEVQ LLESGGGLVQ PGGSLRLSCA ASGFTFDDYA MAWVRQAPGK GLEWVSAISD AGDRTYYADS VRGRFTISRD NSKNTLYLQM NSLRAEDTAV YYCARAEMGA VFDIWGQGTM VTVSSAAALD NEKSNGTIIH VKGKHLCPSP LFPGPSKPFW VLVVVGGVLA CYSLLVTVAF IIFWVRSKRS RLLHSDYMNM TPRRPGPTRK HYQPYAPPRD FAAYRSRVKF SRSADAPAYQ QGQNQLYNEL NLGRREEYDV LDKRRGRDPE MGGKPRRKNP QEGLYNELQK DKMAEAYSEI GMKGERRRGK GHDGLYQGLS TATKDTYDAL HMQALPPR. - In further embodiments, the invention relates to Clone PC-26534 HC DNA (SEQ ID NO: 285) as follows:
-
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGT CCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGG CATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCA GCTATATCTTATGATGGAAGGAATAAACACTATGCAGACTCCGTGAAGG GCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCA AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGA GACGGTACTTATCTAGGTGGTCTCTGGTACTTCGACTTATGGGGGAGAG GTACCTTGGTCACCGTCTCCTCA. - In further embodiments, the invention relates to Clone PC-26534 HC (SEQ ID NO: 286):
-
QVQLVESGGG VVQPGRSLRL SCAASGFTFS EHGMHWVRQA PGKGLEWVAA ISYDGRNKHY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDG TYLGGLWYFD LWGRGTLVTV SS. - In further embodiments, the invention relates to HC CDR1 thereof: FTFSEHGMH (SEQ ID NO: 287). In further embodiments, the invention relates to HC CDR2 thereof: AISYDGRNKHYADSVKG (SEQ ID NO: 288). In further embodiments, the invention relates to HC CDR3 thereof: ARDGTYLGGLWYFDL (SEQ ID NO: 289).
- In further embodiments, the invention relates to Clone PC-26534 LC DNA (SEQ ID NO: 290) as follows:
-
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAG AGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAA TGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCA CAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACA GGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAG AGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGC CTCCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone PC-26534 LC AA sequence (SEQ ID NO: 291):
-
DIVMTQSPLS LPVTPGEPAS ISCRSSQSLL HSNGYNYLDW YLQKPGQSPQ LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCMQGLGLP LTFGGGTKVE IKR. - In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RSSQSLLHSNGYNYLD (SEQ ID NO: 292). In further embodiments, the invention relates to LC CDR2 thereof: LGSNRAS (SEQ ID NO: 293). In further embodiments, the invention relates to LC CDR3 thereof: MQGLGLPLT (SEQ ID NO: 294).
- In further embodiments, the invention relates to Clone PC-26534 CAR DNA H×L (SEQ ID NO: 295) as follows:
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGT CCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACC TTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATGC AGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGT ACTACTGCGCCAGAGACGGTACTTATCTAGGTGGTCTCTGGTACTTCGA CTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCAGGGTCTACATCC GGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGATATTG TGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGC CTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATAC AACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCC TGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAG TGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAG GCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTC TCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCT TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCAC CTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGT TGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGT GGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCAT AGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAG GGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAG AACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAG ACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAG ATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGG GAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGA TACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone PC-26534 CAR H×L AA sequence (SEQ ID NO: 296):
-
MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR LSCAASGFTF SEHGMHWVRQ APGKGLEWVA AISYDGRNKH YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCARD GTYLGGLWYF DLWGRGTLVT VSSGSTSGSG KPGSGEGSTK GDIVMTQSPL SLPVTPGEPA SISCRSSQSL LHSNGYNYLD WYLQKPGQSP QLLIYLGSNR ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCMQGLGL PLTFGGGTKV EIKRAAALDN EKSNGTIIHV KGKHLCPSPL FPGPSKPFWV LVVVGGVLAC YSLLVTVAFI IFWVRSKRSR LLHSDYMNMT PRRPGPTRKH YQPYAPPRDF AAYRSRVKFS RSADAPAYQQ GQNQLYNELN LGRREEYDVL DKRRGRDPEM GGKPRRKNPQ EGLYNELQKD KMAEAYSEIG MKGERRRGKG HDGLYQGLST ATKDTYDALH MQALPPR. - In further embodiments, the invention relates to Clone PC-26534 CAR DNA L×H (SEQ ID NO: 297):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGGATATTGTGATGACTCAGTCTCCACTCTCCCTGCC CGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGC CTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGC CAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTC CGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACA CTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCA TGCAGGGACTCGGCCTCCCTCTCACTTTTGGCGGAGGGACCAAGGTTGA GATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAA GGTAGTACAAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGG TCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAC CTTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG CTGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATG CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAA CACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTG TACTACTGCGCCAGAGACGGTACTTATCTAGGTGGTCTCTGGTACTTCG ACTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCAGCCGCTGCCCT TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCAC CTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGT TGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGT GGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCAT AGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAG GGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAG AACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAG ACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAG ATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGG GAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGA TACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone PC-26534 CAR L×H chain sequences (SEQ ID NO: 298):
-
MALPVTALLL PLALLLHAAR PDIVMTQSPL SLPVTPGEPA SISCRSSQSL LHSNGYNYLD WYLQKPGQSP QLLIYLGSNR ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCMQGLGL PLTFGGGTKV EIKRGSTSGS GKPGSGEGST KGQVQLVESG GGVVQPGRSL RLSCAASGFT FSEHGMHWVR QAPGKGLEWV AAISYDGRNK HYADSVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR DGTYLGGLWY FDLWGRGTLV TVSSAAALDN EKSNGTIIHV KGKHLCPSPL FPGPSKPFWV LVVVGGVLAC YSLLVTVAFI IFWVRSKRSR LLHSDYMNMT PRRPGPTRKH YQPYAPPRDF AAYRSRVKFS RSADAPAYQQ GQNQLYNELN LGRREEYDVL DKRRGRDPEM GGKPRRKNPQ EGLYNELQKD KMAEAYSEIG MKGERRRGKG HDGLYQGLST ATKDTYDALH MQALPPR. - In further embodiments, the invention relates to Clone AJ-26545 HC DNA (SEQ ID NO: 299):
-
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCT CAGTGAAGGTTTCCTGCAGGGCATCTGGATACACCTTCATGGAGCACTA TATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGA GTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGG GCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGA GCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGA GAGAATTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCT CCTCA. - In further embodiments, the invention relates to Clone AJ-26545 HC AA sequence (SEQ ID NO: 300):
-
QVQLVQSGAE VKKPGASVKV SCRASGYTFM EHYMHWVRQA PGQGLEWMGV IGPSGGKTSY AQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARES WPMDVWGQGT TVTVSS. - In further embodiments, the invention relates to HC CDR1 thereof: YTFMEHYMH (SEQ ID NO: 301). In further embodiments, the invention relates to HC CDR2 thereof: VIGPSGGKTSYAQKFQG (SEQ ID NO: 302). In further embodiments, the invention relates to HC CDR3 thereof: ARESWPMDV (SEQ ID NO: 303).
- In further embodiments, the invention relates to Clone AJ-26545 LC DNA (SEQ ID NO: 304):
-
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGG AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTT AGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT GGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGC GGAGGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone AJ-26545 LC AA sequence (SEQ ID NO: 305):
-
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YAAYPTFGGG TKVEIKR. - In further embodiments, the invention relates to LC CDR1 thereof: RASQSVSSNLA (SEQ ID NO: 306). In further embodiments, the invention relates to LC CDR2 thereof: GASTRAT (SEQ ID NO: 307). In further embodiments, the invention relates to the LC CDR3 thereof: QQYAAYPT (SEQ ID NO: 308).
- In further embodiments, the invention relates to Clone AJ-26545 CAR DNA H×L (SEQ ID NO: 309):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAA GAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAGGGCATCTGGATACACC TTCATGGAGCACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGC TTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGC ACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGT ACTACTGCGCCAGAGAGAATTGGCCAATGGACGTATGGGGCCAGGGAAC AACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAAGCCCGGA AGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAG CCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGC CAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTA TCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCAC CATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAG TACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAAC GGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC TAGG. - In further embodiments, the invention relates to Clone AJ-26545 CAR H×L AA sequence (SEQ ID NO: 310):
-
MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK VSCRASGYTF MEHYMHWVRQ APGQGLEWMG VIGPSGGKTS YAQKFQGRVT MTRDTSTSTV YMELSSLRSE DTAVYYCARE SWPMDVWGQG TTVTVSSGST SGSGKPGSGE GSTKGEIVMT QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV YYCQQYAAYP TFGGGTKVEI KRAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR. - In further embodiments, the invention relates to Clone AJ-26545 CAR DNA L×H (SEQ ID NO: 311):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTC TGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT GTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCA GGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAG GTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGC CTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCT ACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTAC ATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAG GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAG TGAAGGTTTCCTGCAGGGCATCTGGATACACCTTCATGGAGCACTATAT GCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGTA ATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGGGCA GAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAG AATTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCT CAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC TAGG. - In further embodiments, the invention relates to Clone AJ-26545 CAR L×H AA sequence (SEQ ID NO: 312):
-
MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY GASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QYAAYPTFGG GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL VQSGAEVKKP GASVKVSCRA SGYTFMEHYM HWVRQAPGQG LEWMGVIGPS GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY YCARESWPMD VWGQGTTVTV SSAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR. - In further embodiments, the invention relates to Clone AJ-26554 HC DNA (SEQ ID NO: 313):
-
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCT CAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACGGAGCACTA TATGCACTGGGTGCGACAGGCCCCTGGACAAAGGCTTGAGTGGATGGGA GTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGG GCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGA GCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGA GAGAGTTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCT CCTCA. - In further embodiments, the invention relates to Clone AJ-26554 HC (SEQ ID NO: 314):
-
QVQLVQSGAE VKKPGASVKV SCKASGYTFT EHYMHWVRQA PGQRLEWMGV IGPSGGKTSY AQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARES WPMDVWGOGT TVTVSS. - In further embodiments, the invention relates to HC CDR1 thereof: YTFTEHYMH (SEQ ID NO: 315). In further embodiments, the invention relates to HC CDR2 thereof: VIGPSGGKTSYAQKFQG (SEQ ID NO: 316). In further embodiments, the invention relates to HC CDR3 thereof: ARESWPMDV (SEQ ID NO: 317).
- In further embodiments, the invention relates to Clone AJ-26554 LC DNA (SEQ ID NO: 318):
-
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGG AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTT AGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT GGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGC GGAGGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone AJ-26554 LC AA sequence (SEQ ID NO: 319):
-
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YAAYPTFGGG TKVEIKR. - In further embodiments, the invention relates to the LC CDR1 thereof: RASQSVSSNLA (SEQ ID NO: 320). In further embodiments, the invention relates to the LC CDR2 thereof: GASTRAT (SEQ ID NO: 321). In further embodiments, the invention relates to LC CDR3 thereof: QQYAAYPT (SEQ ID NO: 322).
- In further embodiments, the invention relates to Clone AJ-26554 CAR DNA H×L (SEQ ID NO: 323):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAA GAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACC TTCACGGAGCACTATATGCACTGGGTGCGACAGGCCCCTGGACAAAGGC TTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGC ACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGT ACTACTGCGCCAGAGAGAGTTGGCCAATGGACGTATGGGGCCAGGGAAC AACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAAGCCCGGA AGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAG CCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGC CAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTA TCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCAC CATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAG TACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAAC GGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC TAGG. - In further embodiments, the invention relates to Clone AJ-26554 CAR H×L AA sequence (SEQ ID NO: 324):
-
MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK VSCKASGYTF TEHYMHWVRQ APGQRLEWMG VIGPSGGKTS YAQKFQGRVT MTRDTSTSTV YMELSSLRSE DTAVYYCARE SWPMDVWGQG TTVTVSSGST SGSGKPGSGE GSTKGEIVMT QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV YYCQQYAAYP TFGGGTKVEI KRAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD LYQGLSTAT KDTYDALHMQ ALPPR. - In further embodiments, the invention relates to Clone AJ-26554 CAR DNA L×H (SEQ ID NO: 325):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTC TGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT GTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCA GGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAG GTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGC CTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCT ACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTAC ATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAG GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAG TGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACGGAGCACTATAT GCACTGGGTGCGACAGGCCCCTGGACAAAGGCTTGAGTGGATGGGAGTA ATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGGGCA GAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAG AGTTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCT CAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC TAGG. - In further embodiments, the invention relates to Clone AJ-26554 CAR L×H AA sequence (SEQ ID NO: 326):
-
MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY GASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QYAAYPTFGG GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL VQSGAEVKKP GASVKVSCKA SGYTFTEHYM HWVRQAPGQR LEWMGVIGPS GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY YCARESWPMD VWGQGTTVTV SSAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGH DGLYQGLSTAT KDTYDALHMQ ALPPR. - In further embodiments, the invention relates to Clone NM-26562 HC DNA (SEQ ID NO: 327):
-
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGAC CCTGTCCCTCACCTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTA GTTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATT GGGTTGATCTATTACGATGGGAGCACCTACTACAACCCGTCCCTCAAGAG TCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGC TGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGC AGGGGATATGAGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAAT GGTCACCGTCTCCTCA. - In further embodiments, the invention relates to Clone NM-26562 HC AA sequence (SEQ ID NO: 328):
-
QVQLQESGPG LVKPSQTLSL TCTVSGGSIG SGGSYWSWIR QHPGKGLEWI GLIYYDGSTY YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARG RGYETSLAFD IWGQGTMVTV SS. - In further embodiments, the invention relates to HC CDR1 thereof: GSIGSGGSYWS (SEQ ID NO: 329). In further embodiments, the invention relates to HC CDR2 thereof: LIYYDGSTYYNPSLKS (SEQ ID NO: 330). In further embodiments, the invention relates to HC CDR3 thereof: ARGRGYETSLAFDI (SEQ ID NO: 331).
- In further embodiments, the invention relates to Clone NM-26562 LC DNA (SEQ ID NO: 332):
-
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGG AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTT AGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTT GGCGGAGGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone NM-26562 LC AA sequence (SEQ ID NO: 333):
-
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RHVWPPTFGG GTKVEIKR. - In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASQSVSSYLA (SEQ ID NO: 334) In further embodiments, the invention relates to LC CDR2 AA sequence thereof: DASNRAT (SEQ ID NO: 335). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQRHVWPPT (SEQ ID NO: 336) (LC CDR3).
- In further embodiments, the invention relates to Clone NM-26562 CAR DNA H×L (SEQ ID NO: 337):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGT GAAGCCTTCACAGACCCTGTCCCTCACCTGTACTGTCTCTGGTGGCTCC ATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGCCAGCACCCAGGGA AGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTACTA CAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAG AACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCAGACACGGCGG TGTACTACTGCGCCAGAGGCAGGGGATATGAGACTTCTTTAGCCTTCGA TATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGGGTCTACATCC GGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTG TGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGC CACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGG TACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCAT CCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGG GACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCA GTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAG GGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTC AAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCC TTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTG GAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTT CTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAAT ATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACG CACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAG ATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAAC GAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCA GAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCA GGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACG GTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCT CCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone NM-26562 CAR H×L (SEQ ID NO: 338):
-
MALPVTALLL PLALLLHAAR PQVQLQESGP GLVKPSQTLS LTCTVSGGSI GSGGSYWSWI RQHPGKGLEW IGLIYYDGST YYNPSLKSRV TISVDTSKNQ FSLKLSSVTA ADTAVYYCAR GRGYETSLAF DIWGQGTMVT VSSGSTSGSG KPGSGEGSTK GEIVLTQSPA TLSLSPGERA TLSCRASQSV SSYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRHVWPPTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. - In further embodiments, the invention relates to Clone NM-26562 CAR DNA L×H (SEQ ID NO: 339):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCAC GCCGCACGCCCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTG TCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC AGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTC ATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGC AGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAA GATTTTGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTT GGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGG AAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAGCTGCAGGAG TCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGTACT GTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGC CAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGG AGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGAC ACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCAGAC ACGGCGGTGTACTACTGCGCCAGAGGCAGGGGATATGAGACTTCTTTAGCC TTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGCCGCTGCC CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCAC CTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTG GTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCT TTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAG CCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTT TCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTAT AACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGC AGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAG GAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCT GAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTG TACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATG CAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone NM-26562 CAR L×H (SEQ ID NO: 340):
-
MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA TLSCRASQSV SSYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRHVWPPTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LQESGPGLVK PSQTLSLTCT VSGGSIGSGG SYWSWIRQHP GKGLEWIGLI YYDGSTYYNP SLKSRVTISV DTSKNQFSLK LSSVTAADTA VYYCARGRGY ETSLAFDIWG QGTMVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. - In further embodiments, the invention relates to Clone TS-26564 HC DNA sequence (SEQ ID NO: 341):
-
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAG CATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCA ACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGACTCTGTGAAGG GCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCA AATGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGA GGTTCTCAGGAGCACCTGATTTTCGATTATTGGGGACAGGGTACATTGG TCACCGTCTCCTCA. - In further embodiments, the invention relates to Clone TS-26564 HC AA sequence (SEQ ID NO: 342):
-
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVST ISSSSSIIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARGS QEHLIFDYWG QGTLVTVSS. - In further embodiments, the invention relates to HC CDR1 AA sequence thereof: FTFSSYSMN (SEQ ID NO: 343). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: TISSSSSIIYYADSVKG (SEQ ID NO: 344). In further embodiments, the invention relates to HC CDR3 AA sequence thereof: ARGSQEHLIFDY (SEQ ID NO: 345).
- In further embodiments, the invention relates to Clone TS-26564 LC DNA (SEQ ID NO: 346):
-
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGG AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTT AGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGAGATTCTACTACCCTTGGACTTTT GGCGGAGGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone TS-26564 LC AA sequence (SEQ ID NO: 347):
-
EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RFYYPWTFGG GTKVEIKR. - In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASQSVSRYLA (SEQ ID NO: 348). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: DASNRAT (SEQ ID NO: 349). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQRFYYPWT (SEQ ID NO: 350).
- In further embodiments, the invention relates to Clone TS-26564 CAR DNA H×L (SEQ ID NO: 351):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGT ACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACC TTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTACGC AGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAAC TCACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCGGTGT ACTACTGCGCCAGAGGTTCTCAGGAGCACCTGATTTTCGATTATTGGGG ACAGGGTACATTGGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGG AAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACAC AGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTC CTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAG AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGG CCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTT CACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTAC TGTCAGCAGAGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAAC AATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCT GGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCG CTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCA CGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTA GAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGA TGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAAC CTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGG ACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCT CTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATA GGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACC AGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCA AGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone TS-26564 CAR H×L AA sequence (SEQ ID NO: 352):
-
MALPVTALLL PLALLLHAAR PEVQLVESGG GLVQPGGSLR LSCAASGFTF SSYSMNWVRQ APGKGLEWVS TISSSSSIIY YADSVKGRFT ISRDNAKNSL YLQMNSLRAE DTAVYYCARG SQEHLIFDYW GQGTLVTVSS GSTSGSGKPG SGEGSTKGEI VLTQSPATLS LSPGERATLS CRASQSVSRY LAWYQQKPGQ APRLLIYDAS NRATGIPARF SGSGSGTDFT LTISSLEPED FAVYYCQQRF YYPWTFGGGT KVEIKRAAAL DNEKSNGTII HVKGKHLCPS PLFPGPSKPF WVLVVVGGVL ACYSLLVTVA FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR KHYQPYAPPR DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE IGMKGERRRG KGHDGLYQGL STATKDTYDA LHMQALPPR. - In further embodiments, the invention relates to Clone TS-26564 CAR DNA L×H (SEQ ID NO: 353):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC ACGCCGCACGCCCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTC TTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT GTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCA GGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAG GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGC CTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGAGATTCTACT ACCCTTGGACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTC TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGG GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAG CATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCA ACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGACTCTGTGAAGG GCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCA AATGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGA GGTTCTCAGGAGCACCTGATTTTCGATTATTGGGGACAGGGTACATTGG TCACCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAAC AATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCT GGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCG CTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCA CGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTA GAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGA TGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAAC CTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGG ACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCT CTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATA GGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACC AGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCA AGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone TS-26564 CAR L×H AA sequence (SEQ ID NO: 354):
-
MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA TLSCRASQSV SRYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRFYYPWTFG GGTKVEIKRG STSGSGKPGS GEGSTKGEVQ LVESGGGLVQ PGGSLRLSCA ASGFTFSSYS MNWVRQAPGK GLEWVSTISS SSSIIYYADS VKGRFTISRD NAKNSLYLQM NSLRAEDTAV YYCARGSQEH LIFDYWGQGT LVTVSSAAAL DNEKSNGTII HVKGKHLCPS PLFPGPSKPF WVLVVVGGVL ACYSLLVTVA FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR KHYQPYAPPR DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE IGMKGERRRG KGHDGLYQGL STATKDTYDA LHMQALPPR. - In further embodiments, the invention relates to Clone RY-26568 HC DNA (SEQ ID NO: 355):
-
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGT CCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGG CATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCA GTTATACATTATGATGGAAGTGTTGAATACTATGCAGACTCCGTGAAGG GCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATCTGCA AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGA ACTGACTTCTGGAGCGGATCCCCTCCAAGCTTAGATTACTGGGGACAGG GTACATTGGTCACCGTCTCCTCA. - In further embodiments, the invention relates to Clone RY-26568 HC AA sequence (SEQ ID NO: 356):
-
QVQLVESGGG VVQPGRSLRL SCAASGFTFG SYGMHWVRQA PGKGLEWVAV IHYDGSVEYY ADSVKGRFTI SRDNSKDTLY LQMNSLRAED TAVYYCARTD FWSGSPPSLD YWGQGTLVTV SS. - In further embodiments, the invention relates to HC CDR1 thereof: FTFGSYGMH (SEQ ID NO: 357). In further embodiments, the invention relates to HC CDR2 thereof: VIHYDGSVEYYADSVKG (SEQ ID NO: 358). In further embodiments, the invention relates to HC CDR3 thereof: ARTDFWSGSPPSLDY (SEQ ID NO: 359).
- In further embodiments, the invention relates to Clone RY-26568 LC DNA (SEQ ID NO: 360):
-
GACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGA CAGAGTCACCATCACTTGTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAG CCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGT GCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC TGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTG CAACTTATTACTGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGA GGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone RY-26568 LC AA sequence (SEQ ID NO: 361):
-
DIQLTQSPSS VSASVGDRVT ITCRASRGIS SWLAWYQQKP GKAPKLLIYG ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ IYTFPFTFGG GTKVEIKR. - In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASRGISSWLA (SEQ ID NO: 362). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: GASSLQS (SEQ ID NO: 363). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQIYTFPFT (SEQ ID NO: 364) (LC CDR3).
- In further embodiments, the invention relates to Clone RY-26568 CAR DNA H×L (SEQ ID NO: 365):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCC AGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTC GGGAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGA GTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTATGCAGACT CCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTG CGCCAGAACTGACTTCTGGAGCGGATCCCCTCCAAGCTTAGATTACTGGG GACAGGGTACATTGGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGG AAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGACATCCAGTTGACCCA GTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTT GTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAA CCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCAGTTTGCAAAG TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTC TCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAG CAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGAT CAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTC ACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTC TCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAA GCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGC CTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATC AGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAA GAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGG CAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGA AGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGG AGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTAC GAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone RY-26568 CAR H×L AA sequence (SEQ ID NO: 366):
-
MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR LSCAASGFTF GSYGMHWVRQ APGKGLEWVA VIHYDGSVEY YADSVKGRFT ISRDNSKDTL YLQMNSLRAE DTAVYYCART DFWSGSPPSL DYWGQGTLVT VSSGSTSGSG KPGSGEGSTK GDIQLTQSPS SVSASVGDRV TITCRASRGI SSWLAWYQQK PGKAPKLLIY GASSLQSGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QIYTFPFTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. - In further embodiments, the invention relates to Clone RY-26568 CAR DNA L×H (SEQ ID NO: 367):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGGACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTG CATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCGGGGTATT AGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCT CCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCA GCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG CCTGAAGATTTTGCAACTTATTACTGTCAGCAGATATACACCTTCCCTTT CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCG GCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAG CTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATACATTAT GATGGAAGTGTTGAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAT CTCCAGAGACAATTCCAAGGACACGCTGTATCTGCAAATGAACAGCCTGA GAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTCTGGAGC GGATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGT CTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTC ACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTC TCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAA GCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGC CTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATC AGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAA GAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGG CAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGA AGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGG AGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTAC GAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone RY-26568 CAR L×H AA sequence (SEQ ID NO: 368):
-
MALPVTALLL PLALLLHAAR PDIQLTQSPS SVSASVGDRV TITCRASRGI SSWLAWYQQK PGKAPKLLIY GASSLQSGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QIYTFPFTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LVESGGGVVQ PGRSLRLSCA ASGFTFGSYG MHWVRQAPGK GLEWVAVIHY DGSVEYYADS VKGRFTISRD NSKDTLYLQM NSLRAEDTAV YYCARTDFWS GSPPSLDYWG QGTLVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. - In further embodiments, the invention relates to Clone PP-26575 HC DNA (SEQ ID NO: 369):
-
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTC GGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCTA TCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGG GTCATCCCTATCTTGGGTCGGGCAAACTACGCACAGAAGTTCCAGGGCAG AGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGCTGA GCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCT GAATACTCCTCCAGCATATGGCACTATTACTACGGCATGGACGTATGGGG CCAGGGAACAACTGTCACCGTCTCCTCA. - In further embodiments, the invention relates to Clone PP-26575 HC AA sequence (SEQ ID NO: 370):
-
QVQLVQSGAE VKKPGSSVKV SCKASGGTLS SLAISWVRQA PGQGLEWMGG VIPILGRANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARTP EYSSSIWHYY YGMDVWGQGT TVTVSS. - In further embodiments, the invention relates to HC CDR1 AA sequence thereof: GILSSLAIS (SEQ ID NO: 371). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: GVIPILGRANYAQKFQG (SEQ ID NO: 372). In further embodiments, the invention relates to HC CDR3 thereof: ARTPEYSSSIWHYYYGMDV (SEQ ID NO: 373).
- In further embodiments, the invention relates to Clone PP-26575 LC DNA (SEQ ID NO: 374):
-
GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGA GAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCA ACAATAAGAACTACTTAGCTTGGTACCAGCAGAAACCAGGACAGCCTCCT AAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCG ATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCC TGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACT CCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone PP-26575 LC AA sequence (SEQ ID NO: 375):
-
DIVMTQSPDS LAVSLGERAT INCKSSQSVL YSSNNKNYLA WYQQKPGQPP KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQFAHT PFTFGGGTKV EIKR. - In further embodiments, the invention relates to
LC CDR 1 AA sequence thereof: KSSQSVLYSSNNKNYLA (SEQ ID NO: 376). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: WASTRES (SEQ ID NO: 377). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQFAHTPFT (SEQ ID NO: 378). - In further embodiments, the invention relates to Clone PP-26575 CAR DNA H×L (SEQ ID NO: 379):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGA AGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTC AGCAGCCTGGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGA GTGGATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACAGA AGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCC TACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTG CGCCAGAACTCCTGAATACTCCTCCAGCATATGGCACTATTACTACGGCA TGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACA TCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGACAT CGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAAT AAGAACTACTTAGCTTGGTACCAGCAGAAACCAGGACAGCCTCCTAAGCT GCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCA GTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG GCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTT CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTG ATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTC TGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGT CGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTT TTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCA GCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGT TTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTG TATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAA GCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACC CCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCC TATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGA CGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTC TCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone PP-26575 CAR H×L AA sequence (SEO TD NO: 3801:
-
MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGSSVK VSCKASGGTL SSLAISWVRQ APGQGLEWMG GVIPILGRAN YAQKFQGRVT ITADESTSTA YMELSSLRSE DTAVYYCART PEYSSSIWHY YYGMDVWGOG TTVTVSSGST SGSGKPGSGE GSTKGDIVMT QSPDSLAVSL GERATINCKS SQSVLYSSNN KNYLAWYQQK PGQPPKLLIY WASTRESGVP DRFSGSGSGT DFTLTISSLQ AEDVAVYYCQ QFAHTPFTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. - In further embodiments, the invention relates to Clone PP-26575 CAR DNA L×H (SEQ ID NO: 381):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGGACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTG TGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTT TTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAGAAACC AGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCG GGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTC ACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCA GTTCGCCCACACTCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCA AACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGT ACAAAGGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCC TGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTCAGCA GCCTGGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGG ATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACAGAAGTT CCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACA TGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCC AGAACTCCTGAATACTCCTCCAGCATATGGCACTATTACTACGGCATGGA CGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTG ATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTC TGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGT CGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTT TTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCA GCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGT TTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTG TATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAA GCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACC CCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCC TATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGA CGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTC TCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone PP-26575 CAR L×H AA sequence (SEQ ID NO: 382):
-
MALPVTALLL PLALLLHAAR PDIVMTQSPD SLAVSLGERA TINCKSSQSV LYSSNNKNYL AWYQQKPGQP PKLLIYWAST RESGVPDRFS GSGSGTDFTL TISSLQAEDV AVYYCQQFAH TPFTFGGGTK VEIKRGSTSG SGKPGSGEGS TKGQVQLVQS GAEVKKPGSS VKVSCKASGG TLSSLAISWV RQAPGQGLEW MGGVIPILGR ANYAQKFQGR VTITADESTS TAYMELSSLR SEDTAVYYCA RTPEYSSSIW HYYYGMDVWG QGTTVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. - In further embodiments, the invention relates to Clone RD-26576 HC DNA (SEQ ID NO: 383):
-
CAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA TACACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTT ATAGGGTATGATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCG TTGCAGGAGCCGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAAC AACTGTCACCGTCTCCTCA. - In further embodiments, the invention relates to Clone RD-26576 HC AA sequence (SEQ ID NO: 384):
-
QVRLVESGGG VVQPGRSLRL SCAASGFTFS SYGIHWVRQA PGKGLEWVAV IGYDGQEKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKGP LQEPPYAFGM DVWGQGTTVT VSS. - In further embodiments, the invention relates to HC CDR1 AA sequence thereof: FTFSSYGIH (SEQ ID NO: 385). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: VIGYDGQEKYYADSVKG (SEQ ID NO: 386). In further embodiments, the invention relates to the HC CDR3 AA sequence thereof: VKGPLQEPPYAFGMDV (SEQ ID NO: 387).
- In further embodiments, the invention relates to Clone RD-26576 LC DNA (SEQ ID NO: 388):
-
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGA AAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAG CCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGC GCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTC TGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTG CAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGA GGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone RD-26576 LC AA sequence (SEQ ID NO: 389):
-
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYS ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ HHVWPLTFGG GTKVEIKR. - In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASQSVSSNLA (SEQ ID NO: 390). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: SASTRAT (SEQ ID NO: 391). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQHHVWPLT (SEQ ID NO: 392).
- In further embodiments, the invention relates to Clone RD-26576 CAR DNA H×L (SEQ ID NO: 393):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGCAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCC AGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTC AGTAGCTATGGCATACACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGA GTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGACT CCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTG CGTCAAGGGGCCGTTGCAGGAGCCGCCATACGCTTTTGGGATGGACGTAT GGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCC GGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGAC GCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCT CCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAG AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGC CACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCA CTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGT CAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGA GATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCA TTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTA CTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAA GAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCT GGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGC TGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGG TGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGC AGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAG CGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGC TACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone RD-26576 CAR H×L AA sequence (SEQ ID NO: 394):
-
MALPVTALLL PLALLLHAAR PQVRLVESGG GVVQPGRSLR LSCAASGFTF SSYGIHWVRQ APGKGLEWVA VIGYDGQEKY YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCVKG PLQEPPYAFG MDVWGQGTTV TVSSGSTSGS GKPGSGEGST KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL QSEDFAVYYC QQHHVWPLTF GGGTKVEIKR AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. - In further embodiments, the invention relates to Clone RD-26576 CAR DNA L×H (SEQ ID NO: 395):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTG TGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTT AGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCT CCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCA GTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAG TCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCT CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCG GCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCGG CTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT TCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGT CCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATG ATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATC TCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAG AGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGC CGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACC GTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCAT TCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCAT CCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTAC TCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAG AAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTG GCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCT GCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGG AAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGT GGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCA GAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGC GGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCT ACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone RD-26576 CAR L×H AA sequence (SEQ ID NO: 396):
-
MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY SASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QHHVWPLTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVR LVESGGGVVQ PGRSLRLSCA ASGFTFSSYG IHWVRQAPGK GLEWVAVIGY DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV YYCVKGPLQE PPYAFGMDVW GQGTTVTVSS AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. - In further embodiments, the invention relates to Clone RD-26578 HC DNA (SEQ ID NO: 397):
-
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTC CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCA TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTT ATAGGGTATGATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCG ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA ACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCG TTGCAGGAGCCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAAC AACTGTCACCGTCTCCTCA. - In further embodiments, the invention relates to Clone RD-26578 HC AA sequence (SEQ ID NO: 398):
-
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SRGMHWVRQA PGKGLEWVAV IGYDGQEKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKGP LQEPPYDYGM DVWGQGTTVT VSS. - In further embodiments, the invention relates to HC CDR1 AA sequence thereof: FTFSSRGMH (SEQ ID NO: 399). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: VIGYDGQEKYYADSVKG (SEQ ID NO: 400). In further embodiments, the invention relates to HC CDR3 thereof: VKGPLQEPPYDYGMDV (SEQ ID NO: 401).
- In further embodiments, the invention relates to Clone RD-26578 LC DNA (SEQ ID NO: 402):
-
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGA AAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAG CCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGC GCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTC TGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTG CAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGA GGGACCAAGGTTGAGATCAAACGG. - In further embodiments, the invention relates to Clone RD-26578 LC AA sequence (SEQ ID NO: 403):
-
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYS ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ HHVWPLTFGG GTKVEIKR. - In further embodiments, the invention relates to LC CDR1 AA sequence: RASQSVSSNLA (SEQ ID NO: 404). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: SASTRAT (SEQ ID NO: 405). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQHHVWPLT (SEQ ID NO: 406).
- In further embodiments, the invention relates to Clone RD-26578 CAR DNA H×L (SEQ ID NO: 407):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCC AGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTC AGTAGCCGTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGA GTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGACT CCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTG CGTCAAGGGGCCGTTGCAGGAGCCGCCATACGATTATGGAATGGACGTAT GGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCC GGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGAC GCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCT CCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAG AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGC CACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCA CTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGT CAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGA GATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCA TTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTA CTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAA GAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCT GGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGC TGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGG TGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGC AGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAG CGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGC TACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone RD-26578 CAR H×L AA sequence (SEQ ID NO: 408):
-
MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR LSCAASGFTF SSRGMHWVRQ APGKGLEWVA VIGYDGQEKY YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCVKG PLQEPPYDYG MDVWGQGTTV TVSSGSTSGS GKPGSGEGST KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL QSEDFAVYYC QQHHVWPLTF GGGTKVEIKR AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. - In further embodiments, the invention relates to Clone RD-26578 CAR DNA L×H (SEQ ID NO: 409):
-
ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA CGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTG TGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTT AGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCT CCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCA GTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAG TCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCT CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCG GCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAG CTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGG TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTAT GATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAT CTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA GAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAG CCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCAC CGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCA TTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTA CTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAA GAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCT GGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGC TGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGG TGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGC AGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAG CGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGC TACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. - In further embodiments, the invention relates to Clone RD-26578 CAR L×H AA sequence (SEQ ID NO: 410):
-
MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY SASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QHHVWPLTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LVESGGGVVQ PGRSLRLSCA ASGFTFSSRG MHWVRQAPGK GLEWVAVIGY DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV YYCVKGPLQE PPYDYGMDVW GQGTTVTVSS AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. - It will be appreciated that the sequences recited herein can be useful by themselves, in combination with one or more sequences recited herein, and/or incorporated into cells (such as CAR or TCR-based T cells) for use in immune- or other therapies. It will be further appreciated that these sequences can be used in accordance with the invention incorporated in vectors for transduction, transfection, and the like, into cells.
- It will be appreciated that adverse events may be minimized by transducing the immune cells (containing one or more CARs or TCRs) with a suicide gene. It may also be desired to incorporate an inducible “on” or “accelerator” switch into the immune cells. Suitable techniques include use of inducible caspase-9 (U.S. Appl. 2011/0286980) or a thymidine kinase, before, after or at the same time, as the cells are transduced with the CAR construct of the present invention. Additional methods for introducing suicide genes and/or “on” switches include TALENS, zinc fingers, RNAi, siRNA, shRNA, antisense technology, and other techniques known in the art.
- In accordance with the invention, additional on-off or other types of control switch techniques may be incorporated herein. These techniques may employ the use of dimerization domains and optional activators of such domain dimerization. These techniques include, e.g., those described by Wu et al., Science 2014 350 (6258) utilizing FKBP/Rapalog dimerization systems in certain cells, the contents of which are incorporated by reference herein in their entirety. Additional dimerization technology is described in, e.g., Fegan et al. Chem. Rev. 2010, 110, 3315-3336 as well as U.S. Pat. Nos. 5,830,462; 5,834,266; 5,869,337; and 6,165,787, the contents of which are also incorporated by reference herein in their entirety. Additional dimerization pairs may include cyclosporine-A/cyclophilin, receptor, estrogen/estrogen receptor (optionally using tamoxifen), glucocorticoids/glucocorticoid receptor, tetracycline/tetracycline receptor, vitamin D/vitamin D receptor. Further examples of dimerization technology can be found in e.g., WO2014/127261, WO2015/090229, US2014/0286987, US2015/0266973, US2016/0046700, U.S. Pat. No. 8,486,693, US2014/0171649, and US2012/0130076, the contents of which are further incorporated by reference herein in their entirety.
- In certain aspects, provided herein are vectors comprising a polynucleotide of the present invention. In some embodiments, the present invention is directed to a vector or a set of vectors comprising a polynucleotide encoding a CAR or a TCR, as described herein. In other embodiments, the present invention is directed to a vector or a set of vectors comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- Any vector known in the art can be suitable for the present invention. In some embodiments, the vector is a viral vector. In some embodiments, the vector is a retroviral vector (such as pMSVG1), a DNA vector, a murine leukemia virus vector, an SFG vector, a plasmid, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector (AAV), a lentiviral vector (such as pGAR), or any combination thereof.
- The pGAR sequence (SEQ ID NO: 413) is as follows:
-
CTGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGT GACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTT CTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGT TCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTC ACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACG TTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCT ATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCT GATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTGCCAT TCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTAT TACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGG GTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGACCCGGGGATGGCGCGCCAGTAATCAATTACGGGGTCATTAGTTCATAGCC CATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATA GGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAG TACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATG GCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAC ATCTACGTATTAGTCATCGCTATTACCATGCTGATGCGGTTTTGGCAGTACATCAATG GGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCC GCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAG CTGGTTTAGTGAACCGGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCT GGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAG TAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTA GTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGA AACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGG CGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAG AGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGGGAAA AAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGC AAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGC TGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTA GATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAA AGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACC GCACAGCAAGCCGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGG AGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTT GTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGA GGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCT CCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATT TGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGA GTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGA AATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAA GAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGT TTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTT GGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGA TATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCG AAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAA CGGATCTCGACGGTATCGGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGT GCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAA AACAAATTACAAAATTCAAAATTTTATCGCGATCGCGGAATGAAAGACCCCACCTGTA GGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAATACATAACTG AGAATAGAGAAGTTCAGATCAAGGTTAGGAACAGAGAGACAGCAGAATATGGGCCAAA CAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCC CAGATGCGGTCCCGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCC CCAAGGACCTGAAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTC GCTTCTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCAC TCGGCGCGCCAGTCCTTCGAAGTAGATCTTTGTCGATCCTACCATCCACTCGACACAC CCGCCAGCGGCCGCTGCCAAGCTTCCGAGCTCTCGAATTAATTCACGGTACCCACCAT GGCCTAGGGAGACTAGTCGAATCGATATCAACCTCTGGATTACAAAATTTGTGAAAGA TTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAA TGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAA ATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTG GTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTC AGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGC CGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTG GTGTTGTCGGGGAAGCTGACGTCCTTTTCATGGCTGCTCGCCTGTGTTGCCACCTGGA TTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCC TTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAG ACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCCTGGTTAATTAAAGTACCTTTAAG ACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGA CTGGAAGGGCGAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGT CTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACT GCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTA GCAGGCATGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAA TGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAC CATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAG GTTCAGGGGGAGGTGTGGGAGGTTTTTTGGCGCGCCATCGTCGAGGTTCCCTTTAGTG AGGGTTAATTGCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGT TATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCA GTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGC GGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCG TTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGA ATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC CGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATC ACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCA GGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACC GGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCT GTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACC CCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCG GTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGA GGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAG AAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTT GGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCA AGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTAC GGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTA TCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCT AAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC TATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAG ATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAG ACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGA GCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGG GAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCA ACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTC GGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGG CAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGC CCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCA TTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG TTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGC GTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGA CACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCA GGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATA GGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC. - The pGAR vector map is set forth in
FIG. 19 . - Suitable additional exemplary vectors include e.g., pBABE-puro, pBABE-neo largeTcDNA, pBABE-hygro-hTERT, pMKO.1 GFP, MSCV-IRES-GFP, pMSCV PIG (Puro IRES GFP empty plasmid), pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE, MSCV IRES Luciferase, pMIG, MDH1-PGK-GFP_2.0, TtRMPVIR, pMSCV-IRES-mCherry FP, pRetroX GFP T2A Cre, pRXTN, pLncEXP, and pLXIN-Luc.
- In other aspects, provided herein are cells comprising a polynucleotide or a vector of the present invention. In some embodiments, the present invention is directed to cells, in vitro cells, comprising a polynucleotide encoding a CAR or a TCR, as described herein. In some embodiments, the present invention is directed to cells, e.g., in vitro cells, comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In other embodiments, the present invention is directed to in vitro cells comprising a polypeptide encoded by a polynucleotide encoding a CAR or a TCR, as disclosed herein. In other embodiments, the present invention is directed to cells, in vitro cells, comprising a polypeptide encoded by a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- Any cell may be used as a host cell for the polynucleotides, the vectors, or the polypeptides of the present invention. In some embodiments, the cell can be a prokaryotic cell, fungal cell, yeast cell, or higher eukaryotic cells such as a mammalian cell. Suitable prokaryotic cells include, without limitation, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobactehaceae such as Escherichia, e.g., E. coli; Enterobacter; Erwinia; Klebsiella; Proteus; Salmonella, e.g., Salmonella typhimurium; Serratia, e.g., Serratia marcescans, and Shigella; Bacilli such as B. subtilis and B. licheniformis; Pseudomonas such as P. aeruginosa; and Streptomyces. In some embodiments, the cell is a human cell. In some embodiments, the cell is an immune cell. In some embodiments, the immune cell is selected from the group consisting of a T cell, a B cell, a tumor infiltrating lymphocyte (TIL), a TCR expressing cell, a natural killer (NK) cell, a dendritic cell, a granulocyte, an innate lymphoid cell, a megakaryocyte, a monocyte, a macrophage, a platelet, a thymocyte, and a myeloid cell. In one embodiment, the immune cell is a T cell. In another embodiment, the immune cell is an NK cell. In certain embodiments, the T cell is a tumor-infiltrating lymphocyte (TIL), autologous T cell, engineered autologous T cell (eACT™), an allogeneic T cell, a heterologous T cell, or any combination thereof.
- The cell of the present invention can be obtained through any source known in the art. For example, T cells can be differentiated in vitro from a hematopoietic stem cell population, or T cells can be obtained from a subject. T cells can be obtained from, e.g., peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In addition, the T cells can be derived from one or more T cell lines available in the art. T cells can also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLL™ separation and/or apheresis. In certain embodiments, the cells collected by apheresis are washed to remove the plasma fraction, and placed in an appropriate buffer or media for subsequent processing. In some embodiments, the cells are washed with PBS. As will be appreciated, a washing step can be used, such as by using a semiautomated flowthrough centrifuge, e.g., the COBE™ 2991 cell processor, the Baxter CYTOMATE™, or the like. In some embodiments, the washed cells are resuspended in one or more biocompatible buffers, or other saline solution with or without buffer. In certain embodiments, the undesired components of the apheresis sample are removed. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety.
- In certain embodiments, T cells are isolated from PBMCs by lysing the red blood cells and depleting the monocytes, e.g., by using centrifugation through a PERCOLL™ gradient. In some embodiments, a specific subpopulation of T cells, such as CD28+, CD4+, CD8+, CD45RA+, and CD45RO+ T cells is further isolated by positive or negative selection techniques known in the art. For example, enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. In some embodiments, cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected can be used. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain embodiments, flow cytometry and cell sorting are used to isolate cell populations of interest for use in the present invention.
- In some embodiments, PBMCs are used directly for genetic modification with the immune cells (such as CARs or TCRs) using methods as described herein. In certain embodiments, after isolating the PBMCs, T lymphocytes are further isolated, and both cytotoxic and helper T lymphocytes are sorted into naive, memory, and effector T cell subpopulations either before or after genetic modification and/or expansion.
- In some embodiments, CD8+ cells are further sorted into naive, central memory, and effector cells by identifying cell surface antigens that are associated with each of these types of CD8+ cells. In some embodiments, the expression of phenotypic markers of central memory T cells includes CD45RO, CD62L, CCR7, CD28, CD3, and CD127 and are negative for granzyme B. In some embodiments, central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28, and CD127 and positive for granzyme B and perforin. In certain embodiments, CD4+ T cells are further sorted into subpopulations. For example, CD4+ T helper cells can be sorted into naive, central memory, and effector cells by identifying cell populations that have cell surface antigens.
- In some embodiments, the immune cells, e.g., T cells, are genetically modified following isolation using known methods, or the immune cells are activated and expanded (or differentiated in the case of progenitors) in vitro prior to being genetically modified. In another embodiment, the immune cells, e.g., T cells, are genetically modified with the chimeric antigen receptors described herein (e.g., transduced with a viral vector comprising one or more nucleotide sequences encoding a CAR) and then are activated and/or expanded in vitro. Methods for activating and expanding T cells are known in the art and are described, e.g., in U.S. Pat. Nos. 6,905,874; 6,867,041; and 6,797,514; and PCT Publication No. WO 2012/079000, the contents of which are hereby incorporated by reference in their entirety. Generally, such methods include contacting PBMC or isolated T cells with a stimulatory agent and costimulatory agent, such as anti-CD3 and anti-CD28 antibodies, generally attached to a bead or other surface, in a culture medium with appropriate cytokines, such as IL-2. Anti-CD3 and anti-CD28 antibodies attached to the same bead serve as a “surrogate” antigen presenting cell (APC). One example is The Dynabeads® system, a CD3 CD28 activator/stimulator system for physiological activation of human T cells. In other embodiments, the T cells are activated and stimulated to proliferate with feeder cells and appropriate antibodies and cytokines using methods such as those described in U.S. Pat. Nos. 6,040,177 and 5,827,642 and PCT Publication No. WO 2012/129514, the contents of which are hereby incorporated by reference in their entirety.
- In certain embodiments, the T cells are obtained from a donor subject. In some embodiments, the donor subject is human patient afflicted with a cancer or a tumor. In other embodiments, the donor subject is a human patient not afflicted with a cancer or a tumor.
- Other aspects of the present invention are directed to compositions comprising a polynucleotide described herein, a vector described herein, a polypeptide described herein, or an in vitro cell described herein. In some embodiments, the composition comprises a pharmaceutically acceptable carrier, diluent, solubilizer, emulsifier, preservative and/or adjuvant. In some embodiments, the composition comprises an excipient. In one embodiment, the composition comprises a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the composition comprises a CAR or a TCR encoded by a polynucleotide of the present invention, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the composition comprises a T cell comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the composition comprises an antibody or an antigen binding molecule thereof encoded by a polynucleotide of the present invention. In another embodiment, the composition comprises an in vitro cell comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof encoded by a polynucleotide of the present invention.
- In some embodiments, the composition includes more than one different antigen binding molecule to BMCA. In some embodiments, the composition included more than one antigen binding molecule to BCMA, wherein the antigen binding molecules to BCMA bind more than one epitope. In some embodiments, the antigen binding molecules will not compete with one another for binding to BCMA. In some embodiments, any of the antigen binding molecules provided herein are combined together in a pharmaceutical composition.
- In other embodiments, the composition is selected for parenteral delivery, for inhalation, or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the ability of one skilled in the art. In certain embodiments, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8. In certain embodiments, when parenteral administration is contemplated, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising a desired antigen binding molecule to BCMA, with or without additional therapeutic agents, in a pharmaceutically acceptable vehicle. In certain embodiments, the vehicle for parenteral injection is sterile distilled water in which an antigen binding molecule to BCMA, with or without at least one additional therapeutic agent, is formulated as a sterile, isotonic solution, properly preserved. In certain embodiments, the preparation involves the formulation of the desired molecule with polymeric compounds (such as polylactic acid or polyglycolic acid), beads or liposomes, that provide for the controlled or sustained release of the product, which are then be delivered via a depot injection. In certain embodiments, implantable drug delivery devices are used to introduce the desired molecule.
- Another aspect of the invention is directed to a method of making a cell expressing a CAR or a TCR comprising transducing a cell with a polynucleotide disclosed herein under suitable conditions. In some embodiments, the method comprises transducing a cell with a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In some embodiments, the method comprises transducing a cell with a vector comprising the polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In other embodiments, the method comprises transducing a cell with a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In some embodiments, the method comprises transducing a cell with a vector comprising the polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as described herein. In some embodiments, the method further comprises isolating the cell.
- Another aspect of the present invention is directed to a method of inducing an immunity against a tumor comprising administering to a subject an effective amount of a cell comprising a polynucleotide described herein, a vector described herein, or a CAR or a TCR described herein. In one embodiment, the method comprises administering to a subject an effective amount of a cell comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising a vector comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising a CAR or a TCR encoded by a polynucleotide disclosed herein, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In other embodiments, the method comprises administering to a subject an effective amount of a cell comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising a vector comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising an antibody or antigen binding molecule thereof encoded by a polynucleotide disclosed herein, wherein the antibody or antigen binding molecule thereof specifically binds to BCMA.
- Another aspect of the present invention is directed to a method of inducing an immune response in a subject comprising administering an effective amount of the engineered immune cells of the present application. In some embodiments, the immune response is a T cell-mediated immune response. In some embodiments, the T cell-mediated immune response is directed against one or more target cells. In some embodiments, the engineered immune cell comprises a CAR or a TCR. In some embodiments, the target cell is a tumor cell.
- Another aspect of the present invention is directed to a method for treating or preventing a malignancy, said method comprising administering to a subject in need thereof an effective amount of at least one isolated antigen binding molecule described herein or at least one immune cell, wherein the immune cell comprises at least one CAR, TCR, and/or an isolated antigen binding molecule as described herein.
- Another aspect of the present invention is directed to a method of treating a hyperproliferative disorder or an inflammatory disease in a subject in need thereof comprising administering to the subject a polynucleotide disclosed herein, a vector disclosed herein, a CAR or a TCR disclosed herein, a cell disclosed herein, or a composition disclosed herein. In some embodiments, the inflammatory disease is selected from the group consisting of rheumatoid arthritis, psoriasis, allergies, asthma, autoimmune diseases such as Crohn's, IBD, fibromyalga, mastocytosis, Celiac disease, and any combination thereof. Additionally, the present invention may be useful to treat diabetes, particularly
Type 1 diabetes. - Another aspect of the present invention is directed to a method of treating a cancer in a subject in need thereof comprising administering to the subject a polynucleotide disclosed herein, a vector disclosed herein, a CAR or a TCR disclosed herein, a cell disclosed herein, or a composition disclosed herein. In one embodiment, the method comprises administering a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering a vector comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering a CAR or a TCR encoded by a polynucleotide disclosed herein, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the method comprises administering a cell comprising the polynucleotide, or a vector comprising the polynucleotide, encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In other embodiments, the method comprises administering a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering a vector comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering an antibody or an antigen binding molecule thereof encoded by a polynucleotide disclosed herein, wherein the antibody or the antigen binding molecule thereof specifically binds to BCMA. In another embodiment, the method comprises administering a cell comprising the polynucleotide, or a vector comprising the polynucleotide, encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein.
- In some embodiments, an antigen binding molecule to BCMA is administered alone. In certain embodiments, an antigen binding molecule to BCMA is administered as part of a CAR, TCR, or other immune cell. In such immune cells, the antigen binding molecule to BCMA can be under the control of the same promoter region, or a separate promoter. In certain embodiments, the genes encoding protein agents and/or an antigen binding molecule to BCMA can be in separate vectors.
- In some embodiments, the methods of treating a cancer in a subject in need thereof comprise a T cell therapy. In one embodiment, the T cell therapy of the present invention is engineered Autologous Cell Therapy (eACT™). According to this embodiment, the method can include collecting blood cells from the patient. The isolated blood cells (e.g., T cells) can then be engineered to express an anti-BCMA CAR of the present invention (“anti-BCMA CAR T cells”). In a particular embodiment, the anti-BCMA CAR T cells are administered to the patient. In some embodiments, the anti-BCMA CAR T cells treat a tumor or a cancer in the patient. In one embodiment the anti-BCMA CAR T cells reduce the size of a tumor or a cancer.
- In some embodiments, the donor T cells for use in the T cell therapy are obtained from the patient (e.g., for an autologous T cell therapy). In other embodiments, the donor T cells for use in the T cell therapy are obtained from a subject that is not the patient.
- The T cells can be administered at a therapeutically effective amount. For example, a therapeutically effective amount of the T cells can be at least about 104 cells, at least about 105 cells, at least about 106 cells, at least about 107 cells, at least about 108 cells, at least about 109 cells, at least about 1010 cells, or at least about 1011 cells. In another embodiment, the therapeutically effective amount of the T cells is about 104 cells, about 105 cells, about 106 cells, about 107 cells, or about 108 cells. In one particular embodiment, the therapeutically effective amount of the anti-BCMA CAR T cells is about 2×106 cells/kg, about 3×106 cells/kg, about 4×106 cells/kg, about 5×106 cells/kg, about 6×106 cells/kg, about 7×106 cells/kg, about 8×106 cells/kg, about 9×106 cells/kg, about 1×107 cells/kg, about 2×107 cells/kg, about 3×107 cells/kg, about 4×107 cells/kg, about 5×107 cells/kg, about 6×107 cells/kg, about 7×107 cells/kg, about 8×107 cells/kg, or about 9×107 cells/kg.
- Another aspect of the present invention is directed to methods of diagnosis, detection, or validation. In some embodiments, the antigen binding molecule is used as a diagnostic or validation tool. In certain embodiments, the antigen binding molecules disclosed herein are used to assay the amount of BCMA present in a sample and/or subject. In some embodiments, the diagnostic antigen binding molecule is not neutralizing. In some embodiments, the antigen binding molecules disclosed herein are used or provided in an assay kit and/or method for the detection of BCMA in mammalian tissues or cells in order to screen/diagnose for a disease or disorder associated with changes in levels of BCMA. In some embodiments, the kit comprises an antigen binding molecule that binds BCMA, along with means for indicating the binding of the antigen binding molecule with BCMA, if present, and optionally BCMA protein levels. Various means for indicating the presence of an antigen binding molecule can be used. For example, fluorophores, other molecular probes, or enzymes can be linked to the antigen binding molecule and the presence of the antigen binding molecule can be observed in a variety of ways. As will be appreciated by one of skill in the art, the degree of antigen binding molecule binding can be used to determine how much BCMA is in a sample.
- The methods of the invention can be used to treat a cancer in a subject, reduce the size of a tumor, kill tumor cells, prevent tumor cell proliferation, prevent growth of a tumor, eliminate a tumor from a patient, prevent relapse of a tumor, prevent tumor metastasis, induce remission in a patient, or any combination thereof. In certain embodiments, the methods induce a complete response. In other embodiments, the methods induce a partial response.
- Cancers that may be treated include tumors that are not vascularized, not yet substantially vascularized, or vascularized. The cancer may also include solid or non-solid tumors. In some embodiments, the cancer is a hematologic cancer. In some embodiments, the cancer is of the white blood cells. In other embodiments, the cancer is of the plasma cells. In some embodiments, the cancer is leukemia, lymphoma, or myeloma. In certain embodiments, the cancer is multiple myeloma, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), chronic or acute leukemia, myeloid diseases including but not limited to acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), T-cell lymphoma, one or more of B-cell acute lymphoid leukemia (“BALL”), T-cell acute lymphoid leukemia (“TALL”), acute lymphoid leukemia (ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, myelodysplasia and myelodysplastic syndrome (MDS), hemophagocytic syndrome (Macrophage Activating Syndrome (MAS), and hemophagocytic lymphohistocytosis (HLH)), chronic or acute granulomatous disease, large cell granuloma, leukocyte adhesion deficiency, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, plasma cell proliferative disorders (e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammapathy of undetermined significance (MGUS), plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, POEMS syndrome (Crow-Fukase syndrome, Takatsuki disease, PEP syndrome), or combinations thereof. In one embodiment, the cancer is a myeloma. In one particular embodiment, the cancer is multiple myeloma.
- In some embodiments, the methods further comprise administering a chemotherapeutic. In certain embodiments, the chemotherapeutic selected is a lymphodepleting (preconditioning) chemotherapeutic. Beneficial preconditioning treatment regimens, along with correlative beneficial biomarkers are described in U.S.
Provisional Patent Applications 62/262,143 and 62/167,750 which are hereby incorporated by reference in their entirety herein. These describe, e.g., methods of conditioning a patient in need of a T cell therapy comprising administering to the patient specified beneficial doses of cyclophosphamide (between 200 mg/m2/day and 2000 mg/m2/day) and specified doses of fludarabine (between 20 mg/m2/day and 900 mg/m2/day). A preferred dose regimen involves treating a patient comprising administering daily to the patient about 500 mg/m2/day of cyclophosphamide and about 60 mg/m2/day of fludarabine for three days prior to administration of a therapeutically effective amount of engineered T cells to the patient. - In other embodiments, the antigen binding molecule, transduced (or otherwise engineered) cells (such as CARs or TCRs), and the chemotherapeutic agent are administered each in an amount effective to treat the disease or condition in the subject.
- In certain embodiments, compositions comprising CAR- and/or TCR-expressing immune effector cells disclosed herein may be administered in conjunction with any number of chemotherapeutic agents. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN™); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine resume; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOL™, Bristol-Myers Squibb) and doxetaxel (TAXOTERE®, Rhone-Poulenc Rorer); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylomithine (DMFO); retinoic acid derivatives such as Targretin™ (bexarotene), Panretin™, (alitretinoin); ONTAK™ (denileukin diftitox); esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. In some embodiments, compositions comprising CAR- and/or TCR-expressing immune effector cells disclosed herein may be administered in conjunction with an anti-hormonal agent that acts to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Combinations of chemotherapeutic agents are also administered where appropriate, including, but not limited to CHOP, i.e., Cyclophosphamide (Cytoxan®), Doxorubicin (hydroxydoxorubicin), Vincristine (Oncovin®), and Prednisone.
- In some embodiments, the chemotherapeutic agent is administered at the same time or within one week after the administration of the engineered cell or nucleic acid. In other embodiments, the chemotherapeutic agent is administered from 1 to 4 weeks or from 1 week to 1 month, 1 week to 2 months, 1 week to 3 months, 1 week to 6 months, 1 week to 9 months, or 1 week to 12 months after the administration of the engineered cell or nucleic acid. In some embodiments, the chemotherapeutic agent is administered at least 1 month before administering the cell or nucleic acid. In some embodiments, the methods further comprise administering two or more chemotherapeutic agents.
- A variety of additional therapeutic agents may be used in conjunction with the compositions described herein. For example, potentially useful additional therapeutic agents include PD-1 inhibitors such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), pembrolizumab, pidilizumab (CureTech), and atezolizumab (Roche).
- Additional therapeutic agents suitable for use in combination with the invention include, but are not limited to, ibrutinib (Imbruvica®), ofatumumab (Arzerra®), rituximab (Rituxan®), bevacizumab (Avastin®), trastuzumab (Herceptin®), trastuzumab emtansine (KADCYLA®), imatinib (Gleevec®), cetuximab (Erbitux®), panitumumab (Vectibix®), catumaxomab, ibritumomab, ofatumumab, tositumomab, brentuximab, alemtuzumab, gemtuzumab, erlotinib, gefitinib, vandetanib, afatinib, lapatinib, neratinib, axitinib, masitinib, pazopanib, sunitinib, sorafenib, toceranib, lestaurtinib, axitinib, cediranib, lenvatinib, nintedanib, pazopanib, regorafenib, semaxanib, sorafenib, sunitinib, tivozanib, toceranib, vandetanib, entrectinib, cabozantinib, imatinib, dasatinib, nilotinib, ponatinib, radotinib, bosutinib, lestaurtinib, ruxolitinib, pacritinib, cobimetinib, selumetinib, trametinib, binimetinib, alectinib, ceritinib, crizotinib, aflibercept, adipotide, denileukin diftitox, mTOR inhibitors such as Everolimus and Temsirolimus, hedgehog inhibitors such as sonidegib and vismodegib, CDK inhibitors such as CDK inhibitor (palbociclib).
- In additional embodiments, the composition comprising CAR- and/or TCR-containing immune are administered with an anti-inflammatory agent. Anti-inflammatory agents or drugs can include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti-inflammatory drugs (NSAIDS) including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate. Exemplary NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors, and sialylates. Exemplary analgesics include acetaminophen, oxycodone, tramadol of proporxyphene hydrochloride. Exemplary glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone. Exemplary biological response modifiers include molecules directed against cell surface markers (e.g., CD4, CD5, etc.), cytokine inhibitors, such as the TNF antagonists, (e.g., etanercept (ENBREL®), adalimumab (HUMIRA®) and infliximab (REMICADE®), chemokine inhibitors and adhesion molecule inhibitors. The biological response modifiers include monoclonal antibodies as well as recombinant forms of molecules. Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, Gold (oral (auranofin) and intramuscular), and minocycline.
- In certain embodiments, the compositions described herein are administered in conjunction with a cytokine. “Cytokine” as used herein is meant to refer to proteins released by one cell population that act on another cell as intercellular mediators. Examples of cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogen; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors (NGFs) such as NGF-beta; platelet-growth factor; transforming growth factors (TGFs) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon-alpha, beta, and -gamma; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, a tumor necrosis factor such as TNF-alpha or TNF-beta; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture, and biologically active equivalents of the native sequence cytokines.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention. To the extent that any of the definitions or terms provided in the references incorporated by reference differ from the terms and discussion provided herein, the present terms and definitions control.
- The present invention is further illustrated by the following examples which should not be construed as further limiting. The contents of all references cited throughout this application are expressly incorporated herein by reference.
- BCMA expression was measured in various cell lines. BCMA was found to be expressed, with a fragments/kilobase of exon/million reads mapped (FPKM) greater than 35, in 99% of multiple myeloma tumor cell lines tested (
FIG. 2A ). BCMA expression was greater than that of CD70, CS-1, CLL-1, DLL-1 and FLT3 (FIG. 2A ). To further characterize the expression of BCMA, EoL-1 (Sigma), NCI-H929 (Molecular Imaging), and MM1S (Molecular Imaging) cells were stained with an anti-BCMA antibody conjugated to PE (Biolegend, San Diego, Calif.) in stain buffer (BD Pharmingen, San Jose, Calif.) for 30 minutes at 4° C. Cells were then washed and resuspended in stain buffer with propidium iodide (BD Pharmingen) prior to data acquisition. Samples were then acquired by flow cytometry and data analyzed (FIGS. 2B-2C ). BCMA expression was observed in the myeloma cell lines MM1S (FIG. 2C ) and NCI-H929 (FIG. 2D ), but not in the human eosinophil cell line EoL-1 (FIG. 2B ). In addition, little to no BCMA expression was observed in normal immune cells (FIG. 2E ). - A third generation lentiviral transfer vector containing the BCMA CAR constructs was used along with the ViraPower Lentiviral Packaging Mix (Life Technologies, FIX′) to generate the lentiviral supernatants. Briefly, a transfection mix was generated by mixing 15 μg of DNA and 22.5 μl of polyethileneimine (Polysciences, 1 mg/ml) in 600 μl of OptiMEM media. The transfection mix was incubated for 5 minutes at room temperature. Simultaneously, 293T cells (ATCC) were trypsinized and counted. A total of 10×106 total 293T cells were then plated in a T75 flask with the transfection mix. Following culture for three days, supernatants were collected and filtered through a 0.45 μm filter and stored at −80° C.
- Peripheral blood mononuclear cells (PBMCs) were isolated from two different healthy donor leukopaks (Hemacare) using ficoll-paque density centrifugation according to the manufacturer's instructions. PBMCs were stimulated using OKT3 (Muromonab-CD3, 50 ng/ml, Miltenyi Biotec) in R10 media supplemented with IL-2 (300 IU/ml, Proleukin®, Prometheus® Therapeutics and Diagnostics). Forty-eight hours post-stimulation, cells were transduced using lentivirus containing the different BCMA CAR constructs at a multiplicity of infection (MOI) of 10. Cells were maintained at 0.5×106-2.0×106 cells/ml prior to use in activity assays.
- At
day 12 post-stimulation, transduced T cells were stained with recombinant BCMA-Fc (R&D Systems) in stain buffer (BD Pharmingen) for 30 minutes at 4° C. Cells were then washed and stained with goat anti-human IgG Fc PE (Jackson ImmunoResearch, West Grove, Pa.) in stain buffer for 30 minutes at 4° C. Cells were then washed and resuspended in stain buffer with propidium iodide (BD Pharmingen) prior to data acquisition. All experiments were performed in two different donors. BCMA CAR expression was observed for each of the constructs in both Donor 1 (FIG. 3A ) and Donor 2 (FIG. 3B ) transduced cells. - Effector cells, e.g., anti-BCMA CAR T cells, were cultured with target cells at a 1:1 effector cell to target cell (E:T) ratio in R10
media 12 days after T cell stimulation. Cell lines tested included EoL-1, NCI-H929 and MM1S. Sixteen hours post-co-culture, supernatants were analyzed by Luminex (EMD Millipore), according to the manufacturer's instructions, for production of the cytokines IFNγ (FIGS. 4A-4B ), TNFα (FIGS. 4C-4D ), and IL-2 (FIGS. 4E-4F ). IFNγ (FIGS. 4A-4B ), TNFα (FIGS. 4C-4D ), and IL-2 (FIGS. 4E-4F ) were observed in the supernatant of NCI-H929 and MM1S target cell co-cultures for each anti-BCMA CAR T cell tested in both donors (FIGS. 4A-4B ); however, IFNγ (FIGS. 4A-4B ), TNFα (FIGS. 4C-4D ), and IL-2 (FIGS. 4E-4F ) were only observed in the supernatant of EoL-1 target cell co-cultures above background for the IR negative control T cells (FIG. 4A ). - Target cell viability was assessed by flow cytometric analysis of propidium iodide (PI) uptake of CD3 negative cells. The anti-BCMA CAR T cells were co-cultured with EoL1 (
FIGS. 5A-5B ), NCI-H929 (FIGS. 5C-5D ), or MM1S (FIGS. 5E-5F ) target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours. Little cytolytic activity was observed in the EoL-1 co-cultures at any time period for the anti-BCMA CAR T cells (FIG. 5A-5B ). However, co-culture of the anti-BCMA CAR T cells and the NCI-H929 or MM1S target cells resulted in a decrease in the percentage of viable target cells at each time point measured for each of the anti-BCMA CAR T cells. - To examine proliferation, anti-BCMA CAR T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) prior to co-culture with EoL-1, NCI-H929, or MM1S target cells at a 1:1 E:T ratio in R10 media. Five days later, T cell proliferation was assessed by flow cytometric analysis of CFSE dilution. Data was analyzed and plotted as histogram using FlowJo™ (
FIGS. 6A-6B ). All experiments were performed in two different donors. - Antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotinylation Kit from Pierce/ThermoFisher (Waltham, Mass.). Goat anti-human F(ab′)2 kappa-FITC (LC-FITC), Extravidin-PE (EA-PE) and streptavidin-633 (SA-633) were obtained from Southern Biotech (Birmingham, Ala.), Sigma (St. Louis, Mo.) and Molecular Probes/Invitrogen (Waltham, Mass.), respectively. Streptavidin MicroBeads and MACS LC separation columns were purchased from Miltenyi Biotec (Gladbachn, Germany).
- Eight naïve human synthetic yeast libraries each of ˜109 diversity were propagated as described herein (see WO2009036379, WO2010105256, and WO2012009568 to Xu et al.). For the first two rounds of selection, a magnetic bead sorting technique utilizing the Miltenyi MACs system was performed, as described (Siegel et al., 2004). Briefly, yeast cells (˜1010 cells/library) were incubated with 3 ml of 100 nM biotinylated monomeric antigen or 10 nM biotinylated Fc fusion antigen for 15 minutes at room temperature in FACS wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)). After washing once with 50 ml ice-cold wash buffer, the cell pellet was resuspended in 40 mL wash buffer, and Streptavidin MicroBeads (500 μl) were added to the yeast and incubated for 15 minutes at 4° C. Next, the yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL was loaded, the column was washed 3 times with 3 ml FACS wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight. The following rounds of sorting were performed using flow cytometry. Approximately 1×108 yeast were pelleted, washed three times with wash buffer, and incubated with decreasing concentrations of biotinylated monomeric or Fc fusion antigen (100 to 1 nM) under equilibrium conditions at room temperature. Yeast were then washed twice and stained with LC-FITC (diluted 1:100) and either SA-633 (diluted 1:500) or EA-PE (diluted 1:50) secondary reagents for 15 minutes at 4° C. After washing twice with ice-cold wash buffer, the cell pellets were resuspended in 0.4 mL wash buffer and transferred to strainer-capped sort tubes. Sorting was performed using a FACS ARIA sorter (BD Biosciences, San Jose, Calif.) and sort gates were assigned to select for specific binders relative to a background control. Subsequent rounds of selection were focused on reduction of non-specific reagent binders (utilizing soluble membrane proteins from CHO cell), as well as pressuring for affinity to BCMA. After the final round of sorting, yeast were plated and individual colonies were picked for characterization.
- Affinity Maturation
- Binding optimization of naïve clones was carried out using three maturation strategies: light chain diversification, diversification of VH CDRH1/CDRH2, and performing VHmut/VKmut selections.
- Light Chain Diversification: Heavy chain plasmids were extracted and transformed into a light chain library with a diversity of 1×106. Selections were performed as described above with one round of MACS sorting and two rounds of FACS sorting using 10 nM or 1 nM biotinylated antigen for respective rounds.
- CDRH1 and CDRH2 Selection: A selected donor CDRH3 was recombined into a premade library with CDRH1 and CDRH2 variants of a diversity of 1×108 and selections were performed as described above. Affinity pressures were applied by incubating the biotinylated antigen-antibody yeast complex with unbiotinylated antigen for varying amounts of time to select for the highest affinity antibodies.
- VHmut/VKmut Selection: This round of affinity maturation included error prone PCR-based mutagenesis of the heavy chain and/or light chain. Selections were performed similar to previous cycles, but employing FACS sorting for all selection rounds. Antigen concentration was reduced and cold antigen competition times were increased to pressure further for optimal affinity.
- Yeast clones were grown to saturation and then induced for 48 h at 30° C. with shaking. After induction, yeast cells were pelleted and the supernatants were harvested for purification. IgGs were purified using a Protein A column and eluted with acetic acid, pH 2.0. Fab fragments were generated by papain digestion and purified over KappaSelect (GE Healthcare LifeSciences, Pittsburgh, Pa.).
- ForteBio affinity measurements were performed generally as previously described (Estep et al., 2013). Briefly, ForteBio affinity measurements were performed by loading IgGs on-line onto AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 minutes and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded IgGs were exposed to 100 nM antigen for 5 minutes, afterwards they were transferred to assay buffer for 5 minutes for off-rate measurement. Kinetics were analyzed using the 1:1 binding model.
- Equilibrium affinity measurements performed generally as previously described (Estep et al., 2013). Briefly, solution equilibrium titrations (SET) were performed in PBS+0.1% IgG-Free BSA (PBSF) with antigen (BCMA monomer) held constant at 10-100 pM and incubated with 3- to 5-fold serial dilutions of Fab or mAbs starting at 10 pM-10 nM (experimental condition is sample dependent). Antibodies (20 nM in PBS) were coated onto standard bind MSD-ECL plates overnight at 4° C. or at room temperature for 30 minutes. Plates were then blocked by BSA for 30 minutes with shaking at 700 rpm, followed by three washes with wash buffer (PBSF+0.05% Tween 20). SET samples were applied and incubated on the plates for 150 seconds with shaking at 700 rpm followed by one wash. Antigen captured on a plate was detected with 250 ng/mL Sulfotag™-labeled streptavidin in PBSF by incubation on the plate for 3 minutes. The plates were washed three times with wash buffer and then read on the MSD Sector Imager 2400™ instrument using 1× Read Buffer T with surfactant. The percent free antigen was plotted as a function of titrated antibody in Prism™ and fit to a quadratic equation to extract the KD. To improve throughput, liquid handling robots were used throughout MSD-SET experiments, including SET sample preparation.
- Epitope binning/ligand blocking was performed using a standard sandwich format cross-blocking assay. Control anti-target IgG was loaded onto AHQ sensors and unoccupied Fc-binding sites on the sensor were blocked with an irrelevant human IgG1 antibody. The sensors were then exposed to 100 nM target antigen followed by a second anti-target antibody or ligand. Data was processed using ForteBio's Data Analysis Software 7.0. Additional binding by the second antibody or ligand after antigen association indicates an unoccupied epitope (non-competitor), while no binding indicates epitope blocking (competitor or ligand blocking).
- A TSKgel SuperSW mAb HTP column (22855) was used for fast SEC analysis of yeast produced mAbs at 0.4 mL/minute with a cycle time of 6 minutes/run. 200 mM Sodium Phosphate and 250 mM Sodium Chloride was used as the mobile phase.
- 10 uL of 20× Sypro Orange™ is added to 20 uL of 0.2-1 mg/mL mAb or Fab solution. A RT-PCR instrument (BioRad CFX96 RT PCR) is used to ramp the sample plate temperature from 40° to 95° C. at 0.5C increment, with 2 minutes to equilibrate at each temperature. The negative of first derivative for the raw data is used to extract Tm.
-
Clone FS-26528 HC DNA (SEQ ID NO: 271) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTC CTGTGCAGCCTCTGGATTCACCTTTGACGACTATGCCATGGCATGGGTCCGCCAGGCTCCAG GGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTACGCAGAC TCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAAT GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGAGCCGAGATGGGAGCCG TATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCA Clone FS-26528 HC. CDRs underlined. (SEQ ID NO: 272) EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAMAWVRQAPGKGLEWVSAISDAGDRTYY ADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAEMGAVFDIWGQGTMVTVSS (SEQ ID NO: 273) SCAASGFTFDDYAMA [HC CDR1] (SEQ ID NO: 274) AISDAGDRTYYADSVRG [HC CDR2] (SEQ ID NO: 275) ARAEMGAVFDI [HC CDR3] Clone FS-26528 LC DNA (SEQ ID NO: 276) GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTT TGCAGTTTATTACTGTCAGCAGAGAATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGG Clone FS-26528 LC. CDRs underlined. (SEQ ID NO: 277) EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARF SGSGSGTDFTLTISSLEPEDFAVYYCQQ RISWPFTFGGGTKVEIKR (SEQ ID NO: 278) RASQSVSRYLA [LC CDR1] (SEQ ID NO: 279) DASNRAT [LC CDR2] (SEQ ID NO: 280) QQRISWPFT [LC CDR3] Clone FS-26528 CAR DNA HxL (SEQ ID NO: 281) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT CCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGCCATGGCATGGGTCCGCCAGGCTCCA GGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTACGCAGA CTCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAA TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGAGCCGAGATGGGAGCC GTATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGGGTCTACATCCGGCTC CGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACACAGTCTCCAG CCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTT AGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGA TGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACT TCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGAGA ATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCT TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCAC CCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCT TGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCG CCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACT ACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGA TCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGG ACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCA AACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCT GAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTT GTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGC CACCTAGG Clone FS-26528 CAR HxL (SEQ ID NO: 282) MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAMAWVRQAP GKGLEWVSAISDAGDRTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAEMGA VFDIWGQGTMVTVSSGSTSGSGKPGSGEGSTKGEIVLTQSPATLSLSPGERATLSCRASQSV SRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQR ISWPFTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLA CYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR Clone FS-26528 CAR DNA LxH (SEQ ID NO: 283) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT TTGCAGTTTATTACTGTCAGCAGAGAATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAG GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC AAAGGGGGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGA GACTCTCCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGCCATGGCATGGGTCCGCCAG GCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTA CGCAGACTCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATC TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGAGCCGAGATG GGAGCCGTATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGCCGCTGCCCT TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCAC CCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCT TGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCG CCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACT ACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGA TCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGG ACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCA AACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCT GAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTT GTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGC CACCTAGG Clone FS-26528 CAR LxH (SEQ ID NO: 284) MALPVTALLLPLALLLHAARPEIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPG QAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRISWPFTFGGGTK VEIKRGSTSGSGKPGSGEGSTKGEVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAMAWVRQ APGKGLEWVSAISDAGDRTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAEM GAVFDIWGQGTMVTVSSAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLA CYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR Clone PC-26534 HC DNA (SEQ ID NO: 285) CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC CTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCAG GCAAGGGGCTGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATGCAGAC TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAGACGGTACTTATCTAG GTGGTCTCTGGTACTTCGACTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCA Clone PC-26534 HC. CDRs underlined. (SEQ ID NO: 286) QVQLVESGGGVVQPGRSLRLSCAASGFTFSEHGMHWVRQAPGKGLEWVAAISYDGRNKHY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTYLGGLWYFDLWGRGTLVTVSS (SEQ ID NO: 287) FTFSEHGMH [HC CDR1] (SEQ ID NO: 288) AISYDGRNKHYADSVKG [HC CDR2] (SEQ ID NO: 289) ARDGTYLGGLWYFDL [HC CDR3] Clone PC-26534 LC DNA (SEQ ID NO: 290) GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGT GGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTCTCACTTTTG GCGGAGGGACCAAGGTTGAGATCAAACGG Clone PC-26534 LC. CDRs underlined. (SEQ ID NO: 291) DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRA SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGLGLPLTFGGGTKVEIKR (SEQ ID NO: 292) RSSQSLLHSNGYNYLD [LC CDR1] (SEQ ID NO: 293) LGSNRAS [LC CDR2] (SEQ ID NO: 294) MQGLGLPLT [LC CDR3] Clone PC-26534 CAR DNA HxL (SEQ ID NO: 295) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCA GGCAAGGGGCTGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATGCAGA CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAA TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAGACGGTACTTATCTA GGTGGTCTCTGGTACTTCGACTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCAGGGTC TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGATATTGTGATGA CTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCT AGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGG GCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGT TCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGAT GTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTCTCACTTTTGGCGGAGGGACCAA GGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACG TGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTG TTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAAT CTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCAC GCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCC TATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAA CCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCA GAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTAT AATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCG GAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTT ATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone PC-26534 CAR HxL (SEQ ID NO: 296) MALPVTALLLPLALLLHAARPQVQLVESGGGVVQPGRSLRLSCAASGFTFSEHGMHWVRQAP GKGLEWVAAISYDGRNKHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTYL GGLWYFDLWGRGTLVTVSSGSTSGSGKPGSGEGSTKGDIVMTQSPLSLPVTPGEPASISCRS SQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAED VGVYYCMQGLGLPLTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWV LVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAA YRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR Clone PC-26534 CAR DNA LxH (SEQ ID NO: 297) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCA TCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTAC CTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGG GGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTCTCACTTTT GGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAG TGGCGAAGGTAGTACAAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGC CTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGGCATG CACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCTATATCTTATGATGG AAGGAATAAACACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCA AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGC GCCAGAGACGGTACTTATCTAGGTGGTCTCTGGTACTTCGACTTATGGGGGAGAGGTACCTT GGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACG TGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTG TTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAAT CTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCAC GCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCC TATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAA CCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCA GAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTAT AATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCG GAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTT ATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone PC-26534 CAR LxH (SEQ ID NO: 298) MALPVTALLL PLALLLHAAR PDIVMTQSPL SLPVTPGEPA SISCRSSQSL LHSNGYNYLD WYLQKPGQSP QLLIYLGSNR ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCMQGLGL PLTFGGGTKV EIKRGSTSGS GKPGSGEGST KGQVQLVESG GGVVQPGRSL RLSCAASGFT FSEHGMHWVR QAPGKGLEWV AAISYDGRNK HYADSVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR DGTYLGGLWY FDLWGRGTLV TVSSAAALDN EKSNGTIIHV KGKHLCPSPL FPGPSKPFWV LVVVGGVLAC YSLLVTVAFI IFWVRSKRSR LLHSDYMNMT PRRPGPTRKH YQPYAPPRDF AAYRSRVKFS RSADAPAYQQ GQNQLYNELN LGRREEYDVL DKRRGRDPEM GGKPRRKNPQ EGLYNELQKD KMAEAYSEIG MKGERRRGKG HDGLYQGLST ATKDTYDALH MQALPPR Clone AJ-26545 HC DNA (SEQ ID NO: 299) CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTC CTGCAGGGCATCTGGATACACCTTCATGGAGCACTATATGCACTGGGTGCGACAGGCCCCTG GACAAGGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAG AAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAATTGGCCAATGG ACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA Clone AJ-26545 HC. CDRs underlined. (SEQ ID NO: 300) QVQLVQSGAEVKKPGASVKVSCRASGYTFMEHYMHWVRQAPGQGLEWMGVIGPSGGKTSY AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARESWPMDVWGQGTTVTVSS (SEQ ID NO: 301) YTFMEHYMH (HC CDR1) (SEQ ID NO: 302) VIGPSGGKTSYAQKFQG (HC CDR2) (SEQ ID NO: 303) ARESWPMDV (HC CDR3) Clone AJ-26545 LC DNA (SEQ ID NO: 304) GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT TGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTG AGATCAAACGG Clone AJ-26545 LC. CDRs underlined. (SEQ ID NO: 305) EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARF SGSGSGTEFTLTISSLQSEDFAVYYCQQYAAYPTFGGGTKVEIKR (SEQ ID NO: 306) RASQSVSSNLA (LC CDR1) (SEQ ID NO: 307) GASTRAT (LC CDR2) (SEQ ID NO: 308) QQYAAYPT (LC CDR3) Clone AJ-26545 CAR DNA HxL (SEQ ID NO: 309) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTT CCTGCAGGGCATCTGGATACACCTTCATGGAGCACTATATGCACTGGGTGCGACAGGCCCCT GGACAAGGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACA GAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGC TGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAATTGGCCAATG GACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAA GCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAGCCACCC TGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGC AACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATC CACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTC TCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCC TACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGA AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone AJ-26545 CAR HxL (SEQ ID NO: 310) MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK VSCRASGYTF MEHYMHWVRQ APGQGLEWMG VIGPSGGKTS YAQKFQGRVT MTRDTSTSTV YMELSSLRSE DTAVYYCARE SWPMDVWGQG TTVTVSSGST SGSGKPGSGE GSTKGEIVMT QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV YYCQQYAAYP TFGGGTKVEI KRAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR Clone AJ-26545 CAR DNA LxH (SEQ ID NO: 311) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT TTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTT GAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAA GGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG TTTCCTGCAGGGCATCTGGATACACCTTCATGGAGCACTATATGCACTGGGTGCGACAGGCC CCTGGACAAGGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGG AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAATTGGCCA ATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGA AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone AJ-26545 CAR LxH (SEQ ID NO: 312) MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY GASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QYAAYPTFGG GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL VQSGAEVKKP GASVKVSCRA SGYTFMEHYM HWVRQAPGQG LEWMGVIGPS GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY YCARESWPMD VWGQGTTVTV SSAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR Clone AJ-26554 HC DNA (SEQ ID NO: 313) CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTC CTGCAAGGCATCTGGATACACCTTCACGGAGCACTATATGCACTGGGTGCGACAGGCCCCTG GACAAAGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAG AAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAGTTGGCCAATGG ACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA Clone AJ-26554 HC. CDRs underlined. (SEQ ID NO: 314) QVQLVQSGAE VKKPGASVKV SCKASGYTFT EHYMHWVRQA PGQRLEWMGV IGPSGGKTSY AQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARES WPMDVWGQGT TVTVSS (SEQ ID NO: 315) YTFTEHYMH (HC CDR1) (SEQ ID NO: 316) VIGPSGGKTSYAQKFQG (HC CDR2) (SEQ ID NO: 317) ARESWPMDV (HC CDR3) Clone AJ-26554 LC DNA (SEQ ID NO: 318) GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT TGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTG AGATCAAACGG Clone AJ-26554 LC. CDRs underlined. (SEQ ID NO: 319) EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPA RFSGSGSGTEFTLTISSLQSEDFAVYYCQQYAAYPTFGGGTKVEIKR (SEQ ID NO: 320) RASQSVSSNLA (LC CDR1) (SEQ ID NO: 321) GASTRAT (LC CDR2) (SEQ ID NO: 322) QQYAAYPT (LC CDR3) Clone AJ-26554 CAR DNA HxL (SEQ ID NO: 323) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTT CCTGCAAGGCATCTGGATACACCTTCACGGAGCACTATATGCACTGGGTGCGACAGGCCCCT GGACAAAGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACA GAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGC TGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAGTTGGCCAATG GACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAA GCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAGCCACCC TGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGC AACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATC CACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTC TCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCC TACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGA AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone AJ-26554 CAR HxL (SEQ ID NO: 324) MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK VSCKASGYTF TEHYMHWVRQ APGQRLEWMG VIGPSGGKTS YAQKFQGRVT MTRDTSTSTV YMELSSLRSE DTAVYYCARE SWPMDVWGQG TTVTVSSGST SGSGKPGSGE GSTKGEIVMT QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV YYCQQYAAYP TFGGGTKVEI KRAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR Clone AJ-26554 CAR DNA LxH (SEQ ID NO: 325) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT TTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTT GAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAA GGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG TTTCCTGCAAGGCATCTGGATACACCTTCACGGAGCACTATATGCACTGGGTGCGACAGGCC CCTGGACAAAGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGG AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAGTTGGCCA ATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGA AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone AJ-26554 CAR LxH (SEQ ID NO: 326) MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY GASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QYAAYPTFGG GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL VQSGAEVKKP GASVKVSCKA SGYTFTEHYM HWVRQAPGQR LEWMGVIGPS GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY YCARESWPMD VWGQGTTVTV SSAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR Clone NM-26562 HC DNA (SEQ ID NO: 327) CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCAC CTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGCCAGC ACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTACTACAAC CCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAA GCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGCAGGGGATATG AGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCA Clone NM-26562 HC. CDRs underlined. (SEQ ID NO: 328) QVQLQESGPGLVKPSQTLSLTCTVSGGSIGSGGSYWSWIRQHPGKGLEWIGLIYYDGSTY YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRGYETSLAFDIWGQGTMVTVSS (SEQ ID NO: 329) GSIGSGGSYWS (HC CDR1) (SEQ ID NO: 330) LIYYDGSTYYNPSLKS (HC CDR2) (SEQ ID NO: 331) ARGRGYETSLAFDI (HC CDR3) Clone NM-26562 LC DNA (SEQ ID NO: 332) GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTT TGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGG Clone NM-26562 LC. CDRs underlined. (SEQ ID NO: 333) EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRHVWPPTFGGGTKVEIKR (SEQ ID NO: 334) RASQSVSSYLA (LC CDR1) (SEQ ID NO: 335) DASNRAT (LC CDR2) (SEQ ID NO: 336) QQRHVWPPT (LC CDR3) Clone NM-26562 CAR DNA HxL (SEQ ID NO: 337) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCA CCTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGCCAG CACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTACTACAA CCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGA AGCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGCAGGGGATAT GAGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGGGTC TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGA CACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCC AGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCT CCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGT CTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTAC TGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACG GGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA TGCAAGCCCTGCCACCTAGG Clone NM-26562 CAR HxL (SEQ ID NO: 338) MALPVTALLL PLALLLHAAR PQVQLQESGP GLVKPSQTLS LTCTVSGGSI GSGGSYWSWI RQHPGKGLEW IGLIYYDGST YYNPSLKSRV TISVDTSKNQ FSLKLSSVTA ADTAVYYCAR GRGYETSLAF DIWGQGTMVT VSSGSTSGSG KPGSGEGSTK GEIVLTQSPA TLSLSPGERA TLSCRASQSV SSYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRHVWPPTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR Clone NM-26562 CAR DNA LxH (SEQ ID NO: 339) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT TTGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAGGGACCAAG GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC AAAGGGGCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGT CCCTCACCTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATC CGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTA CTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCT CCCTGAAGCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGCAGG GGATATGAGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTC AGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA TGCAAGCCCTGCCACCTAGG Clone NM-26562 CAR LxH (SEQ ID NO: 340) MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA TLSCRASQSV SSYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRHVWPPTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LQESGPGLVK PSQTLSLTCT VSGGSIGSGG SYWSWIRQHP GKGLEWIGLI YYDGSTYYNP SLKSRVTISV DTSKNQFSLK LSSVTAADTA VYYCARGRGY ETSLAFDIWG QGTMVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR Clone TS-26564 HC DNA (SEQ ID NO: 341) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTC CTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAG GGAAGGGGCTGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGAC TCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAAT GAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGAGGTTCTCAGGAGCACC TGATTTTCGATTATTGGGGACAGGGTACATTGGTCACCGTCTCCTCA Clone TS-26564 HC. CDRs underlined. (SEQ ID NO: 342) EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSTISSSSSIIYY ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGSQEHLIFDYWGQGTLVTVSS (SEQ ID NO: 343) FTFSSYSMN (HC CDR1) (SEQ ID NO: 344) TISSSSSIIYYADSVKG (HC CDR2) (SEQ ID NO: 345) ARGSQEHLIFDY (HC CDR3) Clone TS-26564 LC DNA (SEQ ID NO: 346) GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTT TGCAGTTTATTACTGTCAGCAGAGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGG Clone TS-26564 LC. CDRs underlined. (SEQ ID NO: 347) EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPA RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRFYYPWTFGGGTKVEIKR (SEQ ID NO: 348) RASQSVSRYLA (LC CDR1) (SEQ ID NO: 349) DASNRAT (LC CDR2) (SEQ ID NO: 350) QQRFYYPWT (LC CDR3) Clone TS-26564 CAR DNA HxL (SEQ ID NO: 351) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT CCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCA GGGAAGGGGCTGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGA CTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAA TGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGAGGTTCTCAGGAGCAC CTGATTTTCGATTATTGGGGACAGGGTACATTGGTCACCGTCTCCTCAGGGTCTACATCCGG CTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACACAGTCTC CAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT GTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTA TGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAG ACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAG AGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGC CCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGT CACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTC GCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCC AGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCT GGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTG GCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATG GCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGG TTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCC TGCCACCTAGG Clone TS-26564 CAR HxL (SEQ ID NO: 352) MALPVTALLL PLALLLHAAR PEVQLVESGG GLVQPGGSLR LSCAASGFTF SSYSMNWVRQ APGKGLEWVS TISSSSSIIY YADSVKGRFT ISRDNAKNSL YLQMNSLRAE DTAVYYCARG SQEHLIFDYW GQGTLVTVSS GSTSGSGKPG SGEGSTKGEI VLTQSPATLS LSPGERATLS CRASQSVSRY LAWYQQKPGQ APRLLIYDAS NRATGIPARF SGSGSGTDFT LTISSLEPED FAVYYCQQRF YYPWTFGGGT KVEIKRAAAL DNEKSNGTII HVKGKHLCPS PLFPGPSKPF WVLVVVGGVL ACYSLLVTVA FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR KHYQPYAPPR DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE IGMKGERRRG KGHDGLYQGL STATKDTYDA LHMQALPPR Clone TS-26564 CAR DNA LxH (SEQ ID NO: 353) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT TTGCAGTTTATTACTGTCAGCAGAGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAG GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC AAAGGGGGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGA GACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAG GCTCCAGGGAAGGGGCTGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTA CGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATC TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGAGGTTCTCAG GAGCACCTGATTTTCGATTATTGGGGACAGGGTACATTGGTCACCGTCTCCTCAGCCGCTGC CCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGT CACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTC GCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCC AGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCT GGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTG GCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATG GCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGG TTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCC TGCCACCTAGG Clone TS-26564 CAR LxH (SEQ ID NO: 354) MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA TLSCRASQSV SRYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRFYYPWTFG GGTKVEIKRG STSGSGKPGS GEGSTKGEVQ LVESGGGLVQ PGGSLRLSCA ASGFTFSSYS MNWVRQAPGK GLEWVSTISS SSSIIYYADS VKGRFTISRD NAKNSLYLQM NSLRAEDTAV YYCARGSQEH LIFDYWGQGT LVTVSSAAAL DNEKSNGTII HVKGKHLCPS PLFPGPSKPF WVLVVVGGVL ACYSLLVTVA FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR KHYQPYAPPR DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE IGMKGERRRG KGHDGLYQGL STATKDTYDA LHMQALPPR Clone RY-26568 HC DNA (SEQ ID NO: 355) CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC CTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAG GCAAGGGGCTGGAGTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTATGCAGAC TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATCTGCAAAT GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTCTGGAGCG GATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTCA Clone RY-26568 HC. CDRs underlined. (SEQ ID NO: 356) QVQLVESGGG VVQPGRSLRL SCAASGFTFG SYGMHWVRQA PGKGLEWVAV IHYDGSVEYY ADSVKGRFTI SRDNSKDTLY LQMNSLRAED TAVYYCARTD FWSGSPPSLD YWGQGTLVTV SS (SEQ ID NO: 357) FTFGSYGMH (HC CDR1) (SEQ ID NO: 358) VIHYDGSVEYYADSVKG (HC CDR2) (SEQ ID NO: 359) ARTDFWSGSPPSLDY (HC CDR3) Clone RY-26568 LC DNA (SEQ ID NO: 360) GACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGA AAGCCCCTAAGCTCCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTC AGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTT TGCAACTTATTACTGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGG Clone RY-26568 LC. CDRs underlined. (SEQ ID NO: 361) DIQLTQSPSSVSASVGDRVTITCRASRGISSWLAWYQQKPGKAPKLLIYGASSLQSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQIYTFPFTFGGGTKVEIKR (SEQ ID NO: 362) RASRGISSWLA (LC CDR1) (SEQ ID NO: 363) GASSLQS (LC CDR2) (SEQ ID NO: 364) QQIYTFPFT (LC CDR3) Clone RY-26568 CAR DNA HxL (SEQ ID NO: 365) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGGTCCGCCAGGCTCCA GGCAAGGGGCTGGAGTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTATGCAGA CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATCTGCAAA TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTCTGGAGC GGATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTCAGGGTC TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGACATCCAGTTGA CCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCG AGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCT CCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT CTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTAC TGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACG GGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA TGCAAGCCCTGCCACCTAGG Clone RY-26568 CAR HxL SEQ ID NO: 366) MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR LSCAASGFTF GSYGMHWVRQ APGKGLEWVA VIHYDGSVEY YADSVKGRET ISRDNSKDTL YLQMNSLRAE DTAVYYCART DFWSGSPPSL DYWGQGTLVT VSSGSTSGSG KPGSGEGSTK GDIQLTQSPS SVSASVGDRV TITCRASRGI SSWLAWYQQK PGKAPKLLIY GASSLQSGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QIYTFPFTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR Clone RY-26568 CAR DNA LxH (SEQ ID NO: 367) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCA TCACTTGTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGG AAAGCCCCTAAGCTCCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTT CAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATT TTGCAACTTATTACTGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAG GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC AAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGA GACTCTCCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGGTCCGCCAG GCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTA TGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATC TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTC TGGAGCGGATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTC AGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA TGCAAGCCCTGCCACCTAGG Clone RY-26568 CAR LxH (SEQ ID NO: 368) MALPVTALLL PLALLLHAAR PDIQLTQSPS SVSASVGDRV TITCRASRGI SSWLAWYQQK PGKAPKLLIY GASSLQSGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QIYTFPFTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LVESGGGVVQ PGRSLRLSCA ASGFTFGSYG MHWVRQAPGK GLEWVAVIHY DGSVEYYADS VKGRFTISRD NSKDTLYLQM NSLRAEDTAV YYCARTDFWS GSPPSLDYWG QGTLVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR Clone PP-26575 HC DNA (SEQ ID NO: 369) CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTC CTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCTATCAGCTGGGTGCGACAGGCCCCTG GACAAGGGCTTGAGTGGATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACAG AAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGCT GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCTGAATACTCCT CCAGCATATGGCACTATTACTACGGCATGGACGTATGGGGCCAGGGAACAACTGTCACCGTC TCCTCA Clone PP-26575 HC. CDRs underlined. (SEQ ID NO: 370) QVQLVQSGAEVKKPGSSVKVSCKASGGTLSSLAISWVRQAPGQGLEWMGGVIPILGRANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARTPEYSSSIWHYYYGMDVWGQGTTVTV SS (SEQ ID NO: 371) GTLSSLAIS (HC CDR1) (SEQ ID NO: 372) GVIPILGRANYAQKFQG (HC CDR2) (SEQ ID NO: 373) ARTPEYSSSIWHYYYGMDV (HC CDR3) Clone PP-26575 LC DNA (SEQ ID NO: 374) GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCC GGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAG CCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTTCACTT TTGGCGGAGGGACCAAGGTTGAGATCAAACGG Clone PP-26575 LC. CDRs underlined. (SEQ ID NO: 375) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTR ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQFAHTPFTFGGGTKVEIKR (SEQ ID NO: 376) KSSQSVLYSSNNKNYLA (LC CDR1) (SEQ ID NO: 377) WASTRES (LC CDR2) (SEQ ID NO: 378) QQFAHTPFT (LC CDR3) Clone PP-26575 CAR DNA HxL (SEQ ID NO: 379) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT CCTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCTATCAGCTGGGTGCGACAGGCCCCT GGACAAGGGCTTGAGTGGATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACA GAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGC TGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCTGAATACTCC TCCAGCATATGGCACTATTACTACGGCATGGACGTATGGGGCCAGGGAACAACTGTCACCGT CTCCTCAGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGG ACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATC AACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTA CCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCG GGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGC CTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTTCACTTT TGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACG GAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCAC CGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACA TGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCT AGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCC CAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGG CATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTG CTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone PP-26575 CAR HxL (SEQ ID NO: 380) MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGSSVK VSCKASGGTL SSLAISWVRQ APGQGLEWMG GVIPILGRAN YAQKFQGRVT ITADESTSTA YMELSSLRSE DTAVYYCART PEYSSSIWHY YYGMDVWGQG TTVTVSSGST SGSGKPGSGE GSTKGDIVMT QSPDSLAVSL GERATINCKS SQSVLYSSNN KNYLAWYQQK PGQPPKLLIY WASTRESGVP DRFSGSGSGT DFTLTISSLQ AEDVAVYYCQ QFAHTPFTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR Clone PP-26575 CAR DNA LxH (SEQ ID NO: 381) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCA TCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGG TACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCA GCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTTCACT TTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGG AAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGA AGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCT ATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGGTCATCCCTAT CTTGGGTCGGGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGT CCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTAC TGCGCCAGAACTCCTGAATACTCCTCCAGCATATGGCACTATTACTACGGCATGGACGTATG GGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACG GAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCAC CGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACA TGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCT AGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCC CAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGG CATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTG CTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG Clone PP-26575 CAR LxH (SEQ ID NO: 382) MALPVTALLL PLALLLHAAR PDIVMTQSPD SLAVSLGERA TINCKSSQSV LYSSNNKNYL AWYQQKPGQP PKLLIYWAST RESGVPDRFS GSGSGTDFTL TISSLQAEDV AVYYCQQFAH TPFTFGGGTK VEIKRGSTSG SGKPGSGEGS TKGQVQLVQS GAEVKKPGSS VKVSCKASGG TLSSLAISWV RQAPGQGLEW MGGVIPILGR ANYAQKFQGR VTITADESTS TAYMELSSLR SEDTAVYYCA RTPEYSSSIW HYYYGMDVWG QGTTVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR Clone RD-26576 HC DNA (SEQ ID NO: 383) CAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC CTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGTCCGCCAGGCTCCAG GCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGAC TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGC CGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA Clone RD-26576 HC. CDRs underlined. (SEQ ID NO: 384) QVRLVESGGGVVQPGRSLRLSCAASGFTFSSYGIHWVRQAPGKGLEWVAVIGYDGQEKYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKGPLQEPPYAFGMDVWGQGTTVTVSS (SEQ ID NO: 385) FTFSSYGIH (HC CDR1) (SEQ ID NO: 386) VIGYDGQEKYYADSVKG (HC CDR2) (SEQ ID NO: 387) VKGPLQEPPYAFGMDV (HC CDR3) Clone RD-26576 LC DNA (SEQ ID NO: 388) GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT TGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGG Clone RD-26576 LC. CDRs underlined. (SEQ ID NO: 389) EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPA RFSGSGSGTEFTLTISSLQSEDFAVYYCQQHHVWPLTFGGGTKVEIKR (SEQ ID NO: 390) RASQSVSSNLA (LC CDR1) (SEQ ID NO: 391) SASTRAT (LC CDR2) (SEQ ID NO: 392) QQHHVWPLT (LC CDR3) Clone RD-26576 CAR DNA HxL (SEQ ID NO: 393) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGTCCGCCAGGCTCCA GGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGA CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAA TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAG CCGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGG GTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGA TGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAG GCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTAT TACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAA ACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC ACATGCAAGCCCTGCCACCTAGG Clone RD-26576 CAR HxL (SEQ ID NO: 394) MALPVTALLL PLALLLHAAR PQVRLVESGG GVVQPGRSLR LSCAASGFTF SSYGIHWVRQ APGKGLEWVA VIGYDGQEKY YADSVKGRET ISRDNSKNTL YLQMNSLRAE DTAVYYCVKG PLQEPPYAFG MDVWGQGTTV TVSSGSTSGS GKPGSGEGST KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL QSEDFAVYYC QQHHVWPLTF GGGTKVEIKR AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR Clone RD-26576 CAR DNA LxH (SEQ ID NO: 395) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT TTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAG GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC AAAGGGGCAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGA GACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGTCCGCCAG GCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTA TGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTG CAGGAGCCGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTC CTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC ACATGCAAGCCCTGCCACCTAGG Clone RD-26576 CAR LxH (SEQ ID NO: 396) MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY SASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QHHVWPLTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVR LVESGGGVVQ PGRSLRLSCA ASGFTFSSYG IHWVRQAPGK GLEWVAVIGY DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV YYCVKGPLQE PPYAFGMDVW GQGTTVTVSS AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR Clone RD-26578 HC DNA (SEQ ID NO: 397) CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC CTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGGTCCGCCAGGCTCCAG GCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGAC TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGC CGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA Clone RD-26578 HC CDRs 1, 2, and 3 are underlined. (SEQ ID NO: 398) QVQLVESGGGVVQPGRSLRLSCAASGFTFSSRGMHWVRQAPGKGLEWVAVIGYDGQEKYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKGPLQEPPYDYGMDVWGQGTTVTVSS (SEQ ID NO: 399) FTFSSRGMH (HC CDR1) (SEQ ID NO: 400) VIGYDGQEKYYADSVKG (HC CDR2) (SEQ ID NO: 401) VKGPLQEPPYDYGMDV (HC CDR3) Clone RD-26578 LC DNA (SEQ ID NO: 402) GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC AGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT TGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGG TTGAGATCAAACGG Clone RD-26578 LC. CDRs underlined. (SEQ ID NO: 403) EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYS ASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHHVWPLTFGGGTKVEIKR (SEQ ID NO: 404) RASQSVSSNLA (LC CDR1) (SEQ ID NO: 405) SASTRAT (LC CDR2) (SEQ ID NO: 406) QQHHVWPLT (LC CDR3) Clone RD-26578 CAR DNA HxL (SEQ ID NO: 407) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT CCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGGTCCGCCAGGCTCCA GGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGA CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAA TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAG CCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGG GTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGA TGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAG GCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTAT TACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAA ACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC ACATGCAAGCCCTGCCACCTAGG Clone RD-26578 CAR HxL (SEQ ID NO: 408) MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR LSCAASGFTF SSRGMHWVRQ APGKGLEWVA VIGYDGQEKY YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCVKG PLQEPPYDYG MDVWGQGTTV TVSSGSTSGS GKPGSGEGST KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL QSEDFAVYYC QQHHVWPLTF GGGTKVEIKR AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR Clone RD-26578 CAR DNA LxH (SEQ ID NO: 409) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT TTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAG GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC AAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGA GACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGGTCCGCCAG GCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTA TGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTG CAGGAGCCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTC CTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC ACATGCAAGCCCTGCCACCTAGG Clone RD-26578 CAR LxH (SEQ ID NO: 410) MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV SSNLAWYQQK PGQAPRLLIY SASTRATGIP ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QHHVWPLTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LVESGGGVVQ PGRSLRLSCA ASGFTFSSRG MHWVRQAPGK GLEWVAVIGY DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV YYCVKGPLQE PPYDYGMDVW GQGTTVTVSS AAALDNEKSN GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR
Claims (20)
1. A polypeptide comprising an antigen binding molecule that specifically binds to B-cell maturation antigen (BCMA), wherein the antigen binding molecule comprises a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 399; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 400; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 401; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 404; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 405; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 406.
2. The polypeptide of claim 1 , wherein the antigen binding molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 398; and a VL comprising the amino acid sequence of SEQ ID NO: 403.
3. The polypeptide of claim 1 , wherein the antigen binding molecule is selected from the group consisting of scFv, Fab, Fab′, Fv, F(ab′)2, and any combination thereof.
4. The polypeptide of claim 3 , wherein the antigen binding molecule comprises an scFv and the VH and the VL are connected by a linker.
5. The polypeptide of claim 4 , wherein the linker comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 174.
6. The polypeptide of claim 1 , wherein the polypeptide is a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
7. The polypeptide of claim 6 , wherein the CAR or TCR further comprises a transmembrane domain.
8. The polypeptide of claim 7 , wherein the transmembrane domain is a transmembrane domain of CD28, 4-1BB, CD8 alpha, CD4, CD19, CD3 epsilon, CD45, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, a zeta chain of a T cell receptor, or any combination thereof.
9. The polypeptide of claim 7 , wherein the CAR further comprises a hinge region between the transmembrane domain and the antigen binding molecule, wherein the hinge region is of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, CD28, or CD8 alpha.
10. The polypeptide of claim 6 , wherein the CAR or TCR further comprises a costimulatory region, wherein the costimulatory region is a signaling region of CD28, OX-40, 4-1BB, CD2, CD7, CD27, CD30, CD40, PD-1, ICOS, LFA-1, CD11α, CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276, LIGHT, NKG2C, Ig alpha, DAP-10, Fc gamma receptor, MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules, activating NK cell receptors, BTLA, a Toll ligand receptor, B7-H3, CDS, GITR, BAFFR, HVEM, KIRDS2, SLAMF7, NKp80, NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, ITGAE, ITGAL, ITGAM, ITGAX, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, TNFR2, TRANCE, DNAM1, SLAMF4, CD84, CD96, CEACAM1, CRTAM, Ly9, CD160, PSGL1, CD100, CD69, SLAMF6, SLAM, BLAME, SELPLG, LTBR, LAT, GADS, SLP-76, PAG, CD19a, a ligand that specifically binds with CD83, or any combination thereof.
11. The polypeptide of claim 6 , wherein the CAR or TCR further comprises an activation domain.
12. The polypeptide of claim 11 , wherein the activation domain is a CD3 zeta domain.
13. One or more polynucleotide(s) encoding the polypeptide of claim 1 .
14. A cell comprising the polypeptide(s) of claim 13 .
15. The cell of claim 14 , which is a tumor-infiltrating lymphocyte (TIL), autologous T cell, engineered autologous T cell (eACT), or an allogeneic T cell.
16. A composition comprising the cell of claim 14 and a carrier.
17. A method of preparing a transduced cell, comprising introducing the one or more polynucleotide(s) of claim 13 into a cell.
18. A method for inducing immunity against a tumor in a subject in need thereof, comprising administering to the subject the polypeptide of claim 1 or a cell expressing the polypeptide.
19. A method for treating a cancer in a subject in need thereof, comprising administering to the subject the polypeptide of claim 1 or a cell expressing the polypeptide.
20. The method of claim 19 , wherein the cancer is multiple myeloma, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), T-cell lymphoma, one or more of B-cell acute lymphoid leukemia (BALL), T-cell acute lymphoid leukemia (TALL), acute lymphoid leukemia (ALL), chronic myelogenous leukemia (CIVIL), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, myelodysplasia and myelodysplastic syndrome, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, a plasma cell proliferative disorder, asymptomatic myeloma, smoldering multiple myeloma, indolent myeloma, monoclonal gammapathy of undetermined significance (MGUS), plasmacytomas, plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, multiple plasmacytoma, systemic amyloid light chain amyloidosis, POEMS syndrome, or a combination thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/055,188 US20230146195A1 (en) | 2016-04-01 | 2022-11-14 | Bcma binding molecules and methods of use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317334P | 2016-04-01 | 2016-04-01 | |
US15/476,309 US10689450B2 (en) | 2016-04-01 | 2017-03-31 | BCMA binding molecules and methods of use thereof |
US16/569,341 US11505613B2 (en) | 2016-04-01 | 2019-09-12 | BCMA binding molecules and methods of use thereof |
US18/055,188 US20230146195A1 (en) | 2016-04-01 | 2022-11-14 | Bcma binding molecules and methods of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/569,341 Continuation US11505613B2 (en) | 2016-04-01 | 2019-09-12 | BCMA binding molecules and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230146195A1 true US20230146195A1 (en) | 2023-05-11 |
Family
ID=59959188
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/476,309 Active US10689450B2 (en) | 2016-04-01 | 2017-03-31 | BCMA binding molecules and methods of use thereof |
US16/569,341 Active 2037-08-04 US11505613B2 (en) | 2016-04-01 | 2019-09-12 | BCMA binding molecules and methods of use thereof |
US18/055,188 Pending US20230146195A1 (en) | 2016-04-01 | 2022-11-14 | Bcma binding molecules and methods of use thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/476,309 Active US10689450B2 (en) | 2016-04-01 | 2017-03-31 | BCMA binding molecules and methods of use thereof |
US16/569,341 Active 2037-08-04 US11505613B2 (en) | 2016-04-01 | 2019-09-12 | BCMA binding molecules and methods of use thereof |
Country Status (25)
Country | Link |
---|---|
US (3) | US10689450B2 (en) |
EP (1) | EP3436036A4 (en) |
JP (2) | JP7366543B2 (en) |
KR (3) | KR102591930B1 (en) |
CN (3) | CN116425876A (en) |
AR (1) | AR108067A1 (en) |
AU (2) | AU2017240150C1 (en) |
BR (1) | BR112018070159A2 (en) |
CA (1) | CA3019135A1 (en) |
CL (1) | CL2018002763A1 (en) |
CO (1) | CO2018010475A2 (en) |
CR (1) | CR20180462A (en) |
CU (1) | CU20180120A7 (en) |
DO (1) | DOP2018000212A (en) |
EA (1) | EA201891966A1 (en) |
EC (1) | ECSP18073836A (en) |
IL (1) | IL261942A (en) |
MX (1) | MX2023007400A (en) |
NZ (1) | NZ746700A (en) |
PE (1) | PE20190120A1 (en) |
PH (1) | PH12018550164A1 (en) |
SG (2) | SG10201912515XA (en) |
TW (4) | TWI707950B (en) |
WO (1) | WO2017173349A1 (en) |
ZA (1) | ZA201806962B (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7152309B2 (en) | 2016-02-17 | 2022-10-12 | シージェン インコーポレイテッド | BCMA antibiotics and their use to treat cancer and immunological disorders |
KR20200068750A (en) | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | Chimeric receptors and methods of use thereof |
CN116425876A (en) | 2016-04-01 | 2023-07-14 | 凯德药业股份有限公司 | BCMA binding molecules and methods of use thereof |
AU2017240667C1 (en) | 2016-04-01 | 2022-11-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
WO2018175476A1 (en) * | 2017-03-20 | 2018-09-27 | Baylor College Of Medicine | Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells |
EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
EP3675897A1 (en) | 2017-09-01 | 2020-07-08 | Dana Farber Cancer Institute, Inc. | Immunogenic peptides specific to bcma and taci antigens for treatment of cancer |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
US20210363260A1 (en) | 2017-11-13 | 2021-11-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
US20230183313A1 (en) | 2018-02-11 | 2023-06-15 | Jiangsu Hengrui Medicine Co., Ltd. | Isolated chimeric antigen receptor, modified t cell comprising same and use thereof |
EP3752531A1 (en) * | 2018-02-14 | 2020-12-23 | Kite Pharma, Inc. | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule |
EA202091974A1 (en) * | 2018-02-21 | 2020-12-08 | Селджин Корпорейшн | BCMA ANTIBODIES BINDERS AND THEIR APPLICATION |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
CN112512557A (en) * | 2018-04-27 | 2021-03-16 | 克里斯珀医疗股份公司 | anti-BCMA CAR-T-cells for plasma cell depletion |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
CN110818802B (en) * | 2018-08-08 | 2022-02-08 | 华夏英泰(北京)生物技术有限公司 | Chimeric T cell receptor STAR and application thereof |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
CA3131138A1 (en) * | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
JP2022539248A (en) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | Recombinant AD35 vectors and related gene therapy improvements |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
CN113045657B (en) * | 2019-12-26 | 2022-06-07 | 杭州济元基因科技有限公司 | Humanized anti-human BCMA monoclonal antibody and CAR-T cell thereof |
CN111234020B (en) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | BCMA binding protein and preparation method and application thereof |
US20230192807A1 (en) * | 2020-05-15 | 2023-06-22 | Precision Biosciences, Inc. | Methods for immunotherapy |
WO2022156739A1 (en) * | 2021-01-20 | 2022-07-28 | 江苏恒瑞医药股份有限公司 | Antigen binding molecule specifically binding to bcma and cd3, and medical use thereof |
US20240067955A1 (en) | 2021-01-20 | 2024-02-29 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
GB202100754D0 (en) | 2021-01-20 | 2021-03-03 | Coding Bio Ltd | Methods for high throughput screening of chimeric antigen receptors |
WO2023019398A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Bcma targetting antibodies, chimeric antigen receptors, and uses thereof |
GB202116514D0 (en) | 2021-11-16 | 2021-12-29 | Coding Bio Ltd | Computational methods for the design and optimisation of chimeric antigen receptors (cars) |
WO2023167903A2 (en) * | 2022-03-01 | 2023-09-07 | Agilent Technologies, Inc. | Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc) |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE87659T1 (en) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
JP3262724B2 (en) | 1996-12-25 | 2002-03-04 | 福岡丸本株式会社 | Cultivation equipment |
US6892139B2 (en) * | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
JP2004500095A (en) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | Simultaneous stimulation and enrichment of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
MXPA05000511A (en) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Super humanized antibodies. |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
EP2322547A1 (en) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | Antibodes to cll-1 |
CN102272153B (en) * | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | High affinity t cell receptor and use thereof |
JP6061469B2 (en) | 2009-03-10 | 2017-01-25 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Anti-BCMA antibody |
WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
CA2780707A1 (en) * | 2009-11-17 | 2011-05-26 | Basf Plant Science Company Gmbh | Plants with increased yield |
WO2011138414A1 (en) | 2010-05-05 | 2011-11-10 | Addex Pharma Sa | Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
ES2754394T3 (en) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Chimeric antigen receptors with an optimized hinge region |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
EP3305798A1 (en) | 2010-12-09 | 2018-04-11 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
CA2824997C (en) | 2011-01-18 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
WO2012103279A2 (en) | 2011-01-26 | 2012-08-02 | Ariad Pharmaceuticals, Incorporated | Methods and compositions for the synthesis of multimerizing agents |
CN106074601A (en) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | Method and composition for cellular immunotherapy |
HUE063461T2 (en) * | 2011-05-27 | 2024-01-28 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - binding proteins |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
KR20140060541A (en) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Rna engineered t cells for the treatment of cancer |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
DE102012204596A1 (en) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Method and device for regulating the speed of a motor vehicle |
CA3116051C (en) | 2012-03-23 | 2023-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
SG11201406414WA (en) | 2012-04-11 | 2014-11-27 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
CN110511278A (en) | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | Anti- B7-H6 antibody, fusion protein and its application method |
US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
TW201425336A (en) * | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
US9963513B2 (en) * | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
EP2953475B1 (en) * | 2013-02-06 | 2019-07-03 | Celgene Corporation | Modified t lymphocytes having improved specificity |
CN105142677B (en) | 2013-02-15 | 2019-08-30 | 加利福尼亚大学董事会 | Chimeric antigen receptor and its application method |
US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
JP6543626B2 (en) | 2013-07-29 | 2019-07-10 | ブルーバード バイオ, インコーポレイテッド | Multipartite signaling proteins and uses thereof |
CA2930587A1 (en) | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
KR20220119176A (en) | 2014-02-04 | 2022-08-26 | 카이트 파마 인코포레이티드 | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
JP6772063B2 (en) | 2014-02-14 | 2020-10-21 | ベリカム ファーマシューティカルズ, インコーポレイテッド | Methods for activating cells using inducible chimeric polypeptides |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
JP6698546B2 (en) | 2014-04-14 | 2020-05-27 | セレクティスCellectis | BCMA (CD269)-specific chimeric antigen receptor for cancer immunotherapy |
RU2741120C2 (en) | 2014-07-21 | 2021-01-22 | Новартис Аг | Treating cancer using a chimeric antigenic cll-1 receptor |
KR102612313B1 (en) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
KR102523934B1 (en) | 2014-07-24 | 2023-04-20 | 2세븐티 바이오, 인코포레이티드 | Bcma chimeric antigen receptors |
MX2017003022A (en) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anti-cll-1 antibodies and immunoconjugates. |
CN107002084B (en) * | 2014-09-19 | 2021-09-10 | 希望之城公司 | Co-stimulatory chimeric antigen receptor T cells targeting IL13R alpha 2 |
WO2016044745A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
CA2969704C (en) | 2014-12-05 | 2023-05-02 | City Of Hope | Cs1 targeted chimeric antigen receptor-modified t cells |
EP4310097A3 (en) | 2014-12-05 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
EP3230321B1 (en) | 2014-12-12 | 2019-08-28 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
CN105445991A (en) | 2014-12-26 | 2016-03-30 | 深圳市华星光电技术有限公司 | Making method for color filter |
EP3283106B1 (en) | 2015-04-13 | 2021-12-22 | Pfizer Inc. | Therapeutic antibodies and their uses |
CN107980046B (en) | 2015-04-13 | 2021-12-24 | 辉瑞公司 | Chimeric antigen receptors targeting B cell maturation antigens |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
KR20200068750A (en) | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | Chimeric receptors and methods of use thereof |
AU2017240667C1 (en) * | 2016-04-01 | 2022-11-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
WO2017173410A1 (en) | 2016-04-01 | 2017-10-05 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
CN116425876A (en) | 2016-04-01 | 2023-07-14 | 凯德药业股份有限公司 | BCMA binding molecules and methods of use thereof |
-
2017
- 2017-03-31 CN CN202310108490.6A patent/CN116425876A/en active Pending
- 2017-03-31 CR CR20180462A patent/CR20180462A/en unknown
- 2017-03-31 BR BR112018070159-9A patent/BR112018070159A2/en unknown
- 2017-03-31 PE PE2018001932A patent/PE20190120A1/en not_active Application Discontinuation
- 2017-03-31 NZ NZ746700A patent/NZ746700A/en unknown
- 2017-03-31 EA EA201891966A patent/EA201891966A1/en unknown
- 2017-03-31 CN CN201780030900.2A patent/CN109414455B/en active Active
- 2017-03-31 SG SG10201912515XA patent/SG10201912515XA/en unknown
- 2017-03-31 KR KR1020237012515A patent/KR102591930B1/en active IP Right Grant
- 2017-03-31 KR KR1020227015639A patent/KR102522622B1/en active IP Right Grant
- 2017-03-31 WO PCT/US2017/025516 patent/WO2017173349A1/en active Application Filing
- 2017-03-31 TW TW106111226A patent/TWI707950B/en active
- 2017-03-31 AR ARP170100822A patent/AR108067A1/en unknown
- 2017-03-31 AU AU2017240150A patent/AU2017240150C1/en active Active
- 2017-03-31 CU CU2018000120A patent/CU20180120A7/en unknown
- 2017-03-31 US US15/476,309 patent/US10689450B2/en active Active
- 2017-03-31 CN CN202310115780.3A patent/CN117903307A/en active Pending
- 2017-03-31 TW TW110147901A patent/TWI795133B/en active
- 2017-03-31 TW TW109115604A patent/TWI761831B/en active
- 2017-03-31 CA CA3019135A patent/CA3019135A1/en active Pending
- 2017-03-31 KR KR1020187031269A patent/KR102397674B1/en active IP Right Grant
- 2017-03-31 JP JP2018550679A patent/JP7366543B2/en active Active
- 2017-03-31 EP EP17776833.0A patent/EP3436036A4/en not_active Withdrawn
- 2017-03-31 TW TW112105413A patent/TW202323273A/en unknown
- 2017-03-31 SG SG11201808403SA patent/SG11201808403SA/en unknown
-
2018
- 2018-09-26 IL IL261942A patent/IL261942A/en unknown
- 2018-09-27 PH PH12018550164A patent/PH12018550164A1/en unknown
- 2018-09-27 CL CL2018002763A patent/CL2018002763A1/en unknown
- 2018-09-28 MX MX2023007400A patent/MX2023007400A/en unknown
- 2018-09-28 CO CONC2018/0010475A patent/CO2018010475A2/en unknown
- 2018-10-01 DO DO2018000212A patent/DOP2018000212A/en unknown
- 2018-10-01 EC ECSENADI201873836A patent/ECSP18073836A/en unknown
- 2018-10-18 ZA ZA2018/06962A patent/ZA201806962B/en unknown
-
2019
- 2019-09-12 US US16/569,341 patent/US11505613B2/en active Active
-
2022
- 2022-02-10 JP JP2022019896A patent/JP2022065073A/en active Pending
- 2022-02-23 AU AU2022201243A patent/AU2022201243A1/en not_active Abandoned
- 2022-11-14 US US18/055,188 patent/US20230146195A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230146195A1 (en) | Bcma binding molecules and methods of use thereof | |
JP7434250B2 (en) | Humanized antigen-binding domain for CD19 and methods of use | |
US20210277132A1 (en) | CD70 Binding Molecules and Methods of Use Thereof | |
OA19653A (en) | BCMA binding molecules and methods of use thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |